20250001697862FALSEFYP3YP3Y0.33330.027830.250.25P5YP5YP5YP5YP5Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesargx:targetiso4217:EURxbrli:sharesiso4217:EURxbrli:pureargx:equityInstrumentutr:Yargx:segmentargx:employeeargx:memberargx:subsidiary00016978622025-01-012025-12-310001697862dei:BusinessContactMember2025-01-012025-12-310001697862argx:AmericanDepositarySharesMember2025-01-012025-12-310001697862ifrs-full:OrdinarySharesMember2025-01-012025-12-3100016978622025-12-3100016978622024-12-3100016978622023-12-3100016978622024-01-012024-12-3100016978622023-01-012023-12-3100016978622022-12-310001697862ifrs-full:IssuedCapitalMember2022-12-310001697862ifrs-full:SharePremiumMember2022-12-310001697862ifrs-full:RetainedEarningsMember2022-12-310001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-12-310001697862ifrs-full:ReserveOfSharebasedPaymentsMember2022-12-310001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2022-12-310001697862ifrs-full:EquityAttributableToOwnersOfParentMember2022-12-310001697862ifrs-full:RetainedEarningsMember2023-01-012023-12-310001697862ifrs-full:EquityAttributableToOwnersOfParentMember2023-01-012023-12-310001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-01-012023-12-310001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2023-01-012023-12-310001697862ifrs-full:IssuedCapitalMember2023-01-012023-12-310001697862ifrs-full:SharePremiumMember2023-01-012023-12-310001697862ifrs-full:ReserveOfSharebasedPaymentsMember2023-01-012023-12-310001697862ifrs-full:IssuedCapitalMember2023-12-310001697862ifrs-full:SharePremiumMember2023-12-310001697862ifrs-full:RetainedEarningsMember2023-12-310001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001697862ifrs-full:ReserveOfSharebasedPaymentsMember2023-12-310001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2023-12-310001697862ifrs-full:EquityAttributableToOwnersOfParentMember2023-12-310001697862ifrs-full:RetainedEarningsMember2024-01-012024-12-310001697862ifrs-full:EquityAttributableToOwnersOfParentMember2024-01-012024-12-310001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-01-012024-12-310001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2024-01-012024-12-310001697862ifrs-full:IssuedCapitalMember2024-01-012024-12-310001697862ifrs-full:SharePremiumMember2024-01-012024-12-310001697862ifrs-full:ReserveOfSharebasedPaymentsMember2024-01-012024-12-310001697862ifrs-full:IssuedCapitalMember2024-12-310001697862ifrs-full:SharePremiumMember2024-12-310001697862ifrs-full:RetainedEarningsMember2024-12-310001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-12-310001697862ifrs-full:ReserveOfSharebasedPaymentsMember2024-12-310001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2024-12-310001697862ifrs-full:EquityAttributableToOwnersOfParentMember2024-12-310001697862ifrs-full:RetainedEarningsMember2025-01-012025-12-310001697862ifrs-full:EquityAttributableToOwnersOfParentMember2025-01-012025-12-310001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-01-012025-12-310001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2025-01-012025-12-310001697862ifrs-full:IssuedCapitalMember2025-01-012025-12-310001697862ifrs-full:SharePremiumMember2025-01-012025-12-310001697862ifrs-full:ReserveOfSharebasedPaymentsMember2025-01-012025-12-310001697862ifrs-full:IssuedCapitalMember2025-12-310001697862ifrs-full:SharePremiumMember2025-12-310001697862ifrs-full:RetainedEarningsMember2025-12-310001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-12-310001697862ifrs-full:ReserveOfSharebasedPaymentsMember2025-12-310001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2025-12-310001697862ifrs-full:EquityAttributableToOwnersOfParentMember2025-12-310001697862ifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMemberifrs-full:BottomOfRangeMember2025-01-012025-12-310001697862ifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMemberifrs-full:TopOfRangeMember2025-01-012025-12-310001697862ifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMemberifrs-full:BottomOfRangeMember2025-01-012025-12-310001697862ifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMemberifrs-full:TopOfRangeMember2025-01-012025-12-310001697862ifrs-full:RightofuseAssetsMemberargx:LeaseEquipmentMemberifrs-full:BottomOfRangeMember2025-01-012025-12-310001697862ifrs-full:RightofuseAssetsMemberargx:LeaseEquipmentMemberifrs-full:TopOfRangeMember2025-01-012025-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2022-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2022-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2022-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2022-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2022-12-310001697862ifrs-full:GrossCarryingAmountMember2022-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2023-01-012023-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2023-01-012023-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2023-01-012023-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2023-01-012023-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2023-01-012023-12-310001697862ifrs-full:GrossCarryingAmountMember2023-01-012023-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2023-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2023-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2023-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2023-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2023-12-310001697862ifrs-full:GrossCarryingAmountMember2023-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2024-01-012024-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2024-01-012024-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2024-01-012024-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2024-01-012024-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2024-01-012024-12-310001697862ifrs-full:GrossCarryingAmountMember2024-01-012024-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2024-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2024-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2024-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2024-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2024-12-310001697862ifrs-full:GrossCarryingAmountMember2024-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2025-01-012025-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2025-01-012025-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2025-01-012025-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2025-01-012025-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2025-01-012025-12-310001697862ifrs-full:GrossCarryingAmountMember2025-01-012025-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2025-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2025-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2025-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2025-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2025-12-310001697862ifrs-full:GrossCarryingAmountMember2025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2022-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2022-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2022-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2022-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2022-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMember2022-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2023-01-012023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2023-01-012023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2023-01-012023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2023-01-012023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2023-01-012023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMember2023-01-012023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMember2023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2024-01-012024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2024-01-012024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2024-01-012024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2024-01-012024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2024-01-012024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMember2024-01-012024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMember2024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2025-01-012025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2025-01-012025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2025-01-012025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2025-01-012025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2025-01-012025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMember2025-01-012025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:ITOfficeAndLabEquipmentMember2025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:BuildingsMember2025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:RightofuseAssetsMemberifrs-full:VehiclesMember2025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberifrs-full:LeaseholdImprovementsMember2025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMember2025-12-310001697862argx:ITOfficeAndLabEquipmentMemberifrs-full:PropertyPlantAndEquipmentMember2023-12-310001697862ifrs-full:BuildingsMemberifrs-full:RightofuseAssetsMember2023-12-310001697862ifrs-full:VehiclesMemberifrs-full:RightofuseAssetsMember2023-12-310001697862ifrs-full:LeaseholdImprovementsMemberifrs-full:PropertyPlantAndEquipmentMember2023-12-310001697862ifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2023-12-310001697862argx:ITOfficeAndLabEquipmentMemberifrs-full:PropertyPlantAndEquipmentMember2024-12-310001697862ifrs-full:BuildingsMemberifrs-full:RightofuseAssetsMember2024-12-310001697862ifrs-full:VehiclesMemberifrs-full:RightofuseAssetsMember2024-12-310001697862ifrs-full:LeaseholdImprovementsMemberifrs-full:PropertyPlantAndEquipmentMember2024-12-310001697862ifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2024-12-310001697862argx:ITOfficeAndLabEquipmentMemberifrs-full:PropertyPlantAndEquipmentMember2025-12-310001697862ifrs-full:BuildingsMemberifrs-full:RightofuseAssetsMember2025-12-310001697862ifrs-full:VehiclesMemberifrs-full:RightofuseAssetsMember2025-12-310001697862ifrs-full:LeaseholdImprovementsMemberifrs-full:PropertyPlantAndEquipmentMember2025-12-310001697862ifrs-full:PropertyPlantAndEquipmentMemberargx:LeaseEquipmentMemberifrs-full:PropertyPlantAndEquipmentSubjectToOperatingLeasesMember2025-12-310001697862ifrs-full:OfficeEquipmentMemberifrs-full:BottomOfRangeMember2025-01-012025-12-310001697862ifrs-full:OfficeEquipmentMemberifrs-full:TopOfRangeMember2025-01-012025-12-310001697862ifrs-full:ComputerEquipmentMember2025-01-012025-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2022-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredInProcessResearchAndDevelopmentMember2022-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:OtherIntangibleAssetsMember2022-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2023-01-012023-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredInProcessResearchAndDevelopmentMember2023-01-012023-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:OtherIntangibleAssetsMember2023-01-012023-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2023-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredInProcessResearchAndDevelopmentMember2023-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:OtherIntangibleAssetsMember2023-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2024-01-012024-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredInProcessResearchAndDevelopmentMember2024-01-012024-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:OtherIntangibleAssetsMember2024-01-012024-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2024-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredInProcessResearchAndDevelopmentMember2024-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:OtherIntangibleAssetsMember2024-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2025-01-012025-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredInProcessResearchAndDevelopmentMember2025-01-012025-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:OtherIntangibleAssetsMember2025-01-012025-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2025-12-310001697862ifrs-full:GrossCarryingAmountMemberargx:AcquiredInProcessResearchAndDevelopmentMember2025-12-310001697862ifrs-full:GrossCarryingAmountMemberifrs-full:OtherIntangibleAssetsMember2025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2022-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredInProcessResearchAndDevelopmentMember2022-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherIntangibleAssetsMember2022-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2023-01-012023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredInProcessResearchAndDevelopmentMember2023-01-012023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherIntangibleAssetsMember2023-01-012023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredInProcessResearchAndDevelopmentMember2023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherIntangibleAssetsMember2023-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2024-01-012024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredInProcessResearchAndDevelopmentMember2024-01-012024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherIntangibleAssetsMember2024-01-012024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredInProcessResearchAndDevelopmentMember2024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherIntangibleAssetsMember2024-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2025-01-012025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredInProcessResearchAndDevelopmentMember2025-01-012025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherIntangibleAssetsMember2025-01-012025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredResearchAndDevelopmentAvailableForUseMember2025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberargx:AcquiredInProcessResearchAndDevelopmentMember2025-12-310001697862ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherIntangibleAssetsMember2025-12-310001697862argx:AcquiredResearchAndDevelopmentAvailableForUseMember2023-12-310001697862argx:AcquiredInProcessResearchAndDevelopmentMember2023-12-310001697862ifrs-full:OtherIntangibleAssetsMember2023-12-310001697862argx:AcquiredResearchAndDevelopmentAvailableForUseMember2024-12-310001697862argx:AcquiredInProcessResearchAndDevelopmentMember2024-12-310001697862ifrs-full:OtherIntangibleAssetsMember2024-12-310001697862argx:AcquiredResearchAndDevelopmentAvailableForUseMember2025-12-310001697862argx:AcquiredInProcessResearchAndDevelopmentMember2025-12-310001697862ifrs-full:OtherIntangibleAssetsMember2025-12-310001697862argx:AcquiredInProcessResearchAndDevelopmentMember2023-01-012023-12-310001697862argx:AcquiredResearchAndDevelopmentAvailableForUseMember2023-01-012023-12-310001697862ifrs-full:OtherIntangibleAssetsMember2023-10-012023-12-3100016978622023-10-012023-12-310001697862srt:MinimumMember2025-01-012025-12-310001697862srt:MaximumMember2025-01-012025-12-310001697862argx:PreferredClassCSharesMemberargx:AgomAbTherapeuticsNVMember2023-10-012023-10-310001697862argx:PreferredClassDSharesMemberargx:AgomAbTherapeuticsNVMember2024-10-012024-10-310001697862argx:ZaiLabMember2021-12-310001697862argx:ZaiLabMember2021-01-012021-12-310001697862argx:PreLaunchInventoryAwaitingFacilityApprovalMember2025-12-310001697862argx:PreLaunchInventoryAwaitingFacilityApprovalMember2024-12-310001697862argx:PreLaunchInventoryAwaitingFacilityApprovalMember2023-12-310001697862argx:TermAccountsMember2025-12-310001697862argx:TermAccountsMember2024-12-310001697862argx:TermAccountsMember2023-12-310001697862currency:EUR2025-12-310001697862currency:EUR2024-12-310001697862currency:EUR2023-12-310001697862argx:GlobalOfferingMember2023-01-012023-12-310001697862argx:UnderwritersOverAllotmentOptionMember2023-01-012023-12-310001697862argx:GlobalOfferingMember2023-07-180001697862argx:AmericanDepositarySharesMemberargx:GlobalOfferingMember2023-07-180001697862argx:AmericanDepositarySharesMemberargx:GlobalOfferingMember2023-07-182023-07-180001697862ifrs-full:OrdinarySharesMemberargx:GlobalOfferingMember2023-07-180001697862ifrs-full:OrdinarySharesMemberargx:GlobalOfferingMember2023-07-182023-07-180001697862argx:AmericanDepositarySharesMemberargx:UnderwritersOverAllotmentOptionMember2023-07-190001697862argx:AmericanDepositarySharesMemberargx:UnderwritersOverAllotmentOptionMember2023-07-192023-07-1900016978622025-05-272025-05-270001697862argx:ShareBasedCompensationAwardsTrancheOneMember2025-01-012025-12-310001697862argx:ShareBasedCompensationAwardsTrancheTwoMember2025-01-012025-12-310001697862argx:StockOptionPlanMemberargx:NonExecutiveDirectorMember2025-01-012025-12-310001697862argx:RestrictedStockUnitsRSUsMemberargx:NonExecutiveDirectorMember2024-01-012024-12-310001697862argx:RestrictedStockUnitsRSUsMember2025-01-012025-12-310001697862argx:A2.87Memberargx:A2024Member2025-12-310001697862argx:A2.87Memberargx:A2024Member2024-12-310001697862argx:A2.87Memberargx:A2024Member2023-12-310001697862argx:A4.64Memberargx:A2024Member2025-12-310001697862argx:A4.64Memberargx:A2024Member2024-12-310001697862argx:A4.64Memberargx:A2024Member2023-12-310001697862argx:A8.43Memberargx:A2024Member2025-12-310001697862argx:A8.43Memberargx:A2024Member2024-12-310001697862argx:A8.43Memberargx:A2024Member2023-12-310001697862argx:A13.44Memberargx:A2025Member2025-12-310001697862argx:A13.44Memberargx:A2025Member2024-12-310001697862argx:A13.44Memberargx:A2025Member2023-12-310001697862argx:A11.13Memberargx:A2025Member2025-12-310001697862argx:A11.13Memberargx:A2025Member2024-12-310001697862argx:A11.13Memberargx:A2025Member2023-12-310001697862argx:A13.48Memberargx:A2026Member2025-12-310001697862argx:A13.48Memberargx:A2026Member2024-12-310001697862argx:A13.48Memberargx:A2026Member2023-12-310001697862argx:A13.37Memberargx:A2026Member2025-12-310001697862argx:A13.37Memberargx:A2026Member2024-12-310001697862argx:A13.37Memberargx:A2026Member2023-12-310001697862argx:A16.61Memberargx:A2026Member2025-12-310001697862argx:A16.61Memberargx:A2026Member2024-12-310001697862argx:A16.61Memberargx:A2026Member2023-12-310001697862argx:A21.63Memberargx:A2027Member2025-12-310001697862argx:A21.63Memberargx:A2027Member2024-12-310001697862argx:A21.63Memberargx:A2027Member2023-12-310001697862argx:A24.87Memberargx:A2027Member2025-12-310001697862argx:A24.87Memberargx:A2027Member2024-12-310001697862argx:A24.87Memberargx:A2027Member2023-12-310001697862argx:A94.96Memberargx:A2028Member2025-12-310001697862argx:A94.96Memberargx:A2028Member2024-12-310001697862argx:A94.96Memberargx:A2028Member2023-12-310001697862argx:A101.43Memberargx:A2028Member2025-12-310001697862argx:A101.43Memberargx:A2028Member2024-12-310001697862argx:A101.43Memberargx:A2028Member2023-12-310001697862argx:A133.35Memberargx:A2024Member2025-12-310001697862argx:A133.35Memberargx:A2024Member2024-12-310001697862argx:A133.35Memberargx:A2024Member2023-12-310001697862argx:A133.35Memberargx:A2029Member2025-12-310001697862argx:A133.35Memberargx:A2029Member2024-12-310001697862argx:A133.35Memberargx:A2029Member2023-12-310001697862argx:A159.51Memberargx:A2024Member2025-12-310001697862argx:A159.51Memberargx:A2024Member2024-12-310001697862argx:A159.51Memberargx:A2024Member2023-12-310001697862argx:A159.51Memberargx:A2029Member2025-12-310001697862argx:A159.51Memberargx:A2029Member2024-12-310001697862argx:A159.51Memberargx:A2029Member2023-12-310001697862argx:A140.45Memberargx:A2025Member2025-12-310001697862argx:A140.45Memberargx:A2025Member2024-12-310001697862argx:A140.45Memberargx:A2025Member2023-12-310001697862argx:A140.45Memberargx:A2030Member2025-12-310001697862argx:A140.45Memberargx:A2030Member2024-12-310001697862argx:A140.45Memberargx:A2030Member2023-12-310001697862argx:A230.48Memberargx:A2025Member2025-12-310001697862argx:A230.48Memberargx:A2025Member2024-12-310001697862argx:A230.48Memberargx:A2025Member2023-12-310001697862argx:A230.48Memberargx:A2030Member2025-12-310001697862argx:A230.48Memberargx:A2030Member2024-12-310001697862argx:A230.48Memberargx:A2030Member2023-12-310001697862argx:A235.26Memberargx:A2025Member2025-12-310001697862argx:A235.26Memberargx:A2025Member2024-12-310001697862argx:A235.26Memberargx:A2025Member2023-12-310001697862argx:A235.26Memberargx:A2030Member2025-12-310001697862argx:A235.26Memberargx:A2030Member2024-12-310001697862argx:A235.26Memberargx:A2030Member2023-12-310001697862argx:A290.93Memberargx:A2025Member2025-12-310001697862argx:A290.93Memberargx:A2025Member2024-12-310001697862argx:A290.93Memberargx:A2025Member2023-12-310001697862argx:A290.93Memberargx:A2030Member2025-12-310001697862argx:A290.93Memberargx:A2030Member2024-12-310001697862argx:A290.93Memberargx:A2030Member2023-12-310001697862argx:A275.42Memberargx:A2026Member2025-12-310001697862argx:A275.42Memberargx:A2026Member2024-12-310001697862argx:A275.42Memberargx:A2026Member2023-12-310001697862argx:A275.42Memberargx:A2031Member2025-12-310001697862argx:A275.42Memberargx:A2031Member2024-12-310001697862argx:A275.42Memberargx:A2031Member2023-12-310001697862argx:A299.74Memberargx:A2026Member2025-12-310001697862argx:A299.74Memberargx:A2026Member2024-12-310001697862argx:A299.74Memberargx:A2026Member2023-12-310001697862argx:A299.74Memberargx:A2031Member2025-12-310001697862argx:A299.74Memberargx:A2031Member2024-12-310001697862argx:A299.74Memberargx:A2031Member2023-12-310001697862argx:A304.91Memberargx:A2026Member2025-12-310001697862argx:A304.91Memberargx:A2026Member2024-12-310001697862argx:A304.91Memberargx:A2026Member2023-12-310001697862argx:A304.91Memberargx:A2031Member2025-12-310001697862argx:A304.91Memberargx:A2031Member2024-12-310001697862argx:A304.91Memberargx:A2031Member2023-12-310001697862argx:A363.31Memberargx:A2025Member2025-12-310001697862argx:A363.31Memberargx:A2025Member2024-12-310001697862argx:A363.31Memberargx:A2025Member2023-12-310001697862argx:A363.31Memberargx:A2026Member2025-12-310001697862argx:A363.31Memberargx:A2026Member2024-12-310001697862argx:A363.31Memberargx:A2026Member2023-12-310001697862argx:A363.31Memberargx:A2031Member2025-12-310001697862argx:A363.31Memberargx:A2031Member2024-12-310001697862argx:A363.31Memberargx:A2031Member2023-12-310001697862argx:A331.94Memberargx:A2027Member2025-12-310001697862argx:A331.94Memberargx:A2027Member2024-12-310001697862argx:A331.94Memberargx:A2027Member2023-12-310001697862argx:A331.94Memberargx:A2032Member2025-12-310001697862argx:A331.94Memberargx:A2032Member2024-12-310001697862argx:A331.94Memberargx:A2032Member2023-12-310001697862argx:A420.06Memberargx:A2027Member2025-12-310001697862argx:A420.06Memberargx:A2027Member2024-12-310001697862argx:A420.06Memberargx:A2027Member2023-12-310001697862argx:A420.06Memberargx:A2032Member2025-12-310001697862argx:A420.06Memberargx:A2032Member2024-12-310001697862argx:A420.06Memberargx:A2032Member2023-12-310001697862argx:A432.99Memberargx:A2027Member2025-12-310001697862argx:A432.99Memberargx:A2027Member2024-12-310001697862argx:A432.99Memberargx:A2027Member2023-12-310001697862argx:A432.99Memberargx:A2032Member2025-12-310001697862argx:A432.99Memberargx:A2032Member2024-12-310001697862argx:A432.99Memberargx:A2032Member2023-12-310001697862argx:A422.53Memberargx:A2027Member2025-12-310001697862argx:A422.53Memberargx:A2027Member2024-12-310001697862argx:A422.53Memberargx:A2027Member2023-12-310001697862argx:A422.53Memberargx:A2032Member2025-12-310001697862argx:A422.53Memberargx:A2032Member2024-12-310001697862argx:A422.53Memberargx:A2032Member2023-12-310001697862argx:A400.32Memberargx:A2028Member2025-12-310001697862argx:A400.32Memberargx:A2028Member2024-12-310001697862argx:A400.32Memberargx:A2028Member2023-12-310001697862argx:A400.32Memberargx:A2033Member2025-12-310001697862argx:A400.32Memberargx:A2033Member2024-12-310001697862argx:A400.32Memberargx:A2033Member2023-12-310001697862argx:A417.60Memberargx:A2028Member2025-12-310001697862argx:A417.60Memberargx:A2028Member2024-12-310001697862argx:A417.60Memberargx:A2028Member2023-12-310001697862argx:A417.60Memberargx:A2033Member2025-12-310001697862argx:A417.60Memberargx:A2033Member2024-12-310001697862argx:A417.60Memberargx:A2033Member2023-12-310001697862argx:A541.21Memberargx:A2028Member2025-12-310001697862argx:A541.21Memberargx:A2028Member2024-12-310001697862argx:A541.21Memberargx:A2028Member2023-12-310001697862argx:A541.21Memberargx:A2033Member2025-12-310001697862argx:A541.21Memberargx:A2033Member2024-12-310001697862argx:A541.21Memberargx:A2033Member2023-12-310001697862argx:A350.97Memberargx:A2028Member2025-12-310001697862argx:A350.97Memberargx:A2028Member2024-12-310001697862argx:A350.97Memberargx:A2028Member2023-12-310001697862argx:A350.97Memberargx:A2033Member2025-12-310001697862argx:A350.97Memberargx:A2033Member2024-12-310001697862argx:A350.97Memberargx:A2033Member2023-12-310001697862argx:A430.17Memberargx:A2029Member2025-12-310001697862argx:A430.17Memberargx:A2029Member2024-12-310001697862argx:A430.17Memberargx:A2029Member2023-12-310001697862argx:A430.17Memberargx:A2034Member2025-12-310001697862argx:A430.17Memberargx:A2034Member2024-12-310001697862argx:A430.17Memberargx:A2034Member2023-12-310001697862argx:A489.27Memberargx:A2029Member2025-12-310001697862argx:A489.27Memberargx:A2029Member2024-12-310001697862argx:A489.27Memberargx:A2029Member2023-12-310001697862argx:A489.27Memberargx:A2034Member2025-12-310001697862argx:A489.27Memberargx:A2034Member2024-12-310001697862argx:A489.27Memberargx:A2034Member2023-12-310001697862argx:A562.47Memberargx:A2029Member2025-12-310001697862argx:A562.47Memberargx:A2029Member2024-12-310001697862argx:A562.47Memberargx:A2029Member2023-12-310001697862argx:A562.47Memberargx:A2034Member2025-12-310001697862argx:A562.47Memberargx:A2034Member2024-12-310001697862argx:A562.47Memberargx:A2034Member2023-12-310001697862argx:A699.60Memberargx:A2029Member2025-12-310001697862argx:A699.60Memberargx:A2029Member2024-12-310001697862argx:A699.60Memberargx:A2029Member2023-12-310001697862argx:A699.60Memberargx:A2034Member2025-12-310001697862argx:A699.60Memberargx:A2034Member2024-12-310001697862argx:A699.60Memberargx:A2034Member2023-12-310001697862argx:A648.60Memberargx:A2030Member2025-12-310001697862argx:A648.60Memberargx:A2030Member2024-12-310001697862argx:A648.60Memberargx:A2030Member2023-12-310001697862argx:A648.60Memberargx:A2035Member2025-12-310001697862argx:A648.60Memberargx:A2035Member2024-12-310001697862argx:A648.60Memberargx:A2035Member2023-12-310001697862argx:A563.18Memberargx:A2030Member2025-12-310001697862argx:A563.18Memberargx:A2030Member2024-12-310001697862argx:A563.18Memberargx:A2030Member2023-12-310001697862argx:A563.18Memberargx:A2035Member2025-12-310001697862argx:A563.18Memberargx:A2035Member2024-12-310001697862argx:A563.18Memberargx:A2035Member2023-12-310001697862argx:A718.16Memberargx:A2030Member2025-12-310001697862argx:A718.16Memberargx:A2030Member2024-12-310001697862argx:A718.16Memberargx:A2030Member2023-12-310001697862argx:A718.16Memberargx:A2035Member2025-12-310001697862argx:A718.16Memberargx:A2035Member2024-12-310001697862argx:A718.16Memberargx:A2035Member2023-12-310001697862argx:A837.78Memberargx:A20302035Member2025-12-310001697862argx:A837.78Memberargx:A20302035Member2024-12-310001697862argx:A837.78Memberargx:A20302035Member2023-12-310001697862argx:BelgianTaxedBeneficiariesMemberifrs-full:BottomOfRangeMember2025-12-012025-12-310001697862argx:BelgianTaxedBeneficiariesMemberifrs-full:TopOfRangeMember2025-12-012025-12-310001697862argx:ExercisePrice13.3716.61Memberifrs-full:BottomOfRangeMember2025-12-310001697862argx:ExercisePrice13.3716.61Memberifrs-full:TopOfRangeMember2025-12-310001697862argx:ExercisePrice13.3716.61Member2025-12-310001697862argx:ExercisePrice13.3716.61Member2025-01-012025-12-310001697862argx:ExercisePrice21.6324.87Memberifrs-full:BottomOfRangeMember2025-12-310001697862argx:ExercisePrice21.6324.87Memberifrs-full:TopOfRangeMember2025-12-310001697862argx:ExercisePrice21.6324.87Member2025-12-310001697862argx:ExercisePrice21.6324.87Member2025-01-012025-12-310001697862argx:ExercisePrice94.96101.43Memberifrs-full:BottomOfRangeMember2025-12-310001697862argx:ExercisePrice94.96101.43Memberifrs-full:TopOfRangeMember2025-12-310001697862argx:ExercisePrice94.96101.43Member2025-12-310001697862argx:ExercisePrice94.96101.43Member2025-01-012025-12-310001697862argx:ExercisePrice133.35159.51Memberifrs-full:BottomOfRangeMember2025-12-310001697862argx:ExercisePrice133.35159.51Memberifrs-full:TopOfRangeMember2025-12-310001697862argx:ExercisePrice133.35159.51Member2025-12-310001697862argx:ExercisePrice133.35159.51Member2025-01-012025-12-310001697862argx:ExercisePrice140.45290.93Memberifrs-full:BottomOfRangeMember2025-12-310001697862argx:ExercisePrice140.45290.93Memberifrs-full:TopOfRangeMember2025-12-310001697862argx:ExercisePrice140.45290.93Member2025-12-310001697862argx:ExercisePrice140.45290.93Member2025-01-012025-12-310001697862argx:ExercisePrice275.42363.31Memberifrs-full:BottomOfRangeMember2025-12-310001697862argx:ExercisePrice275.42363.31Memberifrs-full:TopOfRangeMember2025-12-310001697862argx:ExercisePrice275.42363.31Member2025-12-310001697862argx:ExercisePrice275.42363.31Member2025-01-012025-12-310001697862argx:ExercisePrice331.94432.99Memberifrs-full:BottomOfRangeMember2025-12-310001697862argx:ExercisePrice331.94432.99Memberifrs-full:TopOfRangeMember2025-12-310001697862argx:ExercisePrice331.94432.99Member2025-12-310001697862argx:ExercisePrice331.94432.99Member2025-01-012025-12-310001697862argx:ExercisePrice350.97541.21Memberifrs-full:BottomOfRangeMember2025-12-310001697862argx:ExercisePrice350.97541.21Memberifrs-full:TopOfRangeMember2025-12-310001697862argx:ExercisePrice350.97541.21Member2025-12-310001697862argx:ExercisePrice350.97541.21Member2025-01-012025-12-310001697862argx:ExercisePrice430.17699.60Memberifrs-full:BottomOfRangeMember2025-12-310001697862argx:ExercisePrice430.17699.60Memberifrs-full:TopOfRangeMember2025-12-310001697862argx:ExercisePrice430.17699.60Member2025-12-310001697862argx:ExercisePrice430.17699.60Member2025-01-012025-12-310001697862argx:ExercisePrice563.18837.78Memberifrs-full:BottomOfRangeMember2025-12-310001697862argx:ExercisePrice563.18837.78Memberifrs-full:TopOfRangeMember2025-12-310001697862argx:ExercisePrice563.18837.78Member2025-12-310001697862argx:ExercisePrice563.18837.78Member2025-01-012025-12-3100016978622025-03-012025-03-3100016978622025-06-012025-06-3000016978622025-09-012025-09-3000016978622025-12-012025-12-310001697862ifrs-full:BottomOfRangeMember2025-03-012025-03-310001697862ifrs-full:TopOfRangeMember2025-03-012025-03-310001697862ifrs-full:BottomOfRangeMember2025-06-012025-06-300001697862ifrs-full:TopOfRangeMember2025-06-012025-06-300001697862ifrs-full:BottomOfRangeMember2025-09-012025-09-300001697862ifrs-full:TopOfRangeMember2025-09-012025-09-300001697862ifrs-full:BottomOfRangeMember2025-12-012025-12-310001697862ifrs-full:TopOfRangeMember2025-12-012025-12-3100016978622025-03-3100016978622025-06-3000016978622025-09-300001697862argx:BelgianTaxedBeneficiariesMember2025-12-012025-12-310001697862argx:BelgianTaxedBeneficiariesMemberifrs-full:BottomOfRangeMember2025-12-012025-12-310001697862argx:BelgianTaxedBeneficiariesMemberifrs-full:TopOfRangeMember2025-12-012025-12-310001697862argx:BelgianTaxedBeneficiariesMemberifrs-full:BottomOfRangeMember2025-01-012025-12-310001697862argx:BelgianTaxedBeneficiariesMemberifrs-full:TopOfRangeMember2025-01-012025-12-3100016978622024-04-012024-04-3000016978622024-06-012024-06-3000016978622024-09-012024-09-3000016978622024-12-012024-12-310001697862ifrs-full:BottomOfRangeMember2024-04-012024-04-300001697862ifrs-full:TopOfRangeMember2024-04-012024-04-300001697862ifrs-full:BottomOfRangeMember2024-06-012024-06-300001697862ifrs-full:TopOfRangeMember2024-06-012024-06-300001697862ifrs-full:BottomOfRangeMember2024-09-012024-09-300001697862ifrs-full:TopOfRangeMember2024-09-012024-09-300001697862ifrs-full:BottomOfRangeMember2024-12-012024-12-310001697862ifrs-full:TopOfRangeMember2024-12-012024-12-3100016978622024-04-3000016978622024-06-3000016978622024-09-300001697862argx:BelgianTaxedBeneficiariesMemberifrs-full:BottomOfRangeMember2024-12-012024-12-310001697862argx:BelgianTaxedBeneficiariesMemberifrs-full:TopOfRangeMember2024-12-012024-12-3100016978622023-04-012023-04-3000016978622023-07-012023-07-3100016978622023-10-012023-10-3100016978622023-12-012023-12-310001697862ifrs-full:BottomOfRangeMember2023-04-012023-04-300001697862ifrs-full:TopOfRangeMember2023-04-012023-04-300001697862ifrs-full:BottomOfRangeMember2023-07-012023-07-310001697862ifrs-full:TopOfRangeMember2023-07-012023-07-310001697862ifrs-full:BottomOfRangeMember2023-10-012023-10-310001697862ifrs-full:TopOfRangeMember2023-10-012023-10-310001697862ifrs-full:BottomOfRangeMember2023-12-012023-12-310001697862ifrs-full:TopOfRangeMember2023-12-012023-12-3100016978622023-04-3000016978622023-07-3100016978622023-10-310001697862argx:RestrictedStockUnitsRSUsMemberargx:NonExecutiveDirectorMember2025-01-012025-12-310001697862argx:RestrictedStockUnitsRSUsMember2024-12-310001697862argx:RestrictedStockUnitsRSUsMember2023-12-310001697862argx:RestrictedStockUnitsRSUsMember2022-12-310001697862argx:RestrictedStockUnitsRSUsMember2024-01-012024-12-310001697862argx:RestrictedStockUnitsRSUsMember2023-01-012023-12-310001697862argx:RestrictedStockUnitsRSUsMember2025-12-310001697862argx:PerformanceStockUnitsPSUsMember2025-01-012025-12-310001697862argx:PerformanceStockUnitsPSUsMember2025-06-302025-06-300001697862argx:PerformanceStockUnitsPSUsMember2024-12-310001697862argx:PerformanceStockUnitsPSUsMember2025-12-310001697862argx:RebatesAndChargeBacksMember2022-12-310001697862argx:DistributionFeesAndProductReturnsMember2022-12-310001697862argx:RebatesAndChargeBacksMember2023-01-012023-12-310001697862argx:DistributionFeesAndProductReturnsMember2023-01-012023-12-310001697862argx:RebatesAndChargeBacksMember2023-12-310001697862argx:DistributionFeesAndProductReturnsMember2023-12-310001697862argx:RebatesAndChargeBacksMember2024-01-012024-12-310001697862argx:DistributionFeesAndProductReturnsMember2024-01-012024-12-310001697862argx:RebatesAndChargeBacksMember2024-12-310001697862argx:DistributionFeesAndProductReturnsMember2024-12-310001697862argx:RebatesAndChargeBacksMember2025-01-012025-12-310001697862argx:DistributionFeesAndProductReturnsMember2025-01-012025-12-310001697862argx:RebatesAndChargeBacksMember2025-12-310001697862argx:DistributionFeesAndProductReturnsMember2025-12-310001697862argx:AbbVieMember2023-10-012023-10-310001697862country:US2025-01-012025-12-310001697862country:US2024-01-012024-12-310001697862country:US2023-01-012023-12-310001697862country:JP2025-01-012025-12-310001697862country:JP2024-01-012024-12-310001697862country:JP2023-01-012023-12-310001697862country:CN2025-01-012025-12-310001697862country:CN2024-01-012024-12-310001697862country:CN2023-01-012023-12-310001697862argx:RestOfTheWorldMember2025-01-012025-12-310001697862argx:RestOfTheWorldMember2024-01-012024-12-310001697862argx:RestOfTheWorldMember2023-01-012023-12-310001697862argx:FourCustomersMember2025-01-012025-12-310001697862argx:FiveCustomersMember2024-01-012024-12-310001697862argx:FourCustomersMember2023-01-012023-12-310001697862country:BE2025-12-310001697862country:BE2024-12-310001697862country:BE2023-12-310001697862country:US2025-12-310001697862country:US2024-12-310001697862country:US2023-12-310001697862country:JP2025-12-310001697862country:JP2024-12-310001697862country:JP2023-12-310001697862argx:RestOfTheWorldMember2025-12-310001697862argx:RestOfTheWorldMember2024-12-310001697862argx:RestOfTheWorldMember2023-12-310001697862ifrs-full:PreviouslyStatedMember2023-01-012023-12-310001697862ifrs-full:BuildingsMember2025-12-310001697862ifrs-full:BuildingsMember2024-12-310001697862ifrs-full:BuildingsMember2023-12-310001697862ifrs-full:VehiclesMember2025-12-310001697862ifrs-full:VehiclesMember2024-12-310001697862ifrs-full:VehiclesMember2023-12-310001697862argx:LeaseEquipmentMember2025-12-310001697862argx:LeaseEquipmentMember2024-12-310001697862argx:LeaseEquipmentMember2023-12-310001697862ifrs-full:NotLaterThanOneYearMember2025-12-310001697862ifrs-full:NotLaterThanOneYearMember2024-12-310001697862ifrs-full:NotLaterThanOneYearMember2023-12-310001697862ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2025-12-310001697862ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2024-12-310001697862ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2023-12-310001697862ifrs-full:LaterThanFiveYearsMember2025-12-310001697862ifrs-full:LaterThanFiveYearsMember2024-12-310001697862ifrs-full:LaterThanFiveYearsMember2023-12-310001697862ifrs-full:BuildingsMember2025-01-012025-12-310001697862ifrs-full:BuildingsMember2024-01-012024-12-310001697862ifrs-full:BuildingsMember2023-01-012023-12-310001697862ifrs-full:VehiclesMember2025-01-012025-12-310001697862ifrs-full:VehiclesMember2024-01-012024-12-310001697862ifrs-full:VehiclesMember2023-01-012023-12-310001697862argx:LeaseEquipmentMember2025-01-012025-12-310001697862argx:LeaseEquipmentMember2024-01-012024-12-310001697862argx:LeaseEquipmentMember2023-01-012023-12-3100016978622024-10-012024-12-310001697862argx:InnovationIncomeDeductionMember2025-12-310001697862argx:NetOperatingLossCarryforwardsMember2025-12-310001697862argx:RDCapitalizedExpenseMember2025-12-310001697862argx:IntangibleAssetsMember2025-12-310001697862ifrs-full:AllowanceForCreditLossesMember2025-12-310001697862argx:IncomeTaxBenefitRelatedToShareBasedPaymentsMember2025-12-310001697862argx:ProfitInInventoryMember2025-12-310001697862argx:OtherTaxCarryForwardsMember2025-12-310001697862argx:PropertyPlantAndEquipmentsMember2025-12-310001697862argx:NonCurrentFixedAssetsMember2025-12-310001697862ifrs-full:OtherTemporaryDifferencesMember2025-12-310001697862argx:NettingByTaxableEntityMember2025-12-310001697862argx:InnovationIncomeDeductionMember2024-12-310001697862argx:NetOperatingLossCarryforwardsMember2024-12-310001697862argx:RDCapitalizedExpenseMember2024-12-310001697862argx:IntangibleAssetsMember2024-12-310001697862ifrs-full:AllowanceForCreditLossesMember2024-12-310001697862argx:IncomeTaxBenefitRelatedToShareBasedPaymentsMember2024-12-310001697862argx:ProfitInInventoryMember2024-12-310001697862argx:OtherTaxCarryForwardsMember2024-12-310001697862argx:PropertyPlantAndEquipmentsMember2024-12-310001697862argx:NonCurrentFixedAssetsMember2024-12-310001697862ifrs-full:OtherTemporaryDifferencesMember2024-12-310001697862argx:NettingByTaxableEntityMember2024-12-310001697862ifrs-full:AllowanceForCreditLossesMember2023-12-310001697862argx:IncomeTaxBenefitRelatedToShareBasedPaymentsMember2023-12-310001697862argx:ProfitInInventoryMember2023-12-310001697862argx:OtherTaxCarryForwardsMember2023-12-310001697862argx:PropertyPlantAndEquipmentsMember2023-12-310001697862argx:NonCurrentFixedAssetsMember2023-12-310001697862ifrs-full:OtherTemporaryDifferencesMember2023-12-310001697862argx:NettingByTaxableEntityMember2023-12-310001697862ifrs-full:CountryOfDomicileMember2025-12-310001697862ifrs-full:CountryOfDomicileMember2024-12-310001697862ifrs-full:CountryOfDomicileMember2023-12-310001697862ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberargx:FinancialAssetsNonCurrentMember2025-12-310001697862ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberargx:FinancialAssetsNonCurrentMember2024-12-310001697862ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberargx:FinancialAssetsNonCurrentMember2023-12-310001697862ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberargx:FinancialAssetsNonCurrentMember2025-12-310001697862ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberargx:FinancialAssetsNonCurrentMember2024-12-310001697862ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMemberargx:FinancialAssetsNonCurrentMember2023-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:ResearchAndDevelopmentIncentiveReceivablesNonCurrentMemberMember2025-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:ResearchAndDevelopmentIncentiveReceivablesNonCurrentMemberMember2024-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:ResearchAndDevelopmentIncentiveReceivablesNonCurrentMemberMember2023-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:NoncurrentRestrictedAssetsMember2025-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:NoncurrentRestrictedAssetsMember2024-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:NoncurrentRestrictedAssetsMember2023-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:TradeAndOtherReceivablesMember2025-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:TradeAndOtherReceivablesMember2024-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:TradeAndOtherReceivablesMember2023-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:CurrentFinancialAssetsMember2025-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:CurrentFinancialAssetsMember2024-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:CurrentFinancialAssetsMember2023-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:CurrentResearchAndDevelopmentIncentiveReceivablesMember2025-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:CurrentResearchAndDevelopmentIncentiveReceivablesMember2024-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:CurrentResearchAndDevelopmentIncentiveReceivablesMember2023-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:CashAndCashEquivalents1Member2025-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:CashAndCashEquivalents1Member2024-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:CashAndCashEquivalents1Member2023-12-310001697862ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberargx:CashEquivalents1Member2025-12-310001697862ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberargx:CashEquivalents1Member2024-12-310001697862ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberargx:CashEquivalents1Member2023-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:CashEquivalents1Member2025-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:CashEquivalents1Member2024-12-310001697862ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberargx:CashEquivalents1Member2023-12-310001697862ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberargx:TradeAndOtherPayablesMember2025-12-310001697862ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberargx:TradeAndOtherPayablesMember2024-12-310001697862ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberargx:TradeAndOtherPayablesMember2023-12-310001697862ifrs-full:Level1OfFairValueHierarchyMember2025-12-310001697862ifrs-full:Level2OfFairValueHierarchyMember2025-12-310001697862ifrs-full:Level3OfFairValueHierarchyMember2025-12-310001697862ifrs-full:Level1OfFairValueHierarchyMember2024-12-310001697862ifrs-full:Level2OfFairValueHierarchyMember2024-12-310001697862ifrs-full:Level3OfFairValueHierarchyMember2024-12-310001697862ifrs-full:Level1OfFairValueHierarchyMember2023-12-310001697862ifrs-full:Level2OfFairValueHierarchyMember2023-12-310001697862ifrs-full:Level3OfFairValueHierarchyMember2023-12-310001697862ifrs-full:InterestRateRiskMember2025-01-012025-12-310001697862ifrs-full:InterestRateRiskMember2024-01-012024-12-310001697862ifrs-full:InterestRateRiskMember2023-01-012023-12-310001697862ifrs-full:CurrencyRiskMembercurrency:EUR2025-12-310001697862ifrs-full:CurrencyRiskMembercurrency:EUR2024-12-310001697862ifrs-full:CurrencyRiskMembercurrency:EUR2023-12-310001697862ifrs-full:CurrencyRiskMemberargx:OtherCurrenciesMember2025-12-310001697862ifrs-full:CurrencyRiskMemberargx:OtherCurrenciesMember2024-12-310001697862ifrs-full:CurrencyRiskMemberargx:OtherCurrenciesMember2023-12-310001697862argx:OncoVerityInc.JointVentureMember2025-12-310001697862argx:OncoVerityInc.JointVentureMember2024-12-310001697862argx:OncoVerityInc.JointVentureMember2023-12-310001697862argx:SeniorManagementMember2025-12-310001697862argx:NonExecutiveDirectorsMember2025-12-310001697862argx:SeniorManagementMember2025-01-012025-12-310001697862argx:SeniorManagementMember2024-01-012024-12-310001697862argx:SeniorManagementMember2023-01-012023-12-310001697862argx:RestrictedStockUnitsRSUsMemberargx:SeniorManagementMember2025-01-012025-12-310001697862argx:RestrictedStockUnitsRSUsMemberargx:SeniorManagementMember2024-01-012024-12-310001697862argx:RestrictedStockUnitsRSUsMemberargx:SeniorManagementMember2023-01-012023-12-310001697862argx:PerformanceStockUnitsPSUsMemberargx:SeniorManagementMember2025-01-012025-12-310001697862argx:PerformanceStockUnitsPSUsMemberargx:SeniorManagementMember2024-01-012024-12-310001697862argx:PerformanceStockUnitsPSUsMemberargx:SeniorManagementMember2023-01-012023-12-310001697862argx:NonExecutiveDirectorsMember2025-01-012025-12-310001697862argx:NonExecutiveDirectorsMember2024-01-012024-12-310001697862argx:NonExecutiveDirectorsMember2023-01-012023-12-310001697862argx:HalozymeTherapeuticsIncMember2019-02-280001697862argx:EfgartigimodMemberargx:LonzaAndFujifilmMember2025-12-310001697862argx:EYAccountantsB.V.Member2025-01-012025-12-310001697862argx:ARGENXBVSubsidiaryMember2025-12-310001697862argx:ArgenxBVMember2025-12-310001697862argx:ARGENXSEMembercountry:NL2025-01-012025-12-310001697862argx:ARGENXBVSubsidiaryMembercountry:BE2025-01-012025-12-310001697862argx:ArgenxBeneluxB.V.Membercountry:BE2025-01-012025-12-310001697862argx:ARGENXUSINCMembercountry:US2025-01-012025-12-310001697862argx:ArgenxAustraliaPty.LtdMembercountry:AU2025-01-012025-12-310001697862argx:ArgenxAustriaServicesGmbHMembercountry:AT2025-01-012025-12-310001697862argx:ArgenxBrasilProdutosFarmaceuticosLtdaMembercountry:BR2025-01-012025-12-310001697862argx:ArgenxCanadaIncMembercountry:CA2025-01-012025-12-310001697862argx:ARGENXFRANCESASMembercountry:FR2025-01-012025-12-310001697862argx:ARGENXGERMANYGMBHMembercountry:DE2025-01-012025-12-310001697862argx:ArgenxItalyMembercountry:IT2025-01-012025-12-310001697862argx:ARGENXJAPANKKMembercountry:JP2025-01-012025-12-310001697862argx:ArgenxNetherlandsB.vMembercountry:NL2025-01-012025-12-310001697862argx:ArgenxSpainS.l.Membercountry:ES2025-01-012025-12-310001697862argx:ArgenxSpainS.L.SucursalEmPortugalMembercountry:PT2025-01-012025-12-310001697862argx:ArgenxSwitzerlandS.A.Membercountry:CH2025-01-012025-12-310001697862argx:ArgenxUKLtd.Membercountry:GB2025-01-012025-12-310001697862argx:BroteioPharmaB.V.Membercountry:NL2025-01-012025-12-31
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 20-F
(Mark One)
☐REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES
EXCHANGE ACT OF 1934
OR
☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended December 31, 2025
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from __________ to __________
OR
☐SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Date of event requiring this shell company report __________
Commission file number 001-38097
ARGENX SE
(Exact name of registrant as specified in its charter and translation of Registrant’s name into English)
The Netherlands
(Jurisdiction of incorporation or organization)
Laarderhoogtweg 25
1101 EB,  Amsterdam, The Netherlands
(Address of principal executive offices)
Tim Van Hauwermeiren
argenx BV
Industriepark Zwijnaarde 7,
Building C
9052 Zwijnaarde(Ghent)
Belgium
+31(0)10 70 38 441
TVanHauwermeiren@argenx.com
(Name, telephone, e-mail and/or facsimile number and address of company contact person)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading
Name of each exchange on which registered:
Symbol:
American Depositary Shares, each representing one ordinary share with a nominal value of €0.10 per share
ARGX
Nasdaq Global Select Market
Ordinary shares with a nominal value of €0.10 per share*
Nasdaq Global Select Market*
* Not for trading, but only in connection with the registration of the American Depositary Shares.
Securities registered or to be registered pursuant to Section 12(g) of the Act: None.
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None.
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report:
As of December 31, 2025
61,883,306 ordinary shares were outstanding, including ordinary shares represented by American Depositary Shares.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act
Yes ☒ No ☐
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of “large accelerated filer,”
“accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☒
Accelerated filer ☐
Non-accelerated filer ☐
Emerging growth company ☐
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐
† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section
404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to
previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers
during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
International Financial Reporting Standards as issued
U.S. GAAP ☐
by the International Accounting Standards Board ☒
Other ☐
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.
Item 17 ☐ Item 18 ☐
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS.)
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution
of securities under a plan confirmed by a court.
Yes ☐ No ☐
ii
Table of Contents
TABLE OF CONTENTS
Page
iii
Table of Contents
iv
Table of Contents
Introduction
Unless otherwise indicated, “argenx,” “argenx SE,” “the Company,” “our company,” “we,” “us”, “our” our “Group”
refer to argenx SE and its consolidated subsidiaries.
We own various trademark registrations and applications, and unregistered trademarks, including but not limited to
VYVGART®, VYVGART HYTRULO™, VYVDURA®, ARGENX™, ABDEG™, NHANCE™, SIMPLE
ANTIBODY™, ARGENXMEDHUB™, MG UNITED™, SHINING THROUGH CIDP™, VYVIDLY™ and our
corporate logo. Trade names, trademarks and service marks of other companies appearing in this Annual Report are the
property of their respective holders. Solely for convenience, the trademarks and trade names in this Annual Report may
be referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their
respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use
or display other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship,
any other companies.
VYVGART® (efgartigimod alfa-fcab) (VYVGART) has been approved in the U.S., Japan, the European Union (the EU)
and several other countries such as the United Kingdom (UK), Switzerland, Israel, mainland China (Mainland China),
Canada, South Korea and United Arab Emirates for the intravenous treatment of generalized myasthenia gravis (gMG).
VYVGART is approved in Japan for the treatment of immune thrombocytopenia (ITP).
VYVGART subcutaneous (SC) (efgartigimod alfa + hyaluronidase qvfc) (VYVGART SC) has been approved in the
U.S. and China as VYVGART HYTRULO™ (VYVGART HYTRULO) and in several other countries, in Japan as
VYVDURA® (VYVDURA) and in the EU and the UK as VYVGART for the treatment of gMG. VYVGART SC has
also been approved in the U.S., China, Japan and the EU for the treatment of chronic inflammatory demyelinating
polyneuropathy (CIDP).
Lastly, VYVGART HYTRULO has also been approved as a prefilled syringe (PFS) in the U.S. for self-injection by
adult patients with gMG and CIDP.
For more information on the approval and commercialization status in several jurisdictions, please refer to “Item 4.B -
Our Products and Product Candidates”.
Unless otherwise specified, references in this Annual Report to VYVGART should be read as references to VYVGART
and/or VYVGART SC, including VYVGART HYTRULO in relation to the U.S. and China, VYVGART in relation to
the EU and the UK and VYVDURA in relation to Japan, depending on the context.
Our consolidated financial statements are prepared in accordance with the IFRS® Accounting Standards (IFRS) as issued
by the International Accounting Standards Board (IASB).
Our consolidated financial statements are presented in this Annual Report in U.S. dollars. All references in this Annual
Report to “$,” “US$,” “U.S.$,” “U.S. dollars,” “dollars” and “USD” mean U.S. dollars and all references to “€,” “EUR,”
and “euros” mean euros, unless otherwise noted. Throughout this Annual Report, references to ADSs mean American
depositary shares (ADSs) or ordinary shares represented by ADSs, as the case may be.
Cautionary Statement with Respect to Forward-Looking Statements
This Annual Report contains certain forward-looking statements. A forward-looking statement is any statement that does
not relate to historical facts or events or to facts or events as of the date of this Annual Report or that are derived from
our management’s beliefs and assumptions based on information currently available to our management. Forward-
looking statements are generally identified by the use of forward-looking words, such as “aim”, “anticipate”, “aspire”,
“believe”, “can”, “continue”, “could”, “estimate”, “expect”, “entail”, “forecast”, “future”, “goals”, “hope”, “intend”, “is
designed to”, “likely”, “may”, “might”, “objective”, “plan”, “potential”, “pursue”, “project”, “predict”, “seek”, “should”,
“strategy”, “target”, “will” or other or comparable variations or the negative of such terms, or by discussion of strategy,
plans, objectives, goals, future events or intentions, although not all forward-looking statements contain these identifying
words. These statements relate to our future results of operations and financial positions, prospects, developments,
growth, business strategies, plans and our objectives for future operations, results of clinical trials and regulatory
v
Table of Contents
approvals, and are based on analyses or forecasts of future developments and estimates of amounts not yet determinable.
These forward-looking statements represent the view of management only as of the date of this Annual Report, and we
expressly disclaim any obligation or undertaking to update, review or revise forward-looking statements (whether as a
result of new information, future developments or otherwise), except as may be otherwise required by applicable law.
The forward-looking statements in this Annual Report involve known and unknown risks, future events, assumptions,
uncertainties and other factors that could cause our actual future results of operations and financial positions, prospects,
developments, growth, business strategies, plans and our objectives for future operations, results of clinical trials and
regulatory approvals to differ materially from those forecasted or suggested herein.
Forward-looking statements include, but are not limited to, statements about: 
•the initiation, timing, progress, development and results of clinical trials of our product candidates, including new
indications, alternative dosing regimens, treatment modalities, and methods of administration, including statements
regarding when results or interim analysis of the clinical trials will be available or made public;
•the expansion of our business, including the further development of our sales and marketing abilities and our IIP, and
the value of our pipeline;
•the potential attributes, benefits, and side effects of our products and product candidates, including new indications,
alternative dosing regimens and treatment modalities, and their competitive position with respect to other alternative
treatments;
•our ability to advance product candidates into, and successfully complete, clinical trials;
•our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that
will enroll in our clinical trials;
•the demand and commercialization of our products and product candidates, including new indications, alternative
dosing regimens, treatment modalities, and methods of administration, if approved;
•the anticipated timing or likelihood of market or regulatory decisions relating to or of our products, including new
indications, alternative dosing regimens, treatment modalities, and methods of administration;
•the anticipated pricing and reimbursement of our products and product candidates, if approved;
•our plans to have various programs to help patients afford our products, including patient assistance and co-pay
coupon programs for eligible patients;
•our ability to establish sales, marketing and distribution capabilities for any of our products and product candidates
that achieve regulatory approval;
•our regulatory strategy and our ability to establish and maintain manufacturing arrangements for our products and
product candidates;
•the scope and duration of protection, including any exclusivity period, we are able to establish and maintain for
intellectual property rights covering our products and product candidates, platform and technology, including our
intention to seek patent term extensions where available;
•our estimates regarding expenses, future revenues, cash flow, capital requirements and our needs for additional
financing;
•our expectation that we will benefit from the Belgian innovation income deduction;
•our financial performance, including potential volatility in the price of our ordinary shares and ADSs;
•the competition we face in our drug discovery, development, and commercialization efforts;
•the rate and degree of market acceptance of our products and product candidates, if approved;
vi
Table of Contents
•the potential benefits of our current collaborations, including the possibility to access partner technology platforms or
capabilities;
•our plans and ability to enter into or maintain current collaborations for additional programs or product candidates;
•our plans and ability to enter into or maintain current new distribution partnerships;
•our long-term growth strategy to develop and market additional products and product candidates, including
efgartigimod for new indications, empasiprubart and adimanebart;
•the impact of government laws and regulations on our business;
•our expectations with respect to the timing and amount of any dividends (if any);
•our plans regarding our supply chain, including our reliance on third parties, including contract manufacturing
organizations (CMOs); and
•our business strategies, including Vision 2030, plans, projects, goals and targets and the timing, outcomes and
benefits thereof.
These include changes in general economic and business conditions. You should refer to ”Item 3.D — Risk Factors” of
this Annual Report for a discussion of important factors that may cause our actual results to differ materially from those
expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the
forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking
statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these
forward-looking statements, you should not regard these statements as a representation or warranty by us or any other
person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to
publicly update any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law.
You should read this Annual Report and the documents that we reference in this Annual Report and have filed as
exhibits to the Annual Report completely and with the understanding that our actual future results may be materially
different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
Information regarding market and industry statistics contained in this Annual Report is included based on information
available to us that we believe is accurate. Forecasts and other forward-looking information obtained from this available
information is subject to the same qualifications and the additional uncertainties accompanying any estimates of future
market size, revenue and market acceptance of products and services.
In addition, statements that include “we believe” and similar statements reflect our beliefs and opinions on the relevant
subject. These statements are based upon information available to us as of the date of this Annual Report, and while we
believe such information forms a reasonable basis for such statements, such information may be limited or incomplete,
and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all
potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly
rely upon these statements.
vii
Table of Contents
Summary Risk Factors
Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an
investment decision. These risks are described more fully below. These risks include, among others:
•The commercial success of our products and product candidates, including in new indications or methods of
administration, will depend on the degree of market acceptance.
•We face significant competition for our drug discovery and development efforts.
•We will face significant challenges in successfully commercializing our products and additional product candidates
after they are launched.
•Our products and product candidates for which we have obtained or intend to seek approval as biological products,
including for new indications, may face biosimilar competition.
•Enacted and future legislation and regulations could impact demand for our products which could impact our business
and future results of operations.
•We are subject to government pricing laws, regulation and enforcement, which affect the prices we may charge the
government for our products and the reimbursement our customers may obtain from the government. Changes in such
laws, regulation, and enforcement may place downward pressure on the prices we can charge in the marketplace, and
our failure to comply with these laws could harm our results, operations and/or financial conditions.
•We may not obtain or maintain adequate pricing and coverage or reimbursement status for our products and product
candidates.
•If we fail to obtain orphan drug designation or we do not have valid and enforceable patents covering our products
and their uses and product candidates and fail to obtain and/or maintain orphan drug exclusivity for our products or
product candidates, our competitors may be able to sell products to treat the same conditions and our revenue may be
reduced.
•Failure to successfully identify, select and develop our products in other indications, or additional products or product
candidates could impair our ability to grow.
•Failure to successfully develop or obtain marketing approval for our products and product candidates could
negatively impact our business.
•Certain of our clinical trials have not succeeded, and may in the future also not succeed, and even if they succeed, we
may not obtain regulatory approval for our products or product candidates or regulatory approval may be delayed.
•If we decide to pursue accelerated approval for any of our product candidates, it may not lead to faster development
or regulatory review or approval and we may still need to conduct additional clinical trials, which could increase the
expense of obtaining, if at all, necessary marketing approvals.
•Our products and product candidates may have serious adverse, undesirable or unacceptable side effects, and we or
others may identify undesirable or unacceptable side effects caused by any of our products or product candidates
before and after they have received marketing approval.
•If our target patient population is smaller than expected, we are unable to successfully enroll and retain patients in our
clinical trials, or experience significant delays in doing so, we may not realize the full commercial potential of any
products or product candidates.
•We rely, and expect to continue to rely, on third parties to conduct some of our research activities, manufacturing and
clinical trials and for parts of the development and commercialization of our existing and future research programs,
products and product candidates. If our relationships with such third parties are not successful, our business may be
adversely affected.
viii
Table of Contents
•Disruptions caused by our reliance on third parties for our raw materials and manufacturing process may delay or
disrupt our business, product development and commercialization efforts.
•Accuracy and timing of our financial reporting is partially dependent on information received from third-party
partners, which we do not control.
•We and our third-party manufacturers and suppliers may become exposed to liability, fines, penalties or other
sanctions and substantial expenses in connection with environmental compliance or remediation activities.
•We are subject to healthcare laws, regulation and potential enforcement. The failure to comply with these laws could
harm our results, operations and/or financial condition.
•Our performance tracked by our Environmental, Social and Governance metrics is subject to risks and the outcomes
may not achieve the anticipated benefits or align with new regulations and stakeholders’ expectations.
•We may not be able to be profitable or sustain net profitability in the future and may require additional financing to
fund our operations.
•We may become exposed to costly and damaging liability claims.
•We may engage in strategic transactions, including acquisitions, collaborations, licenses or investments in other
companies or technologies, and we may not realize the benefits of such transactions.
•Our business and operations could suffer in the event of system failures or unauthorized or inappropriate use of or
access to our systems.
•We may be unable to adequately maintain, enforce or protect our intellectual property rights in products, product
candidates and platform technologies which could adversely affect our ability to maximize the value for patients in
our marketed products and product candidates.
•Intellectual property litigation could lead to substantial resource diversion or issued patents could be found invalid,
not infringed, or unenforceable if challenged in the applicable patent office or court.
•Our future growth and ability to compete depends on maintaining our culture, retaining our key personnel and
recruiting additional qualified personnel.
•Global geo- and socio-political threats and macro-economic uncertainty and other unforeseen political crises could
materially and adversely affect our business and financial performance.
•Holders of our ADSs have fewer rights than our ordinary shareholders.
•The price of our ADSs may be volatile and may fluctuate due to factors beyond our control. An active public trading
market may not be sustained.
•Claims of U.S. civil liabilities may not be enforceable against us or the members of our Senior Management Team
and our Board of Directors.
•As a foreign private issuer, we are exempt from various rules and regulations that a U.S. domestic public company
would be required to follow, including those requirements under U.S. securities laws and Nasdaq listing standards.
•We may lose our foreign private issuer status which would then require us to comply with the Exchange Act’s
domestic reporting regime and cause us to incur significant legal, accounting and other expenses.
•If we were to be classified as a passive foreign investment company for U.S. federal income tax purposes, this could
result in adverse U.S. tax consequences to certain U.S. holders.
1
Table of Contents
PART I
ITEM 1.IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
Not applicable.
ITEM 2.OFFER STATISTICS AND EXPECTED TIMETABLE
Not applicable.
ITEM 3.KEY INFORMATION
A.[RESERVED]
B.CAPITALIZATION AND INDEBTEDNESS
Not applicable.
C.REASONS FOR THE OFFER AND USE OF PROCEEDS
Not applicable.
D.RISK FACTORS
Our business faces significant risks, including those described below. You should carefully consider all of the
information set forth in this Annual Report and in our other filings with the SEC, including the following risk factors.
Our business, financial condition or results of operations could be materially and adversely affected if any of these risks
occur. These are not the only risks argenx faces. Additional risks and uncertainties not presently known to argenx or that
it currently considers immaterial or not specific may also impair its business, results of operation and financial condition.
This report also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ
materially and adversely from those anticipated in these forward-looking statements as a result of certain factors
including the risks described below and elsewhere in this Annual Report and as may be described in our subsequent SEC
filings. See “Cautionary Statement with Respect to Forward-Looking Statements”.
Risk Factors Related to Commercialization of argenx’s Products and Product Candidates, Including for New
Indications
The commercial success of our products and product candidates, including in new indications or methods of
administration, will depend on the degree of market acceptance.
Our products and product candidates, including for any new indications or methods of administration, if and when
approved and available on the market, may never achieve an adequate level of acceptance by physicians, patients, the
medical community, or healthcare payors for us to be profitable or sustain net profitability in the future. This will depend
on a number of factors, many of which are beyond our control, including, but not limited to:
•consumer perceptions or publicity regarding our business or the efficacy, safety and quality of the products and
product candidates in our profile, our clinical trials for new indications, or any similar products distributed by other
companies, and the prevalence and severity of any adverse effects discovered before or after marketing approval has
been received;
•approval may be for indications, dosage and methods of administration or patient populations that are not as broad as
intended or desired;
•changes in the standard of care for the targeted indications for any product and product candidate;
•relative availability, cost, and convenience of alternative approved therapies;
•labeling may require significant use or distribution restrictions or safety warnings;
2
Table of Contents
•acceptance by physicians, public health bodies, patients and healthcare payors of each product as safe, effective and
cost-effective; and
•patients continued commitment required to receive periodic in-center infusions.
In addition, because we are developing our products and product candidates for the treatment of different indications,
negative results in a clinical trial evaluating the efficacy and safety of a product or product candidate for one indication,
including by one of our competitors, could negatively impact the perception of the efficacy and safety of such product or
product candidate in a different indication, which could have an adverse effect on our reputation, commercialization
efforts and financial condition.
Moreover, efforts to educate the medical community and third-party payors on the benefits of our products and product
candidates may require significant resources and may never be successful. If our product candidates or methods of use of
existing products or new indications fail to gain market acceptance, it will have a material adverse impact on our ability
to generate revenues. Even if some products achieve market acceptance, they may not be able to retain market
acceptance and/or the market may prove not to be large enough to allow us to generate significant revenues.
We face significant competition for our drug discovery and development efforts.
The market for pharmaceutical products is highly competitive and characterized by rapidly growing understanding of
disease biology, quickly changing technologies, strong intellectual property barriers to entry, and a multitude of
companies involved in the creation, development, and commercialization of novel therapeutics. Many of these
companies are highly sophisticated and often strategically collaborate with each other.
Competition in the autoimmune field is intense and involves multiple mAbs, other biologics and small molecules either
already marketed or in development by many different companies including, but not limited to, large pharmaceutical
companies such as AstraZeneca plc, AbbVie, Inc., Amgen, Inc., Biogen Inc., GlaxoSmithKline plc, F. Hoffman-La
Roche AG, Johnson & Johnson Innovation, Inc. and Novartis AG. In addition, these and other pharmaceutical
companies have mAbs or other biologics in clinical development for the treatment of autoimmune diseases.
Currently, our commercial revenue is generated by VYVGART and VYVGART SC in gMG, CIDP and ITP
(Japan only). We face and expect to continue to face intense competition from other biopharmaceutical companies, who
have launched or are developing products for the treatment of gMG and/or CIDP and other autoimmune diseases,
including products that are in the same class as VYVGART, as well as products that are similar to some of our product
candidates. Competition for other potential future indications is also fierce, with significant development by competitors
in almost all of the indications we are currently developing or planning to develop for our product or product candidates.
For example, we are aware of certain biopharmaceutical companies selling products for the treatment of adult patients
with gMG, and several biopharmaceutical companies are developing drugs that may have utility for the treatment of
gMG and/or CIDP.
Competitive product launches may erode future sales of our products, including our existing products and those currently
under development, or result in unanticipated product obsolescence. Such launches continue to occur, and potentially
competitive products are in various stages of development. We could also face competition for use of limited
international infusion sites, particularly in new markets as competitors launch new products. We cannot predict with
accuracy the timing or impact of the introduction of competitive products that treat diseases and conditions like those
treated by our products or product candidates. In addition, our competitors and potential competitors compete with us in
recruiting and retaining qualified personnel in all areas of our business, establishing clinical trial sites, registering
patients for clinical trials, as well as in acquiring technologies complementary to, or necessary for, the development of
our products.
Competition is also increasing from companies that are utilizing artificial intelligence and other computational
approaches for the development of products. These competitors may incorporate artificial intelligence into their
businesses more quickly or more successfully than us, which could impair our ability to compete effectively and
adversely affect our results of operations. We anticipate that we will continue to face increasing competition in the future
as new companies enter our market and scientific developments surrounding the pharmaceutical market continue to
accelerate. We cannot predict the extent to which these developments will impact potential future sales of our products
or our product candidates. There can be no assurance that our competitors are not currently developing, or will not in the
future develop, technologies and products that are equally or more effective, are more economically attractive, and can
be administered more easily than any of our current or future technologies or products.
Such competing products or technology platforms may gain faster or greater market acceptance than our products or
technology platforms. If we, our products and product candidates or our technology platforms do not compete
effectively, it is likely to have a material adverse effect on our business, financial condition and results of operation.
3
Table of Contents
We will face significant challenges in successfully commercializing our products and additional product candidates
after they are launched.
The commercialization of VYVGART in new indications or other product candidates if and when approved, or entrance
of any of our products or product candidates into new markets will require us to further expand our sales and marketing
organization, enter into collaboration arrangements with third parties, outsource certain functions to third parties, or use
some combination of each. We have built, and continue to expand, our sales force in certain of the countries where
VYVGART is approved and plan to further develop our sales and marketing capabilities to promote our products, and
product candidates, including new indications, if and when marketing approval has been obtained in other relevant
jurisdictions.
Even if we successfully expand our sales and marketing capabilities, either on our own or in collaboration with third
parties, we may fail to launch or market our products effectively. Recruiting and training a specialized sales force is
expensive and the costs of expanding an independent sales, marketing and/or promotion organization could be greater
than we anticipate.
We could further encounter difficulties in our sales or marketing, due to regulatory actions, shut-downs, work stoppages
or strikes, approval delays, withdrawals, recalls, penalties, supply disruptions, shortages or stock-outs at our facilities or
third-party facilities that we rely on, reputational harm, the impact to our facilities due to natural or man-made disasters,
product liability, and/or unanticipated costs. In addition, recruiting and training a sales force is time-consuming and
could delay any product launch. In the event that any such launch is delayed or does not occur for any reason, we would
have prematurely or unnecessarily incurred these commercialization expenses, and our investment would be lost if we
cannot retain or reposition our sales and marketing personnel.
Our products and product candidates for which we have obtained or intend to seek approval as biological products,
including for new indications, may face biosimilar competition.
In the U.S., the Biologics Price Competition and Innovation Act (BPCIA) created an abbreviated approval pathway for
biological products that are demonstrated to be “biosimilar” to or interchangeable with a U.S. FDA-licensed reference
biological product. However, during the 12-year regulatory exclusivity period applicable to reference biological
products, another company may still market a competing version of the reference product if the FDA approves a full
BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-
controlled clinical trials of their product.
We believe that any of our product candidates approved as a biological product under a BLA in the U.S. should qualify
for the Biologics Price Competition and Innovation Act 12-year period of exclusivity, as is the case with VYVGART.
The base regulatory exclusivity period for VYVGART is expected to extend until December 2033 in the U.S. whereas
regulatory protection in the EU is expected to expire in August 2032. However, in the U.S., there is a risk that this
exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product
candidates to be reference products for competing products, potentially creating the opportunity for competition by
biosimilar products sooner than anticipated. The same applies to the EU, as there is also a risk that this exclusivity could
be shortened due to legislative actions.
We are aware that some of our competitors may be actively developing competing or biosimilar products for
VYVGART. It is possible our competitors will be successful in developing biosimilar or interchangeable products for
our products and product candidates, and the approval of such competing products may lead to substantial competition in
the market, a decrease in sales, or force us to make VYVGART available at lower prices due to competitive pressures.
Moreover, an interchangeable biosimilar product, once approved, may be substituted under existing state laws for any
one of our reference products. In addition, the Further Consolidated Appropriations Act, 2020, which incorporated the
framework from the Creating and Restoring Equal Access To Equivalent Samples (CREATES) legislation, allows
biosimilar developers to obtain access to reference biological products, which may facilitate the development of
biosimilars to our products. The FDA has also recently issued guidance eliminating the need for data from comparative
clinical efficiency studies to demonstrate biosimilarity in many circumstances, which may accelerate biosimilar market
entry. If competing or biosimilar products are approved, the market position of our products for existing and recently
approved indications may be adversely affected. 
In the EU, biosimilars are evaluated for marketing authorization pursuant to a set of general and product class-specific
guidelines. Moreover, the EU’s legislative bodies are currently working toward finalizing a reform of the EU
Pharmaceutical Legislation, likely shortening the baseline of market exclusivity periods for medicinal products. In
addition, some EU Member States have adopted, or are considering the adoption of, biosimilar uptake measures or may
impose automatic price reductions upon market entry of one or more biosimilar competitors. While the degree of
competitive effects of biosimilar competition among EU Member States may vary, continuation of policies promoting
4
Table of Contents
biosimilar products in the EU and in EU Member States could erode market share or introduce competitive pricing
pressures for our products and product candidates.
Enacted and future legislation and regulations could impact demand for our products which could impact our
business and future results of operations.
In the U.S. and the EU and other jurisdictions, there have been a number of legislative and regulatory changes to
healthcare systems that could affect our future results of operations. Governmental regulations that mandate price
controls or limitations on patient access to our products or establish prices paid by government entities or programs for
our products could impact our business, and our future results of operations could be adversely affected by changes in
such regulations or policies.
In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to
reduce healthcare costs in general and the cost of pharmaceuticals in particular, including pharmaceutical pricing reforms
under the IRA. The IRA authorizes Medicare drug price negotiation, imposes inflation-based rebate obligations and
significantly redesigns the Medicare Part D benefit, including establishing manufacturer discount requirements and
capping beneficiary out-of-pocket costs. Although the program remains subject to legal challenges, the IRA is being
implemented and may materially reduce the prices we are able to charge for our products, increase our rebate and
discount obligations, and affect coverage, formulary placement and demand for our products and product candidates. See
“Item 4.B. — Business Overview  — Intellectual property — Regulation  — Coverage, Pricing and Reimbursement ” for
additional details.
The HHS has and will continue to issue and update guidance and rulemaking as these IRA programs are implemented.
We cannot predict how the HHS will interpret the IRA in the future, or whether the U.S. Congress will enact legislation
that further amends the law. However, at this time, the Trump administration is continuing to implement the IRA.
Manufacturers that fail to comply with the IRA may be subject to significant penalties, including civil monetary
penalties and excise taxes. The IRA also extends enhanced subsidies for individuals purchasing health insurance
coverage in ACA (as defined below) marketplaces through plan year 2025. To date, none of the legislative attempts to
extend the subsidies has been enacted. While the full economic impact of IRA is unknown at this time, the law’s passage
is likely to affect the pricing of our products and product candidates. The adoption of restrictive price controls in new
jurisdictions, more restrictive controls in existing jurisdictions, the adoption of these lower prices by commercial payors,
or the failure to obtain or maintain timely or adequate pricing could also adversely impact revenue. We expect pricing
pressures will continue globally.
Further, at the U.S. state level, legislatures are increasingly enacting laws and implementing regulations designed to
control pharmaceutical and biological product pricing, including price or reimbursement constraints, discount
requirements, price transparency reporting, and programs designed to encourage importation from other countries and
bulk purchasing. States are also enacting laws modeled on federal policies, such as the IRA and the 340B drug discount
program. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of
which could limit the amounts that federal and state governments will pay for healthcare products and services, including
pharmaceuticals, which could result in reduced demand for our products and product candidates or additional pricing
pressures.
The EU, on the other hand, is in the final stages of adopting new EU Pharmaceutical Legislation in 2026, reforming its
legislative framework for medicinal products (see “Item 3.D — Risk Factors — Agreement on new EU Pharmaceutical
Legislation”).
Depending on the final text, which has yet to be published and is still subject to formal approval, the impact could be
positive with respect to certain regulatory processes. Other aspects may, however, have a negative impact on innovative
pharma and biotech companies such as argenx. In particular, this may be the case for the envisaged shorter baseline
market exclusivity periods. In any case, these legislative changes will only enter into effect after a (not yet specified)
transitional period, which will most likely conclude in 2028 the earliest.
We are subject to government pricing laws, regulation and enforcement, which affect the prices we may charge the
government for our products and the reimbursement our customers may obtain from the government. Changes in
such laws, regulation, and enforcement may place downward pressure on the prices we can charge in the
marketplace, and our failure to comply with these laws could harm our results, operations and/or financial
conditions.
In the U.S., we are required to participate in various government programs for our products to be reimbursed or
purchased by the federal government. We participate in programs such as the Medicaid Drug Rebate Program, the 340B
drug discount program, Medicare Part B, Medicare Part D and the U.S. Department of Veterans Affairs Federal Supply
Schedule pricing program. The requirements vary by program, but we are, among other things, required to enter into
5
Table of Contents
agreements with and calculate and report prices and other information to certain government agencies, charge no more
than statutorily mandated ceiling prices and calculate and pay rebates and refunds for certain products.
The calculations are complex and are often subject to interpretation by us, governmental agencies and the courts. If we
determine that the prices we reported were in error, we may be required to restate those prices and pay additional rebates
or refunds to the extent we understated the rebate or overcharged the government due to the error. Additionally, there are
penalties associated with submission of incorrect pricing or other data by the specified deadline, as well as potential
allegations under the False Claims Act and other laws and regulations.
Statutory or regulatory changes, including changes in CMS guidance, could affect the average sales price calculations
and the resulting Medicare payment rate for VYVGART and our potential future products. Any such measures may
increase our financial obligations to government payors, reduce net realized prices, and adversely affect the demand,
coverage and overall sales of our products. In addition, maintaining compliance with these government price reporting
and discounting obligations is time-consuming and costly, and a failure to comply can result in substantial fines,
penalties, all of which could adversely impact our financial results. See “Item 4.B. — Business Overview  — Intellectual
property — Regulation  — Coverage, Pricing and Reimbursement” for additional details on the regulatory framework
regarding the coverage, pricing and reimbursement of our products and product candidates.
In addition, the current U.S. Presidential administration has taken several steps to try to align U.S. drug prices with drug
prices in other countries through an approach known as MFN pricing, On November 6, 2025, CMS announced the
GENEROUS Model under its CMMI authority. The GENEROUS Model is a voluntary model that tests the impact of
CMS-facilitated supplemental rebate agreements that align the Medicaid net price with a defined MFN price. In
December 2025, CMS issued proposed rules for the GLOBE Model and the GUARD Model under its CMMI authority.
The GLOBE and GUARD Models are mandatory models that, if finalized, would require manufacturers of certain drugs
to pay additional rebates based on the difference between the Medicare price and the price in market basket countries.
CMS proposes that the new rebate would apply to utilization by approximately 25% of Medicare Part B fee-for-service
beneficiaries and 25% of Medicare Part D enrollees. In Congress, there also are pending legislative proposals that, if
enacted, would require MFN pricing in certain healthcare programs.
It is also currently uncertain how these U.S. policy efforts to align US pharmaceutical pricing more closely to
international benchmarks from countries with competing healthcare cost containment measures will affect our business.
Any expansion, finalization or implementation of these or similar MFN-based pricing initiatives could subject our
products to additional rebate obligations, negatively impact our pricing strategies, product demand, or competitive
positioning across global markets, and may result in reduced revenue in critical markets.
We may not obtain or maintain adequate pricing and coverage or reimbursement status for our products and product
candidates.
Sales of VYVGART and our product candidates, if approved, will depend, in part, on the extent to which third-party
payors, including government health programs in the U.S. (such as Medicare Parts B and D and Medicaid) and other
countries, commercial health insurers, and managed care organizations, provide coverage and establish adequate
reimbursement levels for such products and product candidates. Patients generally rely on third-party payors to
reimburse all or part of the associated healthcare costs, and are unlikely to use our products unless coverage is provided
and reimbursement is adequate to cover a significant portion of the cost of our products.
In the U.S., no uniform policy of coverage and reimbursement for products exists among commercial third-party payors.
Commercial third-party payors decide which products they will pay for and establish reimbursement levels, often relying
upon Medicare coverage policy and payment limitations. However, decisions regarding the extent of coverage,
formulary tier placement, utilization management requirements (including step therapy), and the amount of
reimbursement to be provided for any product candidate that we develop through approval will be made on a plan-by-
plan basis. Even under U.S. government healthcare programs such as Medicare and Medicaid, coverage and
reimbursement policies can vary significantly. Medicare Part D is administered by commercial insurance companies
under contract with the CMS, and their coverage and reimbursement policies may vary, subject to certain statutory and
regulatory requirements. Additionally, Medicaid programs vary from state to state in their coverage policies and
reimbursement rates, subject to certain federal requirements. Further, from time to time, typically on an annual basis,
payment rates are updated and revised by third-party payors. Such updates could impact the demand for our products, to
the extent that patients who are prescribed our products, if approved, are not separately reimbursed for the cost of the
product.
The process for determining whether a third-party payor will provide coverage for a product may be separate from the
process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the
product. Even if we do obtain adequate levels of reimbursement, third-party payors, such as government or private
healthcare insurers, carefully review and increasingly question the coverage of, and challenge the prices charged for,
6
Table of Contents
products. Increasingly, third-party payors are requiring that biopharmaceutical companies provide them with
predetermined discounts from list prices and are challenging the prices charged for products. We may also be required to
conduct expensive pharmacoeconomic studies to justify the coverage and the amount of reimbursement for particular
medications. We cannot be sure that coverage and reimbursement will be available for any product that we
commercialize and, if reimbursement is available, what the level of reimbursement will be.
Moreover, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if
favorable coverage and reimbursement status is attained for one or more products for which we receive marketing
approval in one or more indications, less favorable coverage policies and reimbursement rates may be implemented in
the future. For instance, even though favorable coverage and reimbursement status has been attained for VYVGART for
the treatment of gMG and CIDP in the U.S., access to VYVGART for any other indication may be reduced or restricted
by limited payor coverage due to treatment criteria, which may prevent us from realizing its full commercial potential. In
addition, the coverage and reimbursement levels for our products for the treatment in one indication may have an adverse
impact on the coverage and reimbursement levels of such products or product candidates in other indications for which
marketing approval has previously been or may subsequently be obtained. Inadequate coverage or reimbursement may
diminish or prevent altogether any significant demand for our products and/or may prevent us entirely from entering
certain markets or indications, which would prevent us from generating significant revenues or sustaining net
profitability in the future, which would adversely affect our business, financials and results of operations.
In many foreign countries, pricing, coverage, and level of reimbursement of prescription drugs are subject to
governmental and/or third-party payor control, and we and our collaborators may be unable to obtain coverage, pricing,
and/or reimbursement on terms that are favorable to us or necessary for us or our collaborators to successfully
commercialize our marketed products in those countries. In some foreign countries, the proposed pricing for a drug must
be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary
widely from country to country, and may take into account the clinical effectiveness, cost, and service impact of existing,
new, and emerging drugs and treatments. For example, in the EU, pricing and reimbursement of medicinal products, is
almost exclusively a matter for national, rather than EU, provisions and regulations. EU Member States may restrict the
range of medicinal products for which their national health insurance systems provide reimbursement and may control
the prices of medicinal products for human use. An EU Member State may approve a specific price for the medicinal
product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the
medicinal product on the market. Our results of operations may suffer if we or our collaborators are unable to market our
products in foreign countries or if coverage and reimbursement for our marketed products in foreign countries is limited
or delayed. Downward price pressures in the EU and other countries may, in turn, contribute to downward price pressure
in the U.S. because of MFN initiatives.
If we fail to obtain orphan drug designation or we do not have valid and enforceable patents covering our products
and their uses and product candidates and fail to obtain and/or maintain orphan drug exclusivity for our products or
product candidates, our competitors may be able to sell products to treat the same conditions and our revenue may be
reduced.
We have and may from time to time seek orphan drug designation in the U.S., Japan and, the EU for certain indications
addressed by our products and product candidates. With regard to these designations or future designations we may
obtain, we may not be the first to obtain marketing approval of these drugs for such indication due to the uncertainties
associated with developing therapeutic products, and we may not obtain orphan exclusivity upon approval. In the U.S.,
orphan drug exclusivity applies only to the specific uses or indications for which a drug is approved within the
designated rare disease or condition, and therefore may be narrower than the scope of the original orphan designation. In
addition, exclusive marketing rights in the U.S. may be limited if we seek approval for an indication broader than the
orphan-designated indication, or may be lost if the FDA later determines that the request for designation was materially
defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare
disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not
effectively protect the product from competition because different drugs with different active moieties or different
principal molecular structural features can be approved for the same condition. Even after an orphan drug is approved,
the MHRA, the EMA, respectively the European Commission, the FDA, the MHLW (collectively, the Relevant
Regulatory Authorities) or other comparable regulatory authorities can subsequently approve the same drug with the
same principal molecular structural features for the same condition if the regulator concludes that the later drug is safer,
more effective, or makes a major contribution to patient care.
7
Table of Contents
Risk Factors Related to the Development and Clinical Testing of argenx’s Products and Product Candidates
Failure to successfully identify, select and develop our products in other indications, or additional products or
product candidates could impair our ability to grow.
Our long-term growth strategy entails developing and marketing additional products and product candidates, including
efgartigimod for new indications, empasiprubart and adimanebart. This requires substantial resources, whether or not
any product candidates or new indications are ultimately identified. The success of this strategy depends partly upon our
ability to identify, select, develop, and ultimately, commercialize promising product candidates. We are heavily
dependent on precise, accurate and reliable scientific data to identify, select and develop promising product candidates
and products. Our business decisions may therefore be adversely influenced by inaccurate, improper or fraudulent
scientific data, including data sourced from third parties. Even with accurate scientific data, our technology platforms
may fail to discover and to generate additional products and products candidates, that are suitable for further
development.
Even if we identify additional product candidates, they may not be suitable for clinical development as a result of
harmful side effects, limited efficacy or other characteristics that indicate that it is unlikely to be a product that will
receive approval by the Relevant Regulatory Authorities, and other comparable regulatory authorities or achieve market
acceptance. If we do not successfully identify, develop and commercialize product candidates and VYVGART in new
indications based upon our technological approach, we may not be able to obtain product or collaboration revenues in
future periods.
Obtaining regulatory approval for our products and product candidates is inherently uncertain. To obtain the requisite
regulatory approvals to market and sell any of our products and product candidates, we or our collaborators for such
candidates must successfully demonstrate that our products are safe and effective in humans. Clinical trials are expensive
and can take many years to complete, and their outcome is inherently uncertain. Further, success in early clinical trials or
in one indication does not guarantee success in later clinical trials or in other indications.
Failure to successfully develop or obtain marketing approval for our products and product candidates could
negatively impact our business.
The time required to obtain approval by the Relevant Regulatory Authorities and other comparable regulatory authorities
is unpredictable but typically takes many years, if obtained at all, following the commencement of clinical trials and
depends upon numerous factors, including the substantial discretion or interpretation of the regulatory authorities. This
lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain
regulatory approval to market any of our product candidates, including for new indications. We have experienced delays
in our prior clinical trials, and we may experience delays in our ongoing or planned clinical trials, for a large variety of
reasons outside our control in complying with regulatory approvals which can adversely affect the timing of clinical
trials, including as described in “Item 3.D. — Risk Factors — Risk Factors Related to Other Government Regulations —
All aspects of our business ranging from preclinical, clinical trials, marketing and commercialization are highly
regulated and any delay by relevant regulatory authorities could jeopardize our development and approval process or
result in other suspensions, refusals or withdrawal of approvals.”
Over the last several years, the U.S. government has shut down several times and average review times at the FDA have
fluctuated in recent years as a result. If a prolonged government shutdown occurs it could significantly impact the ability
of the FDA to timely review and process our regulatory submissions. Inadequate funding for the FDA and other
government agencies, or other disruptions to these agencies’ operations, could also prevent new products and services
from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing
normal functions on which the operation of our business may rely, which could negatively impact our business.
In addition, ongoing efforts by the current U.S. Presidential administration to limit the size of the FDA and other
agencies of HHS, including through reductions in staff, may further increase the unpredictability in approval timelines
for our products and product candidates. In 2025, HHS announced and implemented a restructuring that included
significant reductions in the FDA’s workforce pursuant to an executive order directing federal workforce optimization.
These staffing reductions together with resignations, resulting in leadership turnover and loss of institutional knowledge,
may disrupt agency operations and adversely affect the timing, consistency or outcome of regulatory review. Ongoing
initiatives by the current U.S. Presidential administration to deregulate and to review the scientific basis for, and
otherwise attempt to influence, FDA decisions and policies create regulatory uncertainty for pharmaceutical companies.
8
Table of Contents
Additionally, uncertainty remains as to how the FDA’s agency-wide implementation of ELSA, a generative artificial
intelligence tool, including for review of drug product applications, as well as its deployment of agentic artificial
intelligence capabilities, will impact the outcomes and timeliness of FDA reviews and other activities. In addition, the
future of the currently applicable Prescription Drug User Fee Act construct to ensure timely FDA review of applications
may be impacted due to expressed concerns about the effect on industry-FDA relations, and staffing shortages.
If we are unable to obtain regulatory approval of our products and product candidates on a timely basis or at all, our
business, financial operations and/or financial condition may be impacted.
Certain of our clinical trials have not succeeded, and may in the future also not succeed, and even if they succeed, we
may not obtain regulatory approval for our products or product candidates or regulatory approval may be delayed.
Certain of our clinical trials have not succeeded, and may in the future also not succeed. We could experience
operational challenges as we undertake an increasing number of clinical trials, including those conducted in countries
outside the EU, UK and the U.S. that may subject us to further delays and expenses as a result of increased shipment
costs, additional regulatory requirements and the engagement of non-EU, non-UK and non-U.S. contract research
organizations (CROs). Such trials may also expose us to risks associated with clinical investigators and institutions who
apply different standards of diagnosis, screening and medical care or are otherwise unfamiliar with standards and
requirements imposed by the Relevant Regulatory Authorities.
If we experience delays in the completion of, or termination of, any clinical trial of our products or product candidates,
may increase our costs, slow down our product candidate development and approval process and jeopardize our ability to
commence product sales and generate revenues. Many of the factors that cause, or lead to, a delay in the commencement
or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates or
result in the development of our product candidates being stopped early. Significant clinical trial delays could also allow
our competitors to bring products to market before we do or shorten any periods during which we have the exclusive
right to commercialize our products and product candidates.
Even if clinical trials are initiated, our development efforts may not be successful. Even if we obtain positive results from
preclinical trials or initial clinical trials, we may not achieve the same success in future clinical trials, which may
negatively impact the price of our ordinary shares or ADSs.
Regulatory approval of our products or product candidates may be delayed or refused for many reasons, including for
reasons outside our control. Some of the reasons for regulatory delay or refusal include:
•the Relevant Regulatory Authorities or other comparable regulatory authorities may disagree with the design or
implementation of our clinical trials;
•we may be unable to demonstrate, to the satisfaction of the Relevant Regulatory Authorities or other comparable
regulatory authorities, that our product candidates are safe, pure, potent and effective for any of their proposed
indications;
•the results of clinical trials may not meet the level of statistical significance required by the Relevant Regulatory
Authorities or other comparable regulatory authorities for approval;
•the chemistry, manufacturing and controls information submitted in an application is insufficient; and
•the facilities of third-party manufacturers with which we contract for the manufacture of our product candidates are
not adequate to support approval of our product candidates.
Any of these occurrences may harm our business, results of operations and financial condition significantly.
If we decide to pursue accelerated approval for any of our product candidates, it may not lead to faster development
or regulatory review or approval and we may still need to conduct additional clinical trials, which could increase the
expense of obtaining, if at all, necessary marketing approvals.
The accelerated approval pathway has come under scrutiny by various stakeholders, and the Food and Drug Omnibus
Reform Act of 2022 (FDORA) revised the requirements for this pathway. Although this legislation did not change the
standard for accelerated approval, it authorized the FDA to require a post-approval clinical trial to be underway prior to
approval or within a specified time period following approval, and must specify conditions of any required post-approval
clinical trial. FDORA also requires sponsors to submit progress reports for required post-approval studies. Failure to
9
Table of Contents
conduct due diligence for required post-approval studies is deemed a prohibited act under the FDCA. FDORA also
details procedures the FDA must follow to withdraw an accelerated approval on an expedited basis, including where the
required post-approval studies are not conducted with due diligence or fail to verify clinical benefit, other evidence
demonstrates that the product is not shown to be safe or effective under the conditions of use, or the sponsor
disseminates false or misleading promotional materials with respect to the product. FDA has been exercising these
authorities and has issued guidance documents regarding the accelerated approval pathway. If we decide to pursue
accelerated approval for any of our product candidates, the failure to obtain accelerated approval (or the withdrawal of
any accelerated approval) could result in a longer time period to commercialization of such product candidate, if any,
and could increase the cost of development of such product candidate and harm our competitive position in the
marketplace. For example, if standard of care were to evolve or if any of our competitors were to receive approval for a
drug or biological product for a disease or condition for which we are seeking accelerated approval before we receive
accelerated approval, we may not be able to demonstrate that our product candidate provides a meaningful advantage
over other available therapies and accelerated approval may not occur.
Our products and product candidates may have adverse, undesirable or unacceptable side effects, and we or others
may identify undesirable or unacceptable side effects caused by any of our products or product candidates before and
after they have received marketing approval.
Undesirable side effects that may be caused by our product candidates, or by the combination of our product candidates
with other medical products, could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could
result in more restrictive labeling or the delay or denial of regulatory approval by the Relevant Regulatory Authorities or
other comparable regulatory authorities. We have observed adverse events and treatment emergent adverse events in our
clinical trials, and we may see additional adverse events and treatment emergent adverse events in our ongoing and
future clinical trials. Such side effects may be more serious than those observed to date, and as a result, our ongoing and
future clinical trials may be negatively impacted. Moreover, as we seek to develop product candidates, including
products in new indications, patients may experience new or more serious effects. Drug-related side effects caused by
any of our products or product candidates that we or others identify could, among other things, affect patient recruitment,
the ability of enrolled patients to complete the clinical trial, result in potential product liability claims, damage sales of
our existing products, result in significant reputational damage for us and our product development, and other issues
including the delay of other programs.
Any undesirable drug-related side effects can also cause the Relevant Regulatory Authorities or other comparable
regulatory authorities to withdraw approvals or revoke licenses of such products and require us to take such products off
the market, require the addition of labeling statements, specific warnings, or a contraindication or other modification of
the product labeling, request the issuance of safety alerts, require a REMS to ensure that the benefits of the product
outweigh its risks, and/or require us to change the way the product is administered, conduct additional clinical trials or
change the labeling of the product.
If our target patient population is smaller than expected, we are unable to successfully enroll and retain patients in
our clinical trials, or experience significant delays in doing so, we may not realize the full commercial potential of
any products or product candidates.
Currently, we mainly develop products or product candidates for the treatment of rare diseases for which the target
patient population can be small. If the actual number of patients with these disorders is smaller than we expected, we
may encounter difficulties in enrolling sufficient patients in our clinical trials, thereby delaying or preventing
development and approval of our products or product candidates. Physicians, who are an important source of patients for
clinical trials, may also be less familiar with these rare diseases and may therefore fail to identify these conditions in
their patients and therefore may not refer them to our clinical trials.
Patient enrollment, a significant factor in the timing of clinical trials, depends on many factors, including the size and
nature of the patient population, eligibility criteria for the clinical trial, the proximity of patients to clinical sites,
competition for patient recruitment from competing clinical trials, the design of the clinical trial, the availability of
alternate approved therapies for the indication the clinical trial is investigating, and clinicians’ and patients’ perceptions
as to the potential advantages of the drug being studied in relation to other available therapies. We compete with other
companies to enroll target patient populations, as set forth in “Item 3.D. Risk Factors — Risk Factors Related to
Commercialization of argenx’s Products and Product Candidates, Including for New Indications—We face significant
competition for our drug discovery and development efforts.” Even if product candidates obtain significant market share
for their approved indications, because certain potential target populations are small, we may never recoup our
investment in such product candidate without obtaining regulatory approval for additional indications for such product
candidates.
Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our clinical trials. In
addition, any negative results we may report in clinical trials of our drug candidates may make it difficult or impossible
to recruit and retain patients in other clinical trials of that same drug candidate. Delays in the completion of any clinical
10
Table of Contents
trial of our product candidates will increase our costs, slow down our product candidate development and approval
process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition,
some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also
ultimately lead to the denial of regulatory approval of our product candidates.
Risk Factors Related to argenx’s Dependence on Third Parties
We rely, and expect to continue to rely, on third parties to conduct some of our research activities, manufacturing and
clinical trials and for parts of the development and commercialization of our existing and future research programs,
products and product candidates. If our relationships with such third parties are not successful, our business may be
adversely affected.
We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators, CROs,
CMOs and other third-party service providers with the applicable protocol, legal and regulatory requirements and
scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. To the
extent our collaborators or the CROs or investigators fail to enroll participants for our clinical trials, fail to conduct the
clinical trial to GCP standards or in full compliance with legal and regulatory requirements or are delayed for a
significant time in the execution of clinical trials, including achieving full enrollment, we may be affected by increased
costs, program delays or both, which may harm our business.
In addition, we are, and expect to continue to be, dependent on partnerships with partners and licensees relating to the
development and commercialization of our existing and future research programs, products and product candidates. We
currently have collaborative research relationships with various pharmaceutical companies such as AbbVie, Zai Lab and
with various academic and research institutions worldwide for the development of product candidates resulting from
such collaborations. We also have distribution agreements in place with several distribution partners for VYVGART. We
have and will continue to have discussions on potential partnering opportunities with various pharmaceutical companies.
If we fail to enter into or maintain collaborations on reasonable terms or at all, our ability to develop our existing or
future research programs and product candidates and to commercialize our existing or future products could be delayed,
the commercial potential of our products could change and our costs of development and commercialization could
increase.
While we have agreements governing our relationships with these third parties, we have limited influence over their
actual performance and control only certain aspects of their activities. If independent investigators, third-party service
providers or CROs fail to devote sufficient resources to the development of our product candidates, or if their
performance is substandard, it may delay or compromise the prospects for approval and commercialization of any
product candidates that we develop. In addition, our collaborators, CROs, CMOs, distributors, and other third-party
service providers are subject to extensive healthcare, regulatory, data privacy, manufacturing, anti-corruption and other
laws and regulations. Although we seek to structure our relationships in compliance with applicable laws and regulations
and monitor the activities of these third parties, we do not control their day-to-day operations and cannot guarantee that
they will comply with all applicable legal and regulatory requirements. Any failure by our third-party partners to comply
with such requirements could result in regulatory enforcement actions, monetary penalties, exclusion from government
healthcare programs, reputational harm, delays in development or commercialization, or other adverse consequences. In
particular, regulatory authorities enforce GCP requirements through periodic inspections of clinical trial sponsors,
principal investigators and clinical trial sites. If we, our investigators or any of our CROs fail to comply with applicable
GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the Relevant Regulatory Authorities
or comparable regulatory authorities may require us to perform additional clinical trials before approving our marketing
applications. In addition, our collaborative partners may not adhere to, or may terminate collaboration agreements with,
all associated consequences or disagree on the interpretation of contractual terms. We may not be able to control our
collaborative partners’ compliance with all applicable requirements for the commercialization of our products, which
could adversely affect such commercialization and the profitability of such products. Failures by our collaborative
partners to meet their contractual, regulatory, or other obligations to us, or any disruption in the relationships between us
and our collaborative partners, could have a material adverse effect on our product pipeline and business.
We face significant competition in establishing successful relationships with third-party service providers and
appropriate collaborative partners. These third-party service providers may have contractual relationships with other
entities, some of which may be our competitors, which may draw their time and resources away from our programs. In
addition, some of our third-party service providers or CROs have the ability to terminate their respective agreements
with us, and if such agreements terminate, we may not be able to enter into arrangements with alternative CROs or
investigators or to do so on commercially reasonable terms. In addition, we may not be able to find appropriate
collaboration partners.
Disruptions caused by our reliance on third parties for our raw materials and manufacturing process may delay or
disrupt our business, product development and commercialization efforts.
11
Table of Contents
We do not have the ability to internally source the raw materials necessary to produce our products or product
candidates, and do not currently have, nor do we plan to acquire, the infrastructure or capability internally to
manufacture our products or product candidates and depend on a worldwide supply chain and third parties for both.
Disruptions caused by our reliance on such third-party suppliers, service providers and manufacturers may delay or
disrupt our business, product development and commercialization efforts.
Reliance on Third-Party Suppliers and Service Providers
For some of our raw materials, we rely on a single source of supply and there are limited supplies of the raw materials. If
prices increased, or we were to experience an unexpected loss of supply of or if any supplier was unable to meet our
demand for any of our products and product candidates, including increased demand if VYVGART is approved for
additional indications, we could experience delays in our research or planned clinical trials or risk shortages in
commercial supply which could materially impact our revenue potential. These issues could be exacerbated by pressure
on the supply chain, for example due to power shortages, natural disasters, extreme weather conditions, public health
crises, changed laws or regulations, military conflicts, executive orders, or geopolitical events, including trade disputes,
embargoes or economic or financial sanctions enacted as a result of international conflict. The cost of our raw materials
may also increase based on actual or threatened trade restrictions or increased tariffs on foreign exports. As we continue
to grow our business we may need to establish additional sources of supply for our products. The lead time needed to
establish a relationship with a new supplier can be lengthy and require us to devote substantial time and resources, which
could result in additional costs, or delays and adversely affect our business.
Additionally, certain of the raw materials required in the manufacture and the formulation of our products and product
candidates may be derived from biological sources, including mammalian tissues, bovine serum and human serum
albumin. There are certain European regulatory restrictions on using these biological source materials including rigorous
testing requirements, which could limit or delay production. Regulatory authorities may require additional studies if we
adopt a new supplier. If there are changes in the regulation requirements that our suppliers are unable to meet, our
clinical development or commercial activities may be delayed or interrupted.
We may not be able to engage a back-up or alternative supplier or service provider in a timely manner or at all if any of
these third parties were to cease or interrupt production or otherwise fail to supply these materials, products, or services
to us for any reasons, including due to regulatory requirements or actions (including recalls), adverse financial
developments at or affecting the supplier, failure by the supplier to comply with cGMPs, contamination, business
interruptions, or labor shortages or disputes. Interruptions in the supply of these materials, products or services may also
result from international conflict, trade disputes, embargoes or economic or financial sanctions imposed, administered or
enforced by the UN Security Council, the U.S., the UK, the EU, or the respective governmental institutions of any of the
foregoing including, without limitation, the Office of Foreign Assets Control of the US Department of the Treasury, the
US Department of Commerce, the US Department of State and any other agency of the US government.
Reliance on Third-Party Manufacturing
We rely on and expect to continue to rely on CMOs. We also rely on certain third parties to perform filling, finishing,
distribution, laboratory testing and other services related to the manufacture and supply of our products and product
candidates.
We do not control the manufacturing process at our CMOs and are completely dependent on them for the production of
our products and product candidates in accordance with relevant regulations (such as cGMPs), although we are
responsible for ensuring that our products comply with regulatory requirements. If our CMOs cannot successfully
manufacture material that conforms to our specifications and the strict regulatory requirements of the Relevant
Regulatory Authorities or other comparable regulatory authorities, our business could be adversely affected, including an
inability to initiate or continue clinical trials of product candidates under development, delay in submitting regulatory
applications, or receiving regulatory approvals for product candidates, including new indications, subjecting third-party
manufacturing facilities to additional inspections by regulatory authorities, requirements to cease distribution or to recall
batches of our products or product candidates and an inability to meet commercial demands for our marketed products.
Most notably, we contract with Lonza for their manufacturing sites in Slough, UK, Portsmouth, U.S., Singapore and
Visp, Switzerland as well as with Fujifilm, based in Denmark, for activities relating to the development of cell banks,
development of our manufacturing processes and the manufacturing of drug substance. We use additional contract
manufacturers to fill, test, label, package, store and distribute our (investigational) drug products. Our products and
product candidates are biologics and require multiple processing steps that are more difficult than those required for most
small molecule chemical pharmaceuticals. While we work with our CMOs and partners on optimization, strengthening
and upscaling our manufacturing, problems with these manufacturing processes, such as capacity issues, or even minor
deviations from the normal process or from the materials used in the manufacturing process, which may not be
detectable by us in a timely manner, could lead to manufacturing failures or product defects, resulting in lot failures,
product recalls, product liability claims and insufficient inventory.
12
Table of Contents
We face risks inherent in relying on limited CMOs, as any failure in their ability to successfully manufacture our
products or product candidates as described above or any disruption, such as supply shortages or disruptions of raw
materials, fires, pandemics, natural hazards or acts of vandalism at the CMO could significantly interrupt our
manufacturing capability. Alternative production plans in place or disaster-recovery facilities available to us may not be
sufficient. In case of a disruption, we may have to establish additional alternative manufacturing sources. This would
require substantial investment on our part, which we may not be able to obtain on commercially acceptable terms or at
all. Additionally, we may experience significant manufacturing delays as we build or locate replacement facilities and
seek and obtain necessary regulatory approvals. If this occurs, we will be unable to satisfy manufacturing needs on a
timely basis, if at all. Also, operating any new facilities may be more expensive than operating at our current facilities.
Further, business interruption insurance may not adequately compensate us for any losses that may occur, and we would
have to bear the additional cost of any disruption. For these reasons, a significant disruptive event of the manufacturing
facility could have drastic consequences, including placing our financial stability at risk.
Accuracy and timing of our financial reporting is partially dependent on information received from third-party
partners, which we do not control.
We have collaborated, and plan to continue to collaborate, with third parties, including distributor and licensing partners,
on certain product candidates. As part of some of these collaborations, our collaboration partners are responsible for
providing us with financial information regarding specific projects, including funds spent, liabilities incurred and
expected future costs, on which we rely for our own financial reporting. If our collaboration partners fail to provide us
with the necessary financial information within the agreed upon timeframes, or if such financial information proves
inaccurate, it would adversely impact the timing and accuracy of our own financial reporting. Any inaccuracy in our
financial reporting could cause investors to lose confidence in our financial reporting, reputational damage or affect our
ability to obtain, and the terms of, any future financing, which may harm our business.
Risk Factors Related to Other Government Regulations
We are subject to healthcare laws, regulation and enforcement. The failure to comply with these laws could harm our
results, operations and/or financial condition.
Our current and future operations are and may become directly, or indirectly through our customers and third-party
payors, subject to various U.S. federal and state, EU and EU Member State, Japanese, Chinese, UK, Canadian and Israeli
healthcare laws, and healthcare laws of other jurisdictions in which we conduct our business. This includes, but is not
limited to, the U.S. FDCA, the U.S. False Claims Act and EU Directive 2001/83/EC.
In particular, our sales, marketing and business arrangements are subject to healthcare fraud and abuse, anti-kickback
and similar laws designed to prevent fraud, misconduct, improper inducements and other abusive practices. For example,
EU Directive 2001/83/EC restricts the provision of gifts, pecuniary advantages or other benefits to persons qualified to
prescribe or supply medicinal products, subject to limited exceptions. Compliance with these complex and evolving
requirements requires significant resources and may constrain our commercial activities.
Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur
significant legal expenses and divert our management’s attention from the operation of our business.
The shifting compliance environment and the need to maintain robust and expandable systems to comply with multiple
jurisdictions with different compliance or reporting requirements increases the possibility that we or our collaborative
partners may run afoul of one or more of these requirements. We continue to expand, enhance and refine our internal
ethics and compliance function and program to ensure compliance with the different healthcare laws and regulations. As
we continue to grow our headcount to support our business, we face increased compliance risk as we need to train and
supervise additional personnel to comply with relevant healthcare laws and regulations. This involves substantial costs
and, notwithstanding our investment, there can be no assurance that our policies and procedures will be followed at all
times or will effectively detect and/or prevent all compliance violations by our employees, consultants, subcontractors,
agents and partners.
It is possible that governmental authorities will conclude that our business practices do not comply with current or future
statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our
operations are found to be in violation of any of these laws or any other governmental regulations applicable to us, we
may be subject to significant civil, criminal and administrative investigations, penalties, damages, fines, disgorgement,
imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid in the
U.S., additional reporting requirements and oversight, reputational harm and the curtailment or restructuring of our
operations. Managing such investigations and defending against or appealing any such actions or penalties can be costly
and time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful
in managing any such governmental investigations and/or defending against or appealing any such actions or penalties
that may be brought against or imposed upon us, our business may be impaired. Efforts to ensure that our business
13
Table of Contents
arrangements with third parties comply with applicable healthcare laws and regulations also involve substantial costs,
and because we do not fully control the operations or compliance practices of these third parties, we cannot assure you
that they will comply with all applicable healthcare laws and regulatory requirements.
The scope, interpretation and enforcement of healthcare laws remain uncertain and subject to change, particularly in the
current environment of healthcare reform. Federal and state authorities in the U.S. have increased scrutiny of interactions
between healthcare companies and healthcare providers, as well as promotional practices, including direct-to-consumer
prescription drug advertising and manufacturer-sponsored platforms that facilitate patient access to products. The FDA
has also heightened its review of the data supporting advertising and promotional claims. Compliance with these
evolving requirements, and responding to investigations or enforcement actions, may require significant time and
resources and could divert management attention, result in penalties or otherwise adversely affect our business.
All aspects of our business, including preclinical research, clinical trials, marketing and commercialization, are
highly regulated, and any delay by relevant regulatory authorities could jeopardize our development and approval
process and/or result in suspensions of marketing authorizations, refusals to approve our products, or withdrawal of
existing approvals.
Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing to
support our IND or planned IND applications in the U.S. or Japan, or our clinical trial applications (CTAs) in the EU, or
comparable applications in other jurisdictions. We cannot be sure that we will be able to submit INDs or CTAs or
comparable applications for our development programs on the timelines we expect, if at all. We also cannot guarantee
that submission of INDs or CTAs or comparable applications will result in the Relevant Regulatory Authorities or other
regulatory authorities allowing clinical trials to begin.
Clinical trials must be conducted in accordance with applicable laws and regulations, Relevant Regulatory Authorities'
and other comparable regulatory authorities’ legal requirements and regulations and are subject to oversight by Relevant
Regulatory Authorities and other comparable regulatory authorities as well as IRBs and ethics committees. In particular,
clinical trials must be conducted in compliance with GCPs and clinical supplies of our products and product candidates
must be produced under cGMPs and other regulations. We could encounter delays if a clinical trial is suspended or
terminated, by us, by the IRB or ethics committee, by the data review committee or data safety monitoring board for
such clinical trial, or by the Relevant Regulatory Authorities or other comparable regulatory authorities. Such authorities
may impose a suspension or termination due to a number of factors, including failure to conduct the clinical trial in
accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or clinical
trial site by the Relevant Regulatory Authorities or other comparable regulatory authorities resulting in the imposition of
a clinical hold, unforeseen safety issues or adverse side effects, including those relating to the class to which our
products and product candidates belong, failure to demonstrate a benefit from using the product or product candidate,
changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial.
If we experience delays in the completion of, or termination of, any clinical trial of our products or product candidates,
the costs of our clinical programs may increase, the commercial prospects of our products and product candidates may be
harmed, and our ability to generate product revenues from any of these products and product candidates may be delayed.
Significant clinical trial delays could also allow our competitors to bring products to market before we do, or shorten any
periods during which we have the exclusive right to commercialize our products and product candidates.
Moreover, we must obtain separate regulatory approvals in each jurisdiction where we want to market, and approval by
one regulatory authority does not ensure approval by any other regulatory authority. As approval procedures can vary
among countries and may change over time, this can require additional clinical testing, and the time required to obtain
approval may differ. We can provide no assurances that such approval will be obtained on the timeline that we expect or
at all. In addition, we anticipate submitting applications for approval of VYVGART in new indications, but can provide
no assurances that such applications will be accepted or that we will receive approval on our anticipated timeline, or at
all.
If VYVGART or any new formulations of VYVGART are not approved in one or more jurisdictions including beyond
the countries where VYVGART is approved, or if such approvals are significantly delayed, it could have a material
adverse effect on our business. It is possible that none of our other existing product candidates or any product candidates
we may seek to develop in the future will ever obtain regulatory approval in any other jurisdiction for any indication.
Even if approval is obtained, the Relevant Regulatory Authorities or other comparable regulatory authorities may
approve the product for fewer or more limited indications or patient sub-segments than requested and/or with a label that
does not include the labeling claims necessary or desirable for the successful commercialization of that product. Further,
the Relevant Regulatory Authorities or other comparable regulatory authorities may impose extensive and ongoing
unique regulatory requirements, such as granting approval contingent on the performance of costly post-marketing
clinical trials, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product.
14
Table of Contents
The costs of compliance with all Relevant Regulatory Authorities' and other applicable authorities' regulations,
requirements or guidelines could be substantial, and failure to comply could result in sanctions, including fines,
injunctions, civil penalties, denial of applications for marketing authorization of our products, delays, suspension or
withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal
prosecutions, any of which could significantly increase our and/or our collaborative partners’ costs or delay or prevent
the development and commercialization of our product candidates. At this time, we cannot guarantee or know the exact
nature, precise timing and detailed costs of the efforts that will be necessary to complete the remainder of the
development of our research programs and product candidates.
We are subject to privacy, cybersecurity and AI laws, regulation and potential enforcement. The failure to comply
with these laws could harm our results, operations and/or financial conditions.
Privacy laws, regulations and related enforcement are particularly relevant to our business as we collect, store and
process personal data and in particular data of vulnerable groups such as patients, and sensitive information including
health data as well as human biological samples. We also collaborate with third parties where we may seek to use data
collected by third parties on our or their behalf, or we may seek to share data collected by us with such third parties to
further our research or commercial initiatives.
The GDPR imposes strict requirements, including access controls, impact assessment and safeguards on cross-border
transfers of personal data and imposes substantial penalties in the event of non-compliance. We face uncertainty as to the
exact interpretation of the requirements under the GDPR, and we may be unsuccessful in implementing all measures
required by data protection authorities or courts. Any investigation by a data protection authority could result in fines
and other penalties. 
The data privacy landscape is complex and fragmented. In the EU, national laws may impose stricter obligations than
the GDPR, particularly for sensitive genetic, ethnic origin or race data, while regulations like the Directive 2002/58/EC
of the European Parliament and of the Council of July 12, 2002 (as amended, the
e-Privacy Directive) add further compliance risks.
This trend expands globally, with evolving laws in countries such as the U.S., Japan, Canada and China. For example,
China has passed a number of laws concerning data protection and the collection, use and transfer of personal data
(including data considered to be relevant as Chinese human genetic resources), and restricting the transfer of this data
outside of China. These evolving laws and regulations impose increasing restrictions on the processing of personal data,
which may require us to modify our data collection or processing practices and to incur significant expenses associated
with our compliance efforts.
Moreover, in the current digital and regulatory landscape, privacy obligations are increasingly interconnected with
broader cybersecurity laws and requirements, reflecting the close link between the protection of personal data and the
security of information systems. Failure to comply with applicable cybersecurity frameworks and directives, including
Directive (EU) 2022/2555 on Network and Information Security (NIS2), could result in significant legal, regulatory, and
operational risks. In addition, inadequate cybersecurity and non-compliance with data protection laws and regulations
increases the risk of personal data breaches, potentially resulting in regulatory sanctions, civil claims, reputational
damage and loss of trust.
Furthermore, our integration of AI solutions into certain of aspects our business, introduce a new layer of regulatory risk.
Most significantly, Regulation (EU) 2024/1689 (AI Act) establishes the world’s first comprehensive legal framework for
AI, impacting how we develop and deploy AI systems in the future. In particular, high-risk AI systems must comply
with strict regulatory requirements to ensure safety, transparency, and fundamental rights protection. Non-compliance
with the AI Act may result in significant penalties. As most provisions will take effect from August 2, 2026, we must
continuously assess and adapt our compliance strategy to mitigate risks from this evolving legal landscape.
If we violate existing laws and regulations or fail to comply with changing laws and regulations, we might be subject to
fines, penalties and other adverse consequences, which could have a material adverse effect on our reputation, business,
results of operations, cash flows or financial condition.
Failure to comply with anti-corruption laws and regulations, anti-money laundering laws and regulations, economic
or financial sanctions, trade embargoes and/or export control regulations and other laws governing our operations
could have an adverse impact on our business, financial conditions and operations.
We are or may become subject to various laws and regulations regarding anti-corruption, anti-money laundering,
economic or financial sanctions, trade embargoes, investment restrictions, anti-fraud, other comprehensive prohibitions
against transaction activity pursuant to anti-terrorism laws or export control laws and regulations issued by multiple
jurisdictions. These include the UK Bribery Act 2010 and the U.S. Foreign Corrupt Practices Act of 1977, in each case,
15
Table of Contents
as amended, as well as comparable laws and regulations in other countries in which we do business, including in the
European Union and China, which prohibit, among other things, payments, offers, or promises made for the purpose of
improperly influencing any act or decision of a foreign government official. In the UK, since September 1, 2025, it is an
offense under the Economic Crime and Corporate Transparency Act 2023 for a large organization to fail to prevent
certain fraudulent activities by an associated person (such as an employee, agent, or subsidiary), unless it can
demonstrate that it had reasonable prevention procedures in place to prevent the fraudulent activity. The nature of our
business means that we engage in significant interactions with foreign officials. Compliance with these laws and
regulations in the U.S. and in foreign jurisdictions is complex, and may increase our cost of doing business
internationally.
We are also subject to economic and financial sanctions, trade embargoes, other comprehensive prohibitions against
transaction activity pursuant to anti-terrorism laws and export control rules and regulations, including those imposed,
administered or enforced by the UN Security Council, the, U.S., the UK, and the EU. Any change in export or import
regulations, economic or financial sanctions regulations, trade embargo regulations or related legislation, shift in the
enforcement or scope of existing regulations, or change in the countries, governments, persons or technologies targeted
by such regulations, could decrease our ability to conduct our planned research and development activities and to
manufacture, import, export or sell our products internationally, which could require us to expend additional resources to
achieve our goals and adversely affect our business, financial conditions and operations.
We have mechanisms in place to promote compliance with such rules and regulations. However, there can be no
assurance that our policies and procedures will be followed at all times or will effectively detect and/or prevent
violations of applicable compliance regimes by our employees, consultants, sub-contractors, agents and partners. In the
event of non-compliance, we could be subject to substantial civil or criminal penalties, including sanctions against us,
incarceration for responsible employees and managers, the possible loss of export or import privileges, debarment from
participation in government contracting, reputational harm, and resulting loss of revenue and profits, which could have a
material adverse impact on our business, financial conditions and operations.
Our performance tracked by our Environmental, Social and Governance metrics is subject to risks and the outcomes
may not achieve the anticipated benefits or align with new regulations and stakeholders’ expectations.
There has been an increasing focus from stakeholders and regulators relating to environmental, social and governance
(ESG) matters across all industries in recent years. The standards and stakeholder expectations continue to evolve,
sometimes with contradictory expectations, and criteria to evaluate ESG practices may change rapidly. We are subject to
evolving rules, including the European Union’s Corporate Sustainability Reporting Directive (CSRD) and ancillary
European Union legislation. The SEC adopted rules in 2024 requiring enhanced climate-related disclosures, but after
legal challenges, subsequently announced that it would end its defense of such climate disclosure rule. As a result,
various U.S. states have enacted or proposed climate- and sustainability-related disclosure laws that may apply to
companies doing business in those jurisdictions, such as California’s climate and carbon market disclosure laws, which
would require in-scope companies to report on greenhouse gas emissions, climate-related financial risks, and the use of
carbon offsets and emissions reduction claims relating to their operations or products. The future of the California
climate disclosure laws is uncertain, as these laws are subject to ongoing litigation.
In response to new ESG initiatives and regulations we may voluntarily elect, or be required, to adopt strategies, policies,
or procedures related to ESG matters. Such efforts could divert management’s attention from central operational matters
and cause us to expend significant capital and human resources. Moreover, increasingly, different stakeholder groups
and regulators have divergent views, particularly in the U.S., on ESG matters, which increases the risk that any action or
lack thereof with respect to sustainability or ESG matters will be perceived negatively by at least some stakeholders and
regulators and adversely impact our business and reputation. The current sociopolitical landscape has led to rapid and
unpredictable shifts in public sentiment, which has resulted in dynamics that increase the risk of reputational damage,
boycotts and shifts in consumer behavior that could adversely affect our business and reputation. Reports could also lead
to the disclosure of information that may have a negative impact on our operations and reputation which may lead to
additional exposure. In addition,
any required disclosures and measurements of ESG metrics are highly dependent on third-parties, such as our suppliers
and CROs, that we do not control. Failure to accurately comply with any sustainability reporting obligations may result
in enforcement actions, sanctions, fines and penalties, reputational harm or private litigation.
We may become exposed to liability and substantial expenses in connection with environmental compliance or
remediation activities.
Our operations, including our research, development and testing, and our third-party manufacturers’ and suppliers’
operations, are subject to numerous environmental, health and safety laws and regulations and for which we may become
liable. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and
the maintenance of a registry for, hazardous materials and biological materials, laboratory procedures and exposure to
16
Table of Contents
pathogens. We do not have control over our manufacturers’ or suppliers’ compliance with environmental, health and
safety laws and regulations.
If we or one of our CMOs or third-party distributors, manufacturers, suppliers, licensees or co-marketers fail to comply
with such laws and regulations, such failure could result in substantial liability, fines, penalties or other sanctions and
incur substantial expenses, and could also face significant reputational loss.
We face a risk of environmental liability inherent in our current and historical activities, including liability relating to
releases of our exposure to hazardous or biological materials. Furthermore, environmental, health and safety laws and
regulations are becoming more stringent. Both us and our third-party manufacturers and suppliers may be required to
incur substantial expenses in connection with future environmental compliance or remediation activities, in which case,
our production and development efforts may be interrupted or delayed, and our financial condition and results of
operations may be materially adversely affected.
Risk Factors Related to argenx’s Financial Position
We may not be able to be profitable or sustain net profitability in the future and may require additional financing to
fund our operations.
To be profitable or sustain net profitability in the future, we must continue to succeed in commercializing products that
generate significant product net sales. Our future results of operations and profitability may fluctuate from period to
period, and we will need to generate significant revenues to be profitable or sustain net profitability in the future. We
may not be able to generate these revenues, and we may never achieve profitability on a sustained basis in the future. If
we do not succeed in sustaining profitability or in funding our operations, we would not be able to use deferred tax assets
against taxable profits which would result in a de-recognition of our deferred tax asset balance.
In addition, we intend to continue to conduct research and development, preclinical testing, clinical trials and regulatory
compliance activities as well as the continued commercialization of VYVGART and other products candidates, for
current and future indications, and we intend to continue our efforts to expand our sales, marketing and distribution
infrastructure. As a result, we anticipate that our operating expenses will increase as we execute on our strategic
objectives and could increase more significantly if we experience delays or encounter issues relating thereto, including
failed clinical trials, ambiguous clinical trial results, safety issues or other regulatory challenges.
To finance our operations, particularly if we are unable to generate sufficient product net sales or otherwise control
expenses, we may need to raise additional capital through a combination of public or private equity or debt financings or
other sources, which may include collaborations with third parties. Our ability to raise additional funds on acceptable
terms or at all will depend on financial, economic and market conditions and other factors, over which we may have no
or limited control. If we cannot raise additional capital when needed on acceptable terms, we may be required to delay,
reduce or terminate research and development programs; defer or forego commercialization of our products and product
candidates (including for new indications); and limit expansion or otherwise fail to capitalize on business opportunities,
any of which could have a material adverse effect on our business, financial condition and results of operations.
Our assets, earnings and cash flows and the investment of our cash and cash equivalents may be subject to risks
which may cause losses and affect the liquidity of these investments.
We invest our cash in accordance with an established internal investment policy. Currently, substantially all of our
available cash and cash equivalents and current financial assets are invested in either current accounts, savings accounts,
term accounts or highly liquid money market funds. Any future investments may include term deposits, corporate bonds,
commercial paper, certificates of deposit, government securities and money market funds in accordance with our cash
investment policy. These investments may be subject to general credit, liquidity, market, inflation, foreign currency and
interest rate risks and we may realize losses in the fair value of these investments or a complete loss of these
investments. The aforementioned risks associated with our cash flows and investment portfolio may adversely affect our
results of operations, liquidity and financial condition.
Due to the international scope of our operations, our assets, earnings and cash flows are influenced by movements in
exchange rates of several currencies, particularly the euro and Japanese Yen, versus the U.S. dollar. Our revenue from
outside of the U.S. will increase as our products, whether commercialized by us or our business partners or our
collaborators gain marketing approval in such jurisdictions. If the U.S. dollar weakens against a specific foreign
currency, our revenues will increase, having a positive impact on net income, but our overall expenses will increase,
having a negative impact on expenses. Conversely, if the U.S. dollar strengthens against a specific foreign currency, our
revenues will decrease, having a negative impact on net income, but our overall expenses will decrease, having a positive
impact on expenses. Continued volatility in foreign exchange rates is likely to impact our operating results and financial
condition.
17
Table of Contents
Risk Factors Related to argenx’s Business and Industry
We may become exposed to costly and damaging liability claims.
We are exposed to potential product liability and professional indemnity risks that are inherent in the research,
development, manufacturing, marketing and use of pharmaceutical products and marketing of human therapeutic
products. The current and future use of products and product candidates by us and our collaborators in clinical trials and
the sale of any approved products may further expose us to liability claims. If any of our products or product candidates
were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to
substantial liabilities. These claims might be made by patients who use the product, healthcare providers, pharmaceutical
companies, physicians, payors, caregivers, investors, employees, government agencies, or our collaborators or others
selling such products. Physicians and patients may not comply with any warnings that identify known potential adverse
effects and patients who should not use our product candidates. Any claims against us, regardless of their merit, could be
difficult and costly to defend and could materially adversely affect the market for our products and product candidates or
any prospects for commercialization of our products and product candidates. Any such claims, regardless of their merit,
could also adversely affect our reputation and the trust that physician and patients place in our products.
Product liability risk in the EU will increase in the future once plaintiff-friendly reforms, such as Directive (EU)
2024/2853 (the new Product Liability Directive), take effect. The new Product Liability Directive introduces claimant-
friendly changes. This includes, for instance, the expansion of the definition of “damage” (e.g. by including medically
recognized psychological harm), creating rebuttable presumptions as to defect and causation to help claimants prove
their case (e.g. if the claimant faces excessive difficulties to prove this due to scientific complexity) and abolishing
minimum or maximum financial thresholds for claims. The new Product Liability Directive, like its predecessor,
provides that claims shall expire if the injured person does not initiate proceedings within ten years after the defective
product was placed on the market. However, it extends this long stop period (a statute of limitations) to 25 years if this is
due to the latency of the underlying personal injury. Member States must transpose the Product Liability Directive into
national law by December 2026.
Regardless of the merits or eventual outcome, litigation or liability claims may result in:
•decreased demand for our products due to negative public perception;
•damage to our reputation;
•withdrawal of clinical trial participants or difficulties in recruiting new clinical trial participants;
•initiation of investigations by regulators;
•costs to defend or settle the related litigation;
•a diversion of management’s time and our resources;
•substantial monetary awards to clinical trial participants or patients;
•product recalls, withdrawals or labeling, marketing or promotional restrictions;
•loss of revenues from product sales; and
•the inability to successfully commercialize our product candidates, if approved.
Although we maintain product liability insurance, we may not be able to maintain insurance coverage at a reasonable
cost or to obtain adequate insurance coverage to satisfy any liability that may arise. Product liability claims could delay
or prevent completion of our clinical development programs. In addition, claims made by patients, healthcare
professionals or others might not be fully covered by product liability insurance and could result in investigations of the
safety of our products or product candidates or may result in recalls. If a successful product liability claim or series of
claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to
cover such claims and our business, financial condition and results of operations would be adversely affected.
In the ordinary course of business we may also face substantial, complex or extended litigation that could cause us to
incur significant costs and distract our management. This is especially relevant for biopharmaceutical companies. Such
litigation or proceedings could substantially increase our operating expenses and could adversely affect our business.
18
Table of Contents
We may engage in strategic transactions, including acquisitions, collaborations, licenses or investments in other
companies or technologies, and we may not realize the benefits of such transactions.
We may enter into strategic transactions, including acquisitions, collaborations, licenses or investments for or in other
companies or technologies that complement or augment our existing business and facilitate our access to new products,
research projects or geographical areas. However, we may not be able to identify appropriate targets or enter into such
transactions under satisfactory conditions. We may be unable to complete a proposed transaction if we or our
shareholders are unable to obtain required regulatory approvals in the various jurisdictions in which we or a potential
acquisition target or acquirer operate. In addition, we may need additional funding to finance these transactions including
through issuances of public or private equity or convertible debt securities, which could be dilutive to our shareholders
and ADS holders.
Integrating any newly acquired companies, business, technologies or products could be expensive, time-consuming, and
may never be successful. Integration efforts often take a significant amount of time, place a significant strain on
managerial, operational and financial resources, result in loss of key personnel and could prove to be more difficult or
expensive than we predict. The diversion of our management’s attention and any delay or difficulties encountered in
connection with any future transactions we may consummate could result in the disruption of our ongoing business or
inconsistencies in standards and controls that could negatively affect our ability to maintain third-party relationships. We
cannot assure that we will achieve the expected synergies to justify any such transaction, which could have a material
adverse effect on our business, financial condition, results of operations and future growth prospects and our investors’
ability to realize on their investment.
Our business and operations could suffer in the event of system failures or unauthorized or inappropriate use of or
access to our systems.
We are increasingly dependent on our and our third-party partners’ information technology systems and infrastructure
for our business. We collect, store and transmit sensitive information including intellectual property, proprietary business
information, including highly sensitive clinical trial data, and personal data in connection with business operations. The
secure maintenance of this information is critical to our operations and business strategy. Some of this information could
be an attractive target of criminal attack or unauthorized access and use by third parties with a wide range of motives and
expertise, including organized criminal groups, “hacktivists”, patient groups, disgruntled current or former employees
and others. Cyber-attacks are of ever-increasing levels of sophistication, and despite our security measures, our
information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to
employee error or malfeasance.
In addition to these threats, we are subject to stringent cybersecurity laws, most notably NIS2 with respect to our
activities in the European Union. As a company involved in the development and manufacturing of pharmaceutical and
medicinal products, our operations could be brought within the scope of NIS2. This would require us to implement
robust measures to secure our network and information systems. We are also subject to cybersecurity laws in other
international jurisdictions in which we conduct our operations, such as the Cybersecurity Review Measures in China.
Failure to comply with these cybersecurity standards could result in significant penalties. See ”Item 3.D. Risk Factors—
Risk Factors Related to Other Government Regulations—We are subject to privacy, cybersecurity and AI laws,
regulation and potential enforcement. The failure to comply with these laws could harm our results, operations and/or
financial conditions.”
Although we are making significant efforts to maintain the security and integrity of our information systems and the
information systems of our third-party partners and are exploring various measures to manage the risk of a security
breach or disruption, there can be no assurance that our security efforts and measures will be effective or that attempted
security breaches or disruptions would not be successful or damaging. Despite the implementation of security measures,
our internal computer systems and those of our third-party partners, contractors and consultants are vulnerable to damage
or interruption from computer viruses, unauthorized or inappropriate access or use, natural disasters, pandemics,
terrorism, war (including the ongoing conflict in Ukraine and conflict in the Middle East), and telecommunication and
electrical failures. For example, the loss of pre-clinical trial data or data from completed or ongoing clinical trials for our
product candidates could result in delays in our regulatory filings and development efforts, as well as delays in the
commercialization of our products, and significantly increase our costs. To the extent that any disruption, security breach
or unauthorized or inappropriate use or access to our systems were to result in a loss of or damage to our data, or
inappropriate disclosure of confidential, personal or proprietary information, we could incur notification obligations to
affected individuals and government agencies, liability, including potential lawsuits from patients, collaborators,
employees, stockholders or other third parties and liability under foreign, federal and state laws that protect the privacy
and security of personal data, and the development and potential commercialization of our product candidates could be
delayed. Disruptions in the our and our third-party partners’ information technology systems could adversely affect our
business operations and harm our competitive position.
19
Table of Contents
Not all of our contracts contain limitations of liability, and even where they do, there can be no assurance that limitations
of liability in our contracts are sufficient to protect us from liabilities, damages or claims related to our data privacy and
security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to
mitigate liabilities arising out of our privacy and security practices.
Risk Factors Related to argenx’s Intellectual Property
We may be unable to adequately maintain, enforce or protect our intellectual property rights in products, product
candidates and platform technologies which could adversely affect our ability to maximize the value for patients in
our marketed products and product candidates.
Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property
rights for our products, product candidates and platform technologies. Failure to obtain, maintain, enforce, protect, or
extend adequate patent and other intellectual property rights, which can be challenging and costly, could adversely affect
our ability to develop and market our products and product candidates and reduce any competitive advantage we may
have.
We cannot be certain that patents will be issued or granted with respect to applications that are currently pending and we
may not be the first to file patent applications related to our product candidates and products. The scope of patent
protection that the European Patent Office and the USPTO will grant with respect to products in our product pipeline is
uncertain and may vary. It is possible that the European Patent Office and USPTO will not allow broad claims that cover
molecules closely related to our products and product candidates as well as the specific molecule, and competitors may
be free to market substantially similar molecules if granted approval, thereby reducing our market potential. We and our
current or future licensors, licensees or collaboration partners may not be able to prepare, file, prosecute and maintain all
necessary or desirable patent applications at a reasonable cost or in a timely manner. Our current and future licensors’,
licensees’ or collaboration partners’ ability to ensure the issuance, scope, validity, enforceability and commercial value
of technology licenses is uncertain and we may need to rely on them to obtain costly additional IP licenses. Additionally,
such parties may not fully comply with applicable patent rules or laws, which could result in loss of patent rights, or such
parties may disagree with us as to the strategy for prosecution, maintenance or enforcement of any such patent rights.
Filing, prosecuting, and defending patents on product candidates in all jurisdictions throughout the world would be
prohibitively expensive and the laws of certain jurisdictions may not protect our rights to the same extent as the laws of
the U.S., UK or EU. We may face difficulties in enforcing patent rights in the future, including in certain jurisdictions
where we have not yet filed patent applications.
Competitors may use our and our licensors’ or collaboration partners’ technologies in jurisdictions where we have not
obtained patent protection, or where broad research exemptions are available, to develop their own products. Third
parties may export otherwise infringing products to territories where we, our licensors or collaboration partners have
patent protection, but where enforcement is not as strong as that in the U.S., UK and the EU. In such cases, we would
have little effective recourse to prevent such products from competing with ours.
In addition, some countries have compulsory licensing laws under which a patent owner may be compelled to grant
licenses to third parties, and other countries limit the enforceability of patents against government agencies or
government contractors. In these countries, the patent owner may have limited remedies, which could materially
diminish the value of such patent.
Intellectual property litigation could lead to substantial resource diversion or issued patents could be found invalid,
not infringed, or unenforceable if challenged in the applicable patent office or court.
Our patents may remain open to invalidity challenges after allowance or grant, whereby third parties can challenge the
scope or validity of such granted patent. In the course of such proceedings, we may be compelled to limit the scope of
patent claims thus challenged or may lose the claims altogether.
We may elect to initiate adversarial proceedings in order to enforce or defend any intellectual property rights owned by
or licensed to us, or to determine or challenge the scope or validity of intellectual property rights of third parties to
protect our competitive position. We may need to divert substantial time and resources to the enforcement and protection
of our or our collaboration partners’ intellectual property rights. In addition, the outcomes of any proceedings could be
uncertain and any remedies or damages awarded may not be meaningful. An adverse ruling of non-infringement,
limiting claim scope, or invalidating one or more of our issued patents could allow third parties to commercialize our
products after the expiration of our market exclusivity or use our platform technologies to compete directly with us,
without payment to us.
20
Table of Contents
In many jurisdictions (including the Unified Patent Court), an action to enforce a patent may not be brought until
immediately before, or even after, the infringing product of a competitor has been launched in the market. In these
jurisdictions, infringement rulings and injunctions (even in preliminary injunction proceedings) are often issued only
after the competing product has already been launched and potentially impaired the competitive advantage on the
market.
We may be subject to claims challenging the inventorship or ownership of our intellectual property or be required to
make additional payments to secure intellectual property from collaborators.
Many of our consultants and employees, including in the senior management team (consisting of our CEO and senior
personnel reporting directly to the CEO) (Senior Management Team), were previously employed at other competing or
potentially competing biotechnology or pharmaceutical companies and some have executed proprietary rights, non-
disclosure and non-competition agreements in connection with such previous employment. Although we take measures
to ensure third parties, consultants and employees do not use such proprietary information in their work for us, we may
be subject to claims that we or these consultants and employees have improperly used or disclosed confidential
information or intellectual property of their former employer.
Additionally, many of our collaborators do not commit to assigning all intellectual property arising out of our
collaborations to us and, instead, grant us options to acquire intellectual property or commit to making such intellectual
property available to us at a fair price. As such, we may be required to make additional payments to secure valuable
intellectual property rights under our existing collaborations or become subject to inventorship disputes.
In addition, although we take steps to ensure that our collaborators do not use our intellectual property rights other than
for the purposes of our collaboration, there may be instances where former or current collaborators or other third parties
nevertheless apply for or obtain patent protection for inventions to which we believe we have rights, in whole or in part.
In such cases, we may elect to assert our ownership of such intellectual property. There is no guarantee that we will be
successful in asserting such claims.
In addition, while it is our policy to require our employees and contractors who may be involved in the development of
intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in
ensuring effective assignment of intellectual property under such agreements. Our assignment agreements may not be
self-executing, or may be breached, and we may be forced to bring or defend against claims to assert ownership of such
intellectual property. There is no guarantee we will be successful in pursuing such claims, which could result in us
paying monetary damages or losing valuable personnel or intellectual property rights.
Third-party intellectual property rights could adversely affect our ability to commercialize our products and product
candidates.
Our revenue generated may suffer if valid and enforceable third-party intellectual property rights cover our products,
product candidates, manufacturing processes, or those of our partners. In such cases, our freedom to develop or
commercialize products or product candidates may require obtaining a license, designing around third party intellectual
property rights with significant time and materials costs, or invalidating the third party rights. If our products are found
to infringe a valid and enforceable patent claim, we and our partners could be prevented from continuing to develop or
commercialize the affected product without an appropriate license, which may be costly or unavailable on commercially
reasonable terms, if at all. Similarly, other companies may have filed patent applications or have patents directed toward
molecules and/or uses of those molecules that modulate similar targets modulated by our products and we may not be
aware of unpublished pending patent applications or patent applications that are amended to cover our products or
platform technologies.
Even if we or our partners can obtain the appropriate license, it may be non-exclusive, thereby providing third parties
with the opportunity to access the same licensed technology. If the breadth and scope of protection provided by our or
our partners’ patents, licensed patents, or patent applications is threatened or limited, it could dissuade companies from
future collaborations with us to license, develop, or commercialize products and product candidates which would have
an adverse effect on our business position.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation,
some of our confidential information could be disclosed in any such proceedings.
We may not be successful in obtaining or maintaining necessary rights to our products and product candidates
through acquisitions and in-licenses.
We may be unable to acquire or in-license third-party intellectual property rights necessary or useful for development or
commercialization of our product, product candidates or technology. We sometimes collaborate with U.S. and non-U.S.
21
Table of Contents
academic institutions and typically receive an option to negotiate a license to the institution’s proprietary interest in any
collaboration technology. However, we may be unable to successfully negotiate such license and the institution may
offer such intellectual property rights to third parties thereby devaluing our exclusive rights to pursue the applicable
program.
In addition, our competitor companies may be unwilling to license desirable or necessary intellectual property rights to
us, or we may be otherwise unable to license or acquire other third party intellectual property rights on commercially
reasonable terms which could negatively impact current development or hinder our ability to pursue development of new
programs.
Under our existing licenses, failure to comply with our obligations thereunder could result in termination of such
licenses, thereby limiting our ability to develop and commercialize products covered by such licensed technology.
Moreover, despite our efforts to comply with our contractual obligations, our licensors could conclude we have
materially breached any such agreement and we could incur significant costs and disruption to our business defending
against any breach alleged by the licensor.
Moreover, several of our existing license agreements are sub-licenses from third parties. We have little control if our
licensors fail to comply with their obligations under their upstream license agreements, whereby the original third-party
licensor may have the right to terminate the original license and possibly our sub-license. In such cases, we may not be
able to procure a direct license covering such intellectual property possibly materially affecting our ability to develop
and commercialize certain products and product candidates.
If our brand protection strategies, including the filing, prosecution and enforcement of trademarks and trade names,
are not adequately executed, we may not be able to build name recognition for approved products in our markets of
interest in line with our strategic priorities.
Third parties may seek to oppose, attempt to cancel our trademark applications, or challenge, infringe or circumvent our
registered and unregistered trademarks, including through counterfeiting of our products. In the event that our
trademarks are successfully challenged, we may not be able to use these trademarks to continue to effectively market our
branded products and could be forced to rebrand them, which could result in loss of their brand recognition or require us
to devote resources to develop new brand profiles. Such efforts could also hinder our efforts to commit to and deliver on
strategic internal initiatives.
If we attempt to enforce our trademarks or assert trademark infringement claims, a court may determine that our
trademarks are invalid or unenforceable or that the party against whom we have asserted trademark infringement has
superior rights with respect to such marks. If we are unable to establish name recognition and adequately protect and
enforce our trademark portfolio, we may not be able to compete effectively in the market or build brand recognition for
new products globally.
We may not be able to obtain protection under the U.S. Drug Price Competition and Patent Term Restoration Act of
1984 (Hatch-Waxman Act) and similar non-U.S. legislation for extending the term of patents covering each of our
products and product candidates.
Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more
of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act and similar
legislation in the EU and the Asia Pacific region. However, the patent term extension under the Hatch Waxman Act
cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one
patent applicable to an approved drug may be extended.
If we are unable to obtain patent term extension, the term of any such extension is less than we request, or the statutes
governing patent term extension are amended to reduce the term of such extensions, our patent exclusivity for that
product will be shortened and our competitors may obtain approval to market competing products sooner than we expect.
Changes in patent laws or patent jurisprudence could diminish the value of patents in general thereby impairing our
ability to protect our products.
Changes in patent law across jurisdictions, or changes in any relevant government’s enforcement procedure may weaken
our ability to obtain new patents or to enforce rights in our owned and licensed patents. For example, the U.S. Supreme
Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in
certain circumstances or weakening the rights of patent owners in certain situations. Relatedly, the U.S. Congress is
considering multiple draft bills that, if passed, may have a significant impact on U.S. patent laws. Any such changes by
22
Table of Contents
the U.S. Congress or U.S. courts and the relevant law-making bodies in other countries may materially affect our patents
or patent applications and we cannot predict the effects of future changes in patent law.
We may be unable to protect the confidentiality of our trade secrets and their disclosure to competitors, harming our
market position.
In addition to patent protection, we rely on trade secret protection to preserve the value of our proprietary information
supporting our business model. We take balanced measures to preserve the commercial value of our trade secrets and
prevent their misappropriation. However,despite these measures, which include segregation of key files, requiring our
licensors, collaborators, suppliers, consultants and advisors to execute confidentiality agreements, we cannot fully
protect against willful or inadvertent unauthorized disclosure of our trade secrets. Trade secret enforcement proceedings
can be unpredictable and vary across geographies and we may not be able to secure adequate legal or equitable remedies
to prevent lost value in our misappropriated trade secrets. Any misappropriation and use, whether willful or inadvertent,
could result in lost value to the company and enable our competitors to duplicate or build upon our technology.
Risk Factors Related to argenx’s Organization and Operations
Our future growth and ability to compete depends on maintaining our culture, retaining our key personnel and
recruiting additional qualified personnel.
We believe that our corporate culture has been, and will continue to be a key contributor to our success. However, as we
implement more complex organizational structures, and increase our headcount to support the growth in our business,
our ability to foster our key values - innovation, co-creation, empowerment, excellence and humility that we believe are
important to support our growth - may be impacted. We may find it increasingly difficult to maintain the beneficial
aspects of our corporate culture, which could similarly negatively impact our ability to attract, retain and motivate
qualified employees and our future success.
As a global organization in a highly competitive and specialized industry, our success also depends upon the continued
contributions of our key management, scientific, medical and technical personnel, many of whom have been
instrumental for us and have substantial experience with our product and related technologies. These key management
individuals include the members of the Board of Directors and Senior Management Team. Difficulties in recruiting or
the loss of key managers, scientific, medical or technical personnel could delay our research and development activities.
In addition, it may be difficult to attract and retain highly qualified management, scientific and medical personnel,
particularly if we expand into fields that will require additional skills. In addition, future leadership transitions and
management changes may cause uncertainty in, or a disruption to, our business, and may increase the likelihood of
senior management or other employee turnover. We are currently undergoing a leadership transition, as in early January
2026, we announced that Karen Massey, our current COO, will transition to the role of CEO and Executive Director and
Tim Van Hauwermeiren, our current CEO, will transition to the role of Non-Executive Director and Chairperson of the
Board of Directors. Both transitions are subject to shareholder approval at the 2026 General Meeting. Any failure to
ensure an effective transition or any future management changes could adversely affect our business, and we cannot
predict the likelihood, timing or effect of future transitions among our executive leadership.
As a Dutch company listed on Euronext Brussels and Nasdaq, our remuneration practices and policies may be limited by
local governance rules or shareholder guidance for EU companies. Such limitations may make it more difficult to
successfully compete for key talent in a number of markets with differing remuneration practices and policies compared
to our competitors. For example, the Dutch Corporate Governance Code 2025 (DCGC) places certain limitations on the
ability to grant equity incentives to Non-Executive Directors, while Belgian law requires Non-Executive Directors to
receive part of their remuneration in the forms of shares, but not stock options. The DCGC also places limitations on
amount of severance payment permitted in the event of dismissal.
Many other biotechnology and pharmaceutical companies and academic institutions that we compete against for
qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry
than we do. Additionally, inflationary pressures and a tight labor market for skilled workers may increase compensation
expectations, requiring us to raise operating costs in order to attract and retain employees. Therefore, we might not be
able to attract or retain these key persons or other employees on conditions that are economically acceptable.
Global geo- and socio-political threats and macro-economic uncertainty and other unforeseen political crises could
materially and adversely affect our business and financial performance.
Many geo- and socio-political threats and macro-economic uncertainties are outside of our control and could adversely
affect consumer confidence and disposable income levels, increase difficulty in forecasting our financial results and have
other impacts on our business and financial performance. Such geo- and socio-political threats could also result in
23
Table of Contents
volatility in stock markets in general, causing our stock to have extreme price and volume fluctuations unrelated to our
business and financial performance.
Such geo- and socio-political threats and uncertainties include:
•general economic and market conditions, including government shutdowns, including the U.S. government shutdown,
instability resulting from inflationary pressures, and increasing interest rates;
•geopolitical events, including natural disasters, public health emergencies, acts of war, and terrorism;
•economic and financial sanctions, trade embargoes, import and export regulations, tariffs, customs, and inbound and
outbound investment restrictions;
•restrictions, changes in trade agreements, trade barriers or other restrictions on foreign trade, and changes in trade
regulations and restrictions, including between the U.S. and other countries;
•global or regional economic conditions that impact companies and customers with which we do business;
•political or social unrest, economic instability, repression, or human rights issues;
•disruptions in supply chains;
•risks related to other government regulation or required compliance with local laws;
•consumer and commercial credit availability, unemployment, and consumer debt levels; and
•local licensing and reporting obligations.
Due to our international operations and the fact that we run clinical trials across multiple jurisdictions, geopolitical
conflicts and related sanctions may, in certain circumstances, impact our ability to conduct or complete clinical trials in
the affected regions. For example, General License 6D issued by the U.S. Department of the Treasury’s Office of
Foreign Assets Control currently authorizes certain clinical trial and medical research activities that would otherwise be
restricted by U.S. sanctions targeting Russia, the scope, availability, or duration of such authorizations may change.
We also perform development activities in a number of countries exposed to geopolitical risk and if conflicts in those
countries were to escalate further and impact neighboring countries, it could impact our development activities in those
countries.
Changes in U.S.-Mainland China relations, including tariffs, export controls, economic and financial sanctions, and other
regulations may adversely impact our collaboration with Zai Lab in Mainland China, Hong Kong, Taiwan and Macau
(together, Greater China). The U.S. government has taken steps and continues to take steps with regard to U.S.-Mainland
China relations that will impact companies with connections to the U.S. or Mainland China, including by imposing
tariffs affecting certain products manufactured in Mainland China, imposing economic and financial sanctions on certain
individuals and entities in the Mainland China, and issuing statements indicating enhanced review of companies with
significant Mainland China-based operations. The U.S. government has also passed laws, including the BIOSECURE
Act, which was signed into law on December 18, 2025, that could limit or restrict our ability to purchase products or
services from, or otherwise collaborate with, certain Chinese biotechnology companies without losing our ability to
contract with or receive funding from the U.S. government. Such restrictions could have an adverse impact on our
operations.
Several countries are considering or have implemented tariffs, trade barriers or restrictions, as well as other measures
impacting cross-border commerce, which could negatively affect our business, financial conditions and results of
operations, including by disrupting our research and development activities, affecting our suppliers and negatively
impacting our supply chain, impacting our ability to sell our products outside of the United States and negatively
impacting our revenues from product sales or our cost of goods sold. The U.S. federal government has implemented
tariffs on certain foreign goods and may implement additional or revised tariffs in the future. Such actions could give rise
to retaliatory tariffs imposed by foreign governments and an escalation of trade measures by the U.S. and impacted
countries. Developments with regard to the timing and manner in which tariffs will be implemented; the amount, scope,
and nature of tariffs; the countries subject to new or additional tariffs imposed by the U.S.; tariffs imposed by other
countries on goods imported from the U.S.; and other wide-ranging retaliatory measures are rapidly evolving and may
change unexpectedly at any time. For example, the U.S. President has repeatedly announced plans to impose 100%
tariffs on imported branded or patented pharmaceuticals, unless the importing company is building U.S. manufacturing
capacity. It is not yet clear whether these tariffs would apply to the importation of active pharmaceutical ingredients and
24
Table of Contents
possibly bulk drug products that are intended for use in clinical trials and not for commercial sale, which could increase
the costs of materials for our clinical trials. Any direct tariffs, if imposed on pharmaceutical products, may result in
increased costs for raw materials and contract manufacturing services, reduced ability to source critical CMOs, and a
delay in our development timelines. Although on February 20, 2026, the U.S. Supreme Court struck down certain tariffs
imposed by the Trump Administration pursuant to the International Emergency Economic Powers Act, the Trump
Administration responded by announcing new tariffs pursuant to another statute. Other countries may, in turn, retaliate
with new tariffs against US exports. These events increase the uncertainty and the risks we face resulting from tariffs
described above.
Any new legislation, executive orders, tariffs, export controls, economic and financial sanctions, trade embargoes and/or
other regulations that may be implemented, any unfavorable government policies on international trade, including tariffs
and export controls, the renegotiation of existing trade agreements, any increased scrutiny on companies with significant
Mainland China-based operations, and any retaliatory actions taken by the U.S., EU, Chinese or other governments due
to trade tensions could have an adverse effect on our business, including the development and commercialization of
products containing argenx-licensed material. Further, general political uncertainty may have an adverse impact on our
business, financial condition and results of operations. 
We face risks related to natural disasters and public health issues, that could negatively affect our business and
financial condition.
Our business could be adversely impacted by the effects of catastrophic global events including natural disasters such as
earthquakes, fires, hurricanes, tornados, floods or significant power outages and public health crises.
For example, the manufacturing of all of our products and product candidates requires using cells which are stored in a
cell bank. We have one master cell bank for each product manufactured in accordance with cGMPs. However, it is
possible that we could lose multiple cell banks and have our manufacturing significantly impacted by the need to replace
these cell banks, which could materially adversely affect our business, prospects, financial condition and results of
operations. Public health issues could also negatively affect our business and financial condition. We operate and
conduct our clinical trials globally. We cannot presently predict the scope and severity of any potential future business
shutdowns or disruptions as a result of public health issues. If we or any of the third parties with whom we engage,
including the suppliers, contract manufacturers, clinical trial sites, regulators and other third parties, were to experience
shutdowns, quarantines, or other business disruptions due to natural disasters or global public health issues, it may
impair our or our third-party partners’ ability to initiate clinical trials and recruit and retain patients, particularly if
quarantine or travel restrictions impede healthcare provider or patient movement, impact the usability of the data due to
treatment interruptions and require protocol amendments. In addition, regulatory authorities may restrict their operations
or be delayed in their operations during a pandemic, the outbreak of new variants or other public health issues, including
further to travel restrictions which could adversely affect our ability to obtain regulatory approval for and to
commercialize our products and product candidates and have a material adverse effect on our business and financial
results.
We are exposed globally to unanticipated changes in tax laws and regulations, adjustments to our tax provisions,
exposure to additional tax liabilities, or adjustments of our tax assets.
As a company active in research and development, we have benefited from certain research and development tax
incentives including tax credits and a payroll withholding tax exemption. We also expect to benefit from the Belgian
innovation income deduction.
The determination of our provision for income taxes and other tax liabilities requires judgment, including the adoption of
certain accounting policies and our determination of whether our deferred tax assets are, and will remain, fully available
in future periods. We cannot guarantee that our interpretation of applicable tax laws (including with respect to our
eligibility for, or our calculation of, tax incentives such as the Belgian R&D tax credit, the Belgian payroll withholding
tax exemption for R&D personnel, the Belgian innovation income deduction and similar tax incentives in other
jurisdictions in which we have material operations or sales), our transfer pricing policies or our organizational and
operational structure will not be questioned by the relevant tax authorities, or that the relevant tax laws and regulations,
or the interpretation thereof, including through tax rulings, will not be subject to change. Our effective tax rates could be
adversely affected, now or in the future, by changes in tax laws, treaties and regulations or the interpretation thereof by
the relevant tax authorities in countries where we have material operations. A successful challenge to tax positions in
Belgium or other country where we have material operations may lead to adjustments in the amounts recorded in our
financial statements and could have a significant impact on our effective tax rate and on our deferred tax assets. An
increase of the effective tax rates could have an adverse effect on our business, financial position, results of operations
and cash flows.
In case of a change of control, we could be exposed to the risk of losing any unused tax credit and innovation income
deduction. Furthermore, if any legislator decides to eliminate, or change the conditions for claiming such tax incentives,
25
Table of Contents
or reduce the scope or the rate of such incentives, any of which it could decide to do at any time, our results of operations
could be adversely affected including through the de-recognition of deferred tax assets.
We may encounter difficulties efficiently managing our growth and our increasing development, regulatory, and sales
and marketing capabilities, which could disrupt our operations.
We have grown, and expect to continue to grow globally, significantly in the number of employees and scope of
operations over recent years, particularly in the areas of drug research, drug development, regulatory affairs, and sales
and marketing. To manage our anticipated future growth and support our expanding global footprint, we must continue
to enhance our managerial, operational and financial systems, expand our facilities and recruit and train additional
qualified personnel and build the internal infrastructure necessary. Any inability to manage growth effectively could
delay the execution of our strategic objectives or disrupt our operations, which in turn could materially harm our
business and prospects.
In particular, our planned international expansion subjects us to a number of risks, including risks following complexities
in monitoring and coordinating research and development, marketing, supply chain and other operations in a large
number of jurisdictions, risks related to laws, regulations and policies, including those implemented following changes in
political leadership and trade, risks related to varying standards and practices in the legal, regulatory and business
cultures in which we operate, risks related to capital and exchange controls, cross-border taxes and tariffs, cross-border
data transfer restrictions, and complex sanctions regimes in various countries such as the U.S., the EU and other
jurisdictions, violations of which could lead to fines or other penalties, risks related to geopolitical and local political
instability and uncertain business environments and risks related to complexities associated with managing local
personnel and preventing misconduct by local third-party partners.
The application of laws and regulations impacting global business operations is often unclear and may at times conflict.
Compliance with these laws and regulations may involve significant costs or require changes in our business practices
that result in reduced revenue and profitability. Non-compliance could also result in fines, damages, criminal sanctions,
prohibited business conduct, and damage to our reputation.
Risk Factors Related to the ADSs
Holders of our ADSs have fewer rights than our ordinary shareholders.
Except as described in this Annual Report or any deposit agreements, holders of ADSs are not treated as our
shareholders unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement
and applicable laws and regulations. The depositary, or its nominee, is the holder of the ordinary shares underlying the
ADSs. ADSs are transferable on the books of the depositary. The depositary may refuse to deliver, transfer or register
transfers of ADSs. Temporary delays in the cancellation of ADSs and withdrawal of the underlying ordinary shares may
arise. In addition, ADS holders may not be able to cancel their ADSs and withdraw the underlying ordinary shares when
they owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply
with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited
securities.
Holders of ADSs may vote them in person or by proxy in accordance with applicable laws and regulations and our
articles of association (Articles of Association). We cannot guarantee that holders of ADSs will receive the voting
materials in time to ensure that they can instruct the depositary to vote the ordinary shares underlying their ADSs.
Holders of our ADSs may not be able to exercise their right to give voting instructions or to vote in person or by proxy
and they may not have any recourse against the depositary or us if their ordinary shares are not voted as they have
requested or if their shares cannot be voted.
The price of our ADSs may be volatile and may fluctuate due to factors beyond our control. An active public trading
market may not be sustained.
The stock markets in general, and biopharmaceutical companies in particular, have experienced extreme price and
volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.
The trading price of our ADSs depends on a number of factors, including those described elsewhere in this “Risk
Factors” section, many of which are beyond our control and may not be related to our operating performance, which may
limit or prevent investors from readily selling their ADSs or ordinary shares and may otherwise negatively affect the
liquidity of our ADSs and ordinary shares. We provide guidance regarding our cash and expenses, which are inherently
uncertain. Any guidance that we provide may not always be accurate or may vary. If we fail to meet our guidance, or if
we have to revise such guidance, the price of our ADSs or ordinary shares could decline. Sales of a substantial number
of ADSs or our ordinary shares in the public market, or the perception that these sales might occur, could depress the
26
Table of Contents
market price of ADSs or our ordinary shares and could impair the market price of our securities or our ability to raise
capital through the sale of additional equity securities.
In addition, an active public trading market for our ADSs may not be sustained. Further, fluctuations in exchange rates
may also impact the price of our ADSs and ordinary shares which may result in heavy trading by investors seeking to
exploit such differences, or impact the proceeds holders receive.
If securities or industry analysts cease coverage of us, or publish inaccurate or unfavorable research about our
business, the price of our ADSs or ordinary shares and our trading volume could decline.
The trading market for the ADSs and ordinary shares depends in part on the research and reports that securities or
industry analysts publish about us or our business. We do not have control over these analysts. If no or too few securities
or industry analysts cover us, the trading price of our ADSs and ordinary shares would likely be negatively affected. If
one or more of the analysts who cover us downgrade our ADSs or ordinary shares or publish inaccurate or unfavorable
research about our business, the price of our ADSs or ordinary shares would likely decline.
If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our
ability to comply with applicable regulations could be impaired, and the trading price of our ADSs may be negatively
impacted.
We are required to comply with various corporate governance and financial requirements under the Sarbanes-Oxley Act
of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing rules of the Nasdaq Global
Market (the Nasdaq Listing Rules) and requirements, and other applicable securities rules and regulations. We are
required to furnish a report by management on, among other things, the effectiveness of our internal control over
financial reporting and an attestation report on internal control over financial reporting issued by our independent
registered public accounting firm. Undetected material weaknesses in our internal controls could lead to financial
statement restatements and require us to incur the expense of remediation. Moreover, any failure to maintain internal
control over financial reporting or any material weaknesses or significant deficiency thereover, could result in a loss of
investors’ in the accuracy, completeness and reliability of our financial statements, subject us to sanctions or
investigations, or negatively impact the trading price of our ADSs or ordinary shares.
Risk Factors Related to being a Foreign Private Issuer or a Dutch Company
The risks in this subsection that relate to our status as a foreign private issuer will change if we lose our status as a
foreign private issuer under U.S. law.
We are a Dutch European public company with limited liability. The rights of our shareholders may be different from
the rights of shareholders in companies governed by the laws of U.S. jurisdictions.
We are a Dutch European public company with limited liability (Societas Europeae). The rights of shareholders and the
responsibilities of members of our Board of Directors may be different from the rights and obligations of shareholders in
companies governed by the laws of U.S. jurisdictions.
As a result of these differences between Dutch corporate law and our Articles of Association, on the one hand, and the
U.S. federal and state laws, on the other hand, in certain instances, our shareholders and holders of our ADSs could
receive less protection than they would as shareholders or ADS holders of a listed U.S. company.
For example, provisions of our Articles of Association may make it more difficult for a third party to acquire control of
us or effect a change in our Board of Directors. We have adopted several provisions that may have the effect of making a
takeover of our Company more difficult or less attractive. These provisions could discourage potential takeover attempts
that other shareholders may consider to be in their best interest and could adversely affect the market price of our
securities.
Holders of our ordinary shares outside the Netherlands, and holders of ADSs may not be able to exercise pre-emptive
rights or preferential subscription rights, respectively.
In the event of an increase in our share capital, holders of our ordinary shares are generally entitled under Dutch law to
full pre-emptive rights, unless these rights are excluded either by a resolution of the shareholders at a General Meeting,
or by a resolution of the Board of Directors (if the Board of Directors has been designated by the shareholders at a
General Meeting for this purpose).
However, making pre-emptive rights available to holders of ordinary shares or ADSs representing ordinary shares also
requires compliance with applicable securities laws in the jurisdictions where holders of those securities are located,
27
Table of Contents
which we may be unable or unwilling to do. In particular, holders of ordinary shares or ADSs located in the U.S. would
not be able to participate in a pre-emptive rights offering unless we registered the securities to which the rights relate
under the U.S. Securities Act of 1933, as amended (Securities Act) or an exemption from the registration requirements.
In addition, ADS holders would not be able to participate in a pre-emptive rights offering unless we made arrangements
with the depositary to extend that offering to holders of ADSs, which we are not required to do.
Claims of U.S. civil liabilities may not be enforceable against us or the members of our Senior Management Team
and our Board of Directors.
A significant amount of our assets are located outside the U.S. The majority of the members of our Senior Management
Team and our directors are not U.S. residents and we do not have significant assets in the U.S. As a result, it may not be
possible, or more difficult, for investors to enforce against them or us in U.S. courts, including judgments predicated
upon the civil liability provisions of the U.S. federal securities laws. There are no treaties between the U.S. with either
the Netherlands or Belgium providing for the reciprocal recognition and enforcement of judgments, other than arbitration
awards, in civil and commercial matters. Consequently, a final judgment for payment given by a court in the U.S. based
on civil liability, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or
enforceable in the Netherlands or in Belgium unless the underlying claim was re-litigated before a Dutch or Belgian
court of competent jurisdiction. This will depend on the applicable Dutch or Belgian national rules. In addition, there is
doubt as to whether a Dutch or Belgian court would impose civil liability on us or the members of our management or of
our Board of Directors in an original action predicated solely upon the U.S. federal securities laws brought in a court of
competent jurisdiction against us, our management or directors.
As a foreign private issuer, we are exempt from various rules and regulations that a U.S. domestic public company
would be required to follow, including those requirements under U.S. securities laws and Nasdaq listing standards.
As a “foreign private issuer” defined in the SEC’s rules and regulations, we are not subject to all of the disclosure and
corporate governance requirements applicable to companies organized within the United States. For example, we are
exempt from certain provisions of the U.S. Securities Exchange Act of 1934, as amended (Exchange Act), that are
applicable to U.S. domestic public companies. In addition, our executive officers, directors and principal shareholders
are exempt from the short-swing profit and recovery provisions contained in Section 16(b) of the Exchange Act. We are
subject to Dutch laws and regulations with regard to such matters. While we furnish quarterly unaudited financial
information to the SEC on Form 6-K, the information we furnish to the SEC is less extensive and less timely compared
to that required to be filed with the SEC by U.S. domestic issuers.
As a foreign private issuer listed on Nasdaq, we are subject to corporate governance listing standards. However, we are
permitted to rely on home country governance requirements and certain exemptions thereunder. Certain of our corporate
governance practices may differ significantly from the Nasdaq corporate governance listing standards. These practices
may afford less protection to shareholders than they would enjoy if we complied fully with corporate governance listing
standards.
As a Dutch public company with limited liability, we are not obligated to, and do not comply with, all the best practice
provisions of the DCGC, which may affect shareholders’ rights. We are required to disclose in our annual report, filed in
the Netherlands, whether we comply with the provisions of the DCGC. If we do not comply with the provisions of the
DCGC, we must list the reasons for any deviation from the DCGC in our annual report filed in the Netherlands.
We may lose our foreign private issuer status which would then require us to comply with the Exchange Act’s
domestic reporting regime and cause us to incur significant legal, accounting and other expenses.
In order to maintain our current status as a foreign private issuer, either (a) a majority of our ordinary shares must be
either directly or indirectly owned of record by non-residents of the U.S. or (b) none of the following conditions may be
true: (i) a majority of our executive officers or directors are U.S. citizens or residents, (ii) more than 50% of our assets
are located in the U.S. and (iii) our business is administered principally in the U.S. As of February 19, 2025, we believe
at least 50% of our outstanding ordinary shares were held by U.S. residents (assuming that all our ordinary shares
represented by ADSs were held by residents of the U.S.).
In June 2025, the SEC issued a concept release soliciting public comment on potential changes to the definition of a
foreign private issuer. This release is the first review of the foreign private issuer framework since 2008, and the SEC is
considering revisions that could significantly impact which foreign companies qualify for the more accommodative U.S.
reporting, corporate governance requirements afforded to foreign private issuers, as well as the lack of Section 16(b)
liability for certain FPI officers, directors and shareholders. The SEC may revise the requirements to qualify as a foreign
private issuer in a way that changes our status as a foreign private issuer and results in us qualifying as a U.S. domestic
issuer. This could cause us to have to comply with regulations applicable to U.S. domestic issuers in a very compressed
timeframe. The regulatory and compliance costs to us as a U.S. domestic issuer may be significantly higher than those
28
Table of Contents
we incur as a foreign private issuer. We also expect that if we were required to comply with the rules and regulations
applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer
liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain
coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of
our Board of Directors.
If we were to be classified as a passive foreign investment company for U.S. federal income tax purposes, this could
result in adverse U.S. tax consequences to certain U.S. holders.
If the Company is classified as a passive foreign investment company (PFIC) for any taxable year, U.S. investors may be
subject to adverse U.S. federal income tax consequences described below under “Item 10.E Taxation — Certain Material
U.S. Federal Income Tax Considerations for U.S. Holders” The Company will be classified as a PFIC for U.S. federal
income tax purposes for any taxable year in which, taking into account a pro rata portion of the income and assets of
25% or more owned subsidiaries, either (i) at least 75% of its gross income consists of “passive income” or (ii) at least
50% of the average quarterly value of its assets is attributable to assets that produce, or are held for the production of,
passive income.
Based on our historic and anticipated operations, the composition of our income and the projected composition and
estimated fair market values of our assets, we do not believe that we were a PFIC for our most recent taxable year and do
not expect to be classified as a PFIC for the current taxable year or for the foreseeable future. However, our status as a
PFIC is a factual determination made on an annual basis, and we cannot provide any assurances regarding our PFIC
status for the current or future taxable years.
ITEM 4.INFORMATION ON THE COMPANY
A.HISTORY AND DEVELOPMENT OF THE COMPANY
Our legal and commercial name is argenx SE. We were incorporated under the laws of the Netherlands on April 25,
2008, as a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid). From
incorporation until August 28, 2009, our research and development activities were initially performed in the Netherlands,
then Belgium, by argenx N.V. and its legal predecessors. Since August 28, 2009, all our research and development
activities have been performed by our wholly-owned subsidiary, argenx BV, under a license provided by argenx N.V.
Throughout this time, argenx BV assigned all resulting intellectual property to argenx N.V. On May 28, 2014, we
converted to a Dutch public company with limited liability (naamloze vennootschap). On April 26, 2017, we converted
to a Dutch European public company with limited liability (Societas Europaea or SE). On May 5, 2017, we transferred
the legal ownership of all intellectual property rights of argenx SE to argenx BV, effective retroactively as of January 1,
2017. As a result, since January 1, 2017, (i) argenx BV holds all legal and economic ownership of our intellectual
property rights, and (ii) the research and development agreement between argenx SE and argenx BV has been
terminated.
Our official seat is in Amsterdam, the Netherlands, and our registered office is at Laarderhoogtweg 25,
1101 EB Amsterdam, the Netherlands. We are registered with the trade register of the Dutch Chamber of Commerce
under number 24435214. Our European legal entity identifier number (LEI) is 7245009C5FZE6G9ODQ71. Our
telephone number is +31 (0) 10 70 38 441. Our website address is www.argenx.com. This website is not incorporated by
reference in this Annual Report. The SEC maintains an Internet site that contains reports, proxy and information
statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov. The registered
agent for service of process in the U.S. is CT Corporation System, with an address at 111 8th Avenue, New York, NY
10011.
For information on our capital expenditure for the years ended December 31, 2025, 2024 and 2023, please see
“Note 4 — Property, Plant and Equipment” and “Note 5 — Intangible Assets” in our consolidated financial statements
which are included at the end of this Annual Report on Form 20-F for the period ended December 31, 2025. We
anticipate our capital expenditure in 2026 to be financed from the cash flows from operating activities and cash reserves.
For more information on our capital expenditures and requirements, see “Item 5.B. — Liquidity and Capital Resources —
Cash Flows — Operating and Capital Expenditure Requirements” in our Annual Report for the period ended
December 31, 2025.
No takeover bid has been instigated by third parties in respect of our equity during the current or previous fiscal years.
29
Table of Contents
B.BUSINESS OVERVIEW
Our legal and commercial name is argenx SE. We were incorporated under the laws of the Netherlands on April 25,
2008, as a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid). From
incorporation until August 28, 2009, our research and development activities were initially performed in the Netherlands,
then Belgium, by argenx N.V. and its legal predecessors. Since August 28, 2009, all our research and development
activities have been performed by our wholly-owned subsidiary, argenx BV, under a license provided by argenx N.V.
Throughout this time, argenx BV assigned all resulting intellectual property to argenx N.V. On May 28, 2014, we
converted to a Dutch public company with limited liability (naamloze vennootschap). On April 26, 2017, we converted
to a Dutch European public company with limited liability (Societas Europaea or SE). On May 5, 2017, we transferred
the legal ownership of all intellectual property rights of argenx SE to argenx BV, effective retroactively as of January 1,
2017. As a result, since January 1, 2017, (i) argenx BV holds all legal and economic ownership of our intellectual
property rights, and (ii) the research and development agreement between argenx SE and argenx BV has been
terminated.
For additional information regarding our Company’s principal markets and revenue breakdown, see “Item 5.A. —
Operating Results” in our Annual Report for the period ended December 31, 2025.
2025 In Brief
Operational Highlights
2025 was a year of strong execution as we advanced our long‑term commitment to patients under Vision 2030: aiming to
treat 50,000 patients globally, secure 10 labeled indications across all approved medicines, and advance five pipeline
candidates into Phase 3 development by 2030. We made significant progress executing against this goal throughout the
year, by expanding our global reach with VYVGART in two blockbuster indications, advancing 10 ongoing
registrational clinical trials, and completed our goal to bring forward four Phase 1 molecules by the end of the decade. 
Throughout 2025, VYVGART continued to deliver meaningful impact for patients globally, reaching more than 19,000
patients across three indications (gMG, CIDP, and ITP) and three product presentations. We successfully launched our
PFS, which expanded access to new patient segments and enabled more convenient treatment options. In gMG, we
strengthened our position as the #1 prescribed and fastest‑growing biologic, supported by increasingly earlier use in the
treatment paradigm and continued expansion into broader patient populations. Positive topline data from the
Seronegative gMG clinical trial strengthened our ambition to be the treatment of choice and to pursue the broadest MG
label to date. In CIDP, real‑world outcomes continued to validate the ADHERE results, with physicians reporting
sustained functional improvement and patients experiencing greater independence and quality of life. This strong
commercial execution resulted in a milestone for the Company, with VYVGART surpassing $1 billion in product net
sales in a single quarter for the first time in the third quarter of 2025.
Across the pipeline, we made meaningful progress on a broad set of programs. We advanced efgartigimod through
additional Phase 3 clinical trials that are expected to read out in 2026: Myositis and ITP, each supported by compelling
biology and robust clinical or proof‑of‑concept data. Together, we believe these programs strengthen efgartigimod’s
position as a foundational FcRn‑based therapy with potential across multiple high‑need autoimmune diseases.
Our second asset, empasiprubart, advanced notably with three Phase 3 clinical trials underway in MMN and CIDP. As a
first‑in‑class antibody targeting complement C2, we further expanded our understanding of C2 biology and its potential
to set a new bar for treatment outcomes in immune‑mediated neuromuscular diseases. Momentum also continued with
adimanebart (ARGX‑119), which entered Phase 3 development in CMS and progressed in a proof-of-concept clinical
trial in spinal muscular atrophy (SMA). Across our early‑stage portfolio, we advanced key next‑generation programs,
which include ARGX-213 and ARGX-124. We have a highly productive IIP, our engine for sourcing novel biology and
accelerating differentiated medicines, with over 25 active programs. Together, these achievements and the progress
across our pipeline position us well for the year ahead as we prepare for multiple registrational readouts and continued
expansion of our global patient impact.
Corporate Achievements
•Subject to shareholder approval, Karen Massey, current COO, will transition to CEO and Executive Director and Tim
Van Hauwermeiren, current CEO, will transition to Non-Executive Chairperson of the Board of Directors. 
•In 2025, Sandrine Piret-Gérard was appointed Chief Commercialization Officer. Sandrine joins from Gilead, where
she lead the U.S. commercial organization.
30
Table of Contents
•Anthony Rosenberg, who has served as a non-executive director since April 2017, was reappointed as a non-
executive director and vice-chairperson of the Board of Directors for a term of 2 years.
•Expansion to 1,863 full-time employees (as of December 31, 2025) to support further growth of our business,
including fully staffed commercial teams in the U.S., Europe, Japan and Canada.
2025 Financial Highlights
•Product net sales of $4.2 billion
•Research & development of $1.4 billion
•Financial Strength to Invest in Sustainable innovation.
2026 Outlook
2026 marks a defining year on the path to Vision 2030 with three strategic priorities:
•Impact more patients globally with VYVGART, driving broader adoption across current patient populations and
unlocking new opportunities with potential label expansions
•Shape the long-term future of FcRn medicines, advancing future FcRn molecules, innovative delivery modalities and
combination approaches designed to transform patient outcomes
•Deliver next wave of immunology innovation, accelerating empasiprubart and diversified pipeline of first-in-class
molecules to drive sustainable value creation
2026 outlook.jpg
31
Table of Contents
The table above is subject to risks and uncertainties that may materially impact the achievement of our 2026 outlook. For
more information, please refer to “Item 3.D. — Risk Factors” of this Annual Report for a discussion of such risks and
uncertainties.
Our Medicines
VYVGART and VYVGART HYTRULO is a first-and-only immunoglobulin G (IgG) Fc-antibody fragment that targets
the FcRn. It is approved for the treatment in three indications, including gMG and CIDP globally and ITP in Japan (as
VYVDURA).
Our Pipeline
•efgartigimod is an IgG1 antibody Fc fragment that has been engineered for increased affinity to FcRn compared to
endogenous IgG. Efgartigimod selectively reduces IgG by blocking FcRn-mediated IgG recycling without impacting
antibody production or affecting other parts of the immune system. It is approved in three indications, including
gMG, CIDP and ITP, and is being evaluated in more than ten additional serious autoimmune indications.
•empasiprubart (C2 inhibitor) is a novel complement inhibitor targeting C2, blocking the function of both the classical
and lectin pathways while leaving the alternative pathway intact. We believe empasiprubart has the potential to be a
pipeline-in-a-product candidate and is being evaluated in two indications currently in Phase 3 clinical trials. 
•adimanebart (MusK agonist): adimanebart is an agonist SIMPLE ANTIBODY™ to the MuSK receptor with potential
in multiple neuromuscular indications. It is currently in clinical trials for CMS (Phase 3 clinical trial) and SMA
(Phase 2).
•Earlier Stage Programs:
◦Two future FcRn molecules are progressing: ARGX-213, an FcRn-targeted antibody engineered for half-life
extension and sustained IgG reduction, and ARGX-124, a first-in-class FcRn pipeline candidate.
◦ARGX-109 (targeting IL-6) and ARGX-121 (a first-in-class molecule targeting immunoglobulin A (IgA)) are also
progressing.
◦Entered into a research collaboration with Tensegrity Pharma, including an option for future acquisition, to
advance Tensegrity’s lead program TSP-101 in autoimmune disease and other indications.
◦Three new molecules expected to enter Phase 1 clinical trials in 2026, including ARGX-118, a first-in-class
molecule targeting Galectin-10, ARGX-125, a first-in-class bispecific antibody, and TSP-101, targeting Fn14.
•In addition to our wholly-owned pipeline, we have candidates that emerged from our IIP that we out-licensed to a
partner for further development and for which we have milestone, royalty or profit-share agreements. These
candidates include, amongst others: cusatuzumab (anti-CD70 antibody – OncoVerity), ARGX-112 (LP-0145 – anti-
IL-22R antibody – LEO Pharma), ARGX-114 (AGMB-101 – agonistic anti-MET antibody – Agomab) and
ARGX-115 (ABBV-151 – anti-GARP antibody – AbbVie).
Immunology Innovation Program (IIP)
Our IIP is the engine behind our robust and expansive pipeline. By fostering deep, ongoing collaboration between
leading academic researchers and our in-house antibody engineers, we aim to translate breakthrough science into first-in-
class therapies across multiple indications. This co-creation model has enabled every candidate in our wholly owned and
partnered pipelines to emerge from IIP collaborations, underscoring our ability to identify and advance novel targets with
speed and precision.
Our approach is designed for scale and sustainability: we run parallel development programs, optimize trial design for
efficiency, and maintain a relentless focus on unmet patient needs. This strategy has delivered measurable results –
accelerating our path to profitability, driving strong commercial growth, and positioning argenx as a leader in
immunology innovation. By integrating the aspirations of patients and the insights of healthcare professionals into every
stage of discovery and development, we are not only building a differentiated pipeline but also setting new standards for
impact and value creation in the sector.We bring to the collaboration our unique suite of antibody discovery and
antibody engineering technologies and experience in clinical development to complement our partners’ expertise in
disease and target biology. Our suite of technologies includes amongst others our SIMPLE ANTIBODY™ platform
technology and NHANCE™, ABDEG™, POTELLIGENT®, and DHS mutations that focus on engineering the Fc region
of antibodies in order to augment their intrinsic therapeutic properties.
32
Table of Contents
Our Suite of Technologies
•SIMPLE ANTIBODY™ platform technology: Our proprietary SIMPLE ANTIBODY™ platform technology, based
on the powerful llama immune system, allows us to exploit novel and complex disease biology targets. The platform
sources antibody variable regions (V-regions) from the immune system of outbred llamas, each of which has a
different genetic background. The llama produces highly diverse panels of antibodies with a high human homology,
or similarity, in their V-regions when immunized with targets of human disease. Our SIMPLE ANTIBODY™
platform technology allows us to access and explore a broad target universe while potentially minimizing the long
timelines associated with generating antibody candidates using traditional methods.
•NHANCE™, ABDEG™, POTELLIGENT®, and DHS mutations focus on engineering the Fc region of antibodies in
order to augment their intrinsic therapeutic properties. In addition, we obtained a non-exclusive research license and
option from Chugai Pharmaceutical Co., Ltd. for the SMART-Ig® (“Recycling Antibody” and part of “Sweeping
Antibody”) and ACT-Ig® (Antibody half-life extending) technologies. These technologies are designed to enable us to
expand the therapeutic index of our product candidates, which is the ratio between toxic and therapeutic dose, by
potentially modifying their half-life, tissue penetration, rate of disease target clearance and potency.
Our Products and Product Candidates
The following table summarizes key information on our portfolio of lead products and product candidates as of the date
of this Annual Report.
Program
Indication
Preclinical
Phase 1
Proof of Concept
Registrational
Commercial
VYVGART
gMG
                                                     
                                                     
                                                     
                                                     
                                                     
ITP (Japan)
                                                     
                                                     
                                                     
                                                     
                                                     
VYVGART
HYTRULO
gMG
                                                     
                                                     
                                                     
                                                     
                                                     
CIDP
                                                     
                                                     
                                                     
                                                     
                                                     
efgartigimod
Seronegative gMG
                                                     
                                                     
                                                     
                                                     
Ocular MG
                                                     
                                                     
                                                     
                                                     
Primary ITP
                                                     
                                                     
                                                     
                     
Graves’ Disease
                                                     
                                                     
                                                     
     
Myositis
                                                     
                                                     
                                                     
                     
SjD
                                                     
                                                     
                                                     
                     
Systemic Sclerosis
                                                     
                                                     
                                 
AMR
                                                     
                                                     
                                 
empasiprubart
MMN
                                                     
                                                     
                                                     
                     
DGF
                                                     
                                                     
                                 
CIDP
                                                     
                                                     
                                                     
                     
adimanebart
CMS
                                                     
                                                     
                                                     
     
SMA
                                                     
                                   
ARGX-213
Undisclosed
                                                     
                                                     
                                                     
   
ARGX-121
IgA Nephropathy
                                                     
                                                     
ARGX-124
Undisclosed
                                                     
                                                     
ARGX-109
Undisclosed
                                                     
                                                     
TSP-101
Undisclosed
                                                     
   
ARGX-118
Undisclosed
                                                     
ARGX-125
Undisclosed
                                                     
                                 
NEUROLOGY
                                 
NEPHROLOGY AND HEMATOLOGY
                                 
ENDOCRINOLOGY
                                 
RHEUMATOLOGY
                                 
UNDISCLOSED
33
Table of Contents
Our Programs
VYVGART
\Approvals and Regulatory Plan
VYVGART is approved in more than 30 countries with three active indications (gMG, CIDP and ITP) and three
presentations (IV, SC, PFS). More approvals and launches of VYVGART in multiple jurisdictions and countries are
planned following pricing and reimbursement negotiations. The following table summarizes the status of regulatory
approvals for VYVGART as of February 2026:
Product
Indication
Geography
Regulatory Status
VYVGART IV
VYVGART
gMG
US
Approved
VYVGART
gMG
Europe
Approved
VYVGART
gMG
Canada
Approved
VYVGART
gMG
Israel
Approved
VYVGART
gMG
Japan
Approved
VYVGART
gMG
The UK
Approved
VYVGART
gMG
China
Approved
VYVGART
gMG
Australia
Approved
VYVGART
gMG
Kuwait
Approved
VYVGART
gMG
Saudi Arabia
Approved
VYVGART
gMG
Korea (the Republic of)
Approved
VYVGART
gMG
United Arab Emirates
Approved
VYVGART
gMG
Switzerland
Approved
Pending
gMG
Brazil
Submitted
VYVGART
gMG
Singapore
Approved
VYVGART
ITP
Japan
Approved
VYVGART SC
VYVGART HYTRULO
gMG
US
Approved
VYVGART HYTRULO
CIDP
US
Approved
VYVGART
gMG
Australia
Approved
VYVGART
CIDP
Australia
Submitted
VYVGART
gMG
Europe
Approved
VYVGART
CIDP
Europe
Approved
VYVGART
gMG
Switzerland
Approved
VYVGART
CIDP
Switzerland
Submitted
VYVGART
gMG
The UK
Approved
VYVGART
CIDP
The UK
Approved
VYVGART SC
gMG
Israel
Approved
VYVGART HYTRULO
gMG
China
Approved
VYVGART HYTRULO
CIDP
China
Approved
VYVDURA
gMG
Japan
Approved
VYVDURA
CIDP
Japan
Approved
PFS
VYVDURA
gMG
Japan
Approved
VYVDURA
CIDP
Japan
Approved
VYVGART HYTRULO
gMG
U.S.
Approved
VYVGART HYTRULO
CIDP
U.S.
Approved
VYVGART
gMG
Europe
Approved
VYVGART
CIDP
Europe
Approved
VYVGART SC
gMG
Canada
Approved
VYVGART SC
CIDP
Canada
Approved
VYVGART
gMG
The UK
Approved
VYVGART
CIDP
The UK
Approved
VYVGART
gMG
Australia
Approved
VYVGART
CIDP
Australia
Submitted
VYVGART
Switzerland
Submitted
VYVGART
gMG
Israel
Submitted
VYVGART
CIDP
Israel
Submitted
34
Table of Contents
Commercialization
We have established our own sales force in the U.S., Japan, Europe and Canada for VYVGART for the treatment of
gMG and CIDP (where approved). We plan to expand our own sales and marketing capabilities and promote our
products and product candidates in other regions if we decide there is a business case to do so after regulatory approval
has been obtained.
Development and commercialization may also be done through collaborations with third parties. In January 2021, we
entered into an exclusive out-license agreement with Zai Lab (Zai Lab Agreement), a commercial-stage
biopharmaceutical company, for the development and commercialization of efgartigimod in Greater China, (which
includes Mainland China, Hong Kong, Taiwan and Macau, Greater China). Zai Lab announced approval of VYVGART
in Mainland China in June 2023 for the treatment of adult gMG patients and in 2024 Zai Lab also announced the
approval of VYVGART SC for gMG and CIDP. Under the Zai Lab Agreement, we received and continue to be eligible
for certain sales-based milestone payments and royalties based on annual product net sales of efgartigimod in Greater
China.
We intend to continue expanding into new markets and will evaluate the most appropriate commercialization approach
for each territory, whether through our own commercial organization or through additional distribution partnerships.
In the U.S., argenx advertises certain products via digital and traditional media channels, including the internet and
television.
For a discussion of total revenues by geographic market, please see “Note 16 — Segment Reporting” in our consolidated
financial statements which are included in our Annual Report for the period ended December 31, 2025.
Pre-Approval Access Program
We are committed to improving the lives of people suffering from rare diseases. We are driven to discover new
treatment approaches fueled by the resilience of patients to urgently deliver them. We aim to do this in partnership; we
listen to patients, supporters and advocacy communities, and we hear their stories. Their insights guide us as we develop
our investigational therapies and motivate us to advance the understanding of rare diseases.
We have a Pre-Approval Access program (PAA) for patients with gMG which opened on February 21, 2021 for patients
who are unable to participate in an ongoing clinical trial. In 2024, we approved access to this PAA for over 403 gMG
patients in 14 countries. The PAA program remains open in countries where VYVGART is not yet launched or
reimbursed.
efgartigimod (ARGX-113) Development
Mechanism of Action
As shown in Figure 1, efgartigimod is a human IgG1 Fc fragment equipped with our ABDEG™ mutations that is
designed to target the FcRn and reduce IgG. FcRn is foundational to the immune system and functions to recycle IgG,
extending its serum half-life over other IgGs that are not recycled by FcRn. IgGs that bind to FcRn are rescued from
lysosomal degradation. By binding to FcRn, efgartigimod can reduce IgG recycling and increase IgG degradation.
35
Table of Contents
efgartigimod’s mechanism of action.jpg
Figure 1: efgartigimod’s mechanism of action blocks the recycling of IgG antibodies and removes them from circulation.
FcRn, neonatal Fc receptor; Ig, immunoglobulin; LDL, low-density lipoprotein.
1) Ulrichts P, et al. J Clin Invest. 2018;128:4372–86
6) Roopenian DC, Akilesh S. Nat Rev Immunol. 2007;7:715–25.
7) Ward ES, Ober RJ. Trends Pharmacol Sci. 2018;39:892–904.
Formulations
Overview
We are developing two formulations of efgartigimod to address the needs of patients, physicians, and payers across
indications and geographies, including efgartigimod IV (VYVGART) and efgartigimod SC (VYVGART SC).
efgartigimod Indications
Clinical trial overview
Clinical
Trial
Stage
Indica­tion
Patients
Primary Endpoint
Status
ADAPT
Registrational
gMG
The proportion of responders based on the
Myasthenia Gravis Activities of Daily
Living (MG-ADL) score
Marketed
ADAPT-SC
Registrational
gMG
The proportion of responders based on the
Myasthenia Gravis Activities of Daily
Living (MG-ADL) score
Marketed
ADAPT-
SERON
Registrational
Seronegative
gMG
119
MG-ADL total score change from baseline
to day 29 (w4)
Positive clinical trial
results reported in
2025 with expected
PDUFA date of
May 10, 2026
ADAPT-
OCULUS
Registrational
Ocular MG
141
Change in MGII PRO ocular score from
baseline to day 29 (w4)
Positive clinical trial
results reported in
February 2026
ADHERE
Registrational
CIDP
322
The hazard ratio for the time to first adjusted
INCAT deterioration
Marketed
ADVANCE-
IV
Registrational
ITP
The proportion of patients that achieved
sustained platelet response
Marketed
36
Table of Contents
Clinical
Trial
Stage
Indica­tion
Patients
Primary Endpoint
Status
ADVANCE-
NXT
Registrational
ITP
63
Extent of disease control (cumulative
number of weeks over the planned 24-week
treatment period with platelet counts of ≥
50×109/L
Ongoing clinical
trial results expected
in 4Q 2026
ALKIVIA
Registrational
Myositis
Target  240
The total improvement score (TIS) at the
end of treatment period
Ongoing clinical
trial results expected
in 3Q 2026
UNITY
Registrational
SjD
Target 580
The change from baseline on the
ClinESSDAI score (w48)
Ongoing clinical
trial results expected
in 2H 2027
In
partnership
with Zai Lab
PoC
LN
Target 60
The change in urine protein creatinine ratio
from baseline to end of the treatment period
Clinical trial
discontinued in
2025
uplighTED
Registrational
TED
Target 108/
trial 
Percentage of participants who were
proptosis responders at week 24
Clinical trial
discontinued in
2025
shAMRock
PoC
AMR
Target 30
Safety and tolerability. Efficacy measures
such as estimated glomerular filtration rate,
histology and urine protein creatinine ratio
are captured in the secondary endpoints
Ongoing clinical
trial
ADAPT-
JUNIOR IV
Phase 2/3
gMG
Target over
12
To confirm an age-adjusted optimum dose
of efgartigimod IV and provide (model-
predicted) evidence for a treatment response
Ongoing clinical
trial
ADAPT-
JUNIOR SC
Phase 2/3
gMG
Target over
12
To confirm an appropriate dose of
efgartigimod PH20 SC in pediatric
participants with gMG
Ongoing clinical
trial
Other clinical
trials
PoC
AIE
To be
confirmed
Ongoing clinical
trial
PoC
AIM
To be
confirmed
To be confirmed
Ongoing clinical
trial
gMG
Overview
gMG is a rare, chronic autoimmune disease in which pathogenic IgG autoantibodies disrupt neuromuscular signaling,
leading to fluctuating and sometimes life‑threatening muscle weakness. Autoantibodies block or remove acetylcholine
receptors and activate complement, damaging the neuromuscular junction. MG often begins with ocular symptoms such
as ptosis and diplopia, and approximately 85% of patients progress to generalized MG (gMG), which can impair bulbar,
limb, and respiratory function. Respiratory crises occur in 15–20% of patients. MG prevalence in the U.S. is estimated at
approximately 20 per 100,000, and roughly 85% of gMG patients have detectable AChR antibodies.
efgartigimod has demonstrated consistent and robust clinical benefit across MG populations. Pivotal ADAPT data
formed the basis for global approvals of VYVGART IV, and positive ADAPT‑SC results supported approval of the
subcutaneous formulation. In 2025, we reported positive topline results from ADAPT‑SERON, our Phase 3 clinical trial
in anti‑AChR antibody‑negative gMG, demonstrating a clear treatment effect and reinforcing the broad applicability of
FcRn across MG subtypes. These data support our supplemental regulatory submission to expand VYVGART into the
seronegative population, which was accpeted for priority review with an expected PDUFA target action date of May 10,
2026. We also reported positive data from our ADAPT OCULUS clinical trial, which met its primary endpoint, showing
that patients living with oMG and treated with VYVGART demonstrated statistically significant improvement from
baseline in Myasthenia Impairment Index (MGII) Patient Reported Outcome (PRO) ocular scores at Week 4 compared
to placebo. The results support our supplemental regulatory submissions to expand VYVGART into the ocular MG
population. We also have ongoing clinical trials in pediatric gMG patients (ADAPT-JUNIOR) with efgartigimod IV and
efgartigimod SC.
37
Table of Contents
CIDP
Overview
CIDP is a chronic autoimmune disorder of peripheral nerves and nerve roots caused by an autoimmune-mediated
destruction of the myelin sheath, or myelin producing cells, insulating the axon of the nerves and enabling speed of
signal transduction. The cause of CIDP is unknown, but abnormalities in both cellular and humoral immunity have been
shown. CIDP is a chronic and progressive disease: onset and progression occur over at least eight weeks in contrast with
the more acute Guillain-Barré-syndrome. Demyelination and axonal damage in CIDP lead to loss of sensory and/or
motor neuron function, which can lead to weakness, sensory loss, imbalance and/or pain. The U.S. prevalence is
estimated at approximately 42,000 patients, of whom roughly 24,000 receive treatment. Most patients rely on IVIg as
first‑line therapy, while glucocorticoids, plasma exchange, and other immunosuppressants are used less frequently given
safety, tolerability, and access limitations.
In July 2023, the pivotal ADHERE clinical trial demonstrated that VYVGART SC significantly reduced the risk of
relapse compared to placebo and provided evidence that pathogenic IgG autoantibodies play an important role in CIDP
biology. Sixty‑seven percent of patients entering the open‑label Stage A improved clinically, and efgartigimod SC was
well tolerated with a safety profile consistent with prior clinical trials. Nearly all eligible patients (99%) continued into
the ADHERE‑Plus OLE. Based on these data, VYVGART SC received regulatory approvals in the U.S. in June 2024, in
China in November 2024, and in Japan in December 2024, with regulatory review ongoing in additional jurisdictions,
including the EU.
Primary ITP
Overview
Primary ITP is an acquired autoimmune bleeding disorder, characterized by a low platelet count 
(<100×109/L) in the absence of other causes associated with thrombocytopenia. In most patients, IgG autoantibodies
directed against platelet receptors can be detected. They accelerate platelet clearance and destruction, inhibit platelet
production, and impair platelet function, resulting in increased risk of bleeding and impaired quality of life. Primary ITP
is differentiated from secondary ITP, which is associated with other illnesses, such as infections or autoimmune diseases,
or which occurs after transfusion or taking other drugs, such as cancer drugs. Platelet deficiency, or thrombocytopenia,
can cause bleeding in tissues, bruising and slow blood clotting after injury. Patients may suffer from depression and
fatigue as well as side effects of existing therapies, impairing their quality of life. Current therapeutic approaches include
non-specific immunosuppression (e.g., steroids and rituximab), inhibition of platelet clearance (e.g., splenectomy, IVIg,
anti-D globulin, and spleen tyrosine kinase inhibitor fostamatinib13) or stimulation of platelet production (e.g.,
thrombopoietin receptor agonist TPO-RA). Splenectomy remains the only treatment that provides sustained remission
off therapy for one year or longer for a high proportion of patients. ITP affects approximately 72,000 patients in the U.S.
In 2022, the Phase 3 ADVANCE (IV) clinical trial met its primary endpoint, demonstrating that a higher proportion of
chronic ITP patients receiving efgartigimod achieved a sustained platelet count response compared to placebo. These
results supported approval of efgartigimod for ITP in Japan. In 2023, the accompanying subcutaneous clinical trial,
ADVANCE‑SC, did not meet its primary endpoint. To fulfill the requirement for two well-controlled trials needed for
global registration, argenx is now conducting ADVANCE‑NEXT, a Phase 3, randomized, double‑blinded,
placebo‑controlled trial evaluating efgartigimod IV in adults with primary ITP. ADVANCE-NEXT remains ongoing,
with topline Phase 3 results expected in the fourth quarter of 2026.
AIM
Overview
AIM are a rare and heterogeneous group of autoimmune diseases that can affect muscle alone or multiple organ systems,
including the skin, joints, lungs, gastrointestinal tract, and heart. These conditions are severe, disabling, and materially
impact quality of life. Advances in understanding disease biology and the discovery of characteristic autoantibodies have
led to clearer differentiation of AIM into clinically meaningful subtypes, including immune‑mediated necrotizing
myopathy (IMNM), antisynthetase syndrome (ASyS), and dermatomyositis (DM). Each subtype presents with distinct
autoantibody profiles and manifestations, though proximal muscle weakness remains a defining feature across AIM.
Today, there are no FDA‑approved therapies for IMNM or ASyS, and treatment is largely dependent on steroids or
broad immunosuppressants; IVIg was approved for DM in 2021.
argenx is advancing the registrational ALKIVIA clinical trial of efgartigimod SC for the treatment of AIM. ALKIVIA is
a seamless Phase 2/3 clinical trial enrolling approximately 240 patients across IMNM, ASyS, and DM, with Total
Improvement Score (TIS) as the primary endpoint and a broad set of functional and quality‑of‑life secondary measures.
38
Table of Contents
In November 2024, following achievement of statistical significance on the primary endpoint in the Phase 2 portion and
consistent improvement across all six core components of the TIS, argenx announced a ‘GO’ decision to proceed with
the Phase 3 portion in all three AIM subtypes. Safety and tolerability were consistent with the known profile of
efgartigimod. ALKIVIA remains ongoing, with topline Phase 3 results expected in the third quarter of 2026.
SjD
Overview
SjD is a chronic, progressive autoimmune disease, characterized by lymphocytic infiltration and progressive destruction
of exocrine glands. B-cells play a pivotal role in the development of the disease and this results amongst others in
production of IgG autoantibodies, especially those which target SSA/Ro, SSB/La ribonuclear complexes. In addition to
symptoms of dry eyes, dry mouth, chronic pain and fatigue, a substantial subset of patients suffer from extraglandular
systemic disease. There are no FDA-approved treatments currently registered for the treatment of SjD.
argenx is advancing the registrational UNITY clinical trial of efgartigimod SC for the treatment of SjD. UNITY is a
Phase 3, randomized, placebo‑controlled, double‑blind clinical trial assessing the safety and efficacy of efgartigimod SC
in 480 patients with at least moderate systemic disease (ClinESSDAI ≥6) who are on stable background therapy and
positive for anti‑SSA/Ro. After the 48‑week treatment period, eligible participants may roll over into an OLE. The
primary endpoint is change from baseline in clinESSDAI, with key secondary endpoints focused on patient‑reported
outcomes, ESSDAI, and STAR. UNITY remains ongoing, with topline Phase 3 results expected in the second half of
2027.
empasiprubart (ARGX-117) Development
Mechanism of Action
empasiprubart is a differentiated therapeutic mAb targeting C2 equipped with our proprietary NHANCE™ mutations.
By addressing a novel target at the intersection of the complement and lectin pathways of the complement cascade, we
believe empasiprubart represents a broad pipeline opportunity across several severe autoimmune indications. Activation
of the classical and lectin pathway of complement may contribute to tissue damage and organ dysfunction in a number of
autoimmune inflammatory diseases and ischemia-reperfusion conditions. Targeting C2 also leaves the alternative
pathway of the complement system intact, which is an important component of the innate defense system.
empasiprubart exhibits both pH- and calcium dependent binding. These unique characteristics enable empasiprubart to
capture free C2 in circulation and release it in the endosome to be sorted for degradation in the lysosome. empasiprubart
is equipped with NHANCE™ mutations increasing its affinity for FcRn and allowing it to recycle back into circulation
to capture more C2.
In addition to an IV formulation, we have exclusive access to Halozyme’s ENHANZE® SC drug delivery technology for
the C2 target.
39
Table of Contents
empasiprubart mechanism of action.jpg
Figure 2: empasiprubart mechanism of action. C2, complement component 2; FcRn, neonatal Fc receptor; IgG,
immunoglobulin G.
1) Van de Walle I, et al. J Allergy Clin Immunol. 2021;147:1420–9.
2) Vaccaro C, et al. Proc Natl Acad Sci. 2006;103:18709–14.
3) Brinkhaus M, et al. Nat Commun. 2022;13:6073.
empasiprubart Indications
MMN
Overview
MMN is a debilitating neuromuscular autoimmune disorder that is characterized by slowly progressive muscle weakness
due to motor neuron degeneration. It mainly affects hands and forearms, mainly in males, and the median age of
diagnosis is around 40 years. Diagnosis takes about a year and a half and is often misdiagnosed as ALS. There are
estimated to be around 12,000 patients across key markets.
Specific pathophysiologic characteristics of MMN include the presence of IgM autoantibodies against the ganglioside
GM1 and conduction block, i.e., impaired propagation of action potentials along the axon.
GM1 is widely expressed in the nervous system by neurons, particularly around the nodes of Ranvier, and Schwann
cells.
IVIg is the only approved treatment for MMN and needs to be dosed frequently to address the disease’s progressive
nature.
Phase 2 POC ARDA Clinical Trial
The Phase 2 POC ARDA clinical trial was a randomized, double‑blinded, placebo‑controlled multicenter clinical trial
evaluating the safety and tolerability, efficacy, PK, PD, and immunogenicity of two dose regimens of empasiprubart in
adults with MMN. Safety and tolerability were the primary endpoint and additional endpoints included time to IVIg
retreatment, biomarker analyses of C2 levels, and changes in key functional scores (modified medical research
council‑10 sum score, grip strength, MMN‑RODS) as well as several patient‑reported quality‑of‑life measures (fatigue
severity score (FSS), chronic acquired polyneuropathy patient‑reported index (CAP‑PRI), and patient global impression
change scale). In 2024, argenx announced positive data from the first cohort (n=16), which were confirmed with the
second cohort (n=16) in July 2024, establishing POC in MMN, with empasiprubart demonstrating a 91% reduction in the
need for IVIg rescue compared to placebo [HR (95% CI)=0.09 (0.02; 0.44)] in cohort 1 and an 84% reduction in IVIg
rescue compared to placebo [HR (95% CI)=0.16 (0.02; 1.54)] in cohort 2.
40
Table of Contents
Based on these results argenx initiated the EMPASSION Phase 3 clinical trial evaluating empasiprubart in MMN head to
head with IVIg at the end of 2024.
Phase 3 EMPASSION Clinical Trial Design
A Phase 3, randomized, double-blinded, double-dummy clinical trial evaluating the efficacy and safety
of empasiprubart versus intravenous immunoglobulin in adults with multifocal motor neuropathy. The clinical trial
comprises a screening period of up to 15 weeks, including a minimum of 2 IVIg cycles; a
24-week (6-month), randomized, double-blinded, double-dummy treatment period (part A) evaluating the efficacy and
safety of empasiprubart vs IVIg continuation; a 24-month OLE period (part B); and a 15-month safety follow-up period
starting after the last dose of IMP. The primary objective is to demonstrate the efficacy of empasiprubart compared to
IVIg in improving functional ability. This will be measured by change from baseline in the 25-item MMN-RODS centile
score at week 24. Additional key secondary endpoints include changes in measurements on key functional scores
(modified medical research council -14 sum score, grip strength) as well as patient-reported quality of life outcome
measures (polyneuropathy patient-reported index, and values of the patient global impression change scale and
evaluation of manual dexterity using 9HPT.
DGF
Delayed graft function (DGF), defined as the need for dialysis in the first week after kidney transplant, affects up to 40%
of deceased‑donor recipients and is associated with poorer long‑term outcomes. Decision for Phase 2 VARVARA
clinical trial is now expected mid-year 2026 to complete 52-week efficacy analysis
CIDP
Overview
Please refer to “Item 4.B — efgartigimod Indications” (CIDP) for more information on CIDP.
Phase 3 EMVIGORATE and EMNERGIZE Clinical Trials
argenx is advancing two Phase 3 clinical trials of empasiprubart in CIDP: EMVIGORATE and EMNERGIZE.
EMVIGORATE is a head‑to‑head clinical trial comparing empasiprubart to IVIg in adults with CIDP. EMNERGIZE is a
randomized, placebo‑controlled clinical trial evaluating the efficacy and safety of empasiprubart. Topline results from
both EMVIGORATE and EMNERGIZE are expected in the second half of 2027. 
adimanebart (ARGX-119) Development
adimanebart is a humanized agonist monoclonal antibody that specifically targets and activates MuSK to promote
maturation and stabilization of the NMJ, with planned development across severe neuromuscular diseases including
CMS, ALS, and SMA. It is the first highly specific agonist mAb targeting human MuSK and was developed using the
SIMPLE ANTIBODY™ platform in collaboration with leading experts, with preclinical proof‑of‑concept demonstrated
in a DOK7‑CMS model.
A Phase 3 clinical trial in CMS is expected to initiate in the third quarter of 2026, following positive results from the
Phase 1b clinical trial.
A proof-of-concept clinical trial is also ongoing in SMA.
Strategy and Objectives
Company’s Strategies
Our objective is to transform the lives of at least 50,000 patients and their communities before 2030 by providing them
with life-changing medicines built on scientific breakthroughs in immunology. To reach this, we aim to deliver on a set
of different goals:
•Transform the lives of 50,000 patients, by redefining treatment expectations in MG & CIDP and delivering at least
eight additional labeled indications and a second self-administered FcRn medicine by 2030.
41
Table of Contents
•Be the precision complement inhibitor that sets a new SOC and improves patient experience and outcomes across
indications, with 3+ labeled indications and five total indications in development by 2030.
•Be the leader in neuromuscular junction (NMJ) therapeutics, redefining patient expectations and reigniting hope in
one labeled indication and at least four total indications by 2030.
•Expand our pipeline of transformational innovation to enable consistent cadence of value creation for patients; >5
new molecules in late stage by 2030.
•Scale in The argenx Way to remain a unique, independent company.
•Solidify our place in the biotech ecosystem as the benchmark for entrepreneurial science delivering value for patients.
Competitive position
We participate in a highly innovative industry characterized by a rapidly growing understanding of disease biology,
quickly changing technologies, strong intellectual property barriers to entry, and a multitude of companies involved in
the creation, development and commercialization of novel therapeutics. Many of these companies are highly
sophisticated and often strategically collaborate with each other.
Competition in the autoimmune field is intense and involves multiple monoclonal antibodies (mAbs), other biologics and
small molecules either already marketed or in development by many different companies, including large pharmaceutical
companies. We compete with a wide range of biopharmaceutical companies that are developing products for the
treatment of gMG, CIDP, ITP and other autoimmune diseases, including products that are in the same class as
VYVGART, as well as products that are similar to some of our product candidates. We are aware of several FcRn
inhibitors that are in clinical development or marketed.
In addition, we may face future competition from biosimilar versions of approved biologics in the autoimmune and
immunology fields. The regulatory frameworks in the United States, Europe and other key markets could evolve in ways
that may facilitate the entry of biosimilars once reference products lose market exclusivity. While FcRn inhibitors are a
relatively new therapeutic class, the broader biologics market has seen an increase in biosimilar development and
commercial activity, supported by maturing regulatory pathways, expanding manufacturing capabilities and ongoing
payer and health‑system initiatives aimed at reducing the cost of care.
Competitive product launches may erode future sales of our products, including our existing products and those currently
under development, or result in unanticipated product obsolescence. Such launches continue to occur, and potentially
competitive products are in various stages of development. We could also face competition for use of limited
international infusion sites, particularly in new markets as competitors launch new products. We cannot predict with
accuracy the timing or impact of the introduction of competitive products that treat diseases and conditions like those
treated by our products or product candidates. In addition, our competitors compete with us to recruit and retain qualified
scientific and management personnel, establish clinical trial sites and patient registration for clinical trials, as well as in
acquiring technologies complementary to, or necessary for, the development of our products. Please refer to “Item 3.D.
— Risk Factors — Risk Factors Related to Commercialization of argenx's Products and Product Candidates, Including
for New Indications — We face significant competition for our drug discovery and development efforts”
We compete in this dynamic landscape by aiming to advancing differentiated, first‑in‑class and best‑in‑class therapies
grounded in novel biology, enabled by our deep scientific expertise and our technology platforms. Our strategy is to
innovate ahead of the field—identifying new pathways, engineering unique mechanisms of action, and continuously
expanding our understanding of Fc‑mediated biology and related immunology. We also actively protect and strengthen
our intellectual property through a comprehensive global portfolio of patents, trade secrets and proprietary know‑how
covering our product candidates, platforms and manufacturing processes. This commitment to scientific innovation and
robust IP protection is central to sustaining our competitive position and delivering long‑term value.
Manufacturing and Supply
At argenx, our manufacturing and supply strategy is built for scale, resilience, and speed, reflecting our commitment to
move science forward and deliver for patients worldwide. We utilize third-party contract manufacturers who act in
accordance with the FDA’s current good manufacturing practices (cGMPs) for the manufacture of drug substances and
drug products. We partner with a global network of contract manufacturers who share our standards for quality and
innovation, with the goal that every step, from cell bank development to large-scale drug substance production, meets the
highest industry benchmarks. Our global supply chain and distribution strategy is to serve patients in region for that
region. We work with Lonza teams based in Slough, UK, Portsmouth, U.S., Singapore and Visp, Switzerland for
42
Table of Contents
activities relating to the development of cell banks, development of our manufacturing processes and the manufacturing
of drug substance, thereby using validated and scalable systems broadly accepted in our industry. In 2022, we started our
collaboration with FUJIFILM Diosynth Biotechnologies Denmark ApS (Fujifilm) based in Hillerød, Denmark, for
activities relating to the large-scale manufacturing of efgartigimod drug substance. In 2025, we expanded our partnership
with Fujifilm to include new manufacturing site in North Carolina, U.S., strengthening our global supply chain and
supporting anticipated growth in efgartigimod and pipeline assets.
We use additional contract manufacturers to fill, label, package, store and distribute (investigational) drug products.
Intellectual Property
Introduction
We strive to protect and maintain exclusivity for the proprietary technologies that we believe are important to our
patients, business, and shareholders. We continue to pursue and maintain patent protection intended to cover core
platform technologies incorporated into, or used to produce, our product candidates and commercial products. We will
seek protection for our patient innovations in key global jurisdictions. We continue to focus our exclusivity strategies on
all aspects of our assets, including our compositions of matter, methods of use for our approved products, and other
inventions that are important to our business (e.g., the patient innovations described in our product labels/product inserts
and our core manufacturing technologies).
Our intellectual property portfolio continues to grow and keep pace with the innovations arising from our discovery,
development, and commercial efforts. We expect the total volume of patent positions under our management to increase
each year as our pipeline evolves. We currently oversee more than 500 pending applications and granted patents. More
importantly, as we continue to innovate for patients, we will work to protect our patient innovations with new intellectual
property filings to enable future reinvestment for patients.
In addition to patent protection, we rely on trademarks and trade secrets to protect aspects of our business that are not
amenable to, or that we do not consider appropriate for, patent protection, including certain aspects of our llama
immunization and antibody affinity maturation approaches.
Our commercial success depends in part upon our ability to obtain and maintain exclusivity, including regulatory
exclusivities, patent, trade secret, and other proprietary protection for commercially important technologies, inventions
and know-how related to our business. We will defend and enforce our intellectual property rights, particularly our
patent rights, and preserve the confidentiality of our trade secrets while operating without infringing valid and
enforceable intellectual property rights of others. Specifically, we are materially dependent on elements of our
regulatory, patent and other proprietary protection, including certain of those related to our core platform technologies,
described in “Item 4.B. — Business Overview — Intellectual Property — Platform Technologies” below and our product
candidates, as described in “Item 4.B. — Business Overview — Intellectual Property — Our internal Programs” below
and “Item 4.B. — Business Overview — Intellectual Property — Our Partnered Programs” below.
The patent positions for biotechnology companies like us are generally uncertain and can involve complex legal,
scientific, and factual issues. In addition, the coverage recited in the claims in a patent application can be significantly
reduced before a patent is issued, and claim scope can be reinterpreted and even challenged after issuance. As a result,
we cannot guarantee that any of our platform technologies and product candidates, or products will be protectable or
remain protected by valid and enforceable patents. We cannot accurately predict whether pending patent applications
will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient
protection from infringing competitors. Any patents we hold may be challenged, circumvented, limited or invalidated by
third parties.
The term of individual patents depends on the patent laws in the countries in which they are obtained. In most countries,
the patent term is 20 years from the earliest date of filing a non-provisional patent application.
In the U.S., the term of a patent covering an FDA-approved drug may be eligible for a limited patent term extension
under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) as compensation for
the loss of patent term during the FDA regulatory review process as described in “Item 4.B. — Business Overview —
Regulation — Licensure and Regulation of Biologics in the U.S.” below. Similar provisions are available in the EU and
in other jurisdictions to extend the term of a patent that covers an approved drug and/or its use. It is possible that issued
U.S. patents covering each of our products/product candidates may be entitled to patent term extensions. If our product
candidates receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of
patents that cover the approved product candidates and/or their uses. We also intend to seek patent term extensions in
any jurisdictions where available. There is no guarantee that the applicable authorities, including the FDA, will agree
with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.
43
Table of Contents
Platform Technologies
With regard to our platform technologies, we own or control intellectual property rights directed to our SIMPLE
ANTIBODY™ discovery platform, the ABDEG™ and NHANCE™ technologies.
With regard to our SIMPLE ANTIBODY™ discovery platform, we have a broad patent portfolio providing exclusivity
on the SIMPLE ANTIBODY™ platform. We expect to enjoy exclusivity under this patent portfolio until between 2029
and 2033.
With regard to the ABDEG™ platform, we co-own the technology with the University of Texas Southwestern Medical
Center and enjoy certain exclusive license rights. We have a broad patent portfolio covering the composition of matter
and uses of certain FcRn antagonists to achieve certain biological effects. A composition of matter patent expires in 2036
in the U.S., whereas in many other countries the base expiry date is 2034.
With regard to the NHANCE™ platform, we exclusively licensed two U.S. patents from the University of Texas
Southwestern Medical Center with composition of matter claims directed to an IgG molecule comprising a variant
human Fc domain, and method of use claims directed to a method of blocking FcRn function in a subject by providing to
the subject such an IgG molecule. The U.S. patents are expected to expire between 2027 to 2028. The patent family also
includes a granted European patent.
Our Internal Programs
efgartigimod
efgartigimod incorporates the ABDEG™ platform technology, for which we co-own the technology with the University
of Texas Southwestern Medical Center and enjoy certain exclusive license rights. We have a broad patent portfolio with
multiple patent families covering the composition of matter and uses of certain FcRn antagonists to achieve disease-
modifying effects. A composition of matter and other relevant patents arising from the same patent family in the U.S.
expire in 2036 and 2037 in Europe whereas in many other countries the base expiry date is 2034. We anticipate several
more patient innovations to evolve during development and commercialization for which we will seek additional patent
protection with later expiration dates.
Our ARGX-109 Product Candidate
With regard to our wholly-owned ARGX-109 product candidate, we have one patent family with composition of matter
claims directed to ARGX-109. The patent family has a base expiry date in 2033. We anticipate several more patient
innovations to evolve during development for which we will seek additional patent protection. Furthermore, ARGX-109
incorporates or employs the SIMPLE ANTIBODY™ platform technology and the NHANCE™ platform technology.
empasiprubart Product Candidate
With regard to the empasiprubart product candidate, we own or have rights to multiple patent families (with several
granted patents and pending patent applications in multiple jurisdictions in North America, South America, the EU and
Asia, directed to composition of matter claims and method of treatment claims. The patent families have base expiry
dates in 2034, 2039 and 2040. We anticipate several more patient innovations to evolve during development for which
we will seek additional patent protection. empasiprubart product candidate incorporates or employs the NHANCE™
platform technology.
adimanebart Product Candidate
With regard to the adimanebart product candidate, we in-licensed patent families from/with New York University
Langone Health, a U.S. medical center based in New York, and additional patent families from/with the Leiden
University Medical Centre, with a U.S. granted patent and several pending applications in multiple jurisdictions . We
anticipate several more patient innovations to evolve during development for which we will seek additional patent
protection.
Our ARGX-118 Product Candidate
With regard to the ARGX-118 product candidate, we co-own a patent portfolio with VIB, an inflammation research
center in Ghent, Brussels, and Ghent University, with one U.S. granted patent and pending patent applications in
multiple jurisdictions in North America, South America, the EU and Asia. The patent family has a base expiry date in
2039.
44
Table of Contents
Our Partnered Programs
Our cusatuzumab (ARGX-110) Product Candidate
With regard to the cusatuzumab product candidate, we have a broad patent portfolio that include claims to the
composition of matter, uses of the molecule, and other important inventions. The issued U.S. patents expire in 2032 and
2033, without taking a potential patent term extension into account. cusatuzumab incorporates or employs the SIMPLE
ANTIBODY™ and POTELLIGENT® platform technologies.
Our ARGX-115 (ABBV-151) Product Candidate
With regard to the ARGX-115 (ABBV-151) product candidate that we co-own with, and exclusively license from, the
Ludwig Institute for Cancer Research and UCL, we have a patent portfolio that includes a U.S. patent with a base expiry
date in 2034, without taking a potential patent term extension into account. There is a second family with meaningful
patent coverage to the composition of matter and epitope claims that are expected to expire in 2036 and 2038.
Furthermore, ARGX-115 (ABBV-151) incorporates or employs the SIMPLE ANTIBODY™ platform technology.
Our ARGX-112 (LP-0145) Product Candidate
With regard to the ARGX-112 (LP-0145) product candidate, we have one patent family with composition of matter
claims directed to an antibody that binds human IL-22R. The patent family has a base expiry date in 2037. Furthermore,
ARGX-112 (LP-0145) incorporates the SIMPLE ANTIBODY™ platform technology.
Collaborations and licenses
At argenx, our approach to collaboration and licensing is rooted in the conviction that progress accelerates when
boundaries are challenged and expertise is shared. We follow a disciplined strategy to maximize the value of our
pipeline. We retain full development and commercialization rights for programs where we believe our platform and
capabilities can deliver the greatest impact, ensuring we capture the full value of our innovation. At the same time, we
actively seek out partnerships with organizations that share our drive to redefine what’s possible, leveraging
complementary strengths to unlock new opportunities for patients.
Our licensing strategy is dynamic and pragmatic: we license out select intellectual property to expand the reach of our
science, while we also in-license or acquire technologies and assets that can amplify our pipeline or accelerate
development. We have partnered, and plan to continue to partner, to develop products and product candidates that we
believe have promising utility in disease areas or have patient populations that may benefit from resources of other
biopharmaceutical companies. We believe every agreement is shaped by a clear-eyed focus on execution, mutual benefit,
and the potential to create lasting change. We aim to be disciplined in our diligence and financial commitments, but not
at the expense of agility or ambition. By building alliances that transcend traditional hierarchies and by staying
relentlessly focused on unmet needs, we are not just advancing our own portfolio, we are helping to reshape the
landscape of immunology for the long term.
We also have several license agreements in place, under which we license patents, patent applications and other
intellectual property to third parties. We have also entered into several license agreements under which we license
patents, patent applications and other intellectual property from third parties. License agreements can relate to research
and development and/or commercialization of the relevant product candidates (and technologies) or products. The
licensed intellectual property covers some of our product candidates and some of the antibody engineering technologies
that we use. Some of these licenses impose various diligence and financial payment obligations on us. We expect to
continue to enter into these types of license agreements in the future.
We have entered into multiple collaboration agreements with pharmaceutical partners and license agreements, some of
which are described below.
Our Strategic Partnership with Zai Lab for efgartigimod
Pursuant to the Zai Lab Agreement, Zai Lab obtained the exclusive right to develop and commercialize efgartigimod in
Greater China. Zai Lab will also contribute patients to our global Phase 3 clinical trials of efgartigimod. Our Zai Lab
strategic collaboration allows us to accelerate development of efgartigimod into new autoimmune indications with Zai
Lab taking operational leadership of selected Phase 2 POC Clinical trials.
We are eligible to receive a one-time sales based milestone and tiered royalties based on annual net sales of efgartigimod
in Greater China thereafter.
45
Table of Contents
Our Exclusive License with Halozyme for ENHANZE®
In February 2019, we entered into an in-license agreement with Halozyme for the use of certain patents, materials and
know-how owned by Halozyme and relating to its ENHANZE®, for application in the field of prevention and treatment
of human diseases (the ENHANZE® License Agreement). Pursuant to the ENHANZE® License Agreement, we were
granted exclusive rights to apply ENHANZE® to biologic products against pre-specified targets, in order to research,
develop and commercialize SC formulations of our therapeutic antibody-based product candidates.
Our first therapeutic target for which we received an exclusive license from Halozyme was FcRn, which allows us to
apply ENHANZE® to efgartigimod and any other product candidates selective and specific for FcRn. Moreover, the
breadth of our exclusive license to FcRn precludes either Halozyme itself or any of its current or future partners from
utilizing ENHANZE® in the context of an FcRn-targeted product. Our second therapeutic target for which we received
an exclusive license from Halozyme was human C2 associated with the product candidate empasiprubart, which is being
developed to treat severe autoimmune diseases. Pursuant to the ENHANZE® License Agreement, we also have the right
to nominate future targets for an exclusive ENHANZE® license if the target in question has not already been licensed by
Halozyme or is not already being pursued by Halozyme.
We have expanded our collaboration with Halozyme for ENHANZE® drug delivery technology to additional targets for
a total of six, including FcRn and C2.
We may terminate the ENHANZE® License Agreement at any time, either in its entirety or on a target-by-target basis,
by sending Halozyme prior written notice. Absent early termination, the ENHANZE® License Agreement will
automatically expire upon the expiry of our royalty payment obligations under the agreement. In the event the
ENHANZE® License Agreement is terminated for any reason, the license granted to us would terminate but Halozyme
would grant our sublicensees a direct license following such termination. In the event the ENHANZE® License
Agreement is terminated other than for our breach, we would retain the right to sell licensed products then on hand for a
certain period of time post-termination.
Our Exclusive License with the University of Texas for NHANCE™ and ABDEG™
In February 2012, we entered into an exclusive in-license with the Board of Regents of the University of Texas System
(UT BoR) for the use of certain patent rights relating to the NHANCE™ platform for any use worldwide (the UT
Agreement). The UT Agreement was amended on December 23, 2014 to also include certain additional patent rights
relating to the ABDEG™ platform. Upon commercialization of any of our products that use the in-licensed patent rights,
we will be obligated to pay UT BoR a percentage of net sales as a royalty until the expiration of any patents covering the
product. This royalty varies with net sales volume and is subject to an adjustment for royalties we receive from a
sublicensee of our rights under the UT Agreement, but in any event does not exceed 1%. In addition, we must make
annual license maintenance payments to UT BoR until termination of the UT Agreement and we have assumed certain
development and commercial milestone payment and reimbursement obligations. We also have diligence requirements
with respect to development and commercialization of products which use the in-licensed patent rights.
Pursuant to the UT Agreement, we may grant sublicenses to third parties. If we receive any non-royalty income in
connection with such sublicenses, we must pay UT BoR a percentage of such income varying from low-middle single
digits to middle-upper single digits depending on the nature of the sublicense. Such fees are waived if a sublicensee
agrees to pay the milestone payments as set forth in the UT Agreement.
We may unilaterally terminate the UT Agreement for convenience upon prior written notice. Absent early termination,
the UT Agreement will automatically expire upon the expiration of all issued patents and filed patent applications within
the patent rights covered by the UT Agreement. Our royalty payment obligations expire, on a product-by-product and
country-by-country basis, at such time as there are no valid claims covering such product.
OncoVerity for cusatuzumab
In 2022, we, the University of Colorado Anschutz Medical Campus and the University of Colorado Health (UCHealth)
created an asset-centric spin-off, OncoVerity, Inc (OncoVerity), focused on optimizing and advancing the development
of cusatuzumab, a novel anti-CD70 antibody, in acute myeloid leukemia (AML). OncoVerity is an entity of co-creation,
combining the extensive translational biology insights from Dr. Clayton Smith, M.D. from the University of Colorado
with our experience on the CD70/CD27 pathway.
In 2023, we granted an exclusive license for cusatuzumab to OncoVerity and provided, together with a joint venture of
University of Colorado Health and University License Equity Holdings, Inc. on the University of Colorado Anschutz
Medical Campus, and funding for ongoing clinical development of cusatuzumab.
46
Table of Contents
In 2024 and 2025, we participated in a further funding round to support the continued, ongoing, clinical development of
cusatuzumab by OncoVerity.
Our Strategic Partnership with AbbVie for ARGX-115 (ABBV-151)
In 2016, we entered into a collaboration agreement with AbbVie for ARGX‑115 (ABBV‑151), targeting GARP in
oncology (the AbbVie Collaboration Agreement). After completing IND‑enabling work, AbbVie exercised its option
and assumed full responsibility for global development and commercialization. We are eligible for up to $625 million in
potential development, regulatory and commercial milestones, plus tiered royalties from the mid‑single digits to lower
teens. We also retain co‑promotion rights in the EEA and Switzerland. The agreement continues on a product‑by‑product
basis until AbbVie’s payment obligations expire, and AbbVie may terminate the AbbVie Collaboration Agreement with
prior notice.
Trade Secret Protection
In addition to patent protection, we rely on trade secret protection to ensure exclusivity for our proprietary information
that is not amenable to, or that we do not consider appropriate for, patent protection, including, for example, certain
aspects of our llama immunization and antibody affinity maturation approaches. However, trade secrets can be difficult
to protect. Although we take steps to protect our proprietary information, including restricting access to our premises and
our confidential information, as well as entering into agreements with our employees, consultants, advisors and potential
collaborators, third parties may independently develop the same or similar proprietary information or may otherwise gain
access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and
proprietary information.
Regulation
Government authorities in the U.S., at the federal, state and local level, and in the EU and its Member States and other
countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture,
quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing,
post-approval monitoring and reporting, and import and export of pharmaceutical products, including biological
products. In addition, many countries and jurisdictions regulate the pricing of pharmaceutical products. The processes for
obtaining marketing approvals in the U.S. and in other countries and jurisdictions, along with subsequent compliance
with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial personnel
and financial resources, and breach of which can result in enforcement activity under civil, administrative and/or
criminal law.
Licensure and Regulation of Biologics in the U.S.
In the U.S., biological products used for the prevention, treatment, or cure of a disease or condition in a human being are
subject to regulation under the U.S. Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations.
Biologics are approved for marketing under provisions of the Public Health Service Act (PHSA) via biologics license
applications (BLAs).
An applicant seeking approval to market and distribute a new biologic in the U.S. generally must satisfactorily complete
each of the following steps:
•preclinical laboratory tests, animal studies and formulation studies all performed in accordance with applicable
requirements, including the GLPs;
•submission to the FDA of an IND application for human clinical testing, which contains results of the preclinical
tests, together with manufacturing information and analytical data and must become effective before human clinical
trials may begin;
•approval by an institutional review board (IRB) representing each clinical site before each clinical trial may be
initiated;
•performance of adequate and well-controlled human clinical trials to establish the safety, potency and purity of the
product candidate for each proposed indication, in accordance with good clinical practices (GCPs);
•preparation and submission to the FDA of a BLA for a biological product requesting marketing for one or more
proposed indications, including submission of detailed information on the manufacture and composition of the
product in clinical development and proposed labeling;
47
Table of Contents
•one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the
product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the
facilities, methods and controls are adequate to preserve the product’s identity, potency, quality and purity;
•FDA inspections of the clinical trial sites and/or sponsor to assure compliance with GCPs, and the integrity of clinical
data in support of the BLA;
•payment of user fees and securing FDA approval of the BLA and licensure of the new biological product; and
•compliance with any post-approval requirements, including the potential requirement to implement a risk evaluation
and mitigation strategy (REMS) and any post-approval studies required by the FDA.
Human Clinical Trials in Support of a BLA
Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional
clinical trials may be required after approval.
•Phase 1 clinical trials are initially conducted in a limited population to test the product candidate for safety, including
adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and PD in healthy humans or, in
patients.
•Phase 2 clinical trials are generally conducted in a limited patient population to identify possible adverse effects and
safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose
tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information
prior to beginning larger Phase 3 clinical trials.
•Phase 3 clinical trials are undertaken within an expanded patient population to gather additional information about
safety and effectiveness necessary to evaluate the overall benefit-risk relationship of the drug and to provide an
adequate basis for physician labeling.
A sponsor who wishes to conduct a clinical trial outside the U.S. may, but is not required to, obtain FDA clearance to
conduct the clinical trial under an effective IND. If a foreign clinical trial is not conducted under an IND, the sponsor
may submit data from the clinical trial to the FDA in support of the BLA so long as the clinical trial is well-designed and
well-conducted in accordance with GCPs, including review and approval by an independent ethics committee, and the
FDA is able to validate the clinical trial data through an onsite inspection, if necessary. In some cases, the FDA may
approve a BLA for a product candidate but require the sponsor, or the sponsor may otherwise choose, to conduct
additional clinical trials to further assess, amongst other things, the product candidate’s safety and effectiveness after
approval. Such post-approval clinical trials are typically referred to as Phase 4 clinical trials. Failure to exhibit due
diligence with regard to conducting required Phase 4 clinical trials could result in FDA enforcement, including
withdrawal of approval for products.
Review and Approval of a BLA
The results of product candidate development, preclinical testing and clinical trials, including negative or ambiguous
results as well as positive findings, are submitted to the FDA as part of a BLA requesting a license to market the product.
The BLA also must contain extensive manufacturing information and detailed information on the composition of the
product and proposed labeling as well as payment of a user fee, unless exempt.
The FDA has 60 days after submission of the application to conduct an initial review to determine whether the BLA is
sufficient to file based on the agency’s threshold determination that it is sufficiently complete to permit substantive
review. If the FDA determines the BLA is not sufficiently complete, it will refuse to file the BLA. Once the submission
has been filed, the FDA begins an in-depth review of the application. Under the goals agreed to by the FDA under the
PDUFA, the FDA has 10 months from the filing date in which to complete its initial review of a standard application and
respond to the applicant, and six months from the filing date for an application granted priority review. The FDA does
not always meet its PDUFA goal dates and they may be extended in certain circumstances.
After the FDA’s evaluation of the application and accompanying information, including the results of any necessary
inspections, the FDA will issue an approval letter, or a complete response letter. An approval letter authorizes
commercial marketing of the product with specific prescribing information for specific indications. Under the PHSA, the
FDA may approve a BLA if it determines that the product is safe, pure and potent and the facility where the product will
be manufactured meets standards designed to ensure that it continues to be safe, pure and potent. If the application is not
approved, the FDA will issue a complete response letter, which will identify the deficiencies in the application. Sponsors
that receive a complete response letter may resubmit to the FDA information addressing the issues identified by the
48
Table of Contents
FDA, withdraw the application, or request a hearing. Even if a BLA is resubmitted with data and information addressing
the deficiencies, the FDA may decide that the BLA does not satisfy the criteria for approval.
The FDA may also refer the application to an advisory committee, consisting of independent experts, for review,
evaluation and recommendation as to whether the application should be approved, particularly when applications present
difficult or novel questions of safety or efficacy. The FDA is not bound by the recommendations of an advisory
committee, but it considers such recommendations carefully when making decisions.
If the FDA approves a new product, it may require testing and surveillance programs to monitor the product after
commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms,
including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include
medication guides, communication plans for healthcare professionals, and/or elements to assure safe use. This can
include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under
certain circumstances, special monitoring, and the use of patent registries. The FDA may prevent or limit further
marketing of a product based on the results of post-market studies or surveillance programs.
After approval, many types of changes to the approved product, such as adding new indications, certain manufacturing
changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.
Expedited Development and Review Programs
The FDA is authorized to designate products meeting certain criteria for expedited development and review programs.
Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets
the conditions for qualification, or the time period for FDA review or approval may not be shortened.
The FDA may designate a product for fast track review if it is intended, whether alone or in combination with one or
more other products, for the treatment of a serious or life-threatening disease or condition, and demonstrates the potential
to address unmet medical needs for such a disease or condition. For fast track products, sponsors may have more
frequent interactions with the FDA and the FDA may initiate review of sections of a fast track product’s application
before the application is complete (rolling review). The sponsor must also provide, and the FDA must approve, a
schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the
FDA’s PDUFA clock for a rolling review application does not begin until the last section of the application is submitted.
A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more
other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that
the product may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain
actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development
process; providing timely advice to the product sponsor regarding development and approval; involving more senior
staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to
design the clinical trials in an efficient manner. Breakthrough therapy designation also comes with all of the benefits of
fast-track designation.
The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved,
would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis,
whether the proposed product represents a significant improvement when compared with other available therapies.
Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition,
elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient
compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new
subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such
applications, and to shorten the FDA’s goal for taking action on a marketing application from 10 months to six months
after accepting the application for filing.
The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful
therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a
surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured
earlier than an effect on irreversible morbidity or mortality (IMM) and that is reasonably likely to predict an effect on
IMM or other clinical benefit (intermediate clinical endpoint), taking into account the severity, rarity, or prevalence of
the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the
same statutory standards for safety and effectiveness as those granted traditional approval.
For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radio-
graphic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of
clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An
49
Table of Contents
intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the
clinical benefit of a product, such as an effect on IMM.
The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended
period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or
intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development
and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve
survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large
clinical trials to demonstrate a clinical or survival benefit.
The accelerated approval pathway is usually contingent on a sponsor’s agreement to conduct, in a diligent manner, a
post-approval confirmatory clinical trial or studies to verify and describe the product’s clinical benefit. These
confirmatory clinical trials must be completed with due diligence, and the FDA may require that the confirmatory
clinical trial be designed, initiated, and/or fully enrolled prior to, or within a certain period following, approval. The FDA
must also specify the conditions of any required post-approval clinical trial. Sponsors are required to submit progress
reports for required post-approval studies, and the failure to conduct with due diligence a required post-approval clinical
trial, including a failure to meet any required conditions specified by the FDA, or to submit timely reports, are prohibited
acts under the FDCA. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-
marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. Unless
otherwise informed by the FDA, all promotional materials for product candidates approved under accelerated approval
are subject to prior review by the agency.
Orphan Drug Designation and Exclusivity
Orphan drug designation in the U.S. is designed to encourage sponsors to develop products intended for rare diseases or
conditions. In the U.S., a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000
individuals in the U.S. or that affects more than 200,000 individuals in the U.S. and for which there is no reasonable
expectation that the cost of developing and making available the product for the disease or condition will be recovered
from sales of the product in the U.S. An application for designation as an orphan product can be made any time prior to
the filing of an application for approval to market the product. If the FDA grants orphan drug designation, the generic
identity of the product and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation qualifies
a company for tax credits. Orphan drug designation does not convey any advantage in or shorten the duration of the
regulatory review and approval process.
If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition
for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not
approve any other application to market the same drug for the same indication for seven years from the date of such
approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan
exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care, or if the
holder of the orphan exclusivity is unable to supply the market. Competitors, however, may receive approval of either a
different product for the same indication or the same product for a different indication, which could be used off-label in
the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a
competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are
seeking approval, or if our product is determined to be contained within the scope of the approval of the competitor’s
product for the same indication or disease.
Post-Approval Regulation
If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will
be required to comply with all post-approval regulatory requirements, including those that the FDA has imposed as part
of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the
FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and
promotional labeling. Manufacturers and other parties involved in the drug supply chain for prescription drug and
biological products must also comply with product tracking and tracing requirements and must notify the FDA of
counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in
the U.S. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and
certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for
compliance with ongoing regulatory requirements, including cGMPs. Accordingly, the sponsor and its third-party
manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain
compliance with cGMPs and other regulatory requirements.
A biological product may also be subject to official lot release, meaning that the manufacturer is required to perform
certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release,
the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of
50
Table of Contents
manufacture of the lot and the results of all of the manufacturer’s tests performed on the lot, to the FDA. The FDA may
in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally,
the FDA will conduct laboratory research related to the safety, purity, potency and effectiveness of biological products.
Any distribution of biological products and samples must comply with the U.S. Prescription Drug Marketing Act and the
PHSA.
Once approval of a BLA is granted, the FDA may revoke or suspend the approval if compliance with regulatory
requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery
of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with
manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or
imposition of distribution or other restrictions under a REMS program. FDA also has authority to require post-market
studies, in certain circumstances, on reduced effectiveness of a product and may require labeling changes related to new
reduced effectiveness information. Other potential consequences for a failure to maintain regulatory compliance include,
among other things:
•restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or
product recalls;
•fines, untitled letters, or warning letters;
•refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of product license approvals;
•product seizure or detention, or refusal to permit the import or export of products; or
•injunctions or the imposition of civil or criminal penalties.
Pediatric Studies and Exclusivity
Under the Pediatric Research Equity Act of 2003, as amended (PREA), certain BLAs or supplements thereto must
contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all
relevant pediatric sub-populations, and to support dosing and administration for each pediatric subpopulation for which
the product is safe and effective. Sponsors must also submit an initial Pediatric Study Plan (PSP), within 60 days of an
end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or
Phase 2/3 clinical trial. The initial PSPs must contain an outline of the proposed pediatric clinical trial or studies the
applicant plans to conduct, including clinical trial objectives and design, any deferral or waiver requests and other
information required by regulation. The applicant and the FDA must agree upon a final plan. The FDA or the applicant
may request an amendment to the plan at any time.
The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all
pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data
requirements. Unless otherwise required by regulation, PREA does not apply to a biologic for an indication for which
orphan designation has been granted, except that PREA will apply to an original BLA for a new active ingredient that is
orphan-designated if the biologic is a molecularly targeted cancer product intended for the treatment of an adult cancer
and is directed at a molecular target that FDA determines to be substantially relevant to the growth or progression of a
pediatric cancer.
Pediatric exclusivity is another type of non-patent regulatory exclusivity in the U.S. and, if granted for a biologic,
provides for the attachment of an additional six months of protection to the term of any existing regulatory exclusivity
(i.e., reference product exclusivity and orphan drug exclusivity) that has at least 9 months left to expiration. This six-
month exclusivity may be granted if a BLA sponsor submits reports of pediatric studies that fairly respond to a written
request from the FDA for such studies, were conducted in accordance with commonly accepted scientific principles and
protocols, and have been reported in accordance with filing requirements.
Biosimilars and Exclusivity
The Biologics Price Competition and Innovation Act (BPCIA) established a regulatory scheme authorizing the FDA to
approve biosimilars and interchangeable biosimilars.
Under the BPCIA, an applicant may submit an application for licensure of a biologic product that is “biosimilar to” or
“interchangeable with” a previously approved biological product or “reference product.” For the FDA to approve a
biosimilar product, it must find that the proposed biosimilar is highly similar to the reference product notwithstanding
51
Table of Contents
minor differences in clinically inactive components and that there are no clinically meaningful differences between the
product and the reference product in terms of safety, purity, or potency. For the FDA to approve a biosimilar product as
interchangeable with a reference product, the agency must find that the biosimilar product is biosimilar to the reference
product and that it can be expected to produce the same clinical results as the reference product in any given patient, and
(for products administered multiple times) that the biologic and the reference biologic may be alternated or switched
after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to
exclusive use of the reference biologic without such alternation or switch.
Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following
the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the
date on which the reference product was approved. Even if a product is considered to be a reference product eligible for
exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such
product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to
demonstrate the safety, purity and potency of their product. We note that patent positions may be available to preclude
the introduction into commerce of such competing product independent of any FDA exclusivities. The BPCIA also
created certain exclusivity periods for biosimilars approved as interchangeable products. Products deemed
interchangeable by the FDA may be substituted by pharmacies as dictated by individual state law.
U.S. Patent Term Restoration
Depending upon the timing, duration, and specifics of FDA review and approval of our product candidates, some of our
U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act that permits restoration of
the patent term of up to five years as compensation for patent term lost during the FDA regulatory review process.
Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the
product’s approval date, and only those claims covering such approved product, a method for using it or a method for
manufacturing it may be extended. The patent-term restoration period is generally one-half the time between the
effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the
approval of that application, except that the review period is reduced by any time during which the applicant failed to
exercise due diligence. Only one patent applicable to an approved biologic is eligible for the extension and the
application for the extension must be submitted within 60 days of approval from FDA and prior to the expiration of the
patent. The U.S. Patent and Trademark Office (USPTO), in consultation with the FDA, reviews and approves the
application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our
currently owned or licensed patents to add patent life beyond the current expiration date, depending on the expected
length of the clinical trials and other factors involved in the filing of the relevant BLA.
Regulation and Procedures Governing Approval of Medicinal Products in the European Union
Similar to the U.S., the EU comprehensively regulates, among other things, the development, manufacturing, placing on
the market, advertising, distribution, import and export of medicinal products. Particularly, the placing on the market of a
medicinal product for human use in the EU requires a marketing authorization (MA). Main provisions governing
medicinal products in the EU are Directive 2001/83/EC and Regulation (EC) No 726/2004 (each as amended).
Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000 (each as amended) are also of particular relevance for
orphan medicinal products. While directives need to be transposed into national law by member states of the EU (EU
Member States) before they are applicable, regulations directly apply in the EU Member States once these have been
enacted.
The process governing approval of MA applications (MAA) for the placing on the market of medicinal products in the
EU generally follows the same lines as in the U.S. It entails satisfactory completion of pharmaceutical development, pre-
clinical trials and adequate and well-controlled clinical trials to establish the safety and efficacy of the medicinal product
for each proposed indication. The EU also requires an application for authorization of clinical trials to relevant
competent authorities and the submission of an MAA to the European Medicines Agency (EMA) or to competent
authorities in EU member states and granting of such MA by the European Commission or relevant national authorities
before the medicinal product can be marketed and sold in the EU or the relevant EU Member States. The below
mentioned principles and rules generally apply within the EEA, i.e., the EU including Iceland, Liechtenstein and
Norway.
Clinical Trial Approval
Both non-clinical and clinical data are generally required to support an MAA for a medicinal product in the EU. Non-
clinical investigations are performed to demonstrate the health or environmental safety of new biological substances.
Non-clinical (pharmaco-toxicological) investigations must generally be conducted in compliance with the principles of
good laboratory practice (GLP) as set forth in EU Directive 2004/10/EC (as amended).
52
Table of Contents
Clinical trials are comprehensively regulated in the EU under the Clinical Trials Regulation (EU) No 536/2014 (CTR),
which entered into application on January 31, 2022, and gradually replaced the Clinical Trials Directive 2001/20/EC
(CTD).
As before, many of the CTR’s legal obligations are on the so-called sponsor, which is defined as the individual,
company, institution, or organization that takes responsibility for the initiation, for the management and for setting up the
financing of a clinical trial. The sponsor must obtain an authorization from the competent authority in the EU Member
State(s) in which the clinical trial will be conducted as well as an approval from the competent national ethics committee
in accordance with relevant national legislation in each of the relevant member states, before the commencement of such
clinical trial.
The CTR also imposes requirements, among others, regarding the conduct of a clinical trial (which must be conducted in
accordance with the protocol and good clinical practice to generate acceptable data for MA submission), safety reporting
of adverse events and reactions, changes to clinical trials, protection and informed consent of clinical trial subjects.
Clinical trials conducted outside the EEA must follow the principles set forth in EU legislation if their results are to be
submitted in an MAA in the EU.
Orphan Designation and Exclusivity
Regulations (EC) No. 141/2000 and No. 847/2000 (each as amended) provide that a product can be designated as an
orphan medicinal product by the European Commission if its sponsor can establish: (i) that the product is intended for
the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition, (ii) either (a) the
prevalence of the condition is not more than five in ten thousand persons in the EU when the application is made, or
(b) without incentives it is unlikely that the marketing of the product in the EU would generate sufficient return to justify
the necessary investment in its development and (iii) there exists no satisfactory method of diagnosis, prevention, or
treatment of the condition in question that has been authorized in the EU or, if such method exists, the product has to be
of a significant benefit compared to products available for the condition.
An orphan designation provides a number of benefits, including fee reductions and, regulatory assistance. If an MA is
granted for an orphan medicinal product, this generally results in a ten-year period of market exclusivity for the approved
orphan indication. It is, however, not possible to combine non-orphan and orphan indications within the same MA. Thus,
for non-orphan indications treated with the same active pharmaceutical ingredient, a separate MA has to be sought.
Alternatively, the orphan designation may be waived to allow for the addition of non-orphan indications to an existing
MA. As a result, the approved medicinal product would no longer profit from the orphan designation’s benefits.
During an orphan medicinal product’s market exclusivity period, neither the EMA, the European Commission nor the
EU Member States can accept an application or grant an MA for a “similar medicinal product.” A “similar medicinal
product”, i.e., a medicinal product containing a similar active substance or substances as contained in an authorized
orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for
the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is
established that the product no longer meets the criteria for orphan designation. For orphan medicinal products intended
for pediatric use, the market exclusivity period may be prolonged by additional two years if they are authorized with a
pediatric indication based on the results from studies conducted under an EMA-approved pediatric investigation plan or
if they are authorized without a pediatric indication but the results of the studies conducted under the EMA-approved
pediatric investigation plan are reflected in the summary of product characteristic and, if appropriate, in the package
leaflet. Market exclusivity may also be revoked in very select cases, such as if (i) it is established that a similar medicinal
product is safer, more effective or otherwise clinically superior; (ii) the MA holder (MAH) for the authorized orphan
medicinal product consents to the second orphan application; or (iii) the MAH for the authorized orphan medicinal
product cannot supply sufficient quantities. Orphan designation must be requested before submitting an MAA and is
reconfirmed during the MAA process. Orphan designation does not convey any advantage in, or shorten the duration of,
the regulatory review and MA approval process.
Marketing Authorization
To obtain an MA for a medicinal product under the EU regulatory framework, an applicant must submit an MAA, either
to the EMA using the centralized procedure or to competent authorities in the EU Member States using the other
procedures (decentralized procedure, national procedure, or mutual recognition procedure). An MA may be granted only
to an applicant established in the EU. Regulation (EC) No. 1901/2006 provides that prior to obtaining an MA in the EU,
an applicant must demonstrate compliance with all measures included in an EMA-approved pediatric investigation plan,
covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver, or a
deferral for one or more of the measures included in the pediatric investigation plan.
The centralized procedure provides for the grant of a single MA by the European Commission that is valid for all EEA
Member States. Pursuant to Regulation (EC) No. 726/2004 (as amended), the centralized procedure is compulsory for
53
Table of Contents
specific products, including for medicines produced by certain biotechnological processes, products designated as
orphan medicinal products, advanced therapy medicinal products (gene therapy, somatic cell therapy or tissue
engineered products) and products with a new active substance indicated for the treatment of certain diseases, including
products for the treatment of cancer and auto-immune diseases and other immune dysfunctions and neurodegenerative
disorders. The centralized procedure is optional for certain other medicinal products.
Under the centralized procedure, the EMA’s Committee for Medicinal Products for Human Use (CHMP) is responsible
for conducting the assessment of a product to define its risk/benefit profile. The CHMP recommendation is then sent to
the European Commission, which adopts a decision binding in all EEA Member States. Under the centralized procedure,
the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information
or written or oral explanation is to be provided by the applicant in response to questions asked by the CHMP, which can
considerably extend the 210 days. Accelerated evaluation (150 days excluding clock stops) may be granted by the
CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in
particular, from the viewpoint of therapeutic innovation.
MAs have an initial validity for five years, in principle, and they may be renewed after five years on the basis of a
reevaluation of the risk benefit balance by the EMA, or by the competent authority of the EU Member State. Once
renewed, the MA is valid for an unlimited period, unless the European Commission or the competent authority decides,
on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any MA
that is not followed by the placement of the medicinal product on the EU market or on the market of the authorizing EU
Member State(s) within three years after authorization, or if the drug is removed from the market for three consecutive
years, ceases to be valid.
European Data and Market Exclusivity
In the EU, innovative medicinal products, approved on the basis of a complete independent data package, qualify for
eight years of data exclusivity upon MA and an additional two years of market exclusivity (for the more comprehensive
protections applying to orphan medicinal products, please refer to “Item 4.B — Business overview — Orphan
Designation and Exclusivity” above). The data exclusivity, if granted, prevents generic or biosimilar applicants from
referencing the innovator’s preclinical and clinical trial data contained in the dossier of the reference product when
applying for a generic or biosimilar MA in the EU, for a period of eight years from the date on which the reference
product was first authorized in the EU. During the additional two-year period of market exclusivity, a generic or
biosimilar MAA can be submitted, and the innovator’s data may be referenced, but no generic or biosimilar product can
be marketed in the EU until the expiration of the market exclusivity period. The overall ten-year period will be extended
to a maximum of 11 years if, during the first eight years of those 10 years, the MAH obtains an MA for one or more new
therapeutic indications which, during the scientific evaluation prior to their authorization, are determined to bring a
significant clinical benefit in comparison with currently approved therapies. There is no guarantee that a product will be
considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if
a product is considered to be an innovative medicinal product so that the innovator gains the prescribed period of data
exclusivity, another company nevertheless could also market another version of the product if such company obtained an
MA based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical
trials.
Regulatory Requirements after Marketing Authorization
Following MA approval, the MAH is required to comply with a range of requirements applicable to the manufacturing,
marketing, promotion and sale of the medicinal product. These include compliance with the EU’s stringent
pharmacovigilance or safety reporting rules under Directive 2001/83/EC and Regulation (EU) 726/2004 (each as
amended) and the associated guideline on good pharmacovigilance practices (as amended), pursuant to which post-
authorization studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized
medicinal products, for which a separate manufacturer’s license is mandatory, must also be conducted in strict
compliance with the principles of good manufacturing practice (GMP) set forth in Commission Directive 2017/1572
GMP and comparable requirements of other regulatory bodies in the EU, which mandate the methods, facilities and
controls used in manufacturing, processing and packing of products to assure their safety and identity. Further, the
wholesale distribution of authorized medicinal products requires a separate distribution license and must be conducted in
strict compliance with good distribution practice standards. Finally, the marketing and promotion of authorized
medicinal products is strictly regulated under Directive 2001/83/EC, (as amended) and as transposed into national laws.
Potential consequences for a failure to maintain regulatory compliance mainly depend on the relevant regulations in the
EU Member States, but are, for example, in Germany, similar to those in the U.S. Please refer to “Item 4.B — Business
overview — Post-Approval Regulations” above.
54
Table of Contents
Agreement on new EU Pharmaceutical Legislation
On December 11, 2025, the EU legislative bodies agreed to overhaul, modernize, and streamline the existing general
pharmaceutical legislation, including e.g., Directive 2001/83/EC, as well as Regulations (EC) No. 726/2004, No.
141/2000, or No. 1901/2006 (EU Pharmaceutical Legislation). This agreement is still subject to formal approval by the
European Parliament and the Council of the EU, before being formally adopted. It is expected that the EU
Pharmaceutical Legislation will become applicable in 2028. Although the final text has not yet been published, agreed
key elements appear to include, among others, certain changes to the baseline marketing exclusivity periods, the
streamlining of regulatory procedures as well as a broadening of the so-called “Bolar exemption”, which allows
developers to undertake testing and to prepare for regulatory submissions before patent expiry.
Regulation and Procedures Governing Approval of Medicinal Products in Japan
In order to market any medical products in Japan, a company must comply with numerous and varying regulatory
requirements regarding quality, safety and efficacy in the context, among other things, of clinical trials, marketing
approval, commercial sales and distribution of products. A person who manufactures or markets medical products in
Japan is subject to the supervision of the Ministry of Health, Labour and Welfare (MHLW), primarily under the Act on
Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices (Pharmaceutical and Medical Devices
Act). This entails the satisfactory completion of pharmaceutical development, preclinical studies and adequate and well-
controlled clinical trials to establish the safety and efficacy of the medical product for each proposed indication. It also
requires the filing of a notification of clinical trials with the Pharmaceuticals and Medical Devices Agency (Japan)
(PMDA) and the obtaining of marketing approval from the relevant authorities before the product can be marketed and
sold in the Japanese market.
Business License
Under the Pharmaceutical and Medical Devices Act, a company or individual must obtain a Marketing Authorization
Holder (MAH) license from the MHLW to engage in the marketing or provision of medical products. This requirement
applies to medical products that are either manufactured by the company itself outsourced to a third party for
manufacturing or imported.
To manufacture medical products for the Japanese market, a company must obtain a manufacturing license from the
MHLW for each production facility. This license is separate from the marketing authorization and is required for both
domestic and foreign manufacturing sites.
Marketing Approval
Under the Pharmaceutical and Medical Devices Act, it is generally required to obtain marketing approval from the
MHLW for the marketing of each medical product. An application for marketing approval must be made through the
PMDA, which implements a marketing approval review.
Clinical Trial
Under the Pharmaceutical and Medical Devices Act, it is required to file notification of clinical trials with the PMDA.
The data of clinical trials and other pertinent data, which must be attached to an application for marketing approval, must
be obtained in compliance with the standards established by the MHLW, such as GLPs and GCPs stipulated by the
ministerial ordinances of the MHLW.
Regulatory Requirements after Marketing Approval
A MAH that has obtained marketing approval for a new pharmaceutical is subject to re-examination by the PMDA for a
specified period after receiving marketing approval. Such re-examination period for VYVGART is stated to be 10 years
after the marketing approval in January 2022. The purpose of this re-examination process is to ensure the safety and
efficacy of a newly approved pharmaceutical by imposing on the MAH the obligation to gather clinical data for a certain
period after the marketing approval was granted to enable the PMDA to re-examine the product. Results of use and other
pertinent data must be attached to an application for a re-examination. An MAH that has obtained a marketing approval
is also required to investigate, among other things, the results of use and to periodically report to the PMDA pursuant to
the Pharmaceutical and Medical Devices Act.
55
Table of Contents
Price Regulation
Japan's public medical insurance systems cover virtually the entire Japanese population. The public medical insurance
system, however, does not cover any medical product which is not listed on the National Health Insurance (NHI) price
list published by the Minister of the MHLW. Accordingly, an MAH of medical products must first have a new medical
product listed on the NHI price list to obtain coverage under the public medical insurance system. VYVGART was listed
on the NHI price list in April 2022 and the price was adjusted in February 2024. VYVDURA was listed in April 2024.
The NHI price of a medical product is determined either by price comparison of comparable medical products with
necessary adjustments for innovation, usefulness or size of the market; or, in the absence of comparable medical
products, by the cost calculation method, determined after considering of the opinion of the manufacturer. Prices on the
NHI price list are subject to revision, generally once every year, based on the actual prices at which the medical products
are purchased by medical institutions.
Coverage, Pricing and Reimbursement
Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may
obtain regulatory approval. Even if our product candidates are approved for marketing, sales of such product candidates
will depend, in part, on the extent to which third-party payors, including government health programs in the U.S. (such
as Medicare and Medicaid), commercial health insurers, and managed care organizations, provide coverage and establish
adequate reimbursement levels for such product candidates. Moreover, increasing efforts by governmental and third-
party payors in the EU, the U.S. and other markets to cap or reduce healthcare costs may cause such organizations to
limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or
provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the
sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health
maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general,
particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result,
increasingly high barriers are being erected to the entry of new products.
In the U.S. and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the
costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs,
such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Patients are unlikely to
use any product candidates we may develop unless coverage is provided and reimbursement is adequate to cover a
significant portion of the cost of such product candidates.
Factors payors consider in determining reimbursement are based on whether the product is (i) a covered benefit under its
health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and
(v) neither experimental nor investigational.
The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental
payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require
pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers
who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the
coverage and reimbursement for our product candidates. No uniform policy for coverage and reimbursement for drug
products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for drug products can differ
significantly from payor to payor including formulary tier placement and utilization management requirements (if any).
As a result, the coverage determination process is often a time-consuming and costly process that will require us to
provide scientific and clinical support for the use of our products to each payor separately, with no assurance that
coverage and adequate reimbursement will be applied consistently or obtained in the first instance. The position of a
product on a formulary generally determines the co-payment that a patient will need to make to obtain the product and
can strongly influence the adoption of a product by patients and physicians. Third-party payors may limit coverage to
specific products on a formulary, which might not include all of the approved products for a particular indication.
Additionally, a payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate
will be approved or that cost-sharing will be acceptable for patients. Coverage policies and third-party reimbursement
rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more of our
products for which we or our collaborators receive marketing approval, less favorable coverage policies and
reimbursement rates may be implemented in the future.
Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of
medical products and services and imposing controls to manage costs, especially drugs when an equivalent generic drug
or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidate and
other therapies (in some cases even off-label treatments) as substitutable and only offer to reimburse patients for the less
expensive product. Even if we show improved efficacy or improved convenience of administration with our product
candidate, pricing of existing drugs may limit the amount we will be able to charge for our product candidate. These
56
Table of Contents
payors may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing
marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product
development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully
commercialize our product candidates and may not be able to obtain a satisfactory financial return on products that we
may develop.
In Mainland China, VYVGART IV has been included in the National Reimbursement Drug List (NRDL) for the
treatment of adults with gMG who are AChR-AB+ after going through price negotiations with the National Healthcare
Security Administration (NHSA) since January 2024, which means that the price of this drug can be (partly) reimbursed
by the social security program of Mainland China for the treatment of this indication in accordance with relevant rules
within certain period. According to the current regulations of Mainland China, if we want our products in addition to
VYVGART IV to be included in the NRDL or want VYVGART to be included in the NRDL for the treatment of other
indications, we will need to go through price negotiations with the NHSA, for which purpose we will likely need to
significantly reduce their prices. Although the inclusion of our products in the NRDL may increase the demand for the
relevant products, our potential revenue from the sales of these products may still decrease as a result of lower prices.
Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we
believe that changes in these rules and regulations are likely. Outside the U.S., we will face challenges in ensuring
obtaining adequate coverage and payment for any product candidates we may develop. Pricing of prescription
pharmaceuticals is subject to governmental control in many countries. In order to secure coverage and reimbursement for
any product that might be approved for sale, we have needed and may need to conduct expensive pharmacoeconomic
studies in order to demonstrate the medical necessity and cost-effectiveness of the product, and the cost of these studies
would be in addition to the costs required to obtain FDA or other comparable marketing approvals. Conducting such
studies could be expensive, involve additional risk and result in delays in our commercialization efforts. Even after
pharmacogenomic studies are conducted, product candidates may not be considered medically necessary or cost-
effective. A decision by a third-party payor not to cover any product candidates we may develop could reduce physician
utilization of such product candidates once approved and have a material adverse effect on our sales, results of
operations and financial condition. Third-party reimbursement and coverage may not be adequate to enable us to
maintain price levels sufficient to realize an appropriate return on our investment in product development. The insurance
coverage and reimbursement status of newly approved products for orphan diseases is particularly uncertain, and failure
to obtain or maintain adequate coverage and reimbursement for any such product candidates could limit our ability to
generate revenue. As noted above, in the U.S., we plan to have various programs to help patients afford our products,
including patient assistance programs and co-pay coupon programs for eligible patients. More specifically, patients can
enroll into MY VYVGART PATH™, a patient support program that provides personalized support from a nurse case
manager and committed support team. In addition to providing support on questions on the treatment and on navigating
the insurance process, the program provides a VYVGART Co-pay Program to eligible patients, aids in referring patients
to charitable foundations that may be able to help with out-of-pocket costs and informs patients of financial assistance
programs that may be available.
The containment of healthcare costs also has become a priority of U.S. federal, state and international governments and
the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in
implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for
substitution of generic products. Net prices for drugs may be reduced by mandatory discounts or rebates required by
government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of
drugs from countries where they may be sold at lower prices than in the U.S. Increasingly, third-party payors are
requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices
charged for medical products. We cannot be sure that reimbursement will be available for any future product candidate
that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical
manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price
and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Adoption
of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing
controls and measures, could further limit our potential revenue from the sale of any products for which we may obtain
approval.
The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and
reimbursement of medicinal products, is almost exclusively governed by national laws, rather than EU legislation.
National governments and health service providers have different priorities and approaches to the delivery of healthcare
and the pricing and reimbursement of products in that context. Therefore, in the EU, pricing and reimbursement schemes
vary widely from EU Member State to another. Some EU Member States provide that products may be marketed only
after a reimbursement price has been agreed. Some EU Member States may require the completion of additional studies
that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health
technology assessments) in order to obtain reimbursement or pricing approval. EU Member States may approve a
specific price for a product or may instead adopt a system of direct or indirect controls on the profitability of the
company placing the medicinal product on the market. Other EU Member States allow companies to fix their own prices
for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions.
57
Table of Contents
Recently, many EU Member States have increased the amount of discounts required on medicinal products and these
efforts could continue as Member States attempt to further manage healthcare expenditures. For example, Germany
introduced a specific discount on certain combination products with new active ingredients. The downward pressure on
healthcare costs in general, particularly medicinal prescription products, has become intense. As a result, increasingly
high barriers are being erected to the entry of new products. Political, economic and regulatory developments may
further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained.
Reference pricing used by various EU Member States and parallel trade (arbitrage between low-priced and high-priced
Member States) can further reduce prices. Special pricing and reimbursement rules may apply to orphan medicinal
products. Inclusion of orphan drugs in reimbursement systems tend to focus on the medical usefulness, need, quality and
economic benefits to patients and the healthcare system as for any drug. Acceptance of any medicinal product for
reimbursement may come with cost, use and often volume restrictions, which again can vary by country. In addition,
results-based rules of reimbursement may apply. There can be no assurance that any EU Member State that has price
controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing
arrangements for any of our products, if approved in those countries. Historically, products launched in the EU do not
follow price structures of the U.S. and generally prices tend to be significantly lower.
The above underlines that, outside the U.S., international operations are generally subject to extensive governmental
price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in
Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of our product
candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of
national health systems. Other countries allow companies to fix their own prices for medical products but monitor and
control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the
amount that we are able to charge for our product candidates. Accordingly, in markets outside the U.S., the
reimbursement for our products may be reduced compared with the U.S. and may be insufficient to generate
commercially reasonable revenue and profits.
Government Pricing and Reimbursement Programs for Marketed Drugs in the U.S.
Medicaid, the 340B Drug Pricing Program, and Medicare
Federal law requires that a pharmaceutical manufacturer, as a condition of having its drug and biological products
receive federal reimbursement under Medicaid and Medicare Part B, must pay rebates to state Medicaid programs for all
units of its covered outpatient drugs dispensed to Medicaid beneficiaries and paid for by a state Medicaid program under
either a fee-for-service arrangement or through a managed care organization. This federal requirement is effectuated
through a Medicaid drug rebate agreement between the manufacturer and the Secretary of U.S. Department of Health
and Human Services (HHS). The Centers for Medicare & Medicaid Services (CMS) administers the Medicaid drug
rebate agreements, which provide, among other things, that the drug manufacturer will pay rebates to each state
Medicaid agency on a quarterly basis and report certain price information on a monthly and quarterly basis. The rebates
are based on prices reported to CMS by manufacturers for their covered outpatient drugs, including average
manufacturer price (AMP) and best price. Effective January 1, 2024, the Medicaid total rebate amount is no longer
capped at 100% of a covered outpatient drug’s AMP, which means that a manufacturer could pay a total rebate amount
on a unit of the drug that is greater than the average price the manufacturer receives for the drug.
The terms of participation in the Medicaid drug rebate program impose an obligation to correct the prices reported in
previous quarters, as may be necessary. Any such corrections could result in additional or lesser rebate liability,
depending on the direction of the correction. In addition to retroactive rebates, if a manufacturer were found to have
knowingly submitted false information to the government, federal law provides for civil monetary penalties for failing to
provide required information, late submission of required information, and false information.
A manufacturer must also participate in a federal program known as the 340B drug pricing program in order for federal
funds to be available to pay for the manufacturer’s drug and biological products under Medicaid and Medicare Part B.
Under this program, the participating manufacturer agrees to charge certain safety net healthcare providers no more than
an established discounted price for its covered outpatient drugs. The formula for determining the discounted price is
defined by statute and is based on the AMP and the unit rebate amount as calculated under the Medicaid drug rebate
program, discussed above. Manufacturers are required to report pricing information to the Health Resources and
Services Administration on a quarterly basis. The Health Resources and Services Administration has also issued
regulations relating to the calculation of the ceiling price as well as imposition of civil monetary penalties for each
instance of knowingly and intentionally overcharging a 340B covered entity.
Federal law also requires that manufacturers report data on a quarterly basis to CMS regarding the pricing of drugs that
are separately reimbursable under Medicare Part B. These are generally drugs and biologics, such as injectable products,
that are administered incident to a physician service and are not generally self-administered. The pricing information
submitted by manufacturers is the basis for reimbursement to physicians and suppliers for drugs covered under Medicare
Part B. Under the Inflation Reduction Act (IRA), manufacturers are also required to provide quarterly rebates for certain
58
Table of Contents
single-source drugs and biologics (including biosimilars) covered under Medicare Part B with prices that increase faster
than the rate of inflation. This requirement started on January 1, 2023 for drugs approved on or before December 1, 2020
and begins six quarters after a drug is first marketed for all other drugs. As with the Medicaid drug rebate program,
federal law provides for civil monetary penalties for failing to provide required information, late submission of required
information, and false information.
Additionally, the Infrastructure Investment and Jobs Act added a requirement, effective January 1, 2023, for
manufacturers of certain single-source drugs (including biologics and biosimilars) separately paid for under Medicare
Part B for at least 18 months and marketed in single-dose containers or packages (known as refundable single-dose
containers or single-use package drugs) to provide annual refunds for any portions of the dispensed drug that are unused
and discarded if those unused or discarded portions exceed an applicable percentage defined by statute or regulation.
Manufacturers will be subject to periodic audits and those that fail to pay refunds for their refundable single-dose
containers or single-use package drugs shall be subject to civil monetary penalties.
Medicare Part D provides prescription drug benefits for seniors and people with disabilities. Beginning in 2025, the IRA
eliminates the coverage gap phase and associated manufacturer discounts under Medicare Part D, significantly lowers
the enrollee maximum out-of-pocket cost and establishes a new manufacturer discount program, which requires 10%
discounts in the initial phase, and 20% discounts in the catastrophic phase. Although these discounts represent a lower
percentage of enrollees’ costs than coverage gap discounts, the new manufacturer contribution during the catastrophic
phase could be considerable for certain high-cost drugs and the total contributions by manufacturers to a Part D
enrollee’s drug expenses may exceed those currently provided. The IRA also requires manufacturers to provide annual
Medicare Part D rebates for single-source drugs and biological products with prices that increase faster than the rate of
inflation.
The IRA also allows HHS to directly negotiate the selling price of a statutorily specified number of drugs and biologics
each year that CMS reimburses under Medicare Part B and Part D. Only high-expenditure single-source biologics that
have been approved for at least 11 years (7 years for single-source drugs) can qualify for negotiation, with the negotiated
price taking effect two years after the selection year. In July 2025, Congress expanded the IRA’s orphan drug exclusion
to protect from selection drugs that are indicated only for orphan indications, as well as to extend the time before an
orphan drug may be selected if it is later approved for a non-orphan indication. Negotiations for Medicare Part D
products began in 2023 with the negotiated price taking effect in 2026, and negotiations for Medicare Part B products
will begin in 2026 with the negotiated price taking effect in 2028.
U.S. Federal Contracting and Pricing Requirements
Manufacturers are also required to make their covered drugs, which are generally drugs approved under NDAs or BLAs,
available to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration. The law also
requires manufacturers to offer deeply discounted FSS contract pricing for purchases of their covered drugs by the
Department of Veterans Affairs, the Department of Defense, the Coast Guard, and the Public Health Service (including
the Indian Health Service) in order for federal funding to be available for reimbursement or purchase of the
manufacturer’s drugs under certain federal programs. FSS pricing to those four federal agencies for covered drugs must
be no more than the Federal Ceiling Price (FCP), which is at least 24% below the Non-Federal Average Manufacturer
Price (Non-FAMP) for the prior year. The Non-FAMP is the average price for covered drugs sold to wholesalers or other
middlemen, net of any price reductions.
The accuracy of a manufacturer’s reported Non-FAMPs, FCPs, or FSS contract prices may be audited by the
government. Among the remedies available to the government for inaccuracies is recoupment of any overcharges to the
four specified federal agencies based on those inaccuracies. If a manufacturer were found to have knowingly reported
false prices, in addition to other penalties available to the government, the law provides for significant civil monetary
penalties per incorrect item. Finally, manufacturers are required to disclose in FSS contract proposals all commercial
pricing that is equal to or less than the proposed FSS pricing, and subsequent to award of an FSS contract, manufacturers
are required to monitor certain commercial price reductions and extend commensurate price reductions to the
government, under the terms of the FSS contract Price Reductions Clause. Among the remedies available to the
government for any failure to properly disclose commercial pricing and/or to extend FSS contract price reductions is
recoupment of any FSS overcharges that may result from such omissions.
Healthcare Law and Regulation
Healthcare providers and third-party payors play a primary role in the recommendation and prescription of
pharmaceutical products that are granted marketing approval. Our current and future arrangements with providers,
researchers, consultants, third-party payors and customers are subject to broadly applicable federal and state fraud and
abuse, anti-kickback, false claims, transparency and patient privacy laws and regulations and other healthcare laws and
regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state
healthcare laws and regulations include, without limitation, the following:
59
Table of Contents
•the U.S. federal Anti-Kickback Statute (AKS) prohibits, among other things, persons and entities from knowingly and
willfully soliciting, receiving, offering, or paying remuneration, directly or indirectly, in cash or in kind, to induce or
reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good facility,
item, or service, for which payment may be made, in whole or in part, under a federal healthcare program such as
Medicare and Medicaid. This statute has been interpreted to apply to arrangements between pharmaceutical
manufacturers on the one hand and prescribers, purchasers formulary managers and other persons and entities on the
other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain activities
from prosecution, the exceptions and safe harbors are drawn narrowly, and arrangements may be subject to scrutiny
or penalty if they do not fully satisfy all elements of an available exception or safe harbor. A person or entity can be
found guilty of violating the AKS without actual knowledge of the statute or specific intent to violate it. In addition,
the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a
false or fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties statute.
Violations of the AKS carry potentially significant civil and criminal penalties, including imprisonment, fines,
administrative civil monetary penalties, and exclusion from participation in federal healthcare programs.
•the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act and federal civil
monetary penalty laws, which, among other things, impose criminal and civil penalties, including through civil
whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented,
to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using
or causing to be made or used, a false record or statement material to a false or fraudulent claim or obligation to pay
or transmit money to the federal government, or from knowingly making a false statement to avoid, decrease or
conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a
claim including items and services resulting from a violation of the AKS constitutes a false or fraudulent claim for
purposes of the False Claims Act. Manufacturers can be held liable under the False Claims Act even when they do not
submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent
claims. The False Claims Act also permits a private individual acting as a “whistleblower” to bring qui tam actions on
behalf of the federal government alleging violations of the False Claims Act and to share in any monetary recovery.
When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil
fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare,
Medicaid and other federal healthcare programs;
•the U.S. federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which imposes criminal and
civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to
defraud any healthcare benefit program, or obtaining by means of false or fraudulent pretenses, representations, or
promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program,
regardless of the pay (e.g., public or private) or knowingly and willfully falsifying, concealing or covering up a
material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare
benefits, items or services relating to healthcare matters; similar to the AKS, a person or entity does not need to have
actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
•HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH)
and its implementing regulations, and as amended again by the Omnibus Rule in 2013, which imposes certain
obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and
transmission of individually identifiable health information without appropriate authorization by covered entities
subject to the Final HIPAA Omnibus Rule, i.e., certain covered health plans, healthcare clearinghouses and healthcare
providers, as well as their business associates, those independent contractors or agents of covered entities that perform
certain services for or on their behalf involving the use or disclosure of individually identifiable health information.
HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties
directly applicable to business associates and possibly other persons, and gave state attorneys general new authority to
file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’
fees and costs associated with pursuing federal civil actions;
•the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient
Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010
(collectively, the ACA), which requires certain manufacturers of drugs, devices, biologics and medical supplies to
report annually to CMS information related to payments and other transfers of value made by that entity to physicians
(currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician
providers such as physician assistants and nurse practitioners and teaching hospitals, as well as ownership and
investment interests held by physicians and their immediate family members. Failure to submit required information
may result in civil monetary penalties for all payments, transfers of value or ownership or investment interests that are
not timely, accurately, and completely reported in an annual submission;
•federal government price reporting laws, which require us to calculate and report complex pricing metrics in an
accurate and timely manner to government programs;
60
Table of Contents
•federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities
that potentially harm consumers;
•analogous state and local laws and regulations, including: state anti-kickback and false claims laws; state laws that
require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and
the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that
may be made to healthcare providers and other potential referral sources; state and local laws that require the
licensure of sales representatives; state laws that require drug manufacturers to report information related to payments
and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing
information; state laws governing the privacy and security of health information in certain circumstances, many of
which differ from each other in significant ways and may not have the same effect; and state laws related to insurance
fraud in the case of claims involving private insurers; and
•EU, UK and other foreign law equivalents, including reporting requirements detailing interactions with and payments
to healthcare providers and data privacy and security laws and regulations that may be more stringent than those in
the U.S.
State and foreign laws, including for example the EU General Data Protection Regulation (GDPR), also govern the
privacy and security of health information in some circumstances, many of which differ from each other in significant
ways and often are not preempted by HIPAA, thus complicating compliance efforts. There are ambiguities as to what is
required to comply with these state requirements and if we fail to comply with an applicable state law requirement, we
could be subject to penalties.
We have and will continue to spend substantial time and money to ensure that our business arrangements with third
parties comply with applicable healthcare laws and regulations. Recent healthcare reform legislation has strengthened
these federal and state healthcare laws. Because of the breadth of these laws and the narrowness of the statutory
exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge
under one or more of such laws.
Other laws that may affect our ability to operate include:
•the anti-inducement law prohibits, among other things, the offering or giving of remuneration, which includes,
without limitation, any transfer of items or services for free or for less than fair market value (with limited
exceptions), to a Medicare or Medicaid beneficiary that the person know or should know is likely to influence the
beneficiary’s selection of a particular supplier of items or services reimbursable by a federal or state governmental
program; and
•European and other foreign law equivalents of each of the laws, including reporting requirements detailing
interactions with and payments to healthcare providers.
In the U.S., to help patients afford our approved product, we may utilize programs to assist them, including patient
assistance programs and co-pay coupon programs for eligible patients. Government enforcement agencies have shown
increased interest in pharmaceutical companies’ product and patient assistance programs, including reimbursement
support services, and a number of investigations into these programs have resulted in significant civil and criminal
settlements. In addition, at least one insurer has directed its network pharmacies to no longer accept co-pay coupons for
certain specialty drugs the insurer identified. Our co-pay coupon programs could become the target of similar insurer
actions. In addition, in November 2013, the CMS issued guidance to the issuers of qualified health plans sold through the
ACA’s marketplaces encouraging such plans to reject patient cost-sharing support from third parties and indicating that
the CMS intends to monitor the provision of such support and may take regulatory action to limit it in the future. The
CMS subsequently issued a rule requiring individual market qualified health plans to accept third-party premium and
cost-sharing payments from certain government-related entities. In September 2014, the Office of the Inspector General
of the HHS issued a Special Advisory Bulletin warning manufacturers that they may be subject to sanctions under the
AKS and/or civil monetary penalty laws if they do not take appropriate steps to exclude Part D beneficiaries from using
co-pay coupons. Accordingly, companies exclude these Part D beneficiaries from using co-pay coupons. Additionally,
certain third-party payors are modifying benefit designs based on the availability of manufacturer cost-sharing assistance
(e.g., copay accumulator or maximizer programs). Following a federal district court decision vacating the provisions of
the 2021 Notice of Benefit and Payment Parameter final rule that provided health plans with discretion whether to
include manufacturer assistance toward the cost-sharing limit, CMS stated its intent to address this issue in future
rulemaking. It is possible that changes in insurer policies regarding co-pay coupons and/or the introduction and
enactment of new legislation or regulatory action could restrict or otherwise negatively affect these patient support
programs, which could result in fewer patients using affected products, and therefore could have a material adverse
effect on our sales, business, and financial condition.
61
Table of Contents
Third-party patient assistance programs that receive financial support from companies have become the subject of
enhanced government and regulatory scrutiny. The Office of the Inspector General of the HHS has established
guidelines that suggest that it is lawful for pharmaceutical manufacturers to make donations to charitable organizations
who provide co-pay assistance to Medicare patients, provided that such organizations, among other things, are bona fide
charities, are entirely independent of and not controlled by the manufacturer, provide aid to applicants on a first-come
basis according to consistent financial criteria and do not link aid to use of a donor’s product. However, donations to
patient assistance programs have received some negative publicity and have been the subject of multiple government
enforcement actions, related to allegations regarding their use to promote branded pharmaceutical products over other
less costly alternatives. Specifically, in recent years, there have been multiple settlements resulting out of government
claims challenging the legality of their patient assistance programs under a variety of federal and state laws. It is possible
that we may make grants to independent charitable foundations that help financially needy patients with their premium,
co-pay, and co-insurance obligations. If we choose to do so, and if we or our vendors or donation recipients are deemed
to fail to comply with relevant laws, regulations or evolving government guidance in the operation of these programs, we
could be subject to damages, fines, penalties, or other criminal, civil, or administrative sanctions or enforcement actions.
We cannot ensure that our compliance controls, policies, and procedures will be sufficient to protect against acts of our
employees, business partners, or vendors that may violate the laws or regulations of the jurisdictions in which we
operate. Regardless of whether we have complied with the law, a government investigation could impact our business
practices, harm our reputation, divert the attention of management, increase our expenses, and reduce the availability of
foundation support for our patients who need assistance.
Violations of these laws or any future enacted laws can subject us to criminal, civil and administrative sanctions
including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation
in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and
oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-
compliance with these laws, reputational harm, and we may be required to curtail or restructure our operations.
Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented,
that could impact our future operations and business.
Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is
possible that some of our business activities could be subject to challenge under one or more of such laws. Ensuring that
our internal operations and future business arrangements with third parties comply with applicable healthcare laws and
regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business
practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable
fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws
described above or any other governmental laws and regulations that may apply to us, we may be subject to significant
penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from
participation in federal and state healthcare programs, individual imprisonment, reputational harm, and the curtailment or
restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a
corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further,
defending against any such actions can be costly and time-consuming, and may require significant financial and
personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought
against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to
do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or
administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of
the above occur, our ability to operate our business and our results of operations could be adversely affected.
Healthcare Reform
In the U.S., the EU and other foreign jurisdictions, there have been a number of legislative and regulatory changes to the
healthcare systems that could affect our future results of operations. In particular, there have been and continue to be a
number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of
healthcare. For example, the ACA, effective since March 2010, is a sweeping law intended to broaden access to health
insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new
transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health
industry and impose additional health policy reforms.
Healthcare reforms that have been adopted, and that may be adopted in the future, could result in further reductions in
coverage and levels of reimbursement for pharmaceutical products, increases in rebates payable under U.S. government
rebate programs and additional downward pressure on pharmaceutical product prices. As discussed above, in August
2022, the IRA was enacted codifying, among other things: a Medicare drug price negotiation program, under which HHS
directly negotiates the selling price of statutorily specified number of Part B and Part D drugs and biologics each year;
inflation rebates which penalizes drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate
greater than the rate of inflation; and a redesign of the Part D benefit. The IRA permits the Secretary of HHS to
implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that
fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The IRA also
62
Table of Contents
extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan
year 2025. To date, none of the legislative attempts to extend the subsidies has been enacted. These IRA provisions
began taking effect progressively starting in 2023, although certain policies have been subject to legal challenges. For
example, the provisions related to the negotiation of selling prices of high-expenditure single-source drugs and biologics
have been challenged in multiple lawsuits. Additionally, we cannot predict whether the U.S. Congress will further amend
the IRA or if the government will adopt new or different interpretations of the law in future guidance or rulemaking.
However, at this time, the Trump administration is continuing to implement the IRA and to defend the law in litigation.
While it is unclear how the IRA will be implemented in the future and the outcome of the litigation, it will likely have a
significant impact on the pharmaceutical industry.
In addition, the Trump administration has taken several steps to try to align U.S. drug prices with drug prices in other
countries through an approach known as most favored nation (MFN) pricing. For example, on May 12, 2025, the current
Presidential administration published an executive order which, among other actions, instructed HHS to communicate
MFN price targets. The executive order also directed certain steps if “significant progress towards [MFN] pricing . . . is
not delivered.” On July 31, 2025, the U.S. President issued letters to 17 pharmaceutical companies (not including
argenx), calling on those manufacturers and “every manufacturer” to take the following steps within 60 days: extend
MFN pricing to Medicaid for all of their existing drugs; guarantee Medicare, Medicaid, and commercial payors receive
MFN pricing for newly-launched drugs; return increased revenues abroad to American patients and taxpayers; and
participate in direct-to-consumer or direct-to-business distribution models to provide “high-volume, high rebate” drugs at
MFN pricing. Certain manufacturers have entered into direct agreements with the government.
On November 6, 2025, CMS announced the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) Model
under its Center for Medicare and Medicaid Innovation authority (CMMI). The GENEROUS Model is a voluntary
model that tests the impact of CMS-facilitated supplemental rebate agreements that align the Medicaid net price with a
defined MFN price. In December 2025, CMS issued the Global Benchmark for Efficient Drug Pricing (GLOBE) Model
and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model proposed rules under its Center for Medicare
and Medicaid Innovation authority. The GLOBE and GUARD models would require manufacturers to pay additional
rebates for certain drugs based on the difference between the Medicare price and the price in market basket countries.
CMS proposes that the agency would apply the new rebate requirement to utilization by approximately 25% of Medicare
Part B fee-for-service enrollees (under GLOBE) and 25% of Medicare Part D enrollees (under GUARD). It is uncertain
if these proposed rules will be finalized and if they are, how they will impact our business.
Additionally, in Congress, there are pending legislative proposals that, if enacted, would require MFN pricing in certain
healthcare programs. We cannot predict if any of these legislative proposals will be enacted, how they would be
implemented, and how they could impact our business.
We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit
the amounts that the U.S. federal government will pay for healthcare products and services, which could result in
reduced demand for our product candidates or additional pricing pressures.
Further, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and
promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be
enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on
the marketing approvals, if any, of our product candidates, may be. In addition, increased scrutiny by the U.S. Congress
of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us to more
stringent product labeling and post-marketing conditions and other requirements.
Individual states in the U.S. have also become increasingly aggressive in passing legislation and implementing
regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement
constraints, affordability review boards, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm
our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and
individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which
suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate
demand for our products or put pressure on our product pricing, which could negatively affect our business, results of
operations, financial condition and prospects.
In international markets, reimbursement and healthcare payment systems vary significantly by country (including across
the EU’s individual member states), and many countries have instituted price ceilings on specific products and therapies.
Future political, economic, and regulatory developments may further affect the ability of pharmaceutical companies to
profitably commercialize current and future products..
63
Table of Contents
Environmental Aspects which may Influence the Use of our Material Fixed Assets
Our primary research and development activities take place in our facilities in Zwijnaarde, Belgium. For these activities
we require, and have obtained, the necessary environmental and biohazard permits from the responsible governments,
required by us for the manner in which we use said facilities.
New shares issued during 2025
As a result of the exercise of stock options and vesting of RSUs under our Equity Incentive Plan, 1,122,349 new shares
were created in 2025. Equity Incentive Plan means the equity incentive plan as adopted by our Board of Directors on
December 18, 2014, which was approved by the General Meeting on May 13, 2015, and amended by the General
Meeting on April 28, 2016, and November 25, 2019, and the Board of Directors on December 18, 2019, November 5,
2020, December 15, 2021, on February 27, 2023, on February 28, 2024, on 30 June 2025 and on 4 March 2026
The following table shows the developments in our share capital for the year ended December 31, 2025 and on February
19, 2026:
Number of shares outstanding on December 31, 2023
 
59,194,488
Exercise of stock options
1,478,225
Vesting of RSUs
88,244
Number of shares outstanding on December 31, 2024
60,760,957
Exercise of stock options
986,507
Vesting of RSUs
135,842
Number of shares outstanding on December 31, 2025
61,883,306
Exercise of stock options
179,582
Number of shares outstanding on February 19, 2026
62,062,888
64
Table of Contents
C.ORGANIZATIONAL STRUCTURE
As of December 31, 2025, argenx SE has one subsidiary, argenx BV, which is based in Belgium, and argenx BV has
sixteen subsidiaries. The following table sets out the following information for each of our principal subsidiaries: the
country of incorporation, and percentage ownership and voting interest held by us (directly or indirectly through
subsidiaries).
As per December 31, 2025
Name
 
 
 
 
Country
 
 
 
 
Participation
argenx SE
the Netherlands
100%
argenx B.V.
Belgium
100%
argenx Benelux B.V.
Belgium
100%
argenx US, Inc.
USA
100%
argenx Australia Pty. Ltd.
Australia
100%
argenx Austria Services GmbH
Austria
100%
argenx Brasil Produtos Farmacêuticos Ltda
Brazil
100%
argenx Canada Inc.
Canada
100%
argenx France SAS
France
100%
argenx Germany GmbH
Germany
100%
argenx Italy S.r.l.
Italy
100%
argenx Japan KK.
Japan
100%
argenx Netherlands Services B.V.
the Netherlands
100%
argenx Spain S.L.
Spain
100%
argenx Spain S.L. - Sucursal em Portugal
Portugal
100%
argenx Switzerland, S.A.
Switzerland
100%
argenx UK Ltd.
United Kingdom
100%
Broteio Pharma B.V.
the Netherlands
100%
The following chart provides an overview of the Group as of the date of this Annual Report. Percentages refer to both
the share of capital and voting rights.
Organisational chart.jpg
65
Table of Contents
D.PROPERTY, PLANTS AND EQUIPMENT
Our principal executive, operational offices and laboratory space are located in Zwijnaarde, Belgium. In 2024, we added
new office space in Zwijnaarde. The total future cash flows related to these leases are represented below in
“Note 20 — Leases” in our consolidated financial statements which are included to our Annual Report for the period
ended December 31, 2025.
We also lease office space in Amsterdam (the Netherlands), Boston (U.S.), Tokyo (Japan), Geneva (Switzerland),
Munich (Germany), Issy-Les-Moulineaux (France), Vaughan, Ontario (Canada), Gerrards Cross (UK), Milan (Italy),
Madrid (Spain) and Sydney (Australia). In addition, our lease liabilities include a lease plan for company cars with
maturity dates up to four years.
For a discussion of contractual obligations, please see “Note 27 — Commitments” in our consolidated financial
statements which are included to our Annual Report for the period ended December 31, 2025.
We have our principal executive, operational offices and laboratory space located in Zwijnaarde, Belgium. The
following table sets forth our key leased facilities worldwide as of December 31, 2025:
Facility location
  
Use
Approx. size (m2)
 
Lease expiry
Zwijnaarde, Belgium (leased)
  
Operations and Laboratory Space
5,339
 
September 30, 2031
Zwijnaarde, Belgium (leased)
Office Space
3,765
September 30, 2036
Boston, Massachusetts (leased)
  
Office Space
2,379
 
August 31, 2030
Tokyo, Japan (leased)
  
Office Space
546
 
January 17, 2027
Environment, Health and Safety
Our primary research and development activities take place in our facilities in Zwijnaarde, Belgium. For these activities
we require, and have obtained, the necessary environmental and biohazard permits from the responsible governments,
required by us for the manner in which we use said facilities. See “Item 3.D. — Risk Factors”.
ITEM 4.A.UNRESOLVED STAFF COMMENTS
Not applicable.
66
Table of Contents
ITEM 5.OPERATING AND FINANCIAL REVIEW AND PROSPECTS
The following “Operating and Financial Review and Prospects” should be read together with the information in our
financial statements and related notes included elsewhere in this Annual Report. The following discussion is based on
our financial information prepared in accordance with the IFRS Accounting Standards (IFRS) as issued by the
International Accounting Standards Board (IASB), which may differ in material respects from generally accepted
accounting principles in other jurisdictions, including U.S. GAAP. The following discussion includes forward-looking
statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those
anticipated in these forward-looking statements as a result of many factors, including but not limited to those described
in “Item 3.D. — Risk Factors” and elsewhere in this Annual Report. Please also see “Cautionary Statement Regarding
Forward-Looking Statements in this Annual Report.
A.OPERATING RESULTS
The review of the financial condition and results of operations of certain items from the year ended December 31, 2023,
and year-to-year comparisons between the years ended December 31, 2024 and December 31, 2023 that are not included
in this Annual Report can be found in “Item 5 — Operating and Financial Review and Prospects” of our annual report
on Form 20-F for the year ended December 31, 2024.
Overview
2025 was a transformative year for argenx as we advanced our mission to deliver innovation to patients. Our commercial
execution reached new heights with the successful expansion of VYVGART, the first-in-class FcRn blocker, which now
offers three administration options, including self-injection with the PFS. The PFS launch began in the U.S. in April of
this year, followed by the EU and Japan.
This evolution reflects our commitment to innovating the patient experience in our two blockbuster indications and
pursuing the broadest label for our medicines. The commercialization of the VYVGART franchise generated global
product net sales of $4.2 billion in 2025 as compared to $2.2 billion in 2024.
Beyond commercial achievements, we continued to execute on a pipeline with breadth and depth, reinforcing our
leadership in immunology. We announced positive topline results from the ADAPT SERON clinical trial of VYVGART
in Seronegative gMG, further expanding the potential reach of VYVGART. In December of this year, we filed the
Seronegative gMG supplemental BLA in pursuit of the broadest MG label of any biologic. In January 2026, the FDA
has accepted for priority review a supplemental BLA for VYVGART for the treatment of adults with Seronegative gMG.
The application has been granted an expected PDUFA date of May 10, 2026.
Additionally, we showcased innovation through our R&D webinar highlighting adimanebart (ARGX-119), a first-in-
class agonistic antibody targeting and MuSK to promote maturation and stabilization of the neuromuscular junction, with
advancement inCMS. These programs underscore our strategy of entrepreneurial clinical development and commitment
to addressing unmet needs across a spectrum of autoimmune and neuromuscular diseases.
Looking ahead, in 2026 our teams will strive to continue delivering VYVGART to as many patients as possible. We also
expect results to be delivered on four registrational readouts in 2026 and two more in 2027:
•Topline results expected in the first quarter of 2026 for Ocular MG (ADAPT OCULUS) with efgartigimod
•Topline results expected in the third quarter of 2026 from ALKIVIA clinical trial evaluating three myositis
subsetsIMNM,ASyS and DM with efgartigimod
•Topline results expected in the fourth quarter of 2026 for EMPASSION clinical trial (MMN) with empasiprubart
•Topline results expected in the fourth quarter of 2026 for primary ITP (ADVANCE-NEXT) with efgartigimod
•Topline results from UNITY clinical trial (SjD) expected in second half of 2027 with efgartigimod
•Topline results from EMVIGORATE clinical trial for empasiprubart (CIDP) expected in second half of 2027
Our Vision 2030 sets the goal to have five new molecules in Phase 3, ten labeled indications, and 50,000 patients on
treatment by 2030. It provides a clear roadmap for scaling impact on patients, physicians, and the innovation ecosystem
we’re shaping. Achieving this vision will be driven by our core competencies: building winning molecules,
entrepreneurial clinical development, and delivering a differentiated patient experience. We plan to continue to prioritize
innovation, expand global access, and leverage partnerships to accelerate growth.
67
Table of Contents
On our research and development, we continue towards advancing a deep pipeline of both clinical and preclinical-stage
product candidates for the treatment of severe autoimmune diseases. Leveraging our technology suite, our ecosystem of
partnerships and clinical expertise, we have advanced several candidates into late-stage clinical development, and we
currently have multiple programs in the discovery stage. argenx continues to target one Investigational New Drug (IND)
application per year in generating a world-class pipeline.
We enter the next phase of our ambitious innovation agenda with a solid balance sheet, providing financial strength and
flexibility to invest confidently in our pipeline and global expansion. As of December 31, 2025 and December 31, 2024,
we had cash and cash equivalents amounting to $3.5 billion and $1.5 billion, respectively; in addition to current financial
assets of $0.9 billion and $1.9 billion, respectively.
As outlined in our consolidated financial statements which are included to our Annual Report, total assets of $8.7 billion
as of the year ended December 31, 2025, compared to $6.2 billion as of the year ended December 31, 2024. The main
reason for the material change in balance sheet total is the operational growth of the Company in the period.
For the year ended December 31, 2025 the Company recorded a second year of profitability with 
$1.3 billion compared to our first annual profit for the year ended December 31, 2024 in the amount of $0.8 billion. This
was the Company’s first year of operational profitability. As of December 31, 2025, we had accumulated losses of
$0.3 billion.
We expect our expenses to continue to increase as we continue to execute registrational and proof-of-concept studies
across efgartigimod, empasiprubart and adimanebart, as well as the continued investment in our IIP. We anticipate that
our expenses will increase if and as we execute on our research and development activities, pre-commercial and
commercial activities and various other activities.
We are actively engaged in the maintenance, expansion and protection of our intellectual property portfolio, including
litigation costs associated with defending against alleged patent infringement claims or enforcing our IP rights against
third parties. We expect that the costs of development and commercialization might also increase due to current and
future collaborations with research and development partners as well as commercial partners.
Information pertaining to the year ended December 31, 2024 was included in our annual report on Form 20-F for the
year ended December 31, 2024 under “Item 5 — Operating and Financial Review and Prospects’’ which was filed with
the SEC on March 20, 2025.
Basis of presentation
‘‘Section 5 Operating and Financial Review and Prospects’’ should be read in parallel to our consolidated financial
statements and ‘‘Item 3.D Risk factors’’ which are included to our Annual Report for the period ended December 31,
2025.
We specifically, but not exhaustively, indicate the following references to the notes of the financial statements
‘‘Note 2 — Material Accounting Policy Information’’:
•the basis of presentation,
•the material accounting policies, and
•the description of the composition of material accounts, which is further detailed in the notes to the consolidated
financial statements.
68
Table of Contents
Results of Operations
Comparison of Years Ended December 31, 2025 and 2024
Year Ended December 31,
(in thousands of $ except for shares and EPS)
2025
2024
% Change
Product net sales
$
4,151,316
$
2,185,883
90%
Other operating income1)
96,734
66,156
46%
Total operating income
 
4,248,050
 
2,252,039
89%
Cost of sales
(450,665)
(227,289)
98%
Research and development expenses
 
(1,364,132)
 
(983,423)
39%
Selling, general and administrative expenses
 
(1,367,057)
 
(1,055,337)
30%
Loss from investment in a joint venture
(12,390)
(7,644)
62%
Total operating expenses
(3,194,244)
(2,273,693)
40%
Operating profit/(loss)
 
$
1,053,806
$
(21,654)
Financial income
 
163,091
157,509
4%
Financial expense
(4,082)
(2,464)
66%
Exchange gains/(losses)
 
65,792
(48,211)
(236)%
Profit for the year before taxes
 
$
1,278,607
 
$
85,180
Income tax benefit
 
$
13,428
$
747,860
(98)%
Profit for the year
 
$
1,292,035
 
$
833,040
55%
Weighted average number of shares used for basic profit per
share
 
61,295,149
59,855,585
Basic profit per share (in $)
21.08
13.92
51%
Weighted average number of shares used for diluted profit per
share
66,029,215
65,177,815
Diluted profit/(loss) per share (in $)
19.57
12.78
53%
1)Comparative figures have been aligned with the presentation adopted in the current period, reflecting the combination of collaboration revenue
and other operating income.
Product Net Sales
Product net sales increased by $2.0 billion to $4.2 billion for the year ended December 31, 2025, compared to
$2.2 billion for the year ended December 31, 2024. Our product net sales have increased in the U.S. and other countries
as the Company continues to execute on the global commercialization of VYVGART and obtain further approvals
worldwide.
Revenue by country arising from the commercial sale of VYVGART is presented under ‘‘Note 16 — Segment
Reporting’’ in our consolidated financial statements which are appended to our Annual Report for the period ended
December 31, 2025.
Other Operating Income
Other operating income increased by $31 million to $97 million for the year ended December 31, 2025, compared to $66
million for the year ended December 31, 2024. The other operating income recognized in the year ended December 31,
2025 was mainly the result of research and development tax incentives, payroll tax rebates and the clinical supply of
product on product net sales of VYVGART in Greater China through Zai Lab.
Other operating income is presented under ‘‘Note 15 — Other Operating Income’’ in our consolidated financial
statements which are appended to our Annual Report for the period ended December 31, 2025.
69
Table of Contents
Research and Development Expenses
Research and development expenses consist principally of:
•external research and development expenses related to (i) chemistry, manufacturing and control costs for our product
candidates, both for preclinical and clinical testing, all of which is conducted by specialized contract manufacturers,
(ii) fees and other costs paid to CROs in connection with preclinical testing and the performance of clinical trials for
our product candidates, (iii) costs associated with regulatory submissions and approvals, QA and pharmacovigilance
and (iv) costs associated with post-approval clinical trials;
•personnel expenses related to compensation of research and development staff and related expenses, including
salaries, benefits and share‑based payment expenses; and
•other expenses.
Our research and development expenses totaled $1.4 billion and $1.0 billion for the years ended December 31, 2025 and
2024, respectively. The increase of $0.4 billion in 2025 as compared to 2024 is primarily driven by an increase in
personnel expenses and external research and development expenses.
Our external research and development expenses for the year ended December 31, 2025 totaled to $0.4 billion, compared
to $0.3 billion for the year ended December 31, 2024. The expenses reflect clinical trial costs and manufacturing
expenses related to the development of our product candidate portfolio.
Personnel expenses relate to internal and external R&D personnel. The expenses also include share-based compensation
expenses related to our research and development employees.
Our research and development expenses may vary substantially from period to period based on the timing of our
research and development activities, including the timing of the initiation of clinical trials, material used in R&D phase
and enrollment of patients in clinical trials. Research and development expenses are expected to increase as we advance
the clinical development of efgartigimod, empasiprubart, adimanebart and further advance the research and development
of our other early-stage pipeline candidates. The successful development of our product candidates is highly uncertain.
At this time, we cannot reasonably estimate the nature, timing and estimated costs of the efforts that will be necessary to
complete the development of, or the period, if any, in which material net cash inflows may commence from any of our
product candidates. This is due to numerous risks and uncertainties associated with developing drugs, as further
described in “Item 3.D. - Risk Factors”.
Research and development expenses are presented under ‘‘Note 17 — Research and Development Expenses’’ in our
consolidated financial statements which are included to our Annual Report for the period ended December 31, 2025.
Selling, General and Administrative Expenses
Selling, general and administrative expenses consist primarily of:
•personnel expenses related to commercial and enabling functions, as well as their related expenses, including salaries,
benefits and share‑based payment expenses;
•marketing and promotional activities related to the global commercialization of VYVGART;
•professional fees related to commercial and enabling functions;
•Board of Directors expenses consisting of directors’ fees, travel expenses and share-based compensation for non-
executive directors; and
•other expenses.
Our selling, general and administrative expenses totaled $1.4 billion and $1.1 billion for the years ended December 31,
2025 and 2024, respectively. The increase of $0.3 billion for the year ended December 31, 2025 principally resulted
from:
•increased professional and marketing fees, including promotional and marketing costs primarily due to the scaling of
our commercial operations relating to VYVGART;
70
Table of Contents
•increased costs of personnel expenses, related to planned increase in the headcount of our Selling, general and
administrative employees recruited to strengthen our enabling functions and the scaling of our commercial operations
relating to VYVGART; and
•continued investment in our Digital Technology infrastructure.
Selling, general and administrative expenses are presented under ‘Note 18 Selling, General and Administrative
Expenses’’ in our consolidated financial statements which are included to our Annual Report for the period ended
December 31, 2025.
Financial Income and (Expense)
For the year ended December 31, 2025, financial income amounted to $163 million compared to $158 million for the
year ended December 31, 2024. The increase of $6 million in 2025 related primarily to the capital increase of our cash,
cash equivalents, and current financial assets.
B.LIQUIDITY AND CAPITAL RESOURCES
Sources of Funds
Our capitalization is detailed in the “Consolidated Statements of Financial Position” which are included to our Annual
Report for the period ended December 31, 2025. As of December 31, 2025 on an actual basis, the Company had a total
equity amount of $7.3 billion.
Since our inception in 2008, we have invested most of our resources in developing our product candidates, building our
intellectual property portfolio, developing our supply chain, conducting business planning, raising capital and providing
general and administrative support for these operations. December 31, 2024To date, we have funded our operations
through (i) public and private placements of equity securities, (ii) upfront, milestone and expense reimbursement
payments received from our collaborators, (iii) funding from governmental bodies, (iv) proceeds from exercise of
employee stock options and (v) interest income from the investment of our cash and cash equivalents, in addition to
current financial assets. Through December 31, 2025, we have raised gross proceeds of $5.9 billion from private and
public offerings of equity securities.
Our commercial operations have also started to contribute to the funding of our operations based on positive cash flow
from operating activities as of the year ended December 31, 2025.
As we continue to invest in innovation, our cash flows may fluctuate, are difficult to forecast and will depend on many
factors.
We have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect
our liquidity over the next five years, other than leases and commitments as part of our operations, which are detailed in
“Note 27 — Commitments” and “Note 24 — Financial Risk Management” in our consolidated financial statements which
are included to our Annual Report for the period ended December 31, 2025.
For more information as to the risks associated with our future funding needs, see “Item 3.D. — Risk Factors — Risk
Factors Related to argenx’s Financial Position and Need for Additional Capital”.
For more information as to our financial instruments, please see “Note 24 — Financial Risk Management” in our
consolidated financial statements which are included to our Annual Report for the period ended December 31, 2025.
71
Table of Contents
Cash Flows
Comparison for the Years Ended December 31, 2025 and 2024
As of December 31, 2025, the Company had $3.5 billion of cash and cash equivalents compared to
$1.5 billion as of December 31, 2024. The Company’s cash and cash equivalents increased by $2.0 billion year-over-
year mainly resulting from positive cash flow from operating activities and a higher amount of capital held in cash and
cash equivalents as opposed to current financial assets.
The Company’s net cash flow from operating activities increased by $0.8 billion for the year ended December 31, 2025
compared to the year ended December 31, 2024 mainly due to increased product net sales of VYVGART partially offset
by buildup of working capital.
Net cash flow used in investing activities increased by $1.7 billion for the year ended December 31, 2025 compared to
the year ended December 31, 2024 mainly due to the nature of financial instruments held as of the reporting date
classified as cash and cash equivalents coming from capital held in the year as current financial assets. This is partially
offset by payments related to regulatory and sales based milestones to Halozyme.
Net cash flow from financing activities decreased by $47 million for the year ended December 31, 2025 compared to the
year ended December 31, 2024 mainly due to proceeds from the exercise of stock options.
For more information, please see “Consolidated Statements of Cash Flows” and “Note 11 Cash and Cash Equivalents”
in our consolidated financial statements which are included to our Annual Report for the period ended December 31,
2025.
Operating and Capital Expenditure Requirements
We recorded a profit of $1.3 billion for the year ended December 31, 2025. Our operating expenditures are detailed
above in our research and development expenses along with our Selling, general and administrative expenses.
We anticipate that our operating expenses will increase as we intend to continue conducting research and development,
as well as continuing our efforts to expand our sales & marketing and establish our distribution infrastructure. Although
we have generated product net sales of $4.2 billion from global product net sales of VYVGART for the year ended
December 31, 2025, which supports our current profitability, we cannot provide assurances that we will be profitable or
able to sustain net profitability in the future based on these indications alone. Furthermore, we cannot provide any
assurances that we will receive the regulatory approvals to commercialize VYVGART in other indications or in other
countries.
On the basis of current assumptions, we expect that our existing cash and cash equivalents and current financial assets
will enable us to fund our operating expenses and capital expenditure requirements through at least the next twelve
months. The adequacy of our available funds to meet our future operating expenses and capital expenditures will depend
on numerous risks and uncertainties associated with the development and commercialization of efgartigimod and our
other product candidates and discovery stage programs and because the extent to which we may enter into collaborations
with third parties for the development of these product candidates is unknown.
We are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing
the research and development of our product candidates. Our future capital requirements for efgartigimod,
empasiprubart, adimanebart, our other product candidates and discovery stage programs will depend on many factors,
including:
•the progress, timing and completion of preclinical testing and clinical trials for our current or any future product
candidates;
•the number of potential new product candidates we identify and decide to develop;
•the time and costs involved in obtaining regulatory approvals for our product candidates and any delays we may
encounter as a result of evolving regulatory requirements or adverse results with respect to any of our product
candidates;
•selling and marketing activities undertaken in connection with the commercialization of VYVGART or potential
commercialization of any of our current or any future product candidates, if approved, and costs involved in the
creation of an effective sales and marketing organization;
72
Table of Contents
•manufacturing activities undertaken for VYVGART and potential commercialization of any of our current or any
future product candidates, if approved, and costs involved in the creation of an effective supply chain;
•the costs involved in growing our organization to the size needed to allow for the research, development and potential
commercialization of our current or any future product candidates;
•the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims or
infringements raised by third parties;
•the maintenance of our existing collaboration agreements, the entry into new collaboration agreements and the pursuit
of other strategic business development opportunities; and
•developments related to global economic uncertainties and political instability.
For more information as to the risks associated with our future funding needs, see “Item 3.D. — Risk Factors — Risk
Factors — Risk Factors Related to argenx’s Financial Position".
Working capital statement
In our opinion, the working capital of the Company is sufficient for the Company’s present requirements, at least for a
period of 12 months from the date of this Annual Report.
Cash Investment Policy
The Company has adopted a policy whereby cash and cash equivalents and current financial assets are invested with
several highly reputable banks and financial institutions. The main purpose of the Cash Investment Policy is to preserve
the available cash and to ensure sufficient short-term liquidity at all times. Therefore, the Company holds its cash, cash
equivalents and current financial assets mainly with banks which are independently rated A- or higher. Amounts of cash
held with banks rated lower than A- are limited to insignificant balances. The maximum amount and tenor of time
deposits depends on the rating of the counterparty bank. The Company also holds cash equivalents in the form of money
market funds with a low historical volatility. These money market funds are highly liquid investments and can be readily
convertible into a known amount of cash. The Company has adopted a policy whereby money market funds must have a
minimum rating of A of which 95% should have a AAA-rating.
For more information as to our treasury policy and liquidity, please see “Note 24 — Financial Risk Management” in our
consolidated financial statements which are included to our Annual Report for the period ended December 31, 2025.
Off-Balance Sheet Arrangements
During the periods presented we did not have, and we do not currently have, any off‑balance sheet arrangements, as
defined in the applicable rules and regulations, such as relationships with unconsolidated entities or financial
partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of
facilitating financing transactions that are not required to be reflected on our balance sheets. Our scope of consolidated
entities is disclosed in “Note 29 — Overview of Consolidation Scope” in our consolidated financial statements which are
included to our Annual Report for the period ended December 31, 2025.
C.RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES
For a discussion of our research and development policies, refer to the “Item 4 — Information on the Company” and
“Item 5 — Operating and Financial Review and Prospects”.
D.TREND INFORMATION
Other than as disclosed elsewhere in this Annual Report, we are not aware of any trends, uncertainties, demands,
commitments or events for the current financial period that are reasonably likely to have a material effect on our net
revenues, income, profitability, liquidity, capital resources or prospects, or that caused the disclosed financial
information to be not necessarily indicative of future operating results or financial conditions.
There has been no significant change in the financial performance or the financial position of the Group since the
balance sheet date of December 31, 2025.
73
Table of Contents
For more information, please refer to “Item 4.B — Business Overview”, “Item 5.A. — Operating Results”, “Item 5.B. —
Liquidity and Capital Resources” and “Note 27 — Commitments’’ in our consolidated financial statements which are
appended to our Annual Report for the period ended December 31, 2025.
E.CRITICAL ACCOUNTING ESTIMATES
See “Note 3 — Critical accounting judgments and major sources of estimation uncertainty’’ in our consolidated
financial statements which are appended to our Annual Report for the period ended December 31, 2025.
ITEM 6.DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
A.DIRECTORS AND SENIOR MANAGEMENT
Our Board of Directors
As at December 31, 2025, we have a one-tier board structure consisting of 1 Executive Director and
8 Non-Executive Directors, and a Senior Management Team responsible for the day-to-day operations.
Our Board of Directors had 6 formal meetings in the course of 2025.The meetings were held in the months February,
April, May, July, September and November/December. The committees of the Board of Directors also convened
regularly and at least once per quarter.. (Refer to “Item 6.C. — Board Practices — Report Audit and Compliance
Committee”, Item 6.C. — Board Practices — Report Audit and Compliance Committee”, “Item 6.C. — Board Practices
— Report Audit and Compliance Committee”, and “Item 6.C. — Board Practices—Report Audit and Compliance
Committee”)” below for the separate reports of the committees.
All Board of Director meetings and 21 out of 24 formal committee meetings were also attended by Tim Van
Hauwermeiren, as executive director. In addition, several members of the Executive Management Team were invited to
discuss specific items included on the Board of Director and committee meetings’ agendas. (please refer to “Item 6.A. —
Directors and Senior Management — Attendance Record Board of Director Meetings”).
Set out below is a summary of certain provisions of Dutch corporate law as of the date of this Annual Report, as well as
a summary of relevant information concerning our Board of Directors and certain provisions of our Articles of
Association and the Board By-Laws.
This summary does not purport to give a complete overview and should be read in conjunction with and is qualified in
its entirety by reference to the relevant provisions of Dutch law as in force on the date of this Annual Report, the Articles
of Association and Board By-Laws. The Articles of Association are available in the governing Dutch language and an
unofficial English translation thereof, and the Board By-Laws are available in English, on our website.
74
Table of Contents
The following table sets forth certain information with respect to the current Non-Executive Directors, including their
ages, as of December 31, 2025:
Name
Age
Position
Nationality
Date of Initial
Appointment
Date of last (re-)
Appointment
Term
expiration
Tim Van Hauwermeiren
53
CEO and
executive
director
Belgium
July 15, 2008
May 10, 2022
AGM 20261)
Peter Verhaeghe
67
Non-Executive
Director
(chairperson)
Belgium
October 15, 2008
May 7, 2024
AGM 20262)
Ana Céspedes
52
Non-Executive
director
Spain
December 12, 2022
December 12, 2022
AGM 2026
James Daly
64
Non-Executive
Director
U.S.
May 8, 2018
May 10, 2022
AGM 2026
Donald deBethizy3)
75
Non-Executive
Director1)
U.S.
May 13, 2015
May 2, 2023
AGM 2025
Pamela Klein
64
Non-Executive
Director
U.S.
April 28, 2016
May 7, 2024
AGM 2026
Brian Kotzin
77
Non-Executive
Director
U.S.
May 7, 2024
May 7, 2024
AGM 2028
Steve Krognes
57
Non-Executive
Director
U.S. and Norway
February 27, 2023
February 27, 2023
AGM 2027
Anthony Rosenberg
72
Non-Executive
Director1)
UK
April 26, 2017
May 27, 2025
AGM 2027
Camilla Sylvest
53
Non-Executive
director
Denmark
September 8, 2022
September 8, 2022
AGM 2026
1)Tim Van Hauwermeiren will step down as Executive Director and CEO at the 2026 General Meeting.
2)Peter Verhaeghe will step down as Non-Executive Director and chairperson of the Board of Directors at the 2026 General Meeting.
3)Donald deBethizy retired from the Board of Directors on May 27, 2025. Anthony Rosenberg succeeded him as the vice-chairperson of the Board of Directors.
Peter Verhaeghe
Peter Verhaeghe has served as a member and chairperson of the board of arGEN-X B.V. since October 2008 and as Non-
Executive Director on our Board of Directors since July 2014.
Peter Verhaeghe is the managing partner of VVGB Advocaten-Avocats, a corporate finance law and tax law firm, a
position he has held since July 1999. He is currently lead counsel to a number of Belgian, Dutch, French, U.S. and Swiss
life sciences companies. Peter Verhaeghe has served on the boards of directors of Participatiemaatschappij Vlaanderen
NV since May 2018 and miDiagnostics NV since April 2020. He has also served as chairman of the board of Haretis SA
(Luxembourg) since March 2011 and as chairman of the LP & advisory committee of Bioqube Factory Fund I NV since
September 2020. Peter Verhaeghe previously served as a member of the board of directors of CzechPak Manufacturing
s.r.o., Fujirebio Europe N.V., Tibotec-Virco NV, and Biocartis SA. He was also the president of the board of directors of
Merisant France SAS, a member of the management board of Merisant Company 2 S.à. rl., and chairman of the board of
directors of PharmaNeuroBoost NV. He holds a degree in law from the University of Leuven and an LL.M. degree from
Harvard Law School.
Ana Céspedes
Ana Céspedes has served as a member of our Board of Directors since December 2022 and as the chairperson of the
Remuneration and Nomination Committee since May 2025. Ana Céspedes is the chief executive officer and president of
Vitamin Angels, a global health organization dedicated to addressing malnutrition among women and children
worldwide.
Prior to joining Vitamin Angels, Ana Céspedes served as chief operating officer of the International AIDS Vaccine
Initiative, where she oversaw global operations across the United States, Europe, Africa and India. Her responsibilities
included strategy and business development, access and commercialization, government affairs and external relations,
communications, legal, human resources, finance, administration, business technology, and regional operations.  Prior to
that, Ana Céspedes held multiple senior leadership roles at Merck KGaA, most recently as Global Head of Strategy and
75
Table of Contents
External Engagement, Government and Public Affairs. She also worked as a senior consultant at Arthur Andersen. She
currently serves as President of the Scientific Committee of the ProPatiens Institute and has led multiple international
initiatives aimed at strengthening collaboration between the pharmaceutical industry and healthcare systems and
advancing professional capabilities in market access and corporate affairs. She holds a Bachelor’s degree in Pharmacy
and a Ph.D. from the Complutense University of Madrid, a Master in General Management (PDG) from IESE Business
School, and an Executive Certificate in Strategy and Innovation from the Massachusetts Institute of Technology.
She obtained the NACD.DC™ (National Association of Corporate Directors Directorship Certification®) in July 2024.
James Daly
James Daly has served as a member of our Board of Directors since May 2018. James Daly currently also serves as a
director of Acadia Pharmaceuticals, Inc., Madrigal Pharmaceuticals, Inc. and Cytokinetics, Inc. He was formerly a
member of the board of Halozyme Therapeutics, Inc., Bellicum Pharmaceuticals, Inc. and Chimerix, Inc.
In 1985, he joined GlaxoSmithKline where he held various positions, including senior vice president of the respiratory
division with full responsibility for sales, marketing and medical affairs. James Daly moved to Amgen Inc. in 2001
where he was senior vice president for the North America commercial operations until 2011. In 2012, he joined Incyte
Corp, a publicly-traded company focused on oncology and inflammation, where he was chief commercial officer until
June 2015. Mr. Daly holds a Bachelor’s of Science and an MBA from the University at Buffalo, State University of New
York.
Pamela Klein
Pamela Klein has served as a member of our Board of Directors since April 2016.
Since 2008, Pamela Klein has been a principal and founder of PMK BioResearch, a company offering strategic
consulting in oncology drug development to corporate boards, management teams and the investment community. She
has also been a venture partner in Ysios Capital Partners, SGIEC, S.A.U. since 2023. She currently serves as a member
of the board of directors of several companies including Shasqi, Frontier Medicines Corp and Ona Therapeutics.
Previously, Pamela Klein served on the board of directors of FStar, Sardona Therapeutics, Patrys Therapeutics, Inc, Jiya
Acquisition Corp, and Spring Bank Pharmaceuticals, Inc. until its merger with F-Star Therapeutics in July 2020. Pamela
Klein previously spent seven years at the National Cancer Institute as research director of the NCI-Navy Breast Center,
after which she joined Genentech as vice president of development until 2001. She also served as chief medical officer
for Intellikine, Inc., which was acquired by Takeda American Holdings. She holds a Bachelor’s degree in biology from
California State University and an M.D. from Stritch School of Medicine, Loyola University Chicago and is trained in
internal medicine and medical oncology.She continues to serve as an advisor for both private and public biotech
companies.
Brian Kotzin
Brian Kotzin has served as a member of our Board of Directors and as a chairperson of our research and development
committee since May 7, 2024.
He is a former member of the board of directors at Vera Therapeutics, Inc., Rigel Pharmaceuticals, Inc. and Kyverna
Therapeutics, Inc. He served as Senior Vice President for Nektar Therapeutics, Inc. from April 2017 to June 2023, and
has held various leadership positions at Nektar Therapeutics, Inc., including serving as Chief Medical Officer and Head
of Clinical Development from January 2021 to September 2021, again from May 2022 to June 2023, and again from
February 2025 to November. He currently is the interim chief medical officer at Nektar Therapeutics, Inc. From 2004 to
2015, Brian Kotzin was Vice President, Global and Clinical Development and Head, Inflammation Therapeutic Area at
Amgen Inc., directing the global development efforts for product candidates in the inflammation area. During his
employment at Amgen Inc, he also served as Vice President of Translational Sciences and Head of Medical Sciences
from 2006 to 2011. Prior to entering the life sciences industry, Brian Kotzin held several positions as a professor at the
University of Colorado Health Sciences Center, where his research focused on immunopathogenesis of inflammatory
diseases. He has also held leadership roles at several national organizations, including as a member of the American
College of Rheumatology (ACR) Board of Directors, Member and Chairperson of the NIH Immunological Sciences
Study Section, Chairperson of the NIH Autoimmunity Centers of Excellence, and Member of the Board of Directors for
the Federation of Clinical Immunology Societies. He is currently an elected Master of the ACR. He received an M.D.
from Stanford University and a Bachelor’s degree in mathematics from the University of Southern California.
Steve Krognes
Steve Krognes has served as a member of our Board of Directors and as a chairperson of our Audit and Compliance
Committee since February 2023.
76
Table of Contents
Steve Krognes also serves on the boards of directors of Guardant Health, Inc., Denali Therapeutics, Inc., and Pliant
Therapeutics, Inc. In September 2023, he also was appointed to the board of directors of ClayvstBio and in March 2026
he was appointed to the Board of Alveus Therapeutics Inc. He previously served on the boards of directors of RLS
Global AB and Corvus Pharmaceuticals, Inc. and Gritstone Bio, Inc. Steve Krognes was the chief financial officer of
Denali Therapeutics, Inc. from 2015 until retiring from that position in April 2022.  Steve Krognes led successful
financings for Denali Therapeutics, Inc., including its initial public offering in 2017, and contributed significantly to the
company’s strategy, growth and strong financial position. His extensive leadership experience in the biotech and
pharmaceutical industries includes 12 years in total at Roche and Genentech, Inc., during which Steve Krognes served as
chief financial officer of Genentech, Inc. for six years and global head of Roche’s mergers & acquisition team for six
years. He also chaired the Genentech Access to Care Foundation and represented Genentech on the board and executive
committee of the California Life Science Association. Before that, Steve Krognes worked as an investment banker at
Goldman Sachs, as a management consultant at McKinsey & Company, and as a venture capitalist in Scandinavia. Mr.
Krognes holds a Master’s of Business Administration (MBA) from Harvard Business School and a Bachelor’s of
Science in economics from the Wharton School of the University of Pennsylvania.
Anthony Rosenberg
Anthony Rosenberg has served as a member of our Board of Directors since April 2017 and as vice-chairperson of our
Board of Directors since May 2025.
He currently serves as chief executive officer of TR Advisory Services GmbH, his own consultancy firm advising on
business development, licensing, and mergers and acquisitions. Anthony Rosenberg also currently serves as chairman of
the boards of directors of NUCLIDIUM AG, Oculis SA and Cullinan Therapeutics Inc. Previously Anthony Rosenberg
held the positions of Managing Director at MPM Capital, a venture capital firm (2015 until 2020); head of M&A and
Licensing of Novartis International (2013 to 2015); and head of business development and licensing at Novartis Pharma
(2005 to 2012). Anthony Rosenberg also previously served on the boards of directors of SiO2 Material Science (until
March 2023), Radius Health Inc., TriNetX, Inc., iOmx Therapeutics AG, and Clinical Ink, Inc. Mr. Rosenberg has a
Bachelor of Science with honors from the University of Leicester and a Master’s of Science in physiology from the
University of London..
Camilla Sylvest
Camilla Sylvest has served as a member of our Board of Directors since September 2022. Camilla Sylvest previously
served as the executive vice president of commercial strategy and corporate affairs of Novo Nordisk A/S until April
2025.
Camilla Sylvest has more than 29 years of working experience at Novo Nordisk A/S during which time she was based in
Switzerland, Denmark, Germany, Malaysia, and Mainland China. Over the years, Camilla Sylvest has headed up Novo
Nordisk A/S affiliates of growing size and complexity in Europe. She was also corporate vice president of the business
area Oceania and Southeast Asia and senior vice president and general manager of the Novo Nordisk A/S region of
Mainland China. Camilla Sylvest also served as a member of the board of Danish Crown A/S until September 2025. She
holds a Master’s of Science in economics from the University of Southern Denmark and an executive MBA from the
Scandinavian Management Institute.
Attendance Record Board of Director Meetings
In 2025, 6 Board of Directors meetings were held. The meeting attendance rate for our directors is set out in the table
below.
77
Table of Contents
Name
Number of meetings attended in 2025 since
appointment (and up to resignation, as
applicable)
Attendance %
Peter Verhaeghe
6
100%
Tim Van Hauwermeiren
6
100%
Steve Krognes
6
100%
Donald deBethizy1)
3
100%
Pamela Klein
6
100%
Anthony Rosenberg (vice-chairperson)
6
100%
James Daly
6
100%
Camilla Sylvest
6
100%
Ana Céspedes
6
100%
Brian Kotzin
6
100%
1)Donald deBethizy retired from the Board of Directors on May 27, 2025.
In 2025, all of the 5 Board of Directors meetings with the Non-Executive Directors being present were held as closed
sessions at the beginning or the end of other meetings. These meetings were attended by all Non-Executive Directors
appointed at such time.
Name
Number of meetings attended in 2025 since
appointment (and up to resignation, as
applicable)
Attendance %
Peter Verhaeghe
5
100%
Donald deBethizy1)
3
100%
Pamela Klein
5
100%
Anthony Rosenberg
5
100%
James Daly
5
100%
Camilla Sylvest
5
100%
Ana Céspedes
5
100%
Brian Kotzin
5
100%
1)Donald deBethizy retired from the Board of Directors on May 27, 2025
Activities
The agenda for the Board of Directors centers around the key business objectives for long-term value creation and the
key risks involved, as well as the manner in which the Executive Management Team implements our strategy including
our research and development pipeline and the commercialization of our products, our culture to ensure proper
monitoring by the Non-Executive Directors, our financial position as well as the results of our subsidiaries, significant
investment proposals, yearly budgets, the internal risk management and control system, talent development, succession
planning and remuneration and appointment matters.
In 2025, the Board of Directors discussed a multitude of different themes. The Board of Directors primarily supervised
and discussed the Company's innovation mission and objectives towards our long-term strategic Vision 2030, reviewed
the scientific pipeline and regulatory developments for all product candidates in several geographies, ensuring the
required progression thereof. The Board of Directors furthermore reviewed and discussed our strategy for manufacturing
processes, our supply chain and identified potential corresponding risks following the geopolitical environment. The
Board also focused on the commercialization strategies and opportunities, contributing to our successful product
launches, including the launch of the PFS in 2025, supporting innovation within commercialization efforts. The Board
spent a significant amount of time on themes around cybersecurity and AI, including on NIS2 Directive requirements. In
line with previous years, the Board of Directors also discussed talent development and succession planning, both for the
senior leaders within the Company (within and beyond the Executive Management Team) and the Board of Directors.
This led to the renewal of the appointment of Anthony Rosenberg as Non-Executive Director and the attraction of
several new members in the Company’s broader leadership team. Time was also spent discussing and evaluating the
Company's strategy surrounding the continued rapid growth and the measures undertaken to preserve our unique
company culture. Finally, the Board of Directors spent a lot time discussing shareholder feedback on our journey on
getting the remuneration policy approved during the 2025 Extraordinary General Meeting.
78
Table of Contents
Our Senior Management
The following table sets forth certain information with respect to the members of our Senior Management Team,
including their ages, as of December 31, 2025:
Name
Age
Position
Nationality
Date of Initial
Appointment
Tim Van Hauwermeiren1)
53
CEO and Executive Director
Belgium
July 15, 2008
Karen Massey2)
47
COO
Australia
March 13, 2023
Karl Gubitz
56
CFO
South Africa and
U.S.
June 1, 2021
Peter Ulrichts
46
Chief Scientific Officer
Belgium
January 1, 2023
Malini Moorthy
56
General Counsel and
Corporate Secretary
Canada and U.S.
February 14, 2022
Luc Truyen
61
Chief Medical Officer
Belgium and U.S.
April 1, 2022
Arjen Lemmen
41
Vice-President Corporate
Development & Strategy
The Netherlands
May 1, 2016
Andria Wilk
53
Global Head of Quality
UK
January 13, 2020
1)Tim Van Hauwermeiren will transition from his current CEO role to the position of Non-Executive chairperson of the Board of Directors after
receiving approval from the shareholders during the 2026 General Meeting.
2)It is envisaged that Karen Massey, our current COO,  will be appointed as an Executive Director at the 2026 General Meeting and subsequently
elected as CEO by the Board of Directors.
Tim Van Hauwermeiren
Tim Van Hauwermeiren co-founded our Company in 2008 and has served as our CEO since July 2008. He has served as
a member of our Board of Directors since July 2014.
Tim Van Hauwermeiren has almost 31 years of general management and business development experience across the
life sciences and consumer goods sectors. He also serves on the board of directors of Lexeo Therapeutics, Inc. and
Denali Therapeutics, Inc.
Karen Massey
Karen Massey has served as our COO since March 2023.
Ms. Massey has over 25 years of experience in the pharmaceutical and biotechnology industry, including in commercial,
product development, corporate strategy, and innovation roles. Prior to joining argenx, Ms. Massey was with Genentech
(Roche Group) for over nine years, where she most recently served as senior vice president of product development and
global clinical operations and previously held various commercial leadership roles across marketing and business
operations, including as the vice president of the multiple sclerosis and neuromyelitis optica business. Ms. Massey
started her biopharmaceutical career in marketing at Pfizer Inc., and returned there, after two years as a management
consultant at Bain & Company, to take on leadership positions in corporate strategy and sales and as a commercial lead
in Latin America.
Karl Gubitz
Karl Gubitz has served as our CFO since June 2021.
Mr. Gubitz previously worked at Pfizer Inc. for nearly 20 years, most recently as vice president of finance within the
global oncology business. Within Pfizer Inc., Mr. Gubitz held country, regional, and global positions, and consistently
delivered top-line growth. He managed teams of over 250 colleagues in financial leadership roles within the global
internal medicine and global innovative products businesses. Prior to joining Pfizer Inc. in 2003, Mr. Gubitz held various
management roles at PricewaterhouseCoopers LLP.
Peter Ulrichts
Peter Ulrichts has served as our chief scientific officer since January 2023. In this role, he oversees the development of
all clinical and pre-clinical compounds within our pipeline.
79
Table of Contents
Dr. Ulrichts previously served in various roles at the Company since he joined us in 2010, including, most recently, as
our head of clinical science. As a research scientist, Dr. Ulrichts was involved in the development of various therapeutic
antibodies for the treatment of cancer and autoimmune diseases. In 2013, he headed the development of our FcRn
antagonist efgartigimod until the first-in-human clinical trial. He subsequently transitioned to become the lead scientist
of our efgartigimod program.
Malini Moorthy
Malini Moorthy has served as our general counsel and corporate secretary since February 2022.
She has over 26 years of extensive global legal and compliance experience in the biopharmaceutical and medical device
industries. She was most recently senior vice president and chief deputy general counsel of legal, compliance, and
government affairs at Medtronic plc, where she played a pivotal role in shaping and driving enterprise and functional
strategies. Before joining Medtronic plc, Ms. Moorthy spent four years at Bayer Corporation as the head of global
litigation and investigations and 10 years at Pfizer Inc., where she progressed to lead civil litigation globally. Ms.
Moorthy began her career as a law firm associate, first with McCarthy Tétrault LLP and Genest Murray Desbrisay
Lamek LLP in Toronto, Canada and then Salans LLP (now Dentons US LLP) in New York City.
Luc Truyen
Luc Truyen has served as our chief medical officer since April 2022 and previously served as our head of research and
development operations management from September 2021 to April 2022.
Prior to this, Dr. Truyen was with Johnson & Johnson (and its subsidiary companies) for over 21 years holding various
leadership positions, primarily within neuroscience. In his most recent position prior to joining argenx, Dr. Truyen was
global head of development and external affairs for neuroscience, managing the strategy and delivery of the early and
late portfolio of assets for mood disorders, schizophrenia, and neurodegenerative and neuroinflammatory disorders.
Besides Dr. Truyen’s strong track record in clinical development resulting in several globally innovative drug approvals,
his broad-based experience also includes leading global clinical development operations for the whole Johnson &
Johnson pharmaceutical group as well as serving as the head of research and development and chief medical officer of
Janssen Alzheimer Immunotherapy Research & Development LLC, an internal spin-out from Johnson & Johnson.
Arjen Lemmen
Arjen Lemmen joined argenx in 2016 and has served as our vice president of corporate development & strategy since
2019. He has successfully executed several transactions including a number of programs within the IIP.
Prior to joining the Company, Mr. Lemmen served as a corporate finance specialist at Kempen & Co NV focusing on
mergers and acquisitions, equity capital markets and strategic advisory transactions in the European life sciences
industry.
Andria Wilk
Andria Wilk joined argenx as global head of quality in January 2020. Ms. Wilk has more than 26 years of experience in
quality assurance within the pharmaceutical industry. Most recently, Ms. Wilk served as senior director, head of medical,
regulatory & clinical quality assurance at H Lundbeck A/S, where she managed the global medical, regulatory & clinical
quality assurance group based in the EU, U.S., and Asia. In this role, she was responsible for the global audit programs
and quality assurance support for all clinical trial and post-marketing activities and related computerized systems.
Prior to H Lundbeck A/S, she held various quality assurance positions of increasing responsibility within AstraZeneca
plc, Takeda Global Research, Development Centre Europe, and Astellas Pharma Inc.
General Information About Our Directors and Senior Management
As of the date of this Annual Report (or in any period before), none of the members of our Board of Directors and senior
management has or has had a family relationship with any other member of our Board of Directors or senior
management, and there are no arrangements or understandings with major shareholders, customers, suppliers or others,
pursuant to which any person referred to above was selected as a member of our Board of Directors or senior
management. For further information regarding any arrangements pursuant to which our Board of Directors or senior
management were appointed, see “Item 7.B. — Related Party Transactions — Agreements with Our Senior
Management”.
80
Table of Contents
B.COMPENSATION
Remuneration Report and Compensation Statement
Letter from the Chairperson of the Remuneration and Nomination Committee
Dear Stakeholders,
Introduction
On behalf of the Remuneration and Nomination Committee, I am pleased to present the 2025 remuneration report (the
2025 Remuneration Report), which outlines the Committee’s activities over the past year and provides insight into how
the Company’s achievements and continued progress in 2025 have shaped the remuneration of our CEO and Board of
Directors.
In compliance with article 2:135b of the Dutch Civil Code, the European Shareholder Rights Directive and the DCGC,
this 2025 Remuneration Report discloses how we implemented our 2021 Remuneration Policy for the Board of Directors
and CEO in 2025 and explains how we will move forward with the 2025 Remuneration Policy, which became effective
upon receiving shareholder approval at the 2025 Extraordinary General Meeting, held on November 18, 2025. In so
doing so we hope that we can demonstrate the CEO is not only rewarded for immediate achievements, but also for
sustained progress in our business strategies, individual objectives, and key strategic non-financial metrics that we
believe underpin our long-term mission and strategy.
argenx performance in 2025
2025 was a year of strong execution and strategic delivery across argenx’ core priorities. We made substantial progress
toward our Vision 2030 ambition of reaching 50,000 patients globally, treating approximately 19,000 patients across
three indications (gMG, CIDP and ITP) and three product presentations. We successfully launched the VYVGART
Hytrulo pre‑filled syringe in MG and CIDP, which expanded access to new patient segments and enabled more
convenient treatment options. At the same time, the Company continued to invest in long‑term value creation by
advancing a robust and diversified pipeline, entering 2026 with 10 ongoing registrational clinical trials and adding four
new molecules to the pipeline. Our Senior Management Team, including the CEO, CFO and COO (Named Executive
Officers or NEOs), guided the organization through a year of operational intensity, progressing late‑stage clinical
programs, supporting regulatory submissions, scaling commercial operations and building the infrastructure required for
sustainable growth, while positioning argenx for its next phase of leadership and innovation.
In gMG, we strengthened our position as the #1 prescribed and fastest‑growing biologic, supported by increasingly
earlier use in the treatment paradigm and continued expansion into broader patient populations. Positive topline data
from the Seronegative gMG clinical trial strengthened our ambition to be the treatment of choice and to pursue the
broadest MG label to date. In CIDP, real‑world outcomes continued to validate the ADHERE results, with physicians
reporting sustained functional improvement and patients experiencing greater independence and quality of life. This
strong commercial execution resulted in a historic milestone for the company, with VYVGART surpassing $1 billion in
product net sales in a single quarter for the first time in the third quarter.
Fixed base pay
After our annual comprehensive base pay review, in 2025 the CEO, CFO and COO’s base pay increased from EUR
700,000 to EUR 732,000 ($827,160), $553,000 to $578,000 and CHF 594,000 to CHF 615,000 ($741,641), which is an
increase of 4.6%, 4.5% and 3.5% respectively. These increases are determined in accordance with the Company’s global
base pay increase principles and guidelines and are consistent with the methodology used to determine base pay
increases for employees across the organization. In addition, they reinforce our commitment to a balanced, performance-
driven remuneration structure that supports sustainable long-term value creation, while maintaining fairness and
transparency and taking into account annually performed scenario analyses, including benchmarking exercises in setting
total remuneration levels.
Even with the above-referenced increase, the CEO’s base pay, at his own request, remained below the 25th percentile of
the 2024 peer group.
Short Term Performance Pay
The CEO, CFO and COO delivered strong performance outcomes in 2025, resulting in STI payouts of 150% of target for
the CEO, 150% for the CFO and 175% for the COO. These outcomes reflect the successful launch of the pre-filled
syringe on April 10, 2025, associated revenue growth and continued delivery against key strategic priorities. The
81
Table of Contents
Remuneration and Nomination Committee considers that these results accurately reflect performance against the targets
set at the start of the year and demonstrate clear alignment between pay and performance. Further details on individual
achievements are provided in the main body of the report.
Long Term Performance Pay
Over 2025, argenx’s share price rose by 20% from €600.00 to €716.80. In fact, over a three-year period, from December
31, 2022 to December 31, 2025, the share price has risen by approximately 106%, from €348.30 to €716.80 per share,
further underscoring the NEOs successful long-term performance.
Under the 2021 Remuneration Policy, as part of the long-term incentive pay (LTIP), the NEOs received RSUs and stock
option grants. For disclosure on these awards vesting in 2025, please refer to ‘‘Section 3.4.3 LTIP’’ of this 2025
Remuneration Report.
Under the 2025 Remuneration Policy approved in November 2025, RSUs have been replaced by PSUs. As a result, the
LTIP is now fully ‘at-risk’ as it is entirely performance-based and a mixture of stock options (no more than 50% of the
annual grant) and PSUs (at least 50% of the annual grant). For the PSU portion of the 2025 grant, they will be assessed
on the following performance metrics and targets:
•Maximize the VYVGART opportunity consisting of the following targets: 2027 annual revenue (50%) and gMG
Label Expansion (15%);
•Build a portfolio of breakthrough antibody-based products consisting of the following target: FDA submissions
(15%);
•Ensure long-term sustainability as an independent company consisting of the following target: Pipeline progression
(10%); and
•Scaling the argenx way consisting of the following target: talent retention (10%).
For further information on the 2026 PSU awards, please refer to ‘‘Item 6.B — Remuneration Report and Compensation
Statement — LTIP’’ of this 2025 Remuneration Report.
Stakeholder Engagement
Shareholders play a crucial role in our success by providing invaluable support and fostering strong partnerships that are
essential to our growth. We deeply appreciate their continued commitment and strive to keep them well-informed,
ensuring a lasting and productive relationship.
During 2025, we directly engaged with our top 60 shareholders and other shareholders who previously engaged with us
(holding a total of approximately 70% of our shares) as well as with proxy advisors, resulting in strong shareholder
endorsement, with approximately 96% of votes cast in favor of the 2025 Remuneration Policy during the 2025
Extraordinary General Meeting held on November 18, 2025, reflecting broad support for the Company’s approach to
executive remuneration.
Looking Forward
As announced on January 5, 2026, our current CEO, Tim Van Hauwermeiren, will transition from his CEO role to the
position of Non-Executive chairperson of the Board of Directors, subject to receiving approval from the shareholders
during the 2026 General Meeting. I would like to express the Committee’s immense appreciation for his great leadership,
contributions and accomplishments delivered since the Company’s founding in 2008. The Board of Directors will
appoint our current COO, Karen Massey, as our new CEO, following the approval of her nomination to Executive
Director by the shareholders during the 2026 General Meeting. We are delighted to receive overwhelmingly positive
feedback from shareholders since the announcement of the leadership transition and strong support for both Tim Van
Hauwermeiren and Karen Massey’s new roles.
Tim Van Hauwermeiren’s anticipated CEO remuneration for 2026 will be in accordance with the provisions of the 2025
Remuneration Policy and is summarized below:
•Treatment of base pay: The annual base pay for 2026 will be paid, pro-rated, up to and including the date of his
resignation as CEO at the 2026 General Meeting.
82
Table of Contents
•Treatment of 2026 STI: The 2026 STI will be paid on a pro-rated basis up to and including the date of his resignation
as CEO at the 2026 General Meeting, in accordance with the Founder CEO legacy agreement. Full details will be
disclosed in the 2026 Remuneration Report.
•Treatment of LTI: All unvested equity other than PSUs will immediately and fully vest at the time of the 2026
General Meeting. The PSUs granted in 2025 will remain subject to their normal three-year performance period and
will vest in 2027, based on performance and pro-rated for time served as CEO in calendar years 2025 and 2026 (up to
and including the date of his resignation as CEO at the 2026 General Meeting). Tim Van Hauwermeiren will not
receive a new pro-rated 2026 LTIP grant, including both stock options and PSUs.
Subject to approval by the shareholders at the 2026 General Meeting, Tim Van Hauwermeiren’s remuneration
arrangements as Non-Executive chairperson of the Board of Directors will be in accordance with the 2025 Remuneration
Policy.
For more information regarding Tim Van Hauwermeiren’s 2026 compensation as CEO and as Non-Executive
chairperson of the Board of Directors, including when details on achievement and pay-out will be available, please refer
to section ‘‘Item 6.B — Remuneration Report and Compensation Statement — Looking Forward’’ below.
More information on Karen Massey’s remuneration will be disclosed in the convocation notice for the 2026 General
Meeting, which will become available on or around the date of this 2025 Remuneration Report.
I share the enthusiasm and excitement expressed by our shareholders about the upcoming leadership transition, and I am
confident that with Tim Van Hauwermeiren as the Non-Executive chairperson of the Board of Directors and Karen
Massey as CEO, argenx is extremely well-positioned for the long term.
We will continue to engage actively on this leadership transition and other relevant topics with our key stakeholders and
proxy advisors throughout 2026 and beyond. We remain available to address any questions regarding corporate
governance and executive compensation.
On behalf of the Remuneration and Nomination Committee I would like to thank all our investors, employees and
stakeholders for their continued support and I ask that shareholders vote to approve this report at the 2026 General
Meeting.
Ana Céspedes
Chairperson, Remuneration and Nomination Committee
Remuneration Policy
Summaries for each approved policy, which guided our backward-looking and forward-looking pay decisions during the
year-under-review are below. For more details on these policies, please refer to the below links provided
•The 2021 Remuneration Policy: https://argenx.com/content/dam/argenx-corp/media-documents/
argenx_remuneration_policy_final_approved_11_May_2021.pdf.
•The 2025 Remuneration Policy: https://argenx.com/content/dam/argenx-corp/media-documents/
EGM_November_2025-Remuneration_Policy.pdf.
83
Table of Contents
Executive Director Remuneration Policy
Pay Element
2021 Remuneration Policy
(77% approval)
2025 Remuneration Policy
(approx. 96% approval)
Base Pay
•Set at or around the 50th percentile of U.S. peer
group for U.S.-based executives, and around the
75th percentile of EU peer group for EU-based
executives.
•Targets the 50th percentile of the Executives in
the peer group.
Benefits and
Pension
•Customary fringe benefits including pension
contributions, hospitalization and disability
insurance, severance arrangement, company car,
phone, and laptop.
•Benefits and pension contributions aligned with
those of other employees within the same legal
entity and in accordance with local market
practice.
Short-Term
Incentive
•Cash-based target STI for CEO is 60% of base
pay at 100% target achievement; maximum
payout of 120% of base pay.
•Typically 60% of targets related to quantitative
targets (building the business) and 40% of targets
related to qualitative targets (building the
organization). Target mix was not fixed.
•Quantum unchanged from 2021 Remuneration
Policy.
•Majority of targets are quantitative and at least
50% of STI linked to financial performance
targets. Qualitative targets will be milestone-based
to the extent possible.
Long-Term
Incentive
•100% time-based LTI (no performance
conditions). Plan consisting of time-based stock
options and time-based RSUs.
•No cap on LTI opportunities included.
•Stock options vest 1/3 after 1 year and then in
monthly installments until the end of the 3-year
period. RSUs vest 25% on each anniversary of the
grant date.
•100% risk-based; LTI with no less than 50%
PSUs and no more than 50% stock options.
•The annual LTIP opportunity is 7x base pay at
target / 10x at maximum.
•As of 2026, stock options and PSUs have a 3-year
cliff vesting period; no equity vests before the end
of the 3 years.
Shareholding
Requirements
•No shareholding requirements.
•Equal to 6x annual base pay in the form of
company equity (excluding non-vested RSUs/
PSUs and stock options), to be built up over a
maximum of five years.
Clawback
provisions
•No clawback policy
•Clawback policy in place applicable to variable
remuneration paid out on the basis of financial
information which is subsequently restated.
Recruitment
Provisions
•Board may grant additional 1x regular equity
grant as sign-on award.
•May offer buyout awards to compensate for value
lost by changing employers.
84
Table of Contents
Pay Element
2021 Remuneration Policy
(77% approval)
2025 Remuneration Policy
(approx. 96% approval)
Leaver
Provisions
•No explicit leaver provisions.
•STIP: Legacy provision for current Executive
Director to be pro-rated for time and performance
upon termination. For any other Executive
Director, there will be no STI payout unless in
service on 31 December of that performance year.
•LTIP: Legacy provision for current Executive
Director provides for immediate and full vesting
at time of termination, except for the PSUs. For
any other Executive Director, upon leaving the
Company, unvested stock options and PSUs are
forfeited without compensation. During
performance period other than dismissal for cause
or underperformance, vesting of PSUs will be pro-
rated for time and performance at the end of 3-
year performance period.
Peer Group
•Reference group includes European and U.S.-
based integrated, commercial-stage life science
companies. Selected for comparability in size,
activities and market presence
•Reference group comprises European and U.S.-
based commercial-stage biopharmaceutical
companies selected for comparability in
innovation focus, global reach, size (revenue and
market value relative to argenx), market presence
and public listing.
Non-Executive Director Remuneration Policy
Pay Element
2021 Policy (77% approval)
2025 Policy (96% approval)
Cash
•Benchmarked regularly fees could be adjusted as
necessary based on regular benchmarking
exercises to ensure continued fair and competitive
remuneration.
•Annual cash retainer fee targets the 50th
percentile of the peer group and benchmarked
annually. 2025 Board of Directors membership
fee: $60k per year, with additional $59.5k for the
chairperson. Committee members receive
(depending on the committee) $10,000-12,500 for
membership or $20,000-25,000 for chairmanship.
Equity
•Share options and/or restricted share units in an
amount that is at or around the 50th percentile of
the U.S. companies in our reference group. Per
2021, we granted 2,700 stock options and 600
RSUs to each Non-Executive Director. Equity
granted was adjusted on the basis of benchmark
outcomes and in consideration of developments in
the composition of equity incentives offered by
argenx to key persons outside the Board of
Directors, including company employees.
•RSUs vest over 4 years and stock options vesting
over 3 years.
•Since 2024, stock options no longer granted to
Non-Executive Directors to avoid any perceived
effect on independence; switched to granting
RSUs.
•Annual equity grant of $400,000 in the form of
restricted shares with no vesting conditions,
targeting the 50th percentile of the peer group and
subject to annual review. No shares may be sold
until after the 4th anniversary of the grant date,
except to the extent necessary to cover immediate
tax obligations resulting from the vest.
•Restricted shares are not subject to vesting
conditions. 4-year holding requirement for equity
grants (except sales to cover immediate tax
obligations).
85
Table of Contents
Pay Element
2021 Policy (77% approval)
2025 Policy (96% approval)
Shareholding
Requirements
•No shareholding requirements.
•Holding of 5x annual Board of Director
membership retainer fees (as at the date of the
2025 Remuneration Policy, the annual retainer fee
was $60,000), to be built over a period of 5 years.
Special travel
allowance
•No special travel allowance.
•Special travel allowance of $5,000 for in-person
attendance at each board meeting held outside of a
Non-Executive Director’s official continent of
residence.
Reference Peer Group
Selection Criteria
The argenx peer group is based on the following selection criteria:
•Sector (Biopharmaceutical companies, excluding diagnostics and animal health companies);
•Innovation focus (at least 25% of revenue is spent on R&D);
•Global reach (generates product revenues both within and outside the US);
•Revenue (1/4x – 4x of our annual revenue);
•Market capitalization (1/4x – 4x of our 30-day average market cap on the last business day prior to the date of the
Company-wide grant in June); and
•Listing location (listed on a major US Stock Exchange).
If there are fewer than 15 companies meeting all six criteria, the peer list will be supplemented with companies that meet
all but one criterion with the least relevant criterion dropped first, in the order as displayed above (from most to least
relevant).
For the 2025 Peer Group that was selected in Q3 2025, we made adjustments to our benchmarking methodology. In
response to shareholder feedback, we shifted the US listing criterion from the second most important criterion to the
criterion with the least significance. This resulted in an increase from 26.67% European peers in the 2025 Peer Group to
40% European peers in the 2025 Peer Group.
The 2025 Peer Group was composed of the following global reference companies
•US Companies: Alnylam Pharmaceuticals, Biogen, BioMarin Pharmaceutical, Incyte, Insmed, Moderna, Regeneron
Pharmaceuticals, Sarepta Therapeutics, Vertex Pharmaceuticals.
•European Companies: Ascendis Pharma, BeOne Medicines, BioNTech, Genmab, Jazz Pharmaceuticals, UCB.
Each year, the Remuneration and Nomination Committee will validate the peer group to ensure its relevance and the
Remuneration and Nomination Committee may recommend adjustments to the Board of Directors, if deemed necessary.
NEO Remuneration in FY25
Base pay
After our annual comprehensive base pay review, the CEO, CFO and COO’s base pay increased from EUR 700,000 to
EUR 732,000 ($827,160), $553,000 to $578,000 and CHF 594,000 to CHF 615,000 ($741,641), which is an increase of
4.6%, 4.5% and 3.5% respectively. These increases are determined in accordance with the Company’s global base pay
increase principles and guidelines and are consistent with the methodology and base pay increases for employees across
the organization. In addition, they reinforce our commitment to a balanced, performance-driven remuneration structure
that supports sustainable long-term value creation, while maintaining fairness and transparency and taking into account
annually performed scenario analyses including benchmarking exercises in setting total remuneration levels.
86
Table of Contents
Pension and fringe benefits
The benefits paid to the NEOs are jurisdiction dependent. For the CEO, these included benefits customary in the Belgian
market, and which are standard components of Belgian-based employee packages: pension contributions, a
hospitalization insurance, a representation allowance and a company car. The Company pension contribution percentage
of base pay for the CEO is equal to the Company pension contribution percentage for all employees in Belgium. For the
COO, these included benefits customary in the Swiss market, and which are standard components of Switzerland-based
employee packages: car allowance, lunch allowance, health insurance allowance, representation allowance and pension
contributions. For the CFO, these included benefits customary in the U.S. market, and which are standard components of
our U.S.-based employee packages: a company-administered health benefit plan and 401k plan.
Short Term Incentive Pay
The CEO, CFO and COO participated in the 2025 STIP with target opportunities of 60%, 40% and 50% of base pay, and
maximum opportunities of 120%, 80% and 100% of base pay, respectively. In assessing performance against the
Company’s 2025 business plan, the Board determined that the NEOs delivered a strong year of execution, resulting in
STIP outcomes of 150% of target for the CEO and CFO and 175% for the COO.
Specifically for the CEO, he delivered strong performance against the measures. He exceeded the annual operating
budget revenue targets, successfully executing the PFS launch in the U.S., resulting in achieving the maximum
opportunity for the revenue goal. Target achievement was reached for the pipeline goal as the MG combination clinical
trial was launched and 3 new candidates were nominated and 3 new molecules graduated. The Innovation goal was also
met at target through championing key innovation projects and embedding innovation goals into the performance targets
of employees. Lastly, succession plans for key senior leaders as well as the CEO succession were accomplished at target
for scaling the argenx way goal to secure long-term leadership strength & organizational capabilities. The overall strong
performance resulted in a total weighted achievement of 150% of target opportunity.
Specifically for the CFO, he delivered a strong performance against the measures. He also exceeded the annual operating
budget revenue targets, successfully executing the PFS launch in the US, resulting in achieving the maximum
opportunity for the revenue goal. Maximum opportunity was also achieved for making substantial progress on the digital
finance transformation goal, including reductions in financial closing timelines, automation of financial processes and
transforming the planning cycle. Target achievement was reached for the P&L goal by effectively managing the
Company’s tax commitments and managing headcount growth within the approved budget parameters, supporting
disciplined scaling for scaling the argenx way goal. The overall strong performance resulted in a total weighted
achievement of 150% of target opportunity.
Specifically for the COO, she delivered a very strong performance against the measures. Just like the CEO and CFO, she
exceeded the annual operating budget revenue targets, successfully executing the PFS launch in the US, resulting in
achieving the maximum opportunity for both the revenue and pipeline acceleration goals. Maximum opportunity was
also achieved for operational and digital transformation priorities, including the successful onboarding of the BIS leaders
and execution of key transformation objectives. Lastly, critical leadership hires were successfully onboarded and
operational excellence initiatives were embedded to accelerate novel therapies to patients, resulting in target achievement
for scaling the argenx way goal. The overall very strong performance resulted in a total weighted achievement of 175%
of target opportunity.
The Board considers the selected performance metrics to remain the most appropriate measures of NEO performance, as
they reflect the Company’s key strategic, operational and financial priorities. The tables below outline the targets set and
the corresponding achievements for each NEO.
87
Table of Contents
CEO 2025 STIP
Performance Metric
and Weighting
Measurement
(how the Board of Directors
evaluated the target) 
Threshold
Target
Max
Achievement 
Vesting
Actual
pay-out
Revenue (50%)
•Annual operating budget
revenue target delivered
•Successful PFS self-
administration approval and
launch in the U.S.
80% of annual
operating budget
target
100% annual operating
budget
120% annual
operating budget
120% annual operating
budget
100%
496,296
Pipeline (20%)
•MG combo clinical trial
launched Q3 and/or
•Nominate 2 new ARGX-xxx
candidates and graduate 3
discovery projects to lead
identification (PPD)
•Combo trial
launched
•1 new ARGX-
xxx candidate
nominated
•2 molecules
graduated
•Combo trial launched
•2 new ARGX-xxx
candidate nominated
•3 molecules graduated
•Combo trial
launched  in Q3
•3 new ARGX-
xxx candidate
nominated
•4 molecules
graduated
•Combo trial launched
•2 new ARGX-xxx
candidate nominated
•3 molecules graduated
20%
99,259
Innovation (20%)
•Champion key innovation
projects AND
•All variable pay eligible
employees have 1x
performance goal linked to
innovation AND
•Key innovations recognized,
celebrated and cascaded
throughout the Company
•1x innovation
projects
championed
AND
•80% of
employees 1x
performance
goal linked to
innovation
AND
•3x key
innovation
celebrated at
the Corporate
update
•3x innovation projects
championed AND
•90% of employees 1x
performance goal
linked to innovation
AND
•3x key innovation
celebrated at the
Corporate update
•5x innovation
projects
championed
AND
•100% of
employees 1x
performance goal
linked to
innovation AND
•3x key
innovation
celebrated at the
Corporate update
•3x innovation projects
championed AND
•90% of employees 1x
performance goal
linked to innovation
AND
•3x key innovation
celebrated at the
Corporate update
20%
99,259
Scaling the argenx way
(10%)
•Succession plan in place for
key senior leaders
No plan in place
Plan in place
N/A
Plan in place
10%
49,630
88
Table of Contents
CFO 2025 STIP
Performance Metric
and Weighting
Measurement
(how the Board of Directors
evaluated the target) 
Threshold
Target
Max
Achievement
Vesting
Actual
pay-out
Revenue (30%)
•Annual operating budget
revenue target delivered AND
•Successful PFS self-
administration approval and
launch in the U.S.
80% of annual
operating budget
100% annual operating
budget
120% annual
operating budget
120% annual operating
budget
60%
138,720
P&L (25%)
•Target effective tax rate in
2025 in line with annual
operating budget
Effective tax rate
5% higher than
annual operating
budget
Effective tax rate in line
with annual operating
budget
Effective tax rate 5%
lower than annual
operating budget
Effective tax rate in line
with annual operating
budget
25%
57,800
Digital transformation (25%)
•Time required to close the
quarter reduced by 50% AND
•Annual operating budget
process transformation AND
•Financial accounts automation
2/3 metrics
achieved
3/3 metrics achieved
Significant additional
digitalization
achieved beyond the
3/3 metric achieved
Significant additional
digitalization achieved
beyond the 3/3 metric
achieved
45%
104,040
Scaling the argenx way
(20%)
•Management headcount growth
Headcount growth
>105% of annual
operating budget
Headcount growth <
102% of annual operating
budget
N/A
Headcount growth >105% of
annual operating budget
20%
46,240
89
Table of Contents
COO 2025 STIP
Performance Metric
and Weighting
Measurement
(how the Board of Directors
evaluated the target) 
Threshold
Target
Max
Achievement
Vesting
Actual
pay-out
Revenue (40%)
•Annual operating budget
revenue target delivered
•Successful PFS self-
administration approval and
launch in the U.S.
80% of annual
operating budget
100% annual operating
budget
120% annual
operating budget
120% annual operating
budget target
80%
296,656
Pipeline Acceleration (20%)
•PFS FDA approval
FDA acceptance
•FDA acceptance with
no concerns and
review on track
•FDA acceptance
with PDUFA
date < 6 months
•FDA acceptance with
PDUFA date < 6
months
40%
148,328
Digital transformation (20%)
•Successful onboarding of
Business Information Systems
(BIS) leader and deliver on the
BIS OGSM
50% of the BIS
OGSM measures
delivered
Onboarded and delivered
per annual operating
budget AND
80% of the BIS OGSM
measures delivered
Onboarded and
delivered per annual
operating budget
AND
90% of the BIS
OGSM measures
delivered
•Onboarded and
delivered per annual
operating budget
AND
•90% of the BIS
OGSM measures
delivered
35%
129,787
Scaling the argenx way
(20%)
•Successful onboarding of key
hires and leadership teams'
their OGSMs AND
•Elevate the operational
excellence community to a
leadership community and their
OGSM delivered
N/A
Accomplished
N/A
Accomplished
20%
74,164
90
Table of Contents
2026 STIP
The majority of the targets will be quantitative in nature and at least 50% of the total STIP opportunity for the NEO will
be linked to financial performance metrics. Qualitative targets will be milestone-based to the extent possible. For the
2026 STIP, the targets chosen are:
CEO: Performance Metric, Target Area and Weighting
Measurement
(how the Board of Directors evaluate the target)
Deliver continued VYVGART growth (50%)
2026 financial plan revenue target delivered
Pipeline Acceleration (25%)
•Deliver Ocular MG, Myositis and MMN top line data read-
outs in 2026 (10%)
•On track to deliver SjD & CIDP data read-outs in 2027
(5%)
•Not disclosed (10%)
Successful CEO transition (25%)
•Retention of key talent (12.5%)
•Shareholder feedback on transition (12.5%)
The STIP for the current CEO Tim Van Hauwermeiren will be pro-rated for time and performance until his resignation
as CEO at the 2026 General Meeting.
CFO: Performance Metric, Target Area and Weighting
Measurement
(how the Board of Directors evaluate the target)
Deliver continued VYVGART growth (50%)
2026 financial plan revenue target delivered
Capital allocation for long-term sustainable growth (25%)
Not disclosed
Champion digitization, automation, simplification and AI (10%)
Simplify and digitize financial processes
Scaling the argenx way (15%)
Headcount growth (15%)
COO: Performance Metric, Target Area and Weighting
Measurement
(how the Board of Directors evaluate the target)
Deliver continued VYVGART growth (50%)
2026 financial plan revenue target delivered
Pipeline Acceleration (25%)
•Deliver Ocular MG, Myositis and MMN top line data read-
outs in 2026 (10%)
•On track to deliver SjD & CIDP data read-outs in 2027
(5%)
•Not disclosed (10%)
Scaling the argenx way (15%)
Headcount growth (15%)
Successful CEO transition (10%)
•Retention of key talent (5%)
•Shareholder feedback on transition (5%)
The Company will disclose the actual targets set on a threshold, target and maximum basis and achievements in the 2026
remuneration report, in line with the disclosure on the 2025 STIP achievements.
LTIP
1.Awards Vesting in 2025:
Under the 2021 Remuneration Policy as part of the long-term variable pay the CEO received RSUs and stock option
grants. As these had various vesting schedules, please refer to the tables included in ‘‘Item 6.B — Remuneration Report
and Compensation Statement — Stock Option Overview’’ below for the disclosure on the value of these awards vesting
in 2025.
91
Table of Contents
2.Awards Granted in 2025:
As per our 2025 Remuneration Policy, non-performance equity (RSUs) has been phased out of the LTIP. The following
information sets out the number, value and key terms of LTIP awards granted to the CEO in 2025. Notably, both stock
options and PSUs are based on three-year vesting schedules as included in our 2025 Remuneration Policy.
•Stock Options: The number of stock options was calculated by dividing the target value through the then applicable
Black-Scholes value based on 30 calendar days preceding the 15th day of the month in which the grant occurs (the
Reference Date), rounded up to the nearest whole number. The stock options granted on June 30, 2025 to the CEO
have an exercise price of €479.30 / $561.74.
•PSUs: The numbers of PSUs was calculated by dividing the target value through the average closing price 30
calendar days preceding the Reference Date, rounded up to the nearest whole number. 
•Target Value: Using the above methodology, the total LTIP target grant was valued at $5,790,000, $3,395,000, and
$3,895,000 which is 7.0, 5.9 and 5.3 times the CEO’s, CFO’s and COO’s base salaries, respectively. The CEO and
CFO received their respective equity grants converted into a number of stock options and PSUs on the Reference
Date of the 30-days average share price of 510.88 EUR/$569.17 per share preceding the Reference Date and the
Black-Scholes model fair market value of 172.92 EUR/$192.65 per stock option. Consequently, 15,027, 8,812,
10,110 stock options (50% of the LTIP grant) and 5,085, 2,983, 3,423 PSUs (50% of the LTIP grant) were granted to
the CEO, CFO and COO, respectively.
•NB: Relevant for CEO only as he is a Belgian beneficiary: these amounts do not reflect the actual economic value
realized by the beneficiary. Amounts included represent the expenses with respect to the assumptions used in the
Black-Scholes model which differ between Belgian beneficiaries versus non-Belgian beneficiaries, resulting in the
CEO’s stock based compensation expenses being higher than other beneficiaries. For a description of the assumptions
used, refer to “Note 13 — Share-Based Payments in the ‘‘Consolidated Financial Statements” which are included to
our Annual Report for the period ended December 31, 2025.
PSUs
Together with the rest of the Senior Management Team, the CFO and the COO Karen Massey, who is envisaged to be
elected as an Executive Director during the 2026 General Meeting and subsequently transition into the role of CEO, are
eligible to receive a PSU grant in 2026.
The current CEO, Tim van Hauwermeiren, will not receive a pro-rated PSU grant for 2026 in connection with his
transition into the role of Non-Executive Director and Chairperson of the Board of Directors at the 2026 General
Meeting.
The four measures of the 2026–2028 PSUs are based on the following principles:
•at least 50% of the pay opportunity will be linked to financial performance metrics such as revenue growth;
•at least 40% of the pay opportunity will be linked to innovation and pipeline progression metrics, such as delivering
clinical and regulatory milestones; and
•up to 10% of the pay opportunity will be linked to people and culture metrics essential for sustainable, long-term
value creation.
92
Table of Contents
Performance Metric 
Target
Measurement (how the
Board of Directors will
evaluate the metric
and why it has been
chosen)
Threshold
Target 
Max
Maximize the
VYVGART opportunity
(50%)
2028 annual revenue
Minimum product net
sales of undisclosed
amount
Targets and Executive Director achievement
will be disclosed retroactively in the 2028
remuneration report, published in 2029
Pipeline progression
(40%)
(s)BLA Approvals (in
addition to potential
Seronegative gMG and
Ocular MG) (20%)
Undisclosed number of
new approvals
Phase (ii) Progression
and/or IND / CTA
Assets Submissions
(20%)
Undisclosed number of
new pipeline assets into
phase 2 and/or
undisclosed number of
new additional pipeline
assets IND / clinical trial
application submitted
Scaling the argenx way
(10%)
Talent retention
Three-year average
voluntary employee
turnover equal to or
below 6.5% (target) or
equal to or below 8.5%
(floor)
Shareholding Requirements
The remuneration policy requires an Executive Director to build up a shareholding requirement 6x their base pay. On
December 31, 2025, the CEO is in compliance with this requirement.
Clawback policy
In the year ended December 31, 2025, no variable remuneration was clawed back and no variable remuneration was
adjusted (retroactively).
Looking Forward – Mr Van Hauwermeiren
2026 CEO position
As Tim Van Hauwermeiren will be treated as a good leaver, his anticipated CEO remuneration for 2026 will be
delivered in accordance with the provisions of the 2025 Remuneration Policy and is outlined below:
•Treatment of base pay: The annual base pay for 2026 will be paid, pro-rated, up to and including the date of his
resignation as CEO at the 2026 General Meeting. This is expected to amount to EUR 261,665, being a 126 day pro-
rated pay out of the full 2026 base pay of EUR 758,000.
•Treatment of 2026 STI: The 2026 STI will be paid on a pro-rated basis up to and including the date of his resignation
as CEO at the 2026 General Meeting. Achievement and pay-out will be determined on the date of resignation at the
2026 General Meeting and will occur shortly thereafter to facilitate his full transition into a Non-Executive Director
and chairperson of the Board of Directors. Since at the date of this 2025 Remuneration Report the performance period
is still running until May 6, 2026, disclosure will be included in the 2026 remuneration report, available in the 2027
annual report.
•Treatment of 2025 LTI: All unvested equity other than PSUs will immediately and fully vest at the time of the 2026
General Meeting. The PSUs granted in 2025 will remain subject to their normal three-year performance period and
will vest in 2027, based on performance and pro-rated for time served as CEO in the calendar years 2025 and 2026
93
Table of Contents
(up to and including the date of his resignation as CEO at the 2026 General Meeting). The achievement and pay-out
will be determined based on the information available to us on May 6, 2026 and the actual vesting and pay-out will
occur at the end of the three-year performance period in 2027. Disclosure will be included in the 2027 remuneration
report, available in the 2028 annual report.
•Treatment of 2026 LTI: Tim Van Hauwermeiren will not receive a new pro-rated LTI for 2026, including both stock
options and PSUs. He will therefore not receive any new LTI for the time he serves as CEO in 2026.
After approval by the 2026 General Meeting, Tim Van Hauwermeiren’s remuneration arrangements as Non-Executive
Chair will be in accordance with the 2025 Remuneration Policy.
Non-Executive Director and chairperson of the Board of Directors
After approval of his appointment as Non-Executive Director by shareholders at the 2026 General Meeting, Mr Van
Hauwermeiren’s remuneration arrangements as Non-Executive Director and chairperson of the Board of Directors will,
in accordance with the 2025 Remuneration Policy, be as follows:
•Cash retainer fees: $124,000, consisting of $53,333 for his Non-Executive Director membership of the Board of
Directors, $53,333 for the role of chairperson of the Board of Directors, $8,667 for his Research & Development
Committee membership and $8,667 for his Remuneration and Nomination Committee membership. These fees are
benchmarked at the 50th percentile of cash remuneration in the 2025 Peer Group.
•Annual equity grant: $400,000 in the form of RSUs, which amount is benchmarked at the 50th percentile of the 2025
Peer Group.
Non-Executive Director Remuneration
Total Non-Executive Director remuneration in the year ended December 31, 2025
Name
 
 
 
 
Cash retainer fees
earned or paid in cash
(in $)1)
 
 
 
 
RSU awards
(in $)
Total
(in $)
Peter Verhaeghe
 
142,000
394,903
536,903
Steve Krognes
 
95,941
394,903
490,844
Pamela Klein
77,500
394,903
472,403
Donald deBethizy2)
 
37,547
—
37,547
Anthony Rosenberg
 
82,500
394,903
477,403
James Daly
97,500
394,903
492,403
Camilla Sylvest
 
70,000
394,903
464,903
Ana Céspedes
 
80,941
394,903
475,844
Brian Kotzin
90,000
394,903
484,903
1)This total amount includes the travel allowance of USD 5,000 for in-person attendance of each board meeting held outside the respective Non-
Executive Director’s official continent of residence in accordance with clause 3.5.2 of the 2025 Remuneration Policy.
2)Donald deBethizy retired from the Board of Directors, the Remuneration and Nomination and Research and Development Committee on May 27,
2025.
•The breakdown of the Non-Executive Director cash-fee structure and RSU grants can be found in the tables on the
next page.
•The annual cash retainer fees were at the 50th percentile of cash remuneration in the peer group for 2025
remuneration. Additionally, the Non-Executive Director RSU target amount of $400,000 was at the 50th percentile of
the 2024 peer group for 2025 remuneration.
•There is a difference between the annual equity compensation target amount of $400,000 and the value at grant of
$394,903. On the Reference Date, the annual equity compensation target amount of $400,000 was divided by the
average closing price of the Company’s shares of the 30 calendar days preceding the Reference Date which amounted
to $569.17. The Company’s share price on the grant date of June 30, 2025 was $561.74.
94
Table of Contents
Non-Executive Director Shareholding
Non-Executive Directors are required to hold at least 5x annual Board of Director membership retainer fees ($60,000 in
2025) worth of Company stock for the duration of their role. As of December 31, 2025, all Non-Executive Directors
comply with this requirement.
Deviations
In the year ended December 31, 2025, the Company did not deviate from the decision-making process for Executive and
Non-Executive Director pay and no deviations took place from the 2021 Remuneration Policy or the 2025 Remuneration
Policy.
95
Table of Contents
Annual Cash (top) and Equity (Bottom) Compensation for Non-Executive Directors
In $
Relevant body
   
Position
   
Fees in $
Peter
Verhaeghe
Steve
Krognes
Pamela
Klein
Donald
deBethizy
Anthony
Rosenberg
James Daly
Camilla
Sylvest
Ana Céspedes
Brian Kotzin
Board of Directors
Chairperson
119,500
119,500
—
—
—
—
—
—
—
—
Member
60,000
—
60,000
60,000
24,355
60,000
60,000
60,000
60,000
60,000
Travel
Allowance
5,000
—
5,000
5,000
—
—
5,000
—
5,000
5,000
Audit and Compliance
Committee
Chairperson
25,000
—
25,000
—
—
—
—
—
—
—
Member
12,500
12,500
—
—
—
12,500
12,500
—
—
—
Remuneration and
Nomination Committee
Chairperson
20,000
—
—
—
8,118
—
—
—
11,882
—
Member
10,000
10,000
5,941
—
—
—
—
—
4,059
—
Commercial Committee
Chairperson
20,000
—
—
—
—
—
20,000
—
—
—
Member
10,000
—
—
—
—
10,000
—
10,000
—
—
Research and Development
Committee
Chairperson
20,000
—
—
—
—
—
—
—
—
25,000
Member
12,500
—
—
12,500
5,074
—
—
—
—
—
Total
142,000
95,941
77,500
37,547
82,500
97,500
70,000
80,941
90,000
RSUs granted in 20251)
Name
# RSUs
Key terms
Value at grant 2)
Total
Peter Verhaeghe
703
(1)
$
394,903
$
394,903
Ana Céspedes
703
(1)
394,903
394,903
James Daly
703
(1)
394,903
394,903
Pamela Klein
703
(1)
394,903
394,903
Brian Kotzin
703
(1)
394,903
394,903
Steve Krognes
703
(1)
394,903
394,903
Anthony Rosenberg
703
(1)
394,903
394,903
Camilla Sylvest
703
(1)
394,903
394,903
1)Donald deBethizy was not granted any RSUs in 2025 because he retired from the Board of Directors on May 27, 2025.
2)There is a difference between the annual equity compensation target amount of $400,000 and the value at grant of $394,903. On the Reference Date, the annual equity compensation target amount of
$400,000 was divided by the average closing price of the Company’s shares of 510.88 EUR/$569.17 in the 30 calendar days preceding the Reference Date. The Company’s share price on the grant date
of June 30, 2025 was $479.30/$561.74.
96
Table of Contents
Pay Ratio
The total expense for the non-equity remuneration paid to the CEO for the year ended December 31, 2025, totalled
$1,631,826. The table below shows the evolution over the past five years of CEO compensation, the performance of the
Company’s stock price and the median remuneration on a full-time equivalent basis (annualized for the employees who
joined or left us during the year) of employees, other than the CEO:
 
 
 
 
2021
 
2022
 
2023
 
2024
2025
Base pay of the CEO (EUR)
€
551,250
606,368
606,368
700,000
732,000
Base pay of the CEO (USD)
$
580,825
638,901
655,787
757,680
827,160
Non-equity remuneration of the CEO (USD) (base pay,
short-term cash incentive, pension contributions and
other compensation elements)
$
1,285,136
1,443,925
1,285,056
1,598,471
1,631,826
Total remuneration of the CEO (USD) (non-equity
remuneration, STI and LTI)
$
7,263,828
7,778,298
11,944,8351)
7,807,786
7,429,771
Non-equity median salary paid to employees (USD)
$
157,349
153,193
159,500
180,543
195,500
Non-equity remuneration ratio employee/CEO
12%
11%
12%
11%
12%
Average remuneration paid to Non-Executive Director
(USD)
$
54,484
48,587
59,230
81,204
85,992
Number of employees on December 31
650
843
1,148
1,599
1,863
Share price at end of year Euronext (EUR) on December
31
€
315.30
348.30
343.50
600.00
716.80
Share price at end of year Euronext (USD) on December
31
$
357.11
371.50
379.57
623.34
842.24
1)Based on the approved 2023 equity allocation scheme, the total equity target value for Tim Van Hauwermeirenis equal to $6,986,986. Please
refer to “Item 6.B. — Compensation — Equity — Determination of target value of CEO equity grant included in “Equity ” above for more
information on the variation in granted equity value between 2023 and 2024.
The comparison of non-equity compensation above is made between the compensation paid to the CEO, the Company’s
sole statutory Executive Director on the Board of Directors, and the median compensation paid to employees. The
Company has opted to compare non-equity salaries, because while the number of stock options granted is linked to the
overall size of remuneration packages granted, the value of equity components depends on the evolution of the
Company’s share price, volatility and the risk-free rate, which is unknown at the time of grant and as such the forward-
looking valuation methods for stock options normally do not provide an accurate representation of actual economic value
granted. In the assumptions used, the fair valuation differs between a Belgian beneficiary versus a non-Belgian
beneficiary. For a description of the assumptions used in valuing these awards, please refer to “Note 13 — Share-Based
Payments“ in the "Consolidated Financial Statements” which are included to our Annual Report for the period ended
December 31, 2025.
Regional pay ratios
Due to the global spread of employees over multiple continents, we have also included the above comparison to a
regional basis for U.S. employees, EU employees and Japanese employees. Due to the overall higher compensation level
in the business sector in the U.S. compared to the EU and Japan, there is a significant difference in the pay ratio when
the CEO’s compensation is compared to the median compensation of all employees, compared to employees in the U.S.
The following information is provided for reference purposes:
Ratio of non-equity compensation of the median employee compared to the CEO for the year ended December 31, 2025
All employees
12%
North American employees
16%
European employees
9%
Japanese employees
5%
Rest of the World employees
13%
Total employment costs (excluding any costs related stock options and RSUs) paid in the year ended December 31, 2025
was split between regions as follows:
97
Table of Contents
Total employment costs in the year ended December 31, 2025
(in millions of $)
North-America
272
Europe
247
Japan
16
Rest of the World
3
Share-based payment ratios
 
 
 
 
2021
2022
2023
2024
2025
Stock options granted to the CEO
 
25,000
25,000
30,000
18,279
15,027
RSUs granted to the CEO
5,700
5,700
6,700
6,762
0
PSUs granted to the CEO
N/A
N/A
N/A
N/A
5,085
Median stock options granted to employees
 
981
900
600
306
221
Median RSUs granted to employees
200
200
94
148
75
Ratio employee/CEO for stock options
 
4%
4%
2%
2%
1%
Ratio employee/CEO for RSUs1)
4%
4%
1%
2%
N/A
Ratio employee RSUs/CEO for PSUs1)
N/A
N/A
N/A
N/A
1%
Median number of stock options granted to Non-Executive
Directors2)
 
2,700
2,700
1,600
N/A
N/A
Median number of RSUs granted to Non-Executive
Directors
600
600
350
1,124
703
Median stock options granted to employees
 
981
900
600
306
120
Ratio Non-Executive Directors/employee stock options2)
 
36%
33%
38%
N/A
N/A
Ratio Non-Executive Directors/employee RSUs
33%
33%
27%
13%
11%
1)In 2025, PSUs were only granted to members of the Executive Management Team and therefore, the median employee has not received PSUs.
2)In 2024 and 2025, the Non-Executive Directors only received RSUs and no longer were granted stock options.
Other Disclosures
Remuneration by subsidiaries
In the year ended December 31, 2025, no remuneration was granted and allocated by subsidiaries or other companies
whose financials are consolidated, other than the regular remuneration payments made by the entities with whom
members of Senior Management Team have their employment contracts.
Severance arrangements
In the year ended December 31, 2025, no severance payments were granted to the Non-Executive Directors.
No loans or guarantees
In the year ended December 31, 2025, no loans or guarantees or the like were provided to the NEOs or the Non-
Executive Directors.
Key terms of equity plan applicable to grants in 2025
Stock options granted pursuant to the Equity Incentive Plan shall vest over a 36-month period, with 12/36ths of the total
grant vesting on the first anniversary of the grant date and the remaining 24/36ths vesting in equal monthly installments
of 1/36th each month thereafter. The number of Stock Options that vest on each vesting date is rounded to the nearest
whole number. Fractions below 0.5000 are rounded down, while fractions of 0.5000 or above are rounded up. If
rounding down, the difference is added to the next vesting date; if rounding up, the difference is deducted from the next
vesting date. Any remaining unvested equity is fully vested on the final day of the applicable vesting period—36 months
98
Table of Contents
for Stock Options, subject, in each case, to the plan participant’s continued employment or mandate. Stock options are
exercisable when vested, and in any case not after the stock option expiration date included in each individual stock
option grant, which is 10 years, or in the case of Belgian tax resident employees, at their election either 5 years or 10
years from the date of grant.
Each stock option shall be granted with an exercise price equal to the fair market value upon the date of grant and shall
have a term equal to five or 10 years from the date of grant. Plan participants may prefer to elect the five-year period as
this may limit their personal tax obligations in respect of the stock option in respect to the jurisdiction where stock
options are taxed at grant, compared to a ten-year stock option. Stock options granted to Belgian tax resident
beneficiaries (including the CEO) are not exercisable prior to the fourth year following the year of the grant. More
specifically, stock options granted to an Executive Director cliff vests on the third anniversary of the grant date. Non-
Executive Directors are not eligible to receive any stock option grants.
RSUs granted under the Equity Incentive Plan shall vest over a period of four years with respect to one fourth of the
shares upon each anniversary of the date of grant. At the time of vesting, the holder of such RSUs receives shares in the
share capital of the Company for free equal to the number of RSUs vested minus a certain number of shares required to
cover employee taxes payable by us on behalf of the holder of RSUs, if applicable. Since 2025, RSUs are no longer
granted to the NEOs.
Any RSUs granted to Non-Executive Directors in 2025 vested after one year instead of four years and are subject to a
three-year holding period. In accordance with our 2025 Remuneration Policy, any RSUs granted in 2026 and beyond to
Non-Executive Directors are not subject to any vesting conditions and the shares must be held until the fourth
anniversary of the grant date, except to the extent necessary to cover immediate tax obligations resulting from the
immediate vest.
Since 2025, PSUs are granted to NEOs under the Equity Incentive Plan. PSUs cliff vest at the end of their three-year
performance period. Pay-out levels depend upon the achievement of the Executive Director’s measures relative to the
threshold, target and maximum levels that were determined by the Board.
Unvested equity incentives shall vest in the event of a (i) sale, merger, consolidation, tender offer or similar acquisition
of shares or other transaction or series of related transactions as a result of which a change in control occurs, (ii) sale or
other disposition of all or substantially all of the Company’s assets or (iii) the Company’s dissolution and/or liquidation.
The Board of Directors, upon approval of a majority of the Non-Executive Directors, may amend or terminate the Equity
Incentive Plan or may amend the terms of the Equity Incentive Plan, or any outstanding stock options or RSUs, provided
that the Company will compensate any affected individual for any direct negative impact of such amendment.
99
Table of Contents
Summary of NEO Remuneration
(in $)
Base pay1)
Base pay in
% change
vs the
prior year1)
Sign on
bonus
Corporate
bonus2)
Variable
short-term
incentive
Variable cash
as % of target
opportunity
Compensation
in the form of
stock options3)
Compensation
in the form of
RSUs
Compensation
in the form of
PSUs
Pension
benefits4)
Fringe
benefits5)
Other
benefits6)
% fixed (of
total)7)
Total
CEO - Tim Van Hauwermeiren8) 11)
2025
827,160
5%
—
—
744,444
60%
2,941,497
—
2,856,448
44,168
16,054
—
12%
7,429,771
2024
757,680
15%
—
—
795,563
60%
3,194,813
3,014,500
—
29,118
16,112
—
10%
7,807,786
2023
655,787
—%
—
—
590,215
60%
8,084,605
2,575,174
—
22,821
16,233
—
6%
11,944,835
CFO - Karl Gubitz
2025
578,000
5%
—
4,690
346,800
40%
1,562,679
—
1,675,670
21,000
46,514
3,466
15%
4,238,819
2024
553,000
7%
—
3,636
331,800
40%
2,018,973
2,100,610
—
13,800
40,832
205,939
15%
5,268,590
2023
516,043
6%
—
3,556
260,866
40%
2,626,062
1,287,587
—
11,600
30,597
20,601
12%
4,756,913
COO - Karen Massey9) 12)
2025
741,641
4%
—
4,708
648,936
50%
1,792,860
—
1,922,836
181,337
184,738
843,989
31%
6,321,045
2024
655,657
37%
—
3,636
573,593
50%
2,018,973
2,100,610
—
165,394
57,348
619,272
24%
6,194,483
2023
481,471
N/A
338,000
2,921
467,662
50%
3,939,093
2,296,517
—
56,550
35,100
35,743
8%
7,653,057
COO - Keith Woods10)
2023
305,022
(48)%
—
—
—
—%
—
—
—
11,600
34,434
—
100%
351,056
1)The base pay of the CEO is paid in EUR and the base pay of the COO is paid in CHF. For 2025, the base pay exchange rate used in this table is 1.13 EUR/USD and 1.21 CHF/USD.
2)All employees are eligible to annually earn a performance based corporate bonus with a maximum value of €3,622 ($4,690) per year, based on three equally weighted Company-wide goals. In 2025, the
targets focused on (i) our commitment to cybersecurity, (ii) building argenx together, and (iii) simplification and digitalization. A maximum pay-out was made to all employees in 2025. The CEO does
not receive the corporate bonus. 
3)Amounts shown represent the expenses with respect to stock options measured using the Black-Scholes model. For a description of the assumptions used in valuing these awards, see “Note 13 — Share-
Based Payments” to our Consolidated Financial Statements which are included to our Annual Report for the period December 31, 2025..
4)Pension benefits include employer pension contributions.
5)Fringe benefits include company car costs, employer-paid medical insurance premiums, lunch allowances and representation allowances. pension contributions, social security costs and other
allowances.
6)Other benefits consists of social security costs, other allowances and benefits. Employer social security costs were impacted by the increase of share-price at year end against the share-price as of
December 31, 2025.
7)Fixed compensation is considered as base pay, pension benefits, fringe benefits and other benefits.
8)Based on the approved 2025 equity allocation scheme, the total equity target value for Tim Van Hauwermeiren is equal to $5,790,000. The CEO received its equity grants at target value converted into a
number of stock options and PSUs on the Reference Date of the 30-days average share price of $569.17 per share preceding the Reference Date and the Black-Scholes model fair market value of
$192.65 per stock option. This results in the number of stock options and PSUs shown above. The amounts shown above represent the actual value received at the grant date of June 30, 2025 at which
date the Company’s share price was equal to $561.74. The difference in the price per share is explained by the stock price movement in the intervening period. For more information on the CEO equity
grant, please refer to “Item 6. B. — Compensation — Equity — Determination of target value of CEO equity grant” included in “Equity“ above. The fair market value based on the Black-Scholes model
for Tim Van Hauwermeiren is $195.75. These amounts do not reflect the actual economic value realized by the beneficiary. Amounts shown represent the expenses with respect to the stock options
awards granted in 2025 measured using the Black-Scholes model with unobservable assumptions. The assumptions used in the fair valuation differ between Belgian beneficiary versus non-Belgian
beneficiary. For a description of the assumptions used in valuing these awards, see “Note 13 — Share-Based Payments“ to our Consolidated Financial Statements which are included to our Annual
Report for the period ended December 31, 2025.
9)Karen Massey joined as COO in March 2023, and consequently no comparison to 2022 is available. Ms. Massey’s remuneration shows the remuneration paid for the period March 13, 2023 through
December 31, 2023. Her 2023 variable pay pay-out has been pro-rated to reflect this as well. The increase year over year for 2024 is not representative as it is comparing to a partial work year. In 2023,
the Company paid a sign-on bonus to Karen Massey to allow the Company to make an overall competitive offer of employment and in recognition of lost corporate benefits as a result of early departure
at Ms. Massey’s previous employer. Ensuring a competitive offer in this way and securing Ms. Massey as the Company’s new COO was deemed by the Board of Directors to be in the best interest of the
Company and its stakeholders.
10)Keith Woods resigned as COO March 2023 and his employment relationship ended on June 30, 2023 and consequently the remuneration numbers show his remuneration for the period January 1, 2023
through June 30, 2023. No equity award or variable pay was paid to Mr. Woods in the year ended December 31, 2023.
11)Tim Van Hauwermeiren will transition from his current CEO role to the position of Non-Executive chairperson of the Board of Directors, subject to shareholder approval at the 2026 General Meeting.
12)It is envisaged that Karen Massey, our current COO, will be appointed as an Executive Director at the 2026 General Meeting and subsequently elected as CEO by the Board of Directors.
100
Table of Contents
Stock option overview
The table below shows (i) the stock options held as of January 1, 2025, (ii) the stock options granted to the NEOs which vested during the year ended December 31,
2025, (iii) the number of stock options scheduled to vest in the years ending December 31, 2026, December 31, 2027 and December 31, 2028 and (iv) the respective
exercise price of such stock options. Each stock option was granted pursuant to the Equity Incentive Plan.
For the CEO, under the 2021 Remuneration Policy, 1/3rd of the stock options vests on the first anniversary of the date of grant and the remaining 2/3rd vest in
monthly installments (24 in total) over the next two years, each time upon the 1st day of each next month. For the CEO, under the new 2025 Remuneration Policy all
stock options granted as of 2026 will vest on the third anniversary of the date of grant.
Information regarding the reported financial year
Opening
Balance
During the Year
Closing balance
Name of Directors,
Position
Specification
plan
Performance
Period
Award
Date
Vesting
date
End of
retention
period
Exercise
Period
Exercise
price of
stock
option (€)
Stock
options
held at the
beginning
of the
period
Stock
options
awarded
Stock
options
exercised
Stock
options
forfeited
Stock
options
vested
Stock
options
subjected
to a service
period
Stock
options
awarded
and
unvested
Stock
options
held at the
end of the
year
Stock
options
subjected
to a
retention
period
Tim Van
Hauwermeiren, CEO
Equity
incentive
plan
21/12/2018 -
01/12/2021
21/12/2018
(1)
31/12/2021
01/01/2022 -
21/12/2028
86.32
80,000
—
—
—
—
—
—
80,000
—
20/12/2019 -
01/12/2022
20/12/2019
(1)
31/12/2022
01/01/2023 -
20/12/2029
135.75
80,000
—
—
—
—
—
—
80,000
—
21/12/2020 -
01/12/2023
21/12/2020
(1)
31/12/2023
01/01/2024 -
21/12/2030
247.60
50,000
—
—
—
—
—
—
50,000
—
24/12/2021 -
01/12/2024
24/12/2021
(1)
31/12/2024
01/01/2025 -
24/12/2031
309.20
25,000
—
—
—
—
—
—
25,000
—
23/12/2022 -
01/12/2025
23/12/2022
(1)
31/12/2025
01/01/2026 -
23/12/2032
359.60
25,000
—
—
—
8,333
—
—
25,000
—
03/07/2023 -
01/07/2026
03/07/2023
(1)
31/12/2026
01/01/2027 -
03/07/2033
355.40
30,000
—
—
—
10,000
5,833
5,833
30,000
30,000
28/06/2024 -
01/06/2027
28/06/2024
(1)
31/12/2027
01/01/2028 -
28/06/2034
416.40
18,279
—
—
—
9,139
9,140
9,140
18,279
18,279
30/06/2025 -
01/06/2028
30/06/2025
(1)
31/12/2028
01/01/2029 -
30/06/2035
479.30
—
15,027
—
—
—
15,027
15,027
15,027
15,027
Total
308,279
15,027
—
—
27,472
30,000
30,000
323,306
63,306
Karl Gubitz, CFO
Equity
incentive
plan
01/07/2021 -
01/07/2024
01/07/2021
(1)
N/A
01/07/2022 -
01/07/2031
255.10
24,000
—
24,000
—
—
—
—
—
—
01/07/2022 -
01/07/2025
01/07/2022
(1)
N/A
01/07/2023 -
01/07/2032
357.50
16,000
—
—
—
3,111
—
—
16,000
—
03/07/2023 -
01/07/2026
03/07/2023
(1)
N/A
03/07/2024 -
03/07/2033
355.40
15,000
—
—
—
5,000
2,917
2,917
15,000
—
28/06/2024 -
01/06/2027
28/06/2024
(1)
N/A
28/06/2025 -
28/06/2034
416.40
12,738
—
—
—
6,369
6,369
6,369
12,738
—
30/06/2025 -
01/06/2028
30/06/2025
(1)
N/A
01/01/2029 -
30/06/2035
479.30
—
8,812
—
—
—
8,812
8,812
8,812
—
Total
67,738
8,812
24,000
—
14,480
18,098
18,098
52,550
—
Karen Massey, COO
Equity
incentive
plan
03/07/2023 -
01/07/2026
03/07/2023
(1)
N/A
03/07/2024 -
03/07/2033
355.40
22,500
—
12,000
—
7,500
4,375
4,375
10,500
—
28/06/2024 -
01/06/2027
28/06/2024
(1)
N/A
28/06/2025 -
28/06/2034
416.40
12,738
—
—
—
6,369
6,369
6,369
12,738
—
30/06/2025 -
01/06/2028
30/06/2025
(1)
N/A
01/01/2029 -
30/06/2035
479.30
—
10,110
—
—
—
10,110
10,110
10,110
—
Total
35,238
10,110
12,000
—
13,869
20,854
20,854
33,348
3
3
,
3
4
8
—
1)1/3rd of the stock options vests on the first anniversary of the date of grant and the remaining 2/3rd vest in equal installments (24 in total) over the next two years, each time upon the 1st day of each next
month.
101
Table of Contents
PSU overview
The table below shows (i) the PSUs held as of January 1, 2025, (ii) the PSUs granted to the NEOs which vested during the year ended December 31, 2025 and (iii)
the number of PSUs scheduled to vest in the years ending December 31, 2026, December 31, 2027 and December 31, 2028. Each PSU was granted pursuant to the
Equity Incentive Plan:
Information regarding the reported financial year
The main conditions of PSU plan
Opening
balance
During the Year
Closing balance
Name of Directors,
Position
Vesting period
Award
Date
Vesting
date
End of
retention
period
PSUs held
at the
beginning
of the year
PSUs
awarded
PSU
Forfeited
PSUs
vested
PSUs
subject to
a service
condition
PSUs
awarded
and
unvested
PSUs
held at
the
closing of
the year
PSUs
subject to
a
retention
period
Tim van Hauwermeiren,
CEO
01/01/2025 - 31/12/2027
30/06/2025
31/12/2027
N/A
–
5,085
–
–
–
5,085
5,085
–
Total
–
5,085
–
–
–
5,085
5,085
–
Karl Gubitz, CFO
01/01/2025 - 31/12/2027
30/06/2025
31/12/2027
N/A
–
2,983
–
–
–
2,983
2,983
–
Total
–
2,983
–
–
–
2,983
2,983
–
Karen Massey, COO
01/01/2025 - 31/12/2027
30/06/2025
31/12/2027
N/A
–
3,423
–
–
–
3,423
3,423
–
Total
–
3,423
–
–
–
3,423
3,423
–
102
Table of Contents
RSU overview
The table below shows (i) the RSUs held as of January 1, 2025, (ii) the RSUs granted to the NEOs which vested during the year ended December 31, 2025 and (iii)
the number of RSUs scheduled to vest in the years ending December 31, 2026, December 31, 2027, December 31, 2028 and December 31, 2029. As of 2025, RSUs
were no longer granted to the NEOs and replaced by PSUs. Each RSU was granted pursuant to the Equity Incentive Plan:
Information regarding the reported financial year
The main conditions of RSU plan
Opening
balance
During the Year
Closing balance
Name of Directors,
Position
Vesting period
Award
Date
Vesting
date
End of
retention
period
RSUs
held at
the
beginning
of the
year
RSUs
awarded
RSU
Forfeited
RSUs
vested
RSUs
subject
to a
service
condition
RSUs
awarded
and
unvested
RSUs
held at
the
closing
of the
year
RSUs
subject
to a
retention
period
Tim van Hauwermeiren,
CEO
24/12/2021 - 24/12/2025
24/12/2021
(1)
N/A
1,425
—
—
1,425
—
—
—
—
23/12/2022 - 23/12/2026
23/12/2022
(1)
N/A
2,850
—
—
1,425
—
1,425
1,425
—
03/07/2023 - 03/07/2027
07/03/2023
(1)
N/A
5,025
—
—
1,675
—
3,350
3,350
—
28/06/2024 - 28/06/2028
28/06/2024
(1)
N/A
6,762
—
—
1,690
—
5,072
5,072
—
Total
16,062
—
—
6,215
—
9,847
9,847
—
Karl Gubitz, CFO
01/07/2021 - 01/07/2025
01/07/2021
(1)
N/A
1,350
—
—
1,350
—
—
—
—
01/07/2022 - 01/07/2026
01/07/2022
(1)
N/A
1,800
—
—
900
—
900
900
—
03/07/2023 - 03/07/2027
03/07/2023
(1)
N/A
2,513
—
—
838
—
1,675
1,675
—
28/06/2024 - 28/06/2028
28/06/2024
(1)
N/A
4,712
—
—
1,178
—
3,534
3,534
—
Total
10,375
—
—
4,266
—
6,109
6,109
—
Karen Massey, COO
03/07/2023 - 03/07/2027
07/03/2023
(1)
N/A
3,769
—
—
1,256
—
2,513
2,513
—
28/06/2024 - 28/06/2028
28/06/2024
(1)
N/A
4,712
—
—
1,178
—
3,534
3,534
—
Total
8,481
—
—
2,434
—
6,047
6,047
—
1) RSUs vest over a period of four years with 1/4th of the total grant vesting at each anniversary of the date of grant.
103
Table of Contents
Remuneration of Other Members of the Senior Management Team
For the purposes of U.S. governance reporting requirements, all senior level employees reporting directly to the CEO
qualify as the Company’s ‘executives’. The remuneration disclosures in relation to this more extensive group of senior
personnel (excluding the NEOs) in this 2025 Remuneration Report is presented on an aggregated basis, with the
exception of equity remuneration, which is presented on an individual basis.
Aggregate compensation for other members of the Senior Management Team
The following table sets forth information regarding aggregate compensation paid to members of the Senior
Management Team (other than the NEOs) during the year ended December 31, 2025.
(in $)
Compensation
Base pay
3,138,512
Variable STI1)
1,526,247
Compensation in the form of stock options
 
10,521,797
Compensation in the form of PSUs
7,443,617
Pension benefits2)
80,045
Fringe benefits3)
107,679
Other benefits4)
 
3,187,985
Total
 
26,005,882
1)Variable STI includes a performance based Company wide corporate bonus of €3,622 ($4,690) per member of the Senior Management Team.
2)Pension benefits include employer pension contributions.
3)Fringe benefits include company car costs, employer-paid medical insurance premiums, lunch allowances and representation allowances. pension
contributions, social security costs and other allowances.
4)Other benefits consists of social security costs, other allowances and benefits. Employer social security costs were impacted by the increase of
share-price at year end against the share-price as of December 31, 2025.
For more information on equity granted to members of the Senior Management Team (other than the NEOs), during
2025, please refer to “Item 6.B. — Compensation — Summary of Other members of the Senior Management Team”
below.
104
Table of Contents
Summary of other members of the Senior Management Team
Stock options overview other members of the Senior Management Team
The following table sets forth information regarding stock option and PSU awards granted to members of the Senior Management Team during the year ended
December 31, 2025:
PSUs granted in 2025
Stock options granted in 2025
Name
# PSUs
Key terms
# Stock
options
Exercise
price in €
Exercise
price in $
Key terms
Arjen Lemmen
3,423
PSUs are subject to a cliff vest
and settlement at the end of a
performance period of 3-years.
10,110
479.30
561.74
1/3 vests after year 1 2/3 vest in
monthly installments in year 2
and 3.
Malini Moorthy
2,983
8,812
479.30
561.74
Luc Truyen
2,983
8,812
479.30
561.74
Peter Ulrichts
2,983
8,812
479.30
561.74
Andria Wilk
 
879
2,596
479.30
561.74
The table below shows (i) the stock options held as of January 1, 2025, (ii) the stock options granted to members of Senior Management Team (other than the NEOs)
which vested during the year ended December 31, 2025, (iii) the number of stock options scheduled to vest in the years ending December 31, 2026, December 31,
2027 and December 31, 2028 and (iv) the respective exercise price of such stock options. Each stock option was granted pursuant to the Equity Incentive Plan:
105
Table of Contents
Information regarding the reported financial year
Opening
balance
During the Year
Closing
balance
Name of Directors,
Position
Specification
plan
Performance period
Award date
Vesting
date
Exercise period
Exercise
price of
stock
option in €
Stock options
held at the
begin­ning of
the year
Stock
options
awarded
Stock
options
exercised
Stock
options
forfeited
Stock
options
vested
Stock
options held
at the end of
the year
Arjen Lemmen, Vice
President of Corporate
Development & Strategy
Equity
incentive plan
21/12/2020 - 01/12/2023
21/12/2020
(1)
01/01/2024 - 21/12/2030
247.60
47,674
—
32,674
—
—
15,000
24/12/2021 - 01/12/2024
24/12/2021
(1)
01/01/2025 - 24/12/2031
309.20
16,000
—
—
—
—
16,000
23/12/2022 - 01/12/2025
23/12/2022
(1)
23/12/2023 - 23/12/2032
359.60
16,000
—
—
—
5,333
16,000
03/07/2023 - 01/07/2026
03/07/2023
(1)
03/07/2024 - 03/07/2033
355.40
15,000
—
—
—
5,000
15,000
28/06/2024 - 01/06/2027
28/06/2024
(1)
01/01/2028 - 28/06/2034
416.40
12,738
—
—
—
6,369
12,738
30/06/2025 - 01/06/2028
30/06/2025
(1)
01/01/2029 - 30/06/2035
479.30
—
10,110
—
—
—
10,110
Total
107,412
10,110
32,674
—
16,702
84,848
Malini Moorthy, Legal
Counsel
Equity
incentive plan
01/04/2022 - 01/04/2025
01/04/2022
(1)
01/04/2023 - 01/04/2032
282.50
6,500
—
6,500
—
2,667
—
03/07/2023 - 01/07/2026
03/07/2023
(1)
03/07/2024 - 03/07/2033
355.40
15,000
—
5,000
—
5,000
10,000
28/06/2024 - 01/06/2027
28/06/2024
(1)
01/01/2028 - 28/06/2034
416.40
12,738
—
—
—
6,369
12,738
30/06/2025 - 01/06/2028
30/06/2025
(1)
01/01/2029 - 30/06/2035
479.30
—
8,812
—
—
—
8,812
Total
34,238
8,812
11,500
—
14,036
31,550
Luc Truyen, CMO
Equity
incentive plan
01/10/2021 - 01/10/2024
01/10/2021
(1)
01/01/2025 - 01/10/2026
259.5
24,000
—
24,000
—
—
—
23/12/2022 - 01/12/2025
23/12/2022
(1)
01/01/2026 - 23/12/2027
359.6
16,000
—
—
—
5,333
16,000
03/07/2023 - 01/07/2026
03/07/2023
(1)
01/01/2027 - 03/07/2028
355.4
15,000
—
—
—
5,000
15,000
28/06/2024 - 01/06/2027
28/06/2024
(1)
01/01/2028 - 28/06/2034
416.40
12,738
—
—
—
6,369
12,738
30/06/2025 - 01/06/2028
30/06/2025
(1)
01/01/2029 - 30/06/2035
479.30
—
8,812
—
—
—
8,812
Total
67,738
8,812
24,000
—
16,702
52,550
Peter Ulrichts, CSO
Equity
incentive plan
20/12/2019 - 01/12/2022
20/12/2019
(1)
01/01/2023 - 20/12/2029
135.75
4,000
—
4,000
—
—
—
21/12/2020 - 01/12/2023
21/12/2020
(1)
01/01/2024 - 21/12/2030
247.60
7,651
—
7,651
—
—
—
24/12/2021 - 01/12/2024
24/12/2021
(1)
01/01/2025 - 24/12/2026
309.20
3,420
—
3,420
—
—
—
23/12/2022 - 01/12/2025
23/12/2022
(1)
01/01/2026 - 23/12/2027
359.60
16,000
—
—
—
3,811
16,000
03/07/2023 - 01/07/2026
03/07/2023
(1)
01/01/2027 - 03/07/2028
355.40
15,000
—
—
—
5,000
15,000
28/06/2024 - 01/06/2027
28/06/2024
(1)
01/01/2028 - 28/06/2034
416.40
12,738
—
—
—
4,978
12,738
30/06/2025 - 01/06/2028
30/06/2025
(1)
01/01/2029 - 30/06/2035
479.30
—
8,812
—
—
1,039
8,812
Total
58,809
8,812
15,071
—
14,828
52,550
Andria Wilk, Global Head
of Quality
Equity
incentive plan
21/12/2020 - 01/12/2023
21/12/2020
(1)
01/01/2024 - 21/12/2025
247.60
87
—
87
—
—
—
24/12/2021 - 01/12/2024
24/12/2021
(1)
01/01/2025 - 24/12/2031
309.20
4,446
—
1,167
—
—
3,279
23/12/2022 - 01/12/2025
23/12/2022
(1)
01/01/2026 - 23/12/2027
359.60
4,600
—
—
—
1,126
4,600
03/07/2023 - 01/07/2026
03/07/2023
(1)
01/01/2027 - 03/07/2033
355.40
4,600
—
—
—
1,276
4,600
28/06/2024 - 01/06/2027
28/06/2024
(1)
01/01/2028 - 28/06/2034
416.40
3,599
—
—
—
1,406
3,599
30/06/2025 - 01/06/2028
30/06/2025
(1)
01/01/2029 - 30/06/2035
479.30
—
2,596
—
—
306
2,596
Total
17,332
2,596
1,254
—
4,114
18,674
1)1/3rd of the stock options vests on the first anniversary of the date of grant and the remaining 2/3rd vest in equal installments (24 in total) over the next two years, each time upon the 1st day of each next
month.
106
Table of Contents
PSU overview other members of the Senior Management Team
The table below shows (i) the PSUs held as of January 1, 2025, (ii) the PSUs granted to members of Senior Management Team (other than the NEOs) which vested
during the year ended December 31, 2025 and (iii) the number of PSUs scheduled to vest in the years ending December 31, 2026, December 31, 2027 and December
31, 2028. Each PSU was granted pursuant to the Equity Incentive Plan:
Information regarding the reported financial year
Main conditions of the PSU plan
Opening
balance
During the Year
Closing balance
Name of Directors, Position
Performance period
Award date
Vesting date
PSU’s held at
the beginning
of the year
PSUs
awarded
PSUs
forfeited
PSUs
vested
PSUs held at
the closing of
the year
Arjen Lemmen, Vice President of Corporate
Development & Strategy
01/01/2025 - 31/12/2027
30/06/2025
31/12/2027
—
3,423
—
—
3,423
Total
—
3,423
—
—
3,423
Malini Moorthy, General Counsel and Corporate
Secretary
01/01/2025 - 31/12/2027
30/6/2025
31/12/2027
—
2,983
—
—
2,983
Total
—
2,983
—
—
2,983
Luc Truyen, CMO
01/01/2025 - 31/12/2027
30/6/2025
31/12/2027
—
2,983
—
—
2,983
Total
—
2,983
—
—
2,983
Peter Ulrichts, CSO
01/01/2025 - 31/12/2027
30/6/2025
31/12/2027
—
2,983
—
—
2,983
Total
—
2,983
—
—
2,983
Andria Wilk, Global Head of Quality
01/01/2025 - 31/12/2027
30/6/2025
31/12/2027
—
879
—
—
879
Total
—
879
—
—
879
RSU overview other members of the Senior Management Team
The table below shows (i) the RSUs held as of January 1, 2025, (ii) the RSUs granted to members of Senior Management Team (other than the NEOs) which vested
during the year ended December 31, 2025 and (iii) the number of RSUs scheduled to vest in the years ending December 31, 2026, December 31, 2027, December 31,
2028 and December 31, 2029. As of 2025, RSUs were no longer granted to the other members of the Senior Management Team and replaced by PSUs. Each RSU
was granted pursuant to the Equity Incentive Plan:
107
Table of Contents
Information regarding the reported financial year
The main conditions of the RSU plan
Opening
balance
During the Year
Closing balance
Name of Directors, Position
Vesting period
Award date
Vesting date
RSU’s held at
the beginning
of the year
RSUs
awarded
RSUs
forfeited
RSUs
vested
RSUs held at
the closing of
the year
Arjen Lemmen, Vice President of Corporate
Development & Strategy
24/12/2021 - 24/12/2025
24/12/2021
(1)
900
—
—
900
—
23/12/2022 - 23/12/2026
23/12/2022
(1)
1,800
—
—
900
900
03/07/2023 - 03/07/2027
03/07/2023
(1)
2,513
—
—
838
1,675
28/06/2024 - 27/06/2028
28/06/2024
(1)
4,712
—
—
1,178
3,534
Total
9,925
—
—
3,816
6,109
Malini Moorthy, General Counsel and Corporate
Secretary
01/04/2022 - 01/04/2026
01/04/2022
(1)
2,700
—
—
1,350
1,350
03/07/2023 - 03/07/2027
03/07/2023
(1)
2,513
—
—
838
1,675
28/06/2024 - 27/06/2028
28/06/2024
(1)
4,712
—
—
1,178
3,534
Total
9,925
—
—
3,366
6,559
Luc Truyen, CMO
01/10/2021 - 01/10/2025
01/10/2021
(1)
1,350
—
—
1,350
—
23/12/2022 - 23/12/2026
23/12/2022
(1)
1,800
—
—
900
900
03/07/2023 - 03/07/2027
03/07/2023
(1)
2,513
—
—
838
1,675
28/06/2024 - 27/06/2028
28/06/2024
(1)
4,712
—
—
1,178
3,534
Total
10,375
—
—
4,266
6,109
Peter Ulrichts, CSO
24/12/2021 - 24/12/2025
24/12/2021
(1)
190
—
—
190
—
23/12/2022 - 23/12/2026
23/12/2022
(1)
1,800
—
—
900
900
03/07/2023 - 03/07/2027
03/07/2023
(1)
2,513
—
—
838
1,675
28/06/2024 - 27/06/2028
28/06/2024
(1)
4,712
—
—
1,178
3,534
Total
9,215
—
—
3,106
6,109
Andria Wilk, Global Head of Quality
24/12/2021 - 24/12/2025
24/12/2021
(1)
247
—
—
247
—
23/12/2022 - 23/12/2026
23/12/2022
(1)
500
—
—
250
250
03/07/2023 - 03/07/2027
03/07/2023
(1)
750
—
—
250
500
28/06/2024 - 27/06/2028
28/06/2024
(1)
1,331
—
—
333
998
Total
2,828
—
—
1,080
1,748
1)RSUs vest over a period of four years with 1/4th of the total grant vesting at each anniversary of the date of grant.
108
Table of Contents
Summary of Non-Executive Director Equity compensation
RSU overview Non-Executive Directors
Information regarding the reported financial year
The main conditions of RSU plan
Opening
balance
During the Year
Closing balance
Name of member of Board of
Directors
Vesting period
Award
date
Vesting
date
End of
holding
period
RSUs held at
the beginning
of the year
RSUs
awarded
RSUs
vested
RSUs subject
to a service
condition
RSUs
awarded and
unvested
RSUs held at
the closing of
the year
Ana Céspedes
23/12/2022 - 23/12/2026
23/12/2022
(1)
N/A
450
—
225
—
225
225
03/07/2023 - 03/07/2027
03/07/2023
(1)
N/A
131
—
43
—
88
88
28/06/2024 - 28/06/2025
28/06/2024
(1)
28/06/2028
1,065
—
1,065
—
—
1,065
30/06/2025 - 30/06/2026
30/06/2025
(1)
30/06/2029
—
703
—
—
703
703
Total
1,646
703
1,333
—
1,016
2,081
James Daly
24/12/2021 - 24/12/2025
24/12/2021
(1)
N/A
150
—
150
—
—
—
23/12/2022 - 23/12/2026
23/12/2022
(1)
N/A
300
—
150
—
150
150
03/07/2023 - 03/07/2027
03/07/2023
(1)
N/A
263
—
88
—
175
175
28/06/2024 - 28/06/2025
28/06/2024
(1)
28/06/2028
1,065
—
1,065
—
—
1,065
30/06/2025 - 30/06/2026
30/06/2025
(1)
30/06/2029
—
703
—
—
703
703
Total
1,778
703
1,453
—
1,028
2,093
Donald deBethizy2)
24/12/2021 - 24/12/2025
24/12/2021
(1)
N/A
150
—
150
—
—
—
23/12/2022 - 23/12/2026
23/12/2022
(1)
N/A
300
—
150
—
150
150
03/07/2023 - 03/07/2027
03/07/2023
(1)
N/A
263
—
263
—
—
—
28/06/2024 - 28/06/2025
28/06/2024
(1)
28/06/2028
1,065
—
1,065
—
—
1,065
Total
1,778
—
1,628
—
150
1,215
Pamela Klein
24/12/2021 - 24/12/2025
24/12/2021
(1)
N/A
300
—
150
—
150
150
23/12/2022 - 23/12/2026
23/12/2022
(1)
N/A
450
—
150
—
300
300
03/07/2023 - 03/07/2027
03/07/2023
(1)
N/A
350
—
87
—
263
263
28/06/2024 - 28/06/2025
28/06/2024
(1)
28/06/2028
1,065
—
1,065
—
—
1,065
30/06/2025 - 30/06/2026
30/06/2025
(1)
30/06/2029
—
703
—
—
703
703
Total
2,165
703
1,452
—
1,416
2,481
Brian Kotzin
28/06/2024 - 28/06/2028
28/06/2024
(1)
28/06/2028
1,598
—
1,598
—
—
1,598
30/06/2025 - 30/06/2026
30/06/2025
(1)
30/06/2029
—
703
—
—
703
703
Total
1,598
703
1,598
—
703
2,301
109
Table of Contents
Information regarding the reported financial year
The main conditions of RSU plan
Opening
balance
During the Year
Closing balance
Steve Krognes
03/04/2023 - 03/04/2027
03/04/2023
(1)
N/A
394
—
132
—
262
262
28/06/2024 - 28/06/2025
28/06/2024
(1)
28/06/2028
1,065
—
1,065
—
—
1,065
30/06/2025 - 30/06/2026
30/06/2025
(1)
30/06/2029
—
703
—
—
703
703
Total
1,459
703
1,197
—
965
2,030
Anthony Rosenberg
24/12/2021 - 24/12/2025
24/12/2021
(1)
N/A
150
—
150
—
—
—
23/12/2022 - 23/12/2026
23/12/2022
(1)
N/A
300
—
150
—
150
150
03/07/2023 - 03/07/2027
03/07/2023
(1)
N/A
263
—
88
—
175
175
28/06/2024 - 28/06/2025
28/06/2024
(1)
28/06/2028
1,065
—
1,065
—
—
1,065
30/06/2025 - 30/06/2026
30/06/2025
(1)
30/06/2029
—
703
—
—
703
703
Total
1,778
703
1,453
—
1,028
2,093
Camilla Sylvest
03/10/2022 - 03/10/2026
03/10/2022
(1)
N/A
450
—
225
—
225
225
03/07/2023 - 03/07/2027
03/07/2023
(1)
N/A
197
—
65
—
132
132
28/06/2024 - 28/06/2025
28/06/2024
(1)
28/06/2028
1,065
—
1,065
—
—
1,065
30/06/2025 - 30/06/2026
30/06/2025
(1)
30/06/2029
—
703
—
—
703
703
Total
1,712
703
1,355
—
1,060
2,125
Peter Verhaeghe
24/12/2021 - 24/12/2025
24/12/2021
(1)
N/A
150
—
150
—
—
—
23/12/2022 - 23/12/2026
23/12/2022
(1)
N/A
300
—
150
—
150
150
03/07/2023 - 03/07/2027
03/07/2023
(1)
N/A
263
—
88
—
175
175
28/06/2024 - 28/06/2025
28/06/2024
(1)
28/06/2028
1,065
—
1,065
—
—
1,065
30/06/2025 - 30/06/2026
30/06/2025
(1)
30/06/2029
—
703
—
—
703
703
Total
1,778
703
1,453
—
1,028
2,093
1)RSUs granted before 2024 vest over a period of four years with 1/4th of the total grant vesting at each anniversary of the date of grant. RSUs granted to Non-Executive Directors in 2024 will all vest on
the 1st anniversary of the grant date in 2025 and are subject to a holding period of 3 years.
2)Donald deBethizy retired from the Board of Directors and the Research and Development Committee on May 27, 2025.
110
Table of Contents
Stock Option overview Non-Executive Director
Information regarding the reported financial year
Opening
balance
During the Year
Closing balance
Name of Directors
Performance
period
Award
date
Vesting
date
End of
retention
period
Exercise
period
Exercise
price of
stock
option (€)
Stock
options
held at the
beginning
of the year
Stock
options
awarded
Stock
options
exercised
Stock
options
vested
Stock
options
subject to
a service
condition
Stock
options
awarded
and
unvested
Stock
options
held at
the end of
the year
Stock
options
subject to a
retention
period
Ana Céspedes
23/12/2022 -
23/12/2025
23/12/2022
(2)
31/12/2025
23/12/2023 -
23/12/2032
359.60
4,050
—
—
4,050
—
—
4,050
—
03/07/2023 -
03/07/2026
03/07/2023
(2)
31/12/2026
03/07/2024 -
03/07/2033
355.40
800
—
—
—
—
800
800
800
Total
4,850
—
—
4,050
—
800
4,850
800
James Daly
21/12/2020 -
21/12/2023
21/12/2020
(1)
N/A
21/12/2021 -
21/12/2030
247.60
10,000
—
10,000
—
—
—
—
—
24/12/2021 -
24/12/2024
24/12/2021
(2)
31/12/2024
24/12/2022 -
24/12/2031
309.20
2,700
—
2,700
—
—
—
—
—
23/12/2022 -
23/12/2025
23/12/2022
(2)
31/12/2025
23/12/2023 -
23/12/2032
359.60
2,700
—
2,700
—
—
—
2,700
—
03/07/2023 -
03/07/2026
03/07/2023
(2)
31/12/2026
03/07/2024 -
03/07/2033
355.40
1,600
—
—
—
—
1,600
1,600
1,600
Total
17,000
—
15,400
—
—
1,600
4,300
1,600
Donald deBethizy 3)
18/06/2016 -
18/06/2019
18/06/2016
(1)
N/A
18/06/2017 -
18/06/2026
11.38
10,000
—
—
—
—
—
10,000
—
21/12/2018 -
21/12/2021
21/12/2018
(1)
N/A
21/12/2019 -
21/12/2028
86.32
10,000
—
—
—
—
—
10,000
—
20/12/2019 -
20/12/2022
20/12/2019
(1)
N/A
20/12/2020 -
20/12/2029
135.75
10,000
—
—
—
—
—
10,000
—
21/12/2020 -
21/12/2023
21/12/2020
(1)
N/A
21/12/2021 -
21/12/2030
247.60
10,000
—
—
—
—
—
10,000
—
24/12/2021 -
24/12/2024
24/12/2021
(2)
31/12/2024
24/12/2022 -
24/12/2031
309.20
2,700
—
2,700
—
—
—
—
—
23/12/2022 -
23/12/2025
23/12/2022
(2)
31/12/2025
23/12/2023 -
23/12/2032
359.60
2,700
—
—
2,700
—
—
2,700
—
03/07/2023 -
03/07/2026
03/07/2023
(2)
31/12/2026
03/07/2024 -
03/07/2033
355.40
1,600
—
—
1,600
—
—
1,600
1,600
Total
47,000
—
2,700
4,300
—
—
44,300
1,600
111
Table of Contents
Information regarding the reported financial year
Opening
balance
During the Year
Closing balance
Name of Directors
Performance
period
Award
date
Vesting
date
End of
retention
period
Exercise
period
Exercise
price of
stock
option (€)
Stock
options
held at the
beginning
of the year
Stock
options
awarded
Stock
options
exercised
Stock
options
vested
Stock
options
subject to
a service
condition
Stock
options
awarded
and
unvested
Stock
options
held at
the end of
the year